,Name_VH,Name_VL,Genbank_protein_id_vh,Genbank_protein_id_vl,Binds_to,Origin,VH,VL,Reference,doi,Description_VH,Description_VL,Date_added,Description_VB,Description_VA,Description_Vunassigned
0,NaN,NaN,UGO91527,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardirdssgwanwfdpwgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1,NaN,NaN,UGO91525,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmssyywswirqppgkglewigyiynsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarlegegqlvdyygmdvwgqgttvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2,NaN,NaN,UGO91523,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqsgrslrlscaasgftfssyamhwvrqapgkglewvavishdgsntyyedsvkgrftisrdnskntlhlqvnslrvedtavyycarakgevryfdwaeqggdywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3,NaN,NaN,UGO91521,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfstyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymglsslrsedtavyycarwvtaygdyvpfdpwgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4,NaN,NaN,UGO91519,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycardivgateidywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
5,NaN,NaN,UGO91517,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsryaiswvrqapgqglewmgriipifgianyaqkfqgrvtitadkststaymevsslrsedtavyycarktyyydssgypeafdiwgqgtmvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
6,NaN,NaN,UGO91515,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslhlqmnslraedtalyycanlltpprrysgydlredyfeywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
7,NaN,NaN,UGO91513,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfspysmnwvrqapgkglewvssisvsniytyyadsvkgrftisrdnaknslylqmnslraedtaiyycardlkkggiqydafdiwgqgtvvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
8,NaN,NaN,UGO91511,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgiswvrqapgqglewmgriipilgtanhaqkfqgrvtitadkstgtvymelsslrsedtavyycardgdsgsyyetlgfdywgqgtlvtvss,NaN,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
9,NaN,NaN,NaN,UGO91528,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgtivtltisgvqaedeadyycqsadssatyvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
10,NaN,NaN,NaN,UGO91526,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvmviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
11,NaN,NaN,NaN,UGO91524,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdnsgdhgvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
12,NaN,NaN,NaN,UGO91522,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
13,NaN,NaN,NaN,UGO91520,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
14,NaN,NaN,NaN,UGO91518,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
15,NaN,NaN,NaN,UGO91516,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydrnnrpsgipdrfsgsssgntasltitgaqaedeadyychsrdssgnplhvvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
16,NaN,NaN,NaN,UGO91514,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvndylawyqqkpgqaprlliydasnratgfparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtrleik,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
17,NaN,NaN,NaN,UGO91512,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Cho,H. et al.; Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern; Sci Transl Med 13 (616), eabj5413 (2021); 2021.",10.1126/scitranslmed.abj5413,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
18,NaN,NaN,ULE72511,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgesltisckasgyrftsnwitwvrqmpgkglewmgridpddpysnsspsfqghatlsldkaintaylhwsslkasdtamyycarvnrvgdgpdfwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
19,NaN,NaN,ULE72510,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfndygvswvrqapgqglewmggiiaifgtanyaqkfqgrvaitadeststaymelsglrsedtavyfcaslggdsyisgthydrsgydpwgqgtlvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
20,NaN,NaN,ULE72509,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewltlisydginkyygdsvkgrftisrdnskntlyiqmnslrpedtavyycarayggnyyygmdvwghgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
21,NaN,NaN,ULE72508,NaN,SARS-CoV-2,Homo sapiens (human),evqlvgsggglvqpggslrlscaasgftfstywmswvrqapgkglewvadikqdgsekyyvdsvkgrftisrdnaknslylqmnslrvedtalyycargglwgtfdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
22,NaN,NaN,ULE72507,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsgasissssyywgwirqppgkglewigtmyyrgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycarrvpgdyycldvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
23,NaN,NaN,ULE72506,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssypitwvrqapgqgfewmgkiipilgiadyaqsfqgrvtitadkstttaymelsslrsedtavyycarekgysssssatyyldfwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
24,NaN,NaN,ULE72505,NaN,SARS-CoV-2,Homo sapiens (human),qvqlrlwgagllkpsetlsltcavsggsfidyywtwirqppgkglewigeinhfggsgynpslksrvsisvdtsknqfslrlnsvtaadtaiyycarkpllhssvnpgafdiwgqgtmltvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
25,NaN,NaN,ULE72504,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssypmywvrqapgigleyvsgitdnggstyygdsvkgrftisrdnskntlnlqmnnlrtedtavyycvkgkiqlwlgadywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
26,NaN,NaN,ULE72503,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfssytiiwvrqapgqglewmgrvipvvhithyaqrfrgrvtisadkststaymelsslrsedtavyycarglwfgdsetvwfdpwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
27,NaN,NaN,ULE72502,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfstsvvqwvrqprgqrlewiggivvgrgntkyaqnfqervtitrdmststaymelsnlrsedtavyycaadpfadywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
28,NaN,NaN,ULE72490,NaN,SARS-CoV-2,Homo sapiens (human),evqlvefggglvqpgrslrlscatsgftfedfdmhwvrqapgkglewvsgstwnsgiigyadsvkgrfttsrdnaknslymqmnnlreedtalyycakdigrydhynifgrvggafdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
29,NaN,NaN,ULE72489,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdgdkryspslknrltitedtsknqvvltmtnmdpvdtatyycahhtvptiydywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
30,NaN,NaN,ULE72488,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglilpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycarggwpsgdtfdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
31,NaN,NaN,ULE72487,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsktqfslklssvtaadtavyycardrrgggwtasfdfwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
32,NaN,NaN,ULE72486,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftlssyamnwvrqapgkglewvsaisgsggstyyadsvkgrvtisrdnskntlylqmnslrvedtavyycakdafyygsgshfyyyyymdvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
33,NaN,NaN,ULE72485,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsdnymswvrqapgkglqwvsviysggntyyadfvkgrfnitrddsknmlylqmnslrredtavyycvrdrrivgyyfgldvwgqgttvtvfs,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
34,NaN,NaN,ULE72484,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsctasggdftyyplswmrqapgrglewlggiipgyggahvarrfqdrvtitadestttvnmelrslrsddsavyycareegsgwwkhdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
35,NaN,NaN,ULE72483,NaN,SARS-CoV-2,Homo sapiens (human),qitleesgptlvtptqtltltcsfsgfsldtigvavawirqppgkalewlgtvfwdydkryspplssrltvikdtsqqyvvlrltdvgpgdtatyycarlliehdafdiwgqgavvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
36,NaN,NaN,ULE72482,NaN,SARS-CoV-2,Homo sapiens (human),evhlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggntyyadsvkgrftisrdnskntlylqmnslraedtavyycardrriigyyfgmdvwgrgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
37,NaN,NaN,ULE72481,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnsysmnwvrqapgkglewvsyistssstmyyadsvkgrftisrdnaknslylqmnslraedtavyycareggwysvgwvdpwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
38,NaN,NaN,ULE72480,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlsctasgitvstnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraddtavyyctrggwpsgdtfdiwglgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
39,NaN,NaN,ULE72470,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgitfkdygmhwvrqapgrglewvafisydgsvqhygdsvkgrftisrddlkstlflqmnslrgddtavyycvkgatkidywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
40,NaN,NaN,ULE72469,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansyiteyaasvkgrftisrddsknslylqmnslktedtavyycarvrggewvgdlgwyyyygmdvwgqgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
41,NaN,NaN,ULE72468,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscvdseftfityamswvrqapgkglewvstisgsgdstsyadsvkgrftisrdsskntlflqmhslraedtalyycaksativlmvsaiywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
42,NaN,NaN,ULE72467,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyswswirqspgtglewvgdiystgstnynpslksrltmsldtskshfslklssvaaadtavyycargageqrlvgglfgvshfyyymdvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
43,NaN,NaN,ULE72466,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqvsgpgllkpsetlsltcivsggsisshywswfrqppgkglewigyiyysgstnynpslksrvaisvdtsknhfslnltsvtaadtavyycargfdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
44,NaN,NaN,ULE72465,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssygmhwvrqapgkglewvtliwfdgsnqyyadsvkgrftisrdnskntlylqmnslrgedtavyycaregavgatsgldywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
45,NaN,NaN,ULE72464,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggsfssyafswvrqapgqglewmggivgmfgttsysqkfqgrliitadeltstaymelsslrsedtavyfcarsggyrlwfgelwgpgtqvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
46,NaN,NaN,ULE72463,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwisayngstnyaqklqgrvtmttdtststaymelrslrsddtavyycardpasyydlwsgyvdyyyygmdvwgqgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
47,NaN,NaN,ULE72462,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyvltwvrqapgqglewmgwisayngstnyaqnlqgrvtmttdtststaymelrslrsddtavyycardpasyydfwsgyvdyyyygmdvwgqgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
48,NaN,NaN,NaN,ULE72521,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllfgngytylnwylqkpgqspqlliylgsnrasgvpdrfsvsgsgtdftliisrveaedvgvyfcmqalqtpwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
49,NaN,NaN,NaN,ULE72520,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgdratlscrasqsissflawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
50,NaN,NaN,NaN,ULE72519,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtatitcsadklgkkyvcwyqqkpgqspvlviyqnnrrpsgiperfsgsnsgntatltisgtqpmdeadyycqawdsstasfvfgtgtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
51,NaN,NaN,NaN,ULE72518,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavywcqqfayslytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
52,NaN,NaN,NaN,ULE72517,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtvtcrasqsisdylnwyqqkpgkapklliyaasslqtgvpprfsgsgsgtdftltisslqpedfatyycqqsfsarvptfgggtkvesk,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
53,NaN,NaN,NaN,ULE72516,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtaprlliyrnsnrpsgvpdrfsgsksgtaaslaisglqaedeadyycqsydssltalvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
54,NaN,NaN,NaN,ULE72515,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeraalscrasqsvagtylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyatsprtfgqgtqleir,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
55,NaN,NaN,NaN,ULE72514,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcranqtissylnwyqqkpgkapkvlifaassleggvpsrfsgsgsgtdftltisslqpedfatyscqqsyntpwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
56,NaN,NaN,NaN,ULE72513,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnityylnwyqqkpgkapnlliytasslqsgvpsrfigsgsgtdftltisslqpedfatyccqqsystpptfgqgtkveir,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
57,NaN,NaN,NaN,ULE72512,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnignntvnwnhqvpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslnawvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
58,NaN,NaN,NaN,ULE72501,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtiscqtsqdisvslnwyqqkpgkppkvliydasnleagapsrfsgsgsgtdftftisslqpediatyycqhydnlprfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
59,NaN,NaN,NaN,ULE72500,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctatssdvgnynyvswyqhhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnplvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
60,NaN,NaN,NaN,ULE72499,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
61,NaN,NaN,NaN,ULE72497,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvtssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
62,NaN,NaN,NaN,ULE72496,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvrnynlvswyqqhpgkapklmifedskrpsgvsnrfsgsksgntasltiaglqpedeadyyccsyattwvfgggtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
63,NaN,NaN,NaN,ULE72495,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisdylawyqekpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlsgypytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
64,NaN,NaN,NaN,ULE72498,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlynsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhystpgytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
65,NaN,NaN,NaN,ULE72494,SARS-CoV-2,Homo sapiens (human),NaN,dvvvtqspvslpatpgepasiscrasqsllhrngkhylhwylqrpgqspqlliylgsnrasgvpdrfsgsgsgtvfslkisrveaedvgiyycmqalhfpytfgqgtkldik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
66,NaN,NaN,NaN,ULE72493,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssyvgsfdlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccpyadtwvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
67,NaN,NaN,NaN,ULE72492,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvssnflawyqqkpgqaprlliygasiratgipdrfsgsgsatdftltisrlepedfavyycqqygssrtfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
68,NaN,NaN,NaN,ULE72491,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypeitfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
69,NaN,NaN,NaN,ULE72479,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsydhvswfqqhagkgpnvvifdvnsrpsgvsnrfsgsksgntasltisglqaedeadyycfsytsggtrvfgsgttvtvv,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
70,NaN,NaN,NaN,ULE72478,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsnghnfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
71,NaN,NaN,NaN,ULE72477,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkaprlmiydvsdrpsgvsnrfsgsksgntasltisglrtedeadyycssytststlvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
72,NaN,NaN,NaN,ULE72476,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
73,NaN,NaN,NaN,ULE72475,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvgsiylawyqqkpgqaprllifgassraigipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
74,NaN,NaN,NaN,ULE72474,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedtkrpsgiperfsgsssgtmatltisgaqvedeadyycysrdssgnplfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
75,NaN,NaN,NaN,ULE72473,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratfscrasqsvnnnylawyqqkpgqaprlltsgtftratgipdrfsgsgsgtdftltisrvesedfavyycqqyggspatfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
76,NaN,NaN,NaN,ULE72472,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygssrltfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
77,NaN,NaN,NaN,ULE72471,SARS-CoV-2,Homo sapiens (human),NaN,elvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnsrltfgpgtkvdik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
78,NaN,NaN,UKY18853,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcivsddsinsyywswirqppgrglewigyiyysgstnydpslksratisldtsknqlslkltsvtaadtavyycarsgsygdrtfdhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
79,NaN,NaN,UKY18852,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgfntnyadsvkgrftisrdnskntlylqmnslraedtavyycakygwgllaaagdafdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
80,NaN,NaN,UKY18851,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkisckpsgytftnyliqwvrqapgqslewmgwinagdgysknslsfrgrvtftrdtsastasmelsslnsedtavyycarggfnyghgldywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
81,NaN,NaN,UKY18850,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasryafttyaihwvrqapgqglewmgwintntgdpmyahgftgrfvfslatsvstayleisslkaedtavyycaredtfyfdywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
82,NaN,NaN,UKY18849,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngdtkysqkfqgrvtitrdtsastaymelrslrsedtavyycarpprgyydrsgyynvllyfqhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
83,NaN,NaN,UKY18848,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftsydlhwvrqapgqrlewmgwinvgngntkysqkflgrvtftrdtsastvymelsslrsedtamyycarpprgyydrtgyynvvhyfqhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
84,NaN,NaN,UKY18847,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsasywswirqppgkglewigeihhsgstnynpslesrvtisvdtsknqfslklssvtatdtavyycareysstvwdnwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
85,NaN,NaN,UKY18846,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqslsltcnvsggsissnnyywnwirqpagkglewigrgyssgstnynpslksrltisldtsknqfslklssvtaadtavyycarstyyydrsgystsdgmdvwgqgttvivss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
86,NaN,NaN,UKY18845,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesgggvvqpgrslrlscavsgftfssygmhwvrqapgkglewvtfisydgsneyyadsvkgrftisrdsskntlylqmnslrpedtavyycakseysyaykvhfldywgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
87,NaN,NaN,UKY18844,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsnysissgyywgwirqppgkglewigsifhsgstyynpslkgrvtisvdrsknqfslkltsvtaadtavylcakegargrgattsfyyyymdvwgkgttvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
88,NaN,NaN,UKY18843,NaN,SARS-CoV-2,Homo sapiens (human),evqlvdsggglvqpggslrvscaasgftvssnhmswvrqapgkglewvsliygdgsthyadsvkgrftmsrdkskntlylqmnslraedtavyycardvthafdlwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
89,NaN,NaN,UKY18842,NaN,SARS-CoV-2,Homo sapiens (human),evllvesggglvkpggslrlscaasgfsfssynmnwvrqapgkglewvssissssnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycanmrtnydiftgyypdafdiwgqgtmvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
90,NaN,NaN,UKY18841,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpgvvkpsetlsltcsvsggsisstnyywawirqppgkglewigsifytgstyynpslksrviisvdtsknqfslrltsvtaadtavyycarytsyydrsgfrrveyfqhwgqgtlvtvss,NaN,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
91,NaN,NaN,NaN,UKY18866,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtatitcsgdklgdkyacwfqqkpgqspvlviyhdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsstavfgtgtkvtvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
92,NaN,NaN,NaN,UKY18865,SARS-CoV-2,Homo sapiens (human),NaN,dvvliqsplslpvtlgqpasiscrssqslvygdgdtylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
93,NaN,NaN,NaN,UKY18864,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvfwyqqhsgkapklmiyevnkrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagvtnnlifgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
94,NaN,NaN,NaN,UKY18863,SARS-CoV-2,Homo sapiens (human),NaN,esvltqspgtlalspgeratlscrasqsvgsrylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspsfgqgtrleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
95,NaN,NaN,NaN,UKY18862,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqyvnlpltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
96,NaN,NaN,NaN,UKY18861,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlsltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
97,NaN,NaN,NaN,UKY18860,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgrhnyvswyqqypgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssayvvfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
98,NaN,NaN,NaN,UKY18859,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgervtlscrasqsvsnslawyqqkpgqaprllidgassratgipdrfsgsgsetdftltisrlepedfavyycqqygsspltfgggtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
99,NaN,NaN,NaN,UKY18858,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnsvqwyqqrpgsapttviyednqrpswvpdrfsgsidsssnsasltisglkaedesdyycqsydssnhvlfgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
100,NaN,NaN,NaN,UKY18857,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigaghdvhwyqqlpgtapklliygntnrpsgvpdrvsgsksgtsaslaisglqaedeadyycqsydislngwvlgggtkltvl,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
101,NaN,NaN,NaN,UKY18856,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqiigmwlawyqqkpgkapklliykassleygvpsrfsgsgsgteftltisslqpddfatyycqqynsdlytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
102,NaN,NaN,NaN,UKY18855,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscsasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslesedfavyycqqyynwppwtfgqgtkveik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
103,NaN,NaN,NaN,UKY18854,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapsllisgsssratdipdrfsgsgsgtdftltisrlepedfavyfcqqygsspytfgqgtkleik,"Shiakolas,A.R. et al.; Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking; Unpublished; 2022.",NaN,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
104,NaN,NaN,UKB89181,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatqggrfycsggscyryyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
105,NaN,NaN,UKB89180,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsdgstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfvvvvaarshddyyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
106,NaN,NaN,UKB89179,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwagadgmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
107,NaN,NaN,UKB89178,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvrpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
108,NaN,NaN,UKB89177,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlsvaggmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
109,NaN,NaN,UKB89176,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardydyvwgsypsaccywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
110,NaN,NaN,UKB89175,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmywvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaralygsgsystqagyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
111,NaN,NaN,UKB89174,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarellllgycsggscypvgpdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
112,NaN,NaN,UKB89173,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissayywgwirqppgkglewigsffhsgstyynpslksrvtitvdtskkqfslklssvtaadtavyycarddygdyavsywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
113,NaN,NaN,UKB89172,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvsshymswvrqapgkglewvsvlysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlhssgpfdafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
114,NaN,NaN,UKB89171,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhegstsplmvknyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
115,NaN,NaN,UKB89170,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyfcardyggnqnyfgywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
116,NaN,NaN,UKB89169,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivlmvyaiprgyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
117,NaN,NaN,UKB89168,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqksqervtitrdlstrtaymelsslrsedtavyycaapycsggscfdafdmwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
118,NaN,NaN,UKB89167,NaN,SARS-CoV-2,Homo sapiens (human),qvqlresgpglakpsgtlsltcavsggsitsiywwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyfcasapgtpwfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
119,NaN,NaN,UKB89166,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmsslraedtavyycardlavygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
120,NaN,NaN,UKB89165,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgysftshamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycartsgwsgpsygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
121,NaN,NaN,UKB89164,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssyymnwvrqppgkglewvsviynggnayyadsvkgrftisrdnsrntlylqmnslraedtavyycargkwlrgafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
122,NaN,NaN,UKB89163,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfsnygmhwvrqapgkglewvavisydgssqyyadsvkgrftisrdnskntlylqmnslrgddtavyycakdrsvgattsqynyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
123,NaN,NaN,UKB89162,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqsspklgddafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
124,NaN,NaN,UKB89161,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgitftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggtchdgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
125,NaN,NaN,UKB89160,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkssetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrlgprgpfdnhgnhfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
126,NaN,NaN,UKB89159,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgrirsktdggtpdyaaplkgrftisrddskntlylqmnslktedtavyycttdsldvgggsyvnfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
127,NaN,NaN,UKB89158,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglecigsihysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhagpyssswianwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
128,NaN,NaN,UKB89157,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhaaprpgdswfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
129,NaN,NaN,UKB89156,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfgsygmhwvrqapgkglewvavisddgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgstgttlgyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
130,NaN,NaN,UKB89155,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkarnyydssgyehdafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
131,NaN,NaN,UKB89154,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycardltqdwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
132,NaN,NaN,UKB89153,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgcirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhvgpysgydknnwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
133,NaN,NaN,UKB89152,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnilraedtavyycarsqstswhdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
134,NaN,NaN,UKB89151,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqlwlrsnfdswgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
135,NaN,NaN,UKB89150,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsgdsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknlfslklssvtaadtavyycarrgwlrgyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
136,NaN,NaN,UKB89149,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasrftfsnywmswvrqapgkglewvanikqdgsekycvdsvkgrftisrdnaknslylqmnslraedtavyycaralsmvrgviippyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
137,NaN,NaN,UKB89148,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargiaarpgdwhfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
138,NaN,NaN,UKB89147,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriqsktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdpnqqpprgyyfyygldvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
139,NaN,NaN,UKB89146,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpsltsrvtisvdtsknqfslklssvtaadtavyycarqfwtrppsvwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
140,NaN,NaN,UKB89145,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargtamaygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
141,NaN,NaN,UKB89144,NaN,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslriscaasgltvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycardlitygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
142,NaN,NaN,UKB89143,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytftsygitwvrqapgqglewmgwisvdngntkyaeklqgrvtmttdtststaymelrslgsddtavyycardggwtgimgainfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
143,NaN,NaN,UKB89142,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsrsavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstsaaymelsslrsedtavyycaapacsstrcydgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
144,NaN,NaN,UKB89141,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgahywswirqhpgkglewigyiyysggtyynpslkslvtisvdtsknhfslklssvtaadtavyycarttaprpgsswfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
145,NaN,NaN,UKB89140,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasglivssnymswvrqapgkglewvsvlysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarwgrvgatglafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
146,NaN,NaN,UKB89139,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsrnaiswvrqapgqglewmggiipifgtahyaqkfqgrvtitadeststaymelsslrsedtavyycarreysstdwfdpwgqgtrvtvs,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
147,NaN,NaN,UKB89138,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycarggavipvwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
148,NaN,NaN,UKB89137,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvafisydgddkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakavysyayavlyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
149,NaN,NaN,UKB89136,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglqwvaiisydesskyyadsvkgrftisrdnskntlylqmnslraedtamyycakdppqfavagtgyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
150,NaN,NaN,UKB89135,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysggtysnpslksrvtisvdtsknqlslklssvtaadtavyycarevapikqwlvsyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
151,NaN,NaN,UKB89134,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmkslraedtavyycardrfydysssgysldafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
152,NaN,NaN,UKB89133,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyytpslksrvtisvdtsknqfslklssvtaadtavyycarftrfaglyyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
153,NaN,NaN,UKB89132,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmsgthssgwyerwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
154,NaN,NaN,UKB89131,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqvawlprddyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
155,NaN,NaN,UKB89130,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
156,NaN,NaN,UKB89129,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaraaydiltgyyrgmdvwgkgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
157,NaN,NaN,UKB89128,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmsslragdtavyycarghfygligymdvwgkgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
158,NaN,NaN,UKB89127,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaignagdtyypasvkgrftisrenarnslylqmnslragdtavyycarvrptmtkgfdwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
159,NaN,NaN,UKB89126,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakdtyydifpdvfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
160,NaN,NaN,UKB89125,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgdtnytqkfqervtitrdmststaymelsslrsedtavyycaapycsgsscldgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
161,NaN,NaN,UKB89124,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakapyaycsstscyadyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
162,NaN,NaN,UKB89123,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycarggivpaatllfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
163,NaN,NaN,UKB89122,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgshntnyaqkfqervtitrdmststaymelssltsedtavyycaaaiiasaapdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
164,NaN,NaN,UKB89121,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnnyemnwvrqapgkglewvsyissggttmyyadsvkgrftisrdnaknslylemnslraedtalyycarvghpdtlfgveywgqgilvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
165,NaN,NaN,UKB89120,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifnnyemnwvrqapgkglewisyissggttvyyadsvkgrftisrdnaknslylqmsslraedtalyycvrvghpdtlfgvdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
166,NaN,NaN,UKB89119,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggwydykgyyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
167,NaN,NaN,UKB89118,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgtqpipdygdffdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
168,NaN,NaN,UKB89117,NaN,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarwaqqlvpsenlkpyyyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
169,NaN,NaN,UKB89116,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarqpreyydfwsgyrrlfyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
170,NaN,NaN,UKB89115,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsggscydafdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
171,NaN,NaN,UKB89114,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgtshyydssgyygadrnwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
172,NaN,NaN,UKB89113,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsihysgstyynpslksrvtisvdtsknqfslklssmtaadtavyycarhtgyydssgyyrleyfqhwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
173,NaN,NaN,UKB89112,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewiayiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsrgynyglglgwfdpwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
174,NaN,NaN,UKB89111,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnglraedtavyycakvlgsycsggscyggsfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
175,NaN,NaN,UKB89110,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksgapaamrgyyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
176,NaN,NaN,UKB89109,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdafgdpqglygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
177,NaN,NaN,UKB89108,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgddygdlfyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
178,NaN,NaN,UKB89107,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkrpgssvkvsckasggtfsnygfswvrqapgqglewmggtsplfhtpnyvqkfqdrvtitadesttsvymelnsltsddtavyycacssgrwgvlgnyfdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
179,NaN,NaN,UKB89106,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssygiswvrqapgqglewmggiipifgtayyaqkfqgrvtitadeststaymelsslrsedtavyycassspllryfdwpheaifdywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
180,NaN,NaN,UKB89105,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrddsknmlylqmnslktedtavyycttdpgytyspaywgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
181,NaN,NaN,UKB89104,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvssissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdvtvdtamvtifdnwgqgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
182,NaN,NaN,UKB89103,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtsgdtyypgsvkgrftisrenaknslylqmnslragdtavyycargggdgynlglwyfdlwgrgtlvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
183,NaN,NaN,UKB89102,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftfpssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcgggscydgfdiwgqgtmvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
184,NaN,NaN,UKB89101,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfpfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfqyvaathspyyyygmdvwgqgttvtvss,NaN,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
185,NaN,NaN,NaN,UKB89262,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgegtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
186,NaN,NaN,NaN,UKB89261,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyknfpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
187,NaN,NaN,NaN,UKB89260,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltitrlepedfavyycqqygssqytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
188,NaN,NaN,NaN,UKB89259,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
189,NaN,NaN,NaN,UKB89258,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssppitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
190,NaN,NaN,NaN,UKB89257,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsglsnrfsgsksgntasltisglqaedeadyycssytsstnwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
191,NaN,NaN,NaN,UKB89256,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyraftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
192,NaN,NaN,NaN,UKB89255,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnhwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
193,NaN,NaN,NaN,UKB89254,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
194,NaN,NaN,NaN,UKB89253,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvaitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgggsgtdftftisslqpediatyycqqydivgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
195,NaN,NaN,NaN,UKB89252,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
196,NaN,NaN,NaN,UKB89251,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnslnwyqqkpgkapklliydasnletgvpssfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
197,NaN,NaN,NaN,UKB89250,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeaayycssytsssppvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
198,NaN,NaN,NaN,UKB89249,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
199,NaN,NaN,NaN,UKB89248,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
200,NaN,NaN,NaN,UKB89247,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqipgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqydsslitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
201,NaN,NaN,NaN,UKB89246,SARS-CoV-2,Homo sapiens (human),NaN,qavvtqepsltvspggtvtltcasstgavtsgyypnwfqqkpgqapraliysisnkhswtparfsgsllggkaaltlsgvqpedeaeyycllyfggaqyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
202,NaN,NaN,NaN,UKB89245,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapitviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdlwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
203,NaN,NaN,NaN,UKB89244,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqfpgtapklliydndkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwetslsaevfgggtrltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
204,NaN,NaN,NaN,UKB89243,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
205,NaN,NaN,NaN,UKB89242,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
206,NaN,NaN,NaN,UKB89241,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrviitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltvsslqpedfatyycqqlnsypwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
207,NaN,NaN,NaN,UKB89240,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsvsvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
208,NaN,NaN,NaN,UKB89239,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteltltisslqpedfatyycqqlnsypltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
209,NaN,NaN,NaN,UKB89238,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqafsswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfptfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
210,NaN,NaN,NaN,UKB89237,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
211,NaN,NaN,NaN,UKB89236,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
212,NaN,NaN,NaN,UKB89235,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgthftlaisslqpedfatyycqqsystppitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
213,NaN,NaN,NaN,UKB89234,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
214,NaN,NaN,NaN,UKB89233,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidtssnsasltisglktedeadyycqsydnnnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
215,NaN,NaN,NaN,UKB89232,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwhqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
216,NaN,NaN,NaN,UKB89231,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
217,NaN,NaN,NaN,UKB89230,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidiysnsasltisglktedeadyycqsydssnhwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
218,NaN,NaN,NaN,UKB89229,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsrgvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
219,NaN,NaN,NaN,UKB89228,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqapmtlicdtsnkhswtparfsgsllgdkaaltlsgaqpedeaeyycllsysgapvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
220,NaN,NaN,NaN,UKB89227,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignyyvswyqqlprtapklliydnnerpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
221,NaN,NaN,NaN,UKB89226,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnniggqsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
222,NaN,NaN,NaN,UKB89225,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyscqhlltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
223,NaN,NaN,NaN,UKB89224,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywcqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
224,NaN,NaN,NaN,UKB89223,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqapslliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
225,NaN,NaN,NaN,UKB89222,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlaitglqtgdeadyycgtwdntlspgrgvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
226,NaN,NaN,NaN,UKB89221,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtariscggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsdsnsgntatltisrveagdeadyycqvwdsssdhhyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
227,NaN,NaN,NaN,UKB89220,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
228,NaN,NaN,NaN,UKB89219,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyshpgitfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
229,NaN,NaN,NaN,UKB89218,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsfasnsvqwyqqrpgsapttmiyednhrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydynnhvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
230,NaN,NaN,NaN,UKB89217,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsknvhwyhqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
231,NaN,NaN,NaN,UKB89216,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvqwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsglvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
232,NaN,NaN,NaN,UKB89215,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnignnavnwfqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
233,NaN,NaN,NaN,UKB89214,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklliyevskrpsgvpdrfsgsksgntasltvsglraddeadyycssyagtvlfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
234,NaN,NaN,NaN,UKB89213,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
235,NaN,NaN,NaN,UKB89212,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvgfynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnyvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
236,NaN,NaN,NaN,UKB89211,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsnsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
237,NaN,NaN,NaN,UKB89210,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgidftltisslqpedfatyycqqsyniastfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
238,NaN,NaN,NaN,UKB89209,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqklgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
239,NaN,NaN,NaN,UKB89208,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlgtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
240,NaN,NaN,NaN,UKB89207,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitiscagtssdlggyyyvswyqhhpgkapklmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlpvfgtgtkvtvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
241,NaN,NaN,NaN,UKB89206,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspdtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftlaisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
242,NaN,NaN,NaN,UKB89205,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssvvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
243,NaN,NaN,NaN,UKB89204,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyscsfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
244,NaN,NaN,NaN,UKB89203,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
245,NaN,NaN,NaN,UKB89202,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscgasqsisstlawyqhkpgqaprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
246,NaN,NaN,NaN,UKB89201,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqapslliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprysfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
247,NaN,NaN,NaN,UKB89200,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
248,NaN,NaN,NaN,UKB89199,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppctfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
249,NaN,NaN,NaN,UKB89198,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgytfgqgtkleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
250,NaN,NaN,NaN,UKB89197,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
251,NaN,NaN,NaN,UKB89196,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
252,NaN,NaN,NaN,UKB89195,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedgadyycqsydsslsgwvfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
253,NaN,NaN,NaN,UKB89194,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylywyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
254,NaN,NaN,NaN,UKB89193,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyddvpftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
255,NaN,NaN,NaN,UKB89192,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydassleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlpsfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
256,NaN,NaN,NaN,UKB89191,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpedeadyycllsysgarevfgggtkltvl,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
257,NaN,NaN,NaN,UKB89190,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfaqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
258,NaN,NaN,NaN,UKB89189,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrtltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
259,NaN,NaN,NaN,UKB89188,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditdylnwyqqkpgqapklliydasnletgvpsrfsgsgsgtdftltisslqpediatyycqqyanllltfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
260,NaN,NaN,NaN,UKB89187,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwsgitfgqgtrleik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
261,NaN,NaN,NaN,UKB89186,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcragqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlftfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
262,NaN,NaN,NaN,UKB89185,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
263,NaN,NaN,NaN,UKB89184,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqrkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnppptfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
264,NaN,NaN,NaN,UKB89183,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygsspwtfgqgtkveik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
265,NaN,NaN,NaN,UKB89182,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylacyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgpgtkvdik,"Reincke SM et al.; SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies; Science, eabm5835 (2022) In press; 2022.",10.1126/science.abm5835,NaN,"anti-SARS-CoV-2 immunoglobulin kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
266,N3113.1,NaN,7VNE_V,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain V, n3113.1",NaN,2022-03-15,NaN,NaN,NaN
267,N3113.1,NaN,7VNE_U,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain U, n3113.1",NaN,2022-03-15,NaN,NaN,NaN
268,N3113.1,NaN,7VNE_W,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasdssfydyemswvrqapgkaqewigsmypsgrtyinpslkslvtisrdnskntlylqlnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain W, n3113.1",NaN,2022-03-15,NaN,NaN,NaN
269,N3113,NaN,7VND_D,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain D, n3113",NaN,2022-03-15,NaN,NaN,NaN
270,N3113,NaN,7VND_V,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain V, n3113",NaN,2022-03-15,NaN,NaN,NaN
271,N3113,NaN,7VNC_V,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain V, n3113",NaN,2022-03-15,NaN,NaN,NaN
272,N3113,NaN,7VNB_A,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasdfsfydyemswvrqapgkalewigsmyhsgrtyinpslkslvtisrdnskntlylqmnslraedtamyycvsnwasgstgdywgqgtlvtvss,NaN,"Yang,Z. et al.; A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants; Signal Transduct Target Ther 6 (1), 378 (2021); 2021.",10.1038/s41392-021-00810-1,"Chain A, n3113",NaN,2022-03-15,NaN,NaN,NaN
273,C5,NaN,7OAU_FFF,NaN,SARS-CoV-2,Lama glama (llama),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, C5",NaN,2022-03-15,NaN,NaN,NaN
274,C5,NaN,7OAU_BBB,NaN,SARS-CoV-2,Lama glama (llama),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain BBB, C5",NaN,2022-03-15,NaN,NaN,NaN
275,H3,NaN,7OAQ_FFF,NaN,SARS-CoV-2,Lama glama (llama),maqvqlvesggglvktggslrlscaasgrtfstysmgwfrqapgkerefvagmrwtgsstfysdsvkgrftvsrnnakdtvylhmnslkpedtavyycaittivrayyteyteadfgswgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain FFF, H3",NaN,2022-03-15,NaN,NaN,NaN
276,H3,NaN,7OAQ_AAA,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqpggslrlscaasgftndfysiawfrqapgkeregvswlsvsdntptyvdsvkdrftisrhnanntvylqmnmlkpedtaiyycaagrfagrdtwpssydywgqgtqvtvsskhhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain AAA, H3",NaN,2022-03-15,NaN,NaN,NaN
277,NaN,NaN,7OAN_H,NaN,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain H, immunoglobulin mu heavy chain",NaN,2022-03-15,NaN,NaN,NaN
278,NaN,NaN,7OAN_G,NaN,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain G, immunoglobulin mu heavy chain",NaN,2022-03-15,NaN,NaN,NaN
279,NaN,NaN,7OAN_F,NaN,SARS-CoV-2,Vicugna pacos (alpaca),maqvqlvesgggsvqaggsltlscvasgvtlgrhaigwfrqapgkerervscirtfdgitsyvestkgrftissnnamntvylqmnslkpedtavyfcalgvtaacsdnpyfwgqgtqvtvsshhhhhh,NaN,"Huo,J. et al.; A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19; Res Sq (2021); 2021.",NaN,"Chain F, immunoglobulin mu heavy chain",NaN,2022-03-15,NaN,NaN,NaN
280,NB21,NaN,7MDW_A,NaN,SARS-CoV-2,Lama glama (llama),qvqlvesggglvqaggslrlscavsglgahrvgwfrrapgkerefvaaiganggntnyldsvkgrftisrdnakntiylqmnslkpqdtavyycaardietaeytywgqgtqvtvss,NaN,"Sun,D. et al.; Potent neutralizing nanobodies resist convergent circulating variants of SARS-CoV-2 by targeting diverse and conserved epitopes; Nat Commun 12 (1), 4676 (2021); 2021.",10.1038/s41467-021-24963-3,"Chain A, nonobody Nb21",NaN,2022-03-15,NaN,NaN,NaN
281,SR31,NaN,7D2Z_A,NaN,"SARS-CoV-2, Spike protein RBD",synthetic construct,gsssqvqlvesggglvqaggslrlscaasgfpvwqgemawyrqapgkerewvaaissmgyktyyadsvkgrftisrdnakntvylqmnslkpedtavyycavmvgfwyagqgtqvtvsagrageqkliseedlnsavdhhhhhh,NaN,"Yao,H. et al.; A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2; PLoS Pathog 17 (3), e1009328 (2021); 2021.",10.1371/journal.ppat.1009328,"Chain A, SR31 against SARS-CoV-2 RBD, non neutralizing",NaN,2022-03-15,NaN,NaN,NaN
282,NaN,NaN,UIK23909,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaiisydgsnkyyadsvkgrftisrdnsnntvylqinslrtedtavyycaksragsyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
283,NaN,NaN,UIK23908,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisctgsgysfttywigwvrqmpgkglewmgviypgdsdtryspsfqgqvtfsadksistaylqwsslkasdtaiyycarhgnryssgwyqptgvdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
284,NaN,NaN,UIK23907,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasigsyywswirqppgkgleyigyiyysgstdynpslksrvtisidtsknlfslnltsvtaadtavyycargfdswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
285,NaN,NaN,UIK23906,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggdvvqpgrslrlscaasgftfstyamhwvrqapgkglewvslisydginkyyagsvkgrfsisrdnskntlylqmnslrvedtavyycarslsggyyygmgvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
286,NaN,NaN,UIK23905,NaN,SARS-CoV-2,Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwyhgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardretstnyvghyyngmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
287,NaN,NaN,UIK23904,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwvnpnsgatncaqkfqgrvtmtrdtsittvymelsrlkfddtavyycargvdfsifgaaisddwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
288,NaN,NaN,UIK23903,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsenlsltcnvagdsisgyywswirqtpgkglefigymyyggstiynpslrtrvtisidtsknqfslnlnsvtaadtaiyycargfdlwgrgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
289,NaN,NaN,UIK23902,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsgyamhwvrqapgkglewvavisydgdnkyyadsvrgrftisrdnskntlylqmnslrvedtavyycarsssgsyfaafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
290,NaN,NaN,UIK23901,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyfwtwirqppgkglewighifysgstyynpslksrvtisldtsknqfslklssvtaadtavyycarvvlaknyydrsgyfhgdwyfygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
291,NaN,NaN,UIK23900,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvssvsgsgdrtyyadsvkghfiisrdnskntlylqmnslraedtavyycatdsyyhdrdgfvnyafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
292,NaN,NaN,UIK23899,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfnfnnvwmswvrqapgkglewvgliksksdggtkdyaapvrgrftisrddprnnlylqmnslktedtavyycstapyyydysaypqihfeywgrgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
293,NaN,NaN,UIK23898,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglecvsviygggptyyadsvkgrftisrdnskntlylqmnslraedtavyycardkripyyfygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
294,NaN,NaN,UIK23897,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasrfpfstygmhwarrapgkglewvslisddgknkyyadsvkgrftisrdnyentlylemnslrpedtavyycakailrgvkyylygvdiwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
295,NaN,NaN,UIK23896,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpgvvkpsetlsltctvsgdsissyywswirqspgkglewigyiyssgstnynpslksrvamsvdtsknhfslkmtsvtaadtavyycargfdfwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
296,NaN,NaN,UIK23895,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsnrymswvrqtpgkglewvsiiysagstyyadsvkgrftisrdnskntlylqmnslrvedtavyycaragsplslrwrphidywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
297,NaN,NaN,UIK23894,NaN,SARS-CoV-2,Homo sapiens (human),qvqvqqwgagllkpsetlsltcavyggsfsdyswtwirqspgkglewigeindsgitnydptlksriimsvdrsknqfslrltsvtaadtavyfcargstvlglsslryyssldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
298,NaN,NaN,UIK23893,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsggevkkpgasvkvsckasgytftnyglswvrqapgqglewmgwisgnngntnyaqkfqgrvtmttdtststgymelrslrsddtavyycardqstvvtfgtfdywgqgtlltvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
299,NaN,NaN,UIK23892,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpggslrlscaasgftfssygmhwvrqapgkglewvafirydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaspsryydssgyylaeyfqhwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
300,NaN,NaN,UIK23891,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpgpvkpsgtlsltcavsgdsitntnwwswvrqspggglewigeihhsgttnyksslksrviisidksknqfslkmrsvtaadtalyycargrynwnggyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
301,NaN,NaN,UIK23890,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvnvsckasggtfssyaiswvrqapgqglewmggifplygttkyaqqfqgrvtfsadestrtaymdlrslrsedtavyycarsadgdyvvgyyhymdvwgkgttvivss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
302,NaN,NaN,UIK23889,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfssytfswvrqapgqglewmgvfipifgttsyaqkfqgrvtitadestytsymelssltsedtamyycasrlgcpngachepdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
303,NaN,NaN,UIK23888,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlsctasgftfntyaihwvrqapgkglesvalisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycargtggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
304,NaN,NaN,UIK23887,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmagimpifgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycasrhsgyryshfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
305,NaN,NaN,UIK23886,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggwvqpggslrlscaasefsvstnymtwvrqapgkglewvsiiysdgrtfyadsvkgrftisrdnskntvylqmnnlrpedtavyfcararvtiivvvvdyffdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
306,NaN,NaN,UIK23885,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvkpggslrlscaasgftfynawmswvrqapgkglewvghikgntnggttdyaapvkgrftisrddskntlylqmnslrtedtgvyycttetllwfgespfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
307,NaN,NaN,UIK23884,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgvtvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrddsmntlylqmsnvraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
308,NaN,NaN,UIK23883,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfnsyaftwvrqapgqglewmgaiipilgianheqkfqdratitadkststaymelrslrsddtavyycasgvvvpatdyyyamdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
309,NaN,NaN,UIK23882,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgfifsssamswvrqapgkglewvsgisdsglrtyygdsvkgrftisrdnskntvsllmnslraedtavyycaygyspdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
310,NaN,NaN,UIK23881,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggttyyadsvkgrftisrdnskntlylqmnnlrdedtamyycardlivygmdvwgqgtpvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
311,NaN,NaN,UIK23880,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymswvrqapgkglewvsiiyaggstfyadsvkgrftisrdnskntlylqmnslraedtavyyctrdlvyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
312,NaN,NaN,UIK23879,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglaqpggslrlscaasgitvssnymswvrqapgkglewvsvmyaggstfysdsvkgrftisrdgpkntlylhmhslraedtavyycardlvhygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
313,NaN,NaN,UIK23878,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwirqapgkglewvaviwsdginkyyvdsvkgrftisrdnskntlylqmnslraddtavyycarapqdpdsssyyyfyygldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
314,NaN,NaN,UIK23877,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftayyihwvrqapgqglewmawinpmsgatnytqkfqgrvtmtrdtsittvymelsrlrsadtavyycarvspptifgvtvdhwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
315,NaN,NaN,UIK23876,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymnwirqapgkglewvssisttgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarddssgyyygsaldwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
316,NaN,NaN,UIK23875,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfytdsvkgrftisrdnskntlylqmnslraedtavyycardlvvlygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
317,NaN,NaN,UIK23874,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaapgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
318,NaN,NaN,UIK23873,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfnnyainwvrqapgqglewmgriipmlgvvnhaqkfqgrvtitadkststaymelsslrsedtavyycatrvsvttmgvnfdgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
319,NaN,NaN,UIK23872,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymtwvrqapgkglewvsvlyaggssfyadsvkgrftisrdnskntlflqmnslraedtavyycardlvaygmdvwgqgttvsvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
320,NaN,NaN,UIK23871,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpessvkvsckvsggtfssygiswvrqapgqglewmgriipslgvvnyaqrfqgrvtftadkststaymdlsslksedtavyycakttvvtpglgkdafdvwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
321,NaN,NaN,UIK23870,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgyiftnfwiawvrqmpgkglewmgiiypddsdvrysppfqgqvtisadksintaylqwsslkasdtamyycarlsflpsgfshyyaldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
322,NaN,NaN,UIK23869,NaN,SARS-CoV-2,Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvalisydgsneyyadsvrgrftisrdnskntlylqmsslraedttmyycaranrgnyyygmdvwgpgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
323,NaN,NaN,UIK23868,NaN,SARS-CoV-2,Homo sapiens (human),qvqleqsgaevkkpgssvkvsckasgssfssyaitwvrqapgqglewmggiipifgtanyaqifqgrvtltaeestgaaymelsslrsedtalyyctiigmfdssgsythywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
324,NaN,NaN,UIK23867,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifntyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskstlylqmnslriedtavyycarsrsgsyfsafdiwgqgtkvtvsp,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
325,NaN,NaN,UIK23866,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvrpgrslrlscaasgftfssygmhwvrqapgkglewvalisydginkyypdsvkgrftisrdnsnntlylqmnslraedtavyycanaktgnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
326,NaN,NaN,UIK23865,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsistyywswirqppgkrlewigyiyysgstnynpslksrvtisvdtsknqfslklnsvtaadtaiyycargfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
327,NaN,NaN,UIK23864,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgdkkyytdsvkgrftisrdnskntlflqmnslraedtavyycararegtyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
328,NaN,NaN,UIK23863,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarlsfgyssssnyyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
329,NaN,NaN,UIK23862,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscavsgftfrsyamswvrqapgkglewvstisgsggrtdyadsvkgrftisrdnskntlyvqmsslraedtavyycalpylgwlrsfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
330,NaN,NaN,UIK23861,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqisgpglekpsgtlsltctvsggsvsrsdfywgwvrqppgkglewigsihysgstyynpslksrvtisvdtsenqlslrlssvtaadtavyycarsggysygravwfdnwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
331,NaN,NaN,UIK23860,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsisaihwvrqapgkglewvavisydgfnkyyedsvkgrfiisrdnskntlylqmnslrvedtavyycakgggsyyhpfdnwgqgtlvsvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
332,NaN,NaN,UIK23859,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptvvkptqtltltctfsgfslsisgegvgwirqppgkalewlaliywnderrytpslksrlsitkdtsknqvvltmtnmdpvdtatyycahtyyydsrgyafdnwgqgtlvpvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
333,NaN,NaN,UIK23858,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavfggsfsayywnwirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargsreqwlvrrawyfdlwgrgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
334,NaN,NaN,UIK23857,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcavsggsisiyywswirqppgkglewigyishsgdtnynpslksrvtisvdtsknqfslrlssvtaadtalyycargdimwtqwltsggrfldywgqgalvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
335,NaN,NaN,UIK23856,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsisgyywswirqspgkglewmgylyysgsinynpslksrvtisidtsknqfslkmrsvtaadtavyycargfeswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
336,NaN,NaN,UIK23855,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgntfidsymhwvrqapgqglewmglidpsgknryypqnfqgrltltrdaststtymqlsslrsqdtavyycarmteagswdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
337,NaN,NaN,UIK23854,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlslqlnslraedtavyycarmhsgsyigyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
338,NaN,NaN,UIK23853,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfitysfhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarqksqwellfrgdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
339,NaN,NaN,UIK23852,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyaihwvrqapgkglewvaliaydgdkkyyadsvrgrftlsrdnskntlylemnslraedtavyycarpysgsyygafeiwgqgtmvtvsa,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
340,NaN,NaN,UIK23851,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnsnstlylqmnslraedtalyycarggyhyfrhfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
341,NaN,NaN,UIK23850,NaN,SARS-CoV-2,Homo sapiens (human),dvllvesggglvqpggslrlscsasgfpfitywmswvrqapgkglewvanikedgsekyyvdsvrgrftisrdnaenslslqmnslraddtavyycartggrgsldrgrfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
342,NaN,NaN,UIK23849,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscvvsgftfntyamhwvrqapgkglewvavisydgnnhysadsvrgrfsvsrdnskktlflqmnslraedtavyycarsyggnylgyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
343,NaN,NaN,UIK23848,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstnynpslksrvtisldtsknqfslkltsvtaadtavyycarrrrgysyghptyhafdmwgqgtmvtvsa,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
344,NaN,NaN,UIK23847,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarhslrggtrggyyyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
345,NaN,NaN,UIK23846,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggavvqpgrslrlsceasgftfstyamhwvrqapgkglewvalvsydgsnkyyadsvkgrftisrdnskntlylqmdslraedsavyycaralsgsyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
346,NaN,NaN,UIK23845,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscavsgftfgsywmswvrqapgrglewvanirqdgsekyyvdsvkgrftisrdnaknsmylqmnslraedtavyycakenivavpaargydyyyymdvwgkgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
347,NaN,NaN,UIK23844,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlsceasgltfinawmswvrqapgkglewvgriksktdggttdfaapvkgrftisrddskntvflqmnslktedtavyycatdllfprdpgdnwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
348,NaN,NaN,UIK23843,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevqkpgeslkiscrasgytftdqwigwvrqmpgkglewvgviypgdsdtryspsfqgqvtisvdksistaylqwsslkasdtamyycarqsafwtgylyyyafdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
349,NaN,NaN,UIK23842,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaaseftfstytmhwvrqapgkglewvalisydgshkyyadsvkgrftisrdnskntlslqmnslraddtavyycararggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
350,NaN,NaN,UIK23841,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggmvqpgrslrlscaasgftfstyaihwvrqapgkglewvavvsydglnkyyadsvrgrftisrdnskntlylqmnnlraedtalyycarsasggywselpywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
351,NaN,NaN,UIK23840,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisrtnyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarlppwynsgwagldsltyqyymdvwgkgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
352,NaN,NaN,UIK23839,NaN,SARS-CoV-2,Homo sapiens (human),qvqlmesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglqwvavisydgnnkyyadsvkgrftisrdnskntlylqintlraedtavyycargyggnyhyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
353,NaN,NaN,UIK23838,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpseilsltctvsggsisshywswirqppgkglewigyisysgstnynpslksrvtisvdtsknqfslkltsvtaadtavyycargfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
354,NaN,NaN,UIK23837,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaelkkpgeslrisckgsgysftsywiiwvrqmpgkglewmgridpsdsytkyspsfqghvtissdksistaylqwnslktsdtavyycarqfatlenvigpaaldwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
355,NaN,NaN,UIK23836,NaN,SARS-CoV-2,Homo sapiens (human),qmhlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqhlewigwivvgsgntnygqkfqervtitrdlststvymelislrsedtavyfcaapyctggscfdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
356,NaN,NaN,UIK23835,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewmavisydgsnkyyadsmkarfsisrdnskntlylhmnslrpedtavyycaraaggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
357,NaN,NaN,UIK23834,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvscraseyaftdyyihwvrqapgqtlewmgiinpsggsaryaqkfqgrvtmtrdtststvymevsslrfedtavyycardpsggssvttqnyfdswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
358,NaN,NaN,UIK23833,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymnwvrqapgkglewvsvlysggstfyadsvkgrftisrdnskntlhlqmnslrvedtavyycardlvaygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
359,NaN,NaN,UIK23832,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnlgfswvrqapgqglewmggiipivalanyaekfqgrvtitadkststvymelsslrsedtavyycatkgdghnyfyyygvdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
360,NaN,NaN,UIK23831,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivssnymnwvrqapgmglewvsviypggttyyadsvkgrftisrdnskntlflqmnslriddtalyycardlvyrgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
361,NaN,NaN,UIK23830,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgiivssnymtwvrqapgkglewvsvifpggstfsadsvkgrftisrdnsnntlylqmnslraedtavyycargegwdlpfdywgqgilvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
362,NaN,NaN,UIK23829,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscktsgytftsydinwvrqatgqglewmgwmnpnsgnrgyaqmfqgrvtmtsnpsigtaymeltslrsedtavyycargtkfgsnwfwfdhwgqgtlltvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
363,NaN,NaN,UIK23828,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasefivsrnymswvrqapgkglewvsiiypggstfyaesvkgrftisrdnskntlflqmnnlraedtaiyycardygdyyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
364,NaN,NaN,UIK23827,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltcsvsgdsitnimsywgwirqspgkalewigsaynsgnsyynpslksrvtisvdtsknqfslklrsvtaadtsvyfcarhryyydgspgyffdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
365,NaN,NaN,UIK23826,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyafswvrqapgqglewmggiipilhipnyaqkfqarltitadrststaymelsslksedtavyycagtaaehdylwgtyreiygldvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
366,NaN,NaN,UIK23825,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifisygiswlrqapgqglewmgwispynsntnyaqkfqgrvtmttdtststaymelrslrsddtavyycardgewggwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
367,NaN,NaN,UIK23824,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscvasgltvssnymtwvrqapgkglewvsvlyvggstfyadsvkgrftisrdkskntlylqmnnlraedtavyycardryvlgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
368,NaN,NaN,UIK23823,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgsyainwvrqapgqglewmgrifpmldkatyaqnfqgrvtftadkstntasmelsslssedtafyycargivgptpfyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
369,NaN,NaN,UIK23822,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssfvinwvrqapgqglewmggiipisatanyaqkfqgrvtitadestrtaymelsslrsedtavyycargsrkpfstdiyghvdyyyygmdvwgqgtavtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
370,NaN,NaN,UIK23821,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesaggvvqpgrslrlscaasgftfsdygmkwvrqapgkglewvaviwhdgsnkyyedsvkgrftisrdnsqntlylhmnslrvedtaiyfcargsgssdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
371,NaN,NaN,UIK23820,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsssamywvrqapgkglewvavisndgsnkyyadtvkgrftisrdiskntlyllmnslrvedtgiyycardslpgyngydapdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
372,NaN,NaN,UIK23819,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadkststasmelsslelsslrsedtavyycarthsydssgyyvdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
373,NaN,NaN,UIK23818,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvdsgggvvqpgrslrlscaasgfifssfamhwvrqtpgkglewvavisydginkyyadsvkgrftvsrdnskntlslqmnslrgedtavyycargqgayktafdswgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
374,NaN,NaN,UIK23817,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssyggyvgyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
375,NaN,NaN,UIK23816,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgasissggyywswirqhpgkglewigyiyytgstyyspslkgrvtisvdtsknqfslklssltaadtavyycargsgpevvvirpyyldnwgpgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
376,NaN,NaN,UIK23815,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifskysmdwvrqapgkglewvsyidsggssryyadsvkgrftisrdnaknslylqmnslraedtavyycvrdardghsnndfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
377,NaN,NaN,UIK23814,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnnyamhwvrqapgkglewvavisydgsnkhyvdsvrgrftisrdnskntlylqmislitedtavyycardwsakmatignfdywgqgslvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
378,NaN,NaN,UIK23813,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfdssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdvstntaymelrslgsedtavyfcaaphcnrttcydafdlwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
379,NaN,NaN,UIK23812,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsistgayywswirqhpgkgleligyiyysettyynpslksrvtmsvdtsenqfslklnsvtaadtavyycarvvhcsgggcsrhnyfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
380,NaN,NaN,UIK23811,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfaihwvrqapgkglewvtvisfdgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglsgnyyyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
381,NaN,NaN,UIK23810,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssfaihwvrqapgkglewvavisydgsnkyyadsvkgrfsisrdnskntlylqmnslrsedtaiyycarplggnyggafdiwgqgalvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
382,NaN,NaN,UIK23809,NaN,SARS-CoV-2,Homo sapiens (human),qvqleesgpglvkpsetlsltcsvsadsisnyywswirqppgkglewigyiyysgstsynpslksrvtmsvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
383,NaN,NaN,UIK23808,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsiastyyywgwirqspgkglewianihyngstynkpslknrvtlsvdtsknqfslklssvtaadtavyycarygpyyydrsgsllsdpfdnwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
384,NaN,NaN,UIK23807,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsetlslsctvsggsissyfwswlrqppgkglewigyisyigstnhnpslksrvtmsvdtskkqfslrlssvtdadtavyycarrfphhydstglssdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
385,NaN,NaN,UIK23806,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvnsgsyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycarvrfcsgsscrshnwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
386,NaN,NaN,UIK23805,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvhpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgnnkysadsvkgrftisrdnskntlylqmnslrpedsavyycarglggnyyaadywgqgslvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
387,NaN,NaN,UIK23804,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydgynkyyadsvkgrftisrdnskntlylqmnslrvedtamyycaralggnyyygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
388,NaN,NaN,UIK23803,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvtvsckasgytftsyyihwvrqapgqglewmgiinpgagstsnaqkfqgrvtmtsdtststvymelsslrsedtavyycasgmdtlipaaqrafdiwgqgtvvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
389,NaN,NaN,UIK23802,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsissgsvfwtwirqhpgkglewighiyyrgttnynpslksrisisvdtsknqfslnltsvtaadtaiyycarkaggcggdcyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
390,NaN,NaN,UIK23801,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqperslrlscaasgftfsrdgmhwvrrapgkglewvavisydgsnkvyaesvkgrftvsrdsskntvylqmnslraedtavyycakdgpqafgtyfdywgqgtlvivss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
391,NaN,NaN,UIK23800,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaeviqpgaslkvsckasgytftayylfwvrqapgrglewmgwinpnnggtnyaqnfqgrvtmtrdtsmstaymelsrlssddtavyfcarwmvavagmgdrgynyhyymdvwgkgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
392,NaN,NaN,UIK23799,NaN,SARS-CoV-2,Homo sapiens (human),evqveesggglvkpggslrlscaasgfnfssygmnwvrqapgkglewvssisrssdfiyyadsvkgrftisrdnaknavflqmnrlrvedtavyycarnlkirssgdlfrgyyyhgmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
393,NaN,NaN,UIK23798,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvdsgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpgsgnylgyfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
394,NaN,NaN,UIK23797,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvlsgaevkkpgasvkvsckasgyiftgyyihwvrqapgqglewmgwinpmsgatnfarkfqgrvtltrdtsittaymelsrlrsddtavyycarvppfyengahfdnwgqgslvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
395,NaN,NaN,UIK23796,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargfwvpaaipgvwfdpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
396,NaN,NaN,UIK23795,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymrwvrqapgkglewvsliyaggstfyadsvkgrfiisrhnsknilylqmnslraedtavyfcardlyvfgmdvwgqgtavtvsa,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
397,NaN,NaN,UIK23794,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgsslrlscaasgfsfisygmhwlrqapgeglewvaiiwfdgrnkyyadsvkgrftisrdnsksmlylqmnslraedtavyycardlpaqkrgdafdiwglgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
398,NaN,NaN,UIK23793,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyythwvrqapgqglewmgwinpnsggtiyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycarwvpprgygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
399,NaN,NaN,UIK23792,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmnwvrqapgkglewvaviwydgnnkyyadsvkgrftisrdnskttlylqmkslraedtavyycaralqyydiltgdysvvrsdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
400,NaN,NaN,UIK23791,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycardrafgvvtvdfdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
401,NaN,NaN,UIK23790,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggtlvkpggslrlscaasgftfsdyamswvrqapgrglewvsalsdsggstffadsvkgrftisrdnskntlylqmsslraedtakyycargevqpfllafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
402,NaN,NaN,UIK23789,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvsrnymswvrqapgkglewvsviyaggstfyadsvkgrftisrhnskntlylqmnslrvedtavyycvrdlvdygmdvwgqgttvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
403,NaN,NaN,UIK23788,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmsvnwirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdsvdtatyycarsvpttaldywgqgtlvivss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
404,NaN,NaN,UIK23787,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftdyymhwvrqapgqglewmgwinpksggtdfaqiflgrvtmtrdtsistaymelrglrsddtavyycargsyprdvvvvpaaapfnwldpwgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
405,NaN,NaN,UIK23786,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavlshdgsesyyadsvkgrftisrdnsknslyvqmnslraedtavyycasacnsfncqlgdafdiwgqgtmvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
406,NaN,NaN,UIK23785,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggrvvqpggslrlscaasgftfhdyamhwvrqapgkglewvslingdgrgryyadsvkgrftisrdnsknslylqmnslrtedtalyycakdmesnwnesdfvdywgqgtlvtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
407,NaN,NaN,UIK23784,NaN,SARS-CoV-2,Homo sapiens (human),qahlvqsgpevkkpgasvkvsckasgyafttfaiswvrqapghglewmgrinpyngktyyaqkvqgrvtmttetststaymevrslrsddtavyycarqypmprgphynymdvwgkgtavtvss,NaN,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
408,NaN,NaN,NaN,UIK24035,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapqlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystwtfgqgtkveir,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
409,NaN,NaN,NaN,UIK24034,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsniylawyqqkpgqaprlliygassraigipdrfsgsgsgtdftltisrlepedsavfycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
410,NaN,NaN,NaN,UIK24033,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpytfgpgtkvgik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
411,NaN,NaN,NaN,UIK24032,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystrtitfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
412,NaN,NaN,NaN,UIK24031,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprllvyaassraigipdrfigsgsgtdftltinrlepedfavyfchqygsspwtfgqgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
413,NaN,NaN,NaN,UIK24030,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntypwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
414,NaN,NaN,NaN,UIK24029,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrvsqsvssnylawfqqkpgqaprllifatssraigipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
415,NaN,NaN,NaN,UIK24028,SARS-CoV-2,Homo sapiens (human),NaN,dfqmtqspsslsasvgdrvtitcrasqtittylnwylqkpgkapdlliyaastlqsgvpsrfsgsgsgtdftltidslqpedfatyycqqsyttpytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
416,NaN,NaN,NaN,UIK24027,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqninrylnwyqqkpgqapklliyaasgvqsgvpsrfsgsvsgtdftltisslqpedfatyhrqqsyitpftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
417,NaN,NaN,NaN,UIK24026,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
418,NaN,NaN,NaN,UIK24025,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasrsvpsdylawyqqkpgqaprlliydtssratgipdrfsggasgtaftltisrlepedfavyychqygtslrtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
419,NaN,NaN,NaN,UIK24024,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqnianwlawyqqkpgkapklliytasnlesgvpsrfsasgsgteftltisslqpddfatyycqqynsysrlvtfgggtkvesk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
420,NaN,NaN,NaN,UIK24023,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtftcrasqgissylawyqlkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlssypftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
421,NaN,NaN,NaN,UIK24022,SARS-CoV-2,Homo sapiens (human),NaN,diqltqsppflsasvgdrvtitcrasqgisrylawyqqkpgkapklliyaastlqsgvpprfsgtgsgteftltisslqpedfatyycqqlntyplafgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
422,NaN,NaN,NaN,UIK24021,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsastgdrvtitcrasqdissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqsedfatyhcqqyysyprtfgqrtkvevk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
423,NaN,NaN,NaN,UIK24020,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgignylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedlatyycqqvnsyppectfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
424,NaN,NaN,NaN,UIK24019,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkfgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwppytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
425,NaN,NaN,NaN,UIK24018,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdfftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
426,NaN,NaN,NaN,UIK24017,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdritltcrasqgisnylawyqqkpgkapklliyaastlqggvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
427,NaN,NaN,NaN,UIK24016,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspaflsasvgdrvritcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqltnyppdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
428,NaN,NaN,NaN,UIK24015,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsispwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisglqpddfatyycqqyngysntfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
429,NaN,NaN,NaN,UIK24014,SARS-CoV-2,Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsyppvfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
430,NaN,NaN,NaN,UIK24013,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydastlesgvpsrfsgsgsgteftltisslqpddfatyycqqyhsyspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
431,NaN,NaN,NaN,UIK24012,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvggrvtitcrasqgissslawyqqkpgkapklliygastlrtgvpsrfsgsgsgteftltisslqpedfatyycqqlnsdlytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
432,NaN,NaN,NaN,UIK24011,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapnlliydasnlesgvpsrfsgsgsgteftltisglqpddfatyycqqyhsyspltfgggtkvefk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
433,NaN,NaN,NaN,UIK24010,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvrnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftitisrlepedfavyycqqygrahgafgpgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
434,NaN,NaN,NaN,UIK24009,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqqpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysspftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
435,NaN,NaN,NaN,UIK24008,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqnrrnwpplltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
436,NaN,NaN,NaN,UIK24007,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnslnwyqqrpgrapkllihaasslqsgvpsrfsgsgsgtdftltiaglqpedfatyycqqsfttpftsgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
437,NaN,NaN,NaN,UIK24006,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsigsylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgteftltmsslqpedfatyycqqsysshtfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
438,NaN,NaN,NaN,UIK24005,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvssiylawfqqkpgqaprlliyaassraigipdrfsgsgsgtdftltisrlepedfavyyclqsgnspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
439,NaN,NaN,NaN,UIK24004,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgrapklliyaasslesgvpsrfsgsgsgtdftlsvsslqpedfatyycqqsyntpqtfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
440,NaN,NaN,NaN,UIK24003,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllingassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssqgtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
441,NaN,NaN,NaN,UIK24002,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssyltwyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrtdwppevtfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
442,NaN,NaN,NaN,UIK24001,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqrpgqaprlliagtstratgipdrfsgsgsgtdftltisrlepedfavyycqqygasytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
443,NaN,NaN,NaN,UIK24000,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqsliswlawyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfpvtfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
444,NaN,NaN,NaN,UIK23999,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynnypytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
445,NaN,NaN,NaN,UIK23998,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplslsvtpgqpvsisctssqsllhgggktslnwyhqkpgqppqlliygvsnrfsgvpdrfsgsgsgtdftlkisrvqaddvgvyycmqsislpwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
446,NaN,NaN,NaN,UIK23997,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsslylawsqqkpgqaprllvfgassraigipdrfsgsgsgtdftliisrlepedfavyychqygsspwtfgqgtkvevk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
447,NaN,NaN,NaN,UIK23996,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspdtlslspgeratlscrasqsigsrylawyqqkpgqaprllitaassratgipdrisgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleir,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
448,NaN,NaN,NaN,UIK23995,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrlpvafgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
449,NaN,NaN,NaN,UIK23994,SARS-CoV-2,Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlngyplfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
450,NaN,NaN,NaN,UIK23993,SARS-CoV-2,Homo sapiens (human),NaN,ekvmtqspatlsmspgeratlscrasqsisnnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedsavyycqqynnwpftfgqgtklemk,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
451,NaN,NaN,NaN,UIK23992,SARS-CoV-2,Homo sapiens (human),NaN,dfvmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
452,NaN,NaN,NaN,UIK23991,SARS-CoV-2,Homo sapiens (human),NaN,diqmsqspsslsasvgdrvtitcrasqdiayslnwyqqipgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
453,NaN,NaN,NaN,UIK23990,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinsylnwfqqkpgkapnlliyaasslqsgvpsrfsgggsgtdftltisrlqpedfatyycqqsystpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
454,NaN,NaN,NaN,UIK23989,SARS-CoV-2,Homo sapiens (human),NaN,dtvmtqsplslpvtpgepapiscrssqsllhsngynyldwylqksgqtpqlliylgshrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmealqtplftfgpgtkvhik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
455,NaN,NaN,NaN,UIK23988,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylvwyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsygytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
456,NaN,NaN,NaN,UIK23987,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrtsqsvntklvwyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqhndwprsfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
457,NaN,NaN,NaN,UIK23986,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqtyntphtfgqgtkldik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
458,NaN,NaN,NaN,UIK23985,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprllisgassratgipdrfsgsgsgtdftltisrlepedfavyhcqqygtspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
459,NaN,NaN,NaN,UIK23984,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscranqsvssylawyrqkpgqaprllihdasnratgiparisgsgsgtdftltisslepedfavyycqqrsnwpgftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
460,NaN,NaN,NaN,UIK23983,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
461,NaN,NaN,NaN,UIK23982,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvnsiylawhqqkpgqaprlliygassraigipdrfsdsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
462,NaN,NaN,NaN,UIK23981,SARS-CoV-2,Homo sapiens (human),NaN,etvltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlviygpstratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
463,NaN,NaN,NaN,UIK23980,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqdgvpsrfsgsgsgteftltisslqpedfatyycqqlnnypftfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
464,NaN,NaN,NaN,UIK23979,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisshlawyqqkpgkapkllifaastlqsgvpsrfsgsgsgtefsltisslqpadfatyfcqhlemfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
465,NaN,NaN,NaN,UIK23978,SARS-CoV-2,Homo sapiens (human),NaN,divltqtplsspvtlgqpasiscrssqglvhsdgntylswlhqrpgqpprvliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqvtqfpfnfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
466,NaN,NaN,NaN,UIK23977,SARS-CoV-2,Homo sapiens (human),NaN,kiqmtqspsslsasvgdrviitcqasqdinkylhwyqqkpgeapklviydasnletgvpsrfsgsgsgtdftftisslqpedlaryycqqydnlpptfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
467,NaN,NaN,NaN,UIK23976,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
468,NaN,NaN,NaN,UIK23975,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlqisrveaedvgvyycmqttqfpdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
469,NaN,NaN,NaN,UIK23974,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtltcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqelnsypffgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
470,NaN,NaN,NaN,UIK23973,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
471,NaN,NaN,NaN,UIK23972,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqvisnslnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpptfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
472,NaN,NaN,NaN,UIK23971,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistwlawyqqkpgkvpkllihkasnlhsgvpsrfsgsgsgteftltinslqpedfatyycqqynsystwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
473,NaN,NaN,NaN,UIK23970,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
474,NaN,NaN,NaN,UIK23969,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
475,NaN,NaN,NaN,UIK23968,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrashsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltitslqsediavyycqqynnwppltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
476,NaN,NaN,NaN,UIK23967,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
477,NaN,NaN,NaN,UIK23966,SARS-CoV-2,Homo sapiens (human),NaN,yiqmtqspsslsasvgdrvtitcrasqnidtylnwyqqtpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyscqqsysspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
478,NaN,NaN,NaN,UIK23965,SARS-CoV-2,Homo sapiens (human),NaN,nivltqspaalsfspgeratlscrasqsvsiflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpitfgqgtrleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
479,NaN,NaN,NaN,UIK23964,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasglqsgvpsrfsgsgsgtdftltissllpedfatyycqqsyrtpfnfgpgtkvdik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
480,NaN,NaN,NaN,UIK23963,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvrssylawyqqkpgqaprlliygpssratgipdrfsgsgsgtdftltinrlepedfavyycqqydrspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
481,NaN,NaN,NaN,UIK23962,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsasssylawyqhkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyychqfgssfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
482,NaN,NaN,NaN,UIK23961,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssrylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltigrlepedfavyychqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
483,NaN,NaN,NaN,UIK23960,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvgsnylawyqqkpgqsprlliyatssraigfpdrfigsgsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
484,NaN,NaN,NaN,UIK23959,SARS-CoV-2,Homo sapiens (human),NaN,evvltqspgtlslspgeratlscrasqglsssslawyqqrpgqaprlliygasnratgisdrfsgsgsgtdftlsvsrlepedfavyycqqysnspltfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
485,NaN,NaN,NaN,UIK23958,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtftcrasqaissklvwyqqkpgkapkvlisdasslqsgapsrfsgsgsgtdftltisslqpedfatyycqqakslpltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
486,NaN,NaN,NaN,UIK23957,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrstqsfagsylawyqqkagqaprllihgassrapgipdrfsgsgsgtdftltisrlepedfavyycqqyggsqwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
487,NaN,NaN,NaN,UIK23956,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqlygssprytfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
488,NaN,NaN,NaN,UIK23955,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratisckssqtvffisnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgpgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
489,NaN,NaN,NaN,UIK23954,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllmygassratgipdrfsgsgsgtdftltigrlepedfavyycqqygssvvtfgggttveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
490,NaN,NaN,NaN,UIK23953,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqpprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynnwppwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
491,NaN,NaN,NaN,UIK23952,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlcvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
492,NaN,NaN,NaN,UIK23951,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgrapklliyaastlqsgvpsrfsgsgsgtvftltisslqpedfatyycqqlnsdsstfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
493,NaN,NaN,NaN,UIK23950,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsvsvgdrvtitcrasqsisnylnwyqqkpgkapnllifaasslqrgvpsrfsgsgsgtdftltisslqpedfaayycqqsystpltfgqgtkvevn,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
494,NaN,NaN,NaN,UIK23949,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstflawyqqkagqaprlliygastrapgipdrfsgsgsgtdftltisrlepedfavyycqqfgssltfgggskveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
495,NaN,NaN,NaN,UIK23948,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsgtylawyqqkpgqaprlliygassrasgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
496,NaN,NaN,NaN,UIK23947,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqginsylawyqqkpgkapklliygastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysrdtfgqgtkleik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
497,NaN,NaN,NaN,UIK23946,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgtapklliysasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysiprtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
498,NaN,NaN,NaN,UIK23945,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplslpvtpgepasfscrssqslldsddgntyldwylqkpgqspqlliysvsyrasgvpdrvsgsgsgtdftlkisrveaedvgvyycmqrtefpwtfgqgtkveik,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
499,NaN,NaN,NaN,UIK23944,SARS-CoV-2,Homo sapiens (human),NaN,qtvviqepsfsvspggtvtltcglssgsvssnyyptwykqtpgqapstliyttntrssgvpdrfsgsilgnkaaltitgaqaddeceyhcalymgsgiwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
500,NaN,NaN,NaN,UIK23943,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsespgqsitisctgtssdvgnynlvswyqhhpgkapklmiyevtkrpsgvsirfsgsksgntasltvsglqtedeadyyccsyagnstlvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
501,NaN,NaN,NaN,UIK23942,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtisctgtssdigsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytsnntfvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
502,NaN,NaN,NaN,UIK23941,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvihedfkrpsgiperfsgsssgtmatltirraqaedeadyycystdnsgnrvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
503,NaN,NaN,NaN,UIK23940,SARS-CoV-2,Homo sapiens (human),NaN,pyeltqppsvsvspgqtaritcsgdalprqfaywyqqkpgqapvlliykdterpsriperfsgsssgttftltisgvqaedeadyycqsaenggtypvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
504,NaN,NaN,NaN,UIK23939,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgttsdvggynyvswyqqhpgkapkvmiyevsnrpsgisnrfsgsksgntasltisglqaedeadyycssytssstlgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
505,NaN,NaN,NaN,UIK23938,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasatpgqrvtiscsgsssnigsnpvnwyqqlpgtapklliynndqrpsrvpdrfsgsksgtsaslaisglqsedeadyycaawddslnglwvfgggtkmtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
506,NaN,NaN,NaN,UIK23937,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgrnsdigsntvnwyqqfpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddrlhgwvfgggtklavl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
507,NaN,NaN,NaN,UIK23936,SARS-CoV-2,Homo sapiens (human),NaN,sfvltqppsvsvapgqtaritcggnniggktvhwyqqkpgqapvlvvhddsdrpsgiperfsgsnsgntatltisrvelgdeadyycqvwdssgghfyvfgagtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
508,NaN,NaN,NaN,UIK23935,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsmsaapgqkvtiscsgsssnignnyvswyqqvpgtapklliynsnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycaawdsslsayvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
509,NaN,NaN,NaN,UIK23934,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnfvywyqqfpgtapkvliyrnslrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsarwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
510,NaN,NaN,NaN,UIK23933,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagnnnfvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
511,NaN,NaN,NaN,UIK23932,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnsvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
512,NaN,NaN,NaN,UIK23931,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgnssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
513,NaN,NaN,NaN,UIK23930,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqaasvsgtpgqsitisctgtisnigsynyvswyqqhpgkapklliyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
514,NaN,NaN,NaN,UIK23929,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggykyvswyqqhpgkapklmiyevsnwpsgvsnrfsgsksgntasltisglqaedeadyycssytssitlyvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
515,NaN,NaN,NaN,UIK23928,SARS-CoV-2,Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrnyyanwyqqkpgqapvfvingknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhpwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
516,NaN,NaN,NaN,UIK23927,SARS-CoV-2,Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapilviygqskrpsgipdrfsgstsgntasltitgaqaedeadyycssrdssgnhlvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
517,NaN,NaN,NaN,UIK23926,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgapgqrvtisctgsssnigagydvhwyqqlpgtppklliygndnrpsgvpdrfsgsksgtsaslaitglqvedeadyycqsydsslsgslfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
518,NaN,NaN,NaN,UIK23925,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigigyavhwyqqlpgtapkllifgtsrrpsgvpdrfsgsrsgtsaslaitglqaedeavyycqsydnsqtdsvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
519,NaN,NaN,NaN,UIK23924,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgppgqsvtisctgtssdvggyhyvswyqqhpgkapklmiygvtrrpsgvpdrfsgsksgntasltvsglqaddeadyycssyagsntvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
520,NaN,NaN,NaN,UIK23923,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsskdmifgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
521,NaN,NaN,NaN,UIK23922,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnpvswyqqlpgtapkllmydndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddtlnghfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
522,NaN,NaN,NaN,UIK23921,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
523,NaN,NaN,NaN,UIK23920,SARS-CoV-2,Homo sapiens (human),NaN,qsvlmqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydnslsdvlfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
524,NaN,NaN,NaN,UIK23919,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
525,NaN,NaN,NaN,UIK23918,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgiapklliygnnirpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
526,NaN,NaN,NaN,UIK23917,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigsgyvvhwyqhlpntapkllifgnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
527,NaN,NaN,NaN,UIK23916,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvgkrpsgvpdrfsgsksdntasltisglqaedeadyyccsyagspwvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
528,NaN,NaN,NaN,UIK23915,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsittsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstsnyvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
529,NaN,NaN,NaN,UIK23914,SARS-CoV-2,Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhhvvfgggtkltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
530,NaN,NaN,NaN,UIK23913,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtstdvggydyvswyqqhpgkapkvmiygvsnrpsgvssrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
531,NaN,NaN,NaN,UIK23912,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagyvvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqsydsrlfvfgtgtkvtvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
532,NaN,NaN,NaN,UIK23911,SARS-CoV-2,Homo sapiens (human),NaN,sfeltqppsvsvspgqtarircsgnalprryaywyqqkpgqapvlviykdserpsgiperfssstsgttvtltisgvqaedeadyycqssdsngsymfgggtkltal,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
533,NaN,NaN,NaN,UIK23910,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvtnrppgvsnrfsgsksgntasltisglqaedeadyycssytststrvfgggtyltvl,"Vanshylla,K. et al.; Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers; Cell Host Microbe (2021) In press; 2022.",10.1016/j.chom.2021.12.010,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
534,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,"Chain E, pYLQ7 T cell receptor beta chain",NaN,NaN
535,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,NaN,"Chain D, pYLQ7 T cell receptor alpha chain",NaN
536,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,"Chain E, pRLQ3 T cell receptor beta chain",NaN,NaN
537,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,NaN,"Chain D, pRLQ3 T cell receptor alpha chain",NaN
538,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,"Chain B, pYLQ7 T cell receptor beta chain",NaN,NaN
539,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,NaN,"Chain A, pYLQ7 T cell receptor alpha chain",NaN
540,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,"Chain E, pRLQ3 T cell receptor beta chain",NaN,NaN
541,NaN,NaN,NaN,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,NaN,"Wu,D. et al.; Structural basis for recognition of two HLA-A2-restricted SARS-CoV-2 spike epitopes by public and private T cell receptors; Biorxiv (2021); 2021.",NaN,NaN,NaN,2022-03-15,NaN,"Chain D, pRLQ3 T cell receptor alpha chain",NaN
542,AB8,NaN,7MJI_E,NaN,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain E, VH ab8",NaN,2022-03-15,NaN,NaN,NaN
543,AB8,NaN,7MJH_F,NaN,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain F, VH ab8",NaN,2022-03-15,NaN,NaN,NaN
544,AB8,NaN,7MJH_E,NaN,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain E, VH ab8",NaN,2022-03-15,NaN,NaN,NaN
545,AB8,NaN,7MJH_D,NaN,"SARS-CoV-2, Spike protein",synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvsssgqaghhhhhhgdykddddkg,NaN,"Zhu,X. et al.; Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies; PLoS Biol 19 (4), e3001237 (2021); 2021.",10.1371/journal.pbio.3001237,"Chain D, VH ab8",NaN,2022-03-15,NaN,NaN,NaN
546,NaN,NaN,7LX5_A,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlqesggglvqpggslrlscaasgftfrrylmgwarqvpgkglewvsgiysdgstyyadsvkgrftisrdnakntvylqmnslkpedtavyycakdrmdgstwperdfgswgqgtqvtvss,NaN,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.",10.1073/pnas.2101918118,"Chain A, WNb 10",NaN,2022-03-15,NaN,NaN,NaN
547,NaN,NaN,7LX5_C,NaN,SARS-CoV-2,Vicugna pacos (alpaca),qvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssggntkyadsvkgrftasrdnakntfylqmnslkpedtavyycaaiaatyysgsyyfqcphdgmdywgkgtqvtvss,NaN,"Pymm,P. et al.; Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice; Proc Natl Acad Sci U S A 118 (19) (2021); 2021.",10.1073/pnas.2101918118,"Chain C, WNb 2",NaN,2022-03-15,NaN,NaN,NaN
548,NaN,NaN,7JWB_D,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvssggggtggggsggggsggggsevqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvssggggsggggsggggsggggsevqlvesggglvqpggslrlscaasgfriysyysyigwvrrapgkgeelvariypssgytyyadsvkgrftisadtskntaylqmnslraedtavyycarwdfaspyypgssgldywgqgtlvtvss,NaN,"Bracken,C.J. et al.; Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike; bioRxiv (2020); 2020.",10.1101/2020.08.08.242511,"Chain D, autonomous human heavy chain variable domain",NaN,2022-03-15,NaN,NaN,NaN
549,NaN,NaN,QYU59153,NaN,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),vqlqqsgpevvrpgvsvkisckgsgytftdyaihwvkqshakslewigvisshngnrgynqkfkgmatvtvdrssstaymelarltsedsaiyycaifdydfdywgqgttvmvss,NaN,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARS-CoV-2 RBD-based antigen; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
550,NaN,NaN,QXI90084,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgyslievsvhwvrqapgkglewmggfdpenaetiyaqkfqgrvtmtedtstdtaymelsslkyedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
551,NaN,NaN,QXI90082,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvhlvqsgaevkkpgasvkvsckvsgytlvevsvhwvrqapgkgfewmggfdpenaatiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagplyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
552,NaN,NaN,QXI90080,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslryedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
553,NaN,NaN,QXI90078,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaktiyaqkfqgrvtmtedtstdtaymelsslssedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
554,NaN,NaN,QXI90076,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapekglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfyyyyygmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
555,NaN,NaN,QXI90074,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mdctwrilllvaaatgthaqvqlvqsgaevkkpgasvkvsckvsgytltevsvhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyfcatapavagpfynfyygidvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
556,NaN,NaN,QXI90072,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
557,NaN,NaN,QXI90070,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycvretvdgmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
558,NaN,NaN,QXI90068,NaN,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),mefglswvflvallrgvqcqvqvvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgkglewvaviwydgsnqyyadsvkgrftisrdnskntlylqmnslrvedtavyhcvretvdgmdvwgqgttvtvss,NaN,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,"anti-SARS-CoV-2 spike immunoglobulin heavy chain, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
559,NaN,NaN,NaN,QXI90085,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
560,NaN,NaN,NaN,QXI90083,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
561,NaN,NaN,NaN,QXI90081,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mdmrllaqllgllmlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagteftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
562,NaN,NaN,NaN,QXI90079,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mvsplqligflllwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
563,NaN,NaN,NaN,QXI90077,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mdmrlrdqlmglimlwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprliiykvsnrfcgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
564,NaN,NaN,NaN,QXI90075,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mvsplqligflllwvpgssgdivmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykvsnrfsgvpdrfsgsgagtdftlkisrveaedvgvyyctqatqfphtfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
565,NaN,NaN,NaN,QXI90073,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
566,NaN,NaN,NaN,QXI90071,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
567,NaN,NaN,NaN,QXI90069,"SARS-CoV-2, Spike protein",Mus musculus (house mouse),NaN,mdmrvpaqllgllllwfpgarcniqmtqspsamsasvgdsvtitcrarqdinnylawfqqkpgkvpkhliyaassllsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Peter,A.S. et al.; A pair of non-competing neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model; Eur J Immunol (2021) In press; 2021.",10.1002/eji.202149374,NaN,"anti-SARS-CoV-2 spike immunoglobulin light chain, partial [Mus musculus]",2022-03-15,NaN,NaN,NaN
568,NaN,NaN,QYT87288,NaN,SARS-CoV-2,Unknown.,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 440 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 440 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
569,NaN,NaN,QYT87225,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywiswvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgiiqpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 377 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 377 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
570,NaN,NaN,QYT87224,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgstasyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 376 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 376 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
571,NaN,NaN,QYT87223,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 375 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 375 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
572,NaN,NaN,QYT87222,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipvlhtvdyaqrlqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 374 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 374 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
573,NaN,NaN,QYT87221,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 373 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 373 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
574,NaN,NaN,QYT87220,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgynftdyhiqwvrqapgqglewvgmiiprhggtayaqrfqgrvtitadeststaymelsslrsedtavyycaggsglttpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 372 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 372 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
575,NaN,NaN,QYT87219,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtlssyaiswvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistprsvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 371 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 371 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
576,NaN,NaN,QYT87218,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggegistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 370 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 370 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
577,NaN,NaN,QYT87217,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpysgntgyaqkfqgrvtitadeststaymelsslrsedtavyycavlsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 369 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 369 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
578,NaN,NaN,QYT87216,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfstywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 368 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 368 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
579,NaN,NaN,QYT87215,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdstarysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistlydvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 367 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 367 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
580,NaN,NaN,QYT87214,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgqinpsgdstryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 366 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 366 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
581,NaN,NaN,QYT87213,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfisyaiswvrqapgqglewmggiiptlgtynyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 365 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 365 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
582,NaN,NaN,QYT87212,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 364 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 364 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
583,NaN,NaN,QYT87211,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgilepmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 363 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 363 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
584,NaN,NaN,QYT87210,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 362 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 362 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
585,NaN,NaN,QYT87209,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 361 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 361 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
586,NaN,NaN,QYT87208,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 360 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 360 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
587,NaN,NaN,QYT87207,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 359 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 359 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
588,NaN,NaN,QYT87206,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 358 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 358 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
589,NaN,NaN,QYT87205,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsglltpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 357 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 357 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
590,NaN,NaN,QYT87204,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnnglswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycrmgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 356 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 356 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
591,NaN,NaN,QYT87203,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgwinpnsggtkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpidvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 355 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 355 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
592,NaN,NaN,QYT87202,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 354 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 354 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
593,NaN,NaN,QYT87201,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfisywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycagsdgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 353 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 353 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
594,NaN,NaN,QYT87200,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgypftnygiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycatlsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 352 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 352 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
595,NaN,NaN,QYT87199,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetnysqkfqgrvtitadeststaymelsslrsedtavyycaggsglftpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 351 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 351 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
596,NaN,NaN,QYT87198,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttnysqkfqgrvtitadeststaymelsslrsedtavyycaghwgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 350 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 350 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
597,NaN,NaN,QYT87197,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgiyvpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 349 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 349 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
598,NaN,NaN,QYT87196,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 348 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 348 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
599,NaN,NaN,QYT87195,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfsdyyihwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 347 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 347 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
600,NaN,NaN,QYT87194,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysftdyhihwvrqapgqglewmamivprggsttyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 346 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 346 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
601,NaN,NaN,QYT87193,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgyrftdyhlhwvrqapgqglewmggivpfsgttnfaqkfqgrvtitadeststaymelsslrsedtavyycaggsgettpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 345 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 345 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
602,NaN,NaN,QYT87192,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiiptlgtanyaqkfqgrvtitadeststaymelsslrsedtavyycagswgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 344 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 344 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
603,NaN,NaN,QYT87191,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfstywigwvrqapgqglewvgwinpnsgatkyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 343 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 343 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
604,NaN,NaN,QYT87190,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 342 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 342 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
605,NaN,NaN,QYT87189,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgissdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 341 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 341 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
606,NaN,NaN,QYT87188,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgggfitywigwvrqapgqglewmgiiypgdsetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgvltpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 340 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 340 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
607,NaN,NaN,QYT87187,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdsetryaqkfqgrvtitadeststaymelsslrsedtavyycaggsglytpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 339 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 339 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
608,NaN,NaN,QYT87186,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfstyafnwvrqapgqglewmgvintgggsvtyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpgavwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 338 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 338 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
609,NaN,NaN,QYT87185,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyyclpgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 337 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 337 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
610,NaN,NaN,QYT87184,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgygfitywigwvrqapgqglewmgiiypgdgetrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 336 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 336 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
611,NaN,NaN,QYT87183,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwmrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 335 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 335 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
612,NaN,NaN,QYT87182,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgminpgggntnyaekfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 334 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 334 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
613,NaN,NaN,QYT87181,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 333 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 333 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
614,NaN,NaN,QYT87180,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftnyginwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtitadeststaymelsslrsedtavyycaavsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 332 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 332 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
615,NaN,NaN,QYT87179,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfstywigwvrqapgqglewmgwidpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 331 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 331 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
616,NaN,NaN,QYT87178,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgsvipvfgrpnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 330 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 330 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
617,NaN,NaN,QYT87177,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnssinwvrqapgqglewmgrinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 329 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 329 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
618,NaN,NaN,QYT87176,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfnshaiswvrqapgqglewmgwinpnsgatnyaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpvgvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 328 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 328 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
619,NaN,NaN,QYT87175,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywigwvrqapgqglewmgiiypgdgearysqkfqgrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 327 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 327 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
620,NaN,NaN,QYT87174,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfsdyhvhwvrqapgqglewvgmiiprhggtayaqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 326 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 326 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
621,NaN,NaN,QYT87173,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdyyihwvrqapgqglewmgwmnpnsgntgyaqnfqgrvtitadeststaymelsslrsedtavyycaggsgistawdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 325 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 325 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
622,NaN,NaN,QYT87172,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfitywiywvrqapgqglewmgiiypgdgearysqkfygrvtitadeststaymelsslrsedtavyycagsggistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 324 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 324 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
623,NaN,NaN,QYT87171,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststaymelsslrsedtavyycagewgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 323 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 323 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
624,NaN,NaN,QYT87170,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftghymhwvrqapgqglewmgiiypgdsearysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 322 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 322 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
625,NaN,NaN,QYT87169,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnhaiswvrqaygqglewmgiiypgdgttrysqkfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 321 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 321 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
626,NaN,NaN,QYT87168,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 320 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 320 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
627,NaN,NaN,QYT87167,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiidpsggstsyaqqfqgrvtitadeststaymelsslrsedtavyycaggsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 319 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 319 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
628,NaN,NaN,QYT87166,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgiiypgdsttrysqkfqgrvtitadeststaymelsslrsedtavyycysgsgistpmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 318 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 318 from patent US 11034762,NaN,2022-03-15,NaN,NaN,NaN
629,NaN,NaN,NaN,QYT87289,SARS-CoV-2,Unknown.,NaN,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 441 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 441 from patent US 11034762,2022-03-15,NaN,NaN,NaN
630,NaN,NaN,NaN,QYT87285,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 437 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 437 from patent US 11034762,2022-03-15,NaN,NaN,NaN
631,NaN,NaN,NaN,QYT87284,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywsslresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytapftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 436 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 436 from patent US 11034762,2022-03-15,NaN,NaN,NaN
632,NaN,NaN,NaN,QYT87283,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 435 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 435 from patent US 11034762,2022-03-15,NaN,NaN,NaN
633,NaN,NaN,NaN,QYT87282,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqylstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 434 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 434 from patent US 11034762,2022-03-15,NaN,NaN,NaN
634,NaN,NaN,NaN,QYT87281,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 433 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 433 from patent US 11034762,2022-03-15,NaN,NaN,NaN
635,NaN,NaN,NaN,QYT87280,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqhyyntpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 432 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 432 from patent US 11034762,2022-03-15,NaN,NaN,NaN
636,NaN,NaN,NaN,QYT87279,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssrilsyspdnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqsyitpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 431 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 431 from patent US 11034762,2022-03-15,NaN,NaN,NaN
637,NaN,NaN,NaN,QYT87278,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 430 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 430 from patent US 11034762,2022-03-15,NaN,NaN,NaN
638,NaN,NaN,NaN,QYT87277,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywatnresgvpdrfsgsgsgtdftltisslqaedvavyychqyyntpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 429 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 429 from patent US 11034762,2022-03-15,NaN,NaN,NaN
639,NaN,NaN,NaN,QYT87276,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyrsnnlhylawyqqkpgqppklliywastrssgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 428 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 428 from patent US 11034762,2022-03-15,NaN,NaN,NaN
640,NaN,NaN,NaN,QYT87275,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinctssqsvlhssnnlnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 427 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 427 from patent US 11034762,2022-03-15,NaN,NaN,NaN
641,NaN,NaN,NaN,QYT87274,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlhssnnlnyfawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 426 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 426 from patent US 11034762,2022-03-15,NaN,NaN,NaN
642,NaN,NaN,NaN,QYT87273,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 425 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 425 from patent US 11034762,2022-03-15,NaN,NaN,NaN
643,NaN,NaN,NaN,QYT87272,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckstqsvlyssinknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 424 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 424 from patent US 11034762,2022-03-15,NaN,NaN,NaN
644,NaN,NaN,NaN,QYT87271,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 423 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 423 from patent US 11034762,2022-03-15,NaN,NaN,NaN
645,NaN,NaN,NaN,QYT87270,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 422 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 422 from patent US 11034762,2022-03-15,NaN,NaN,NaN
646,NaN,NaN,NaN,QYT87269,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasfresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygtpftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 421 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 421 from patent US 11034762,2022-03-15,NaN,NaN,NaN
647,NaN,NaN,NaN,QYT87268,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 420 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 420 from patent US 11034762,2022-03-15,NaN,NaN,NaN
648,NaN,NaN,NaN,QYT87267,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 419 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 419 from patent US 11034762,2022-03-15,NaN,NaN,NaN
649,NaN,NaN,NaN,QYT87266,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 418 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 418 from patent US 11034762,2022-03-15,NaN,NaN,NaN
650,NaN,NaN,NaN,QYT87265,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 417 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 417 from patent US 11034762,2022-03-15,NaN,NaN,NaN
651,NaN,NaN,NaN,QYT87264,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqtisyssdnknylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 416 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 416 from patent US 11034762,2022-03-15,NaN,NaN,NaN
652,NaN,NaN,NaN,QYT87263,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliyrastrasgvpdrfsgsgsgtdftltisslqaedvavyycqqyystvitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 415 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 415 from patent US 11034762,2022-03-15,NaN,NaN,NaN
653,NaN,NaN,NaN,QYT87262,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 414 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 414 from patent US 11034762,2022-03-15,NaN,NaN,NaN
654,NaN,NaN,NaN,QYT87261,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 413 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 413 from patent US 11034762,2022-03-15,NaN,NaN,NaN
655,NaN,NaN,NaN,QYT87260,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratincrssqsvlyssnnknyfawyqqkpgqppklliywasirgsgvpdrfsgsgsgtdftltisslqaedvavyychqyyttpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 412 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 412 from patent US 11034762,2022-03-15,NaN,NaN,NaN
656,NaN,NaN,NaN,QYT87259,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 411 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 411 from patent US 11034762,2022-03-15,NaN,NaN,NaN
657,NaN,NaN,NaN,QYT87258,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 410 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 410 from patent US 11034762,2022-03-15,NaN,NaN,NaN
658,NaN,NaN,NaN,QYT87257,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 409 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 409 from patent US 11034762,2022-03-15,NaN,NaN,NaN
659,NaN,NaN,NaN,QYT87256,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlhsainknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqysttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 408 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 408 from patent US 11034762,2022-03-15,NaN,NaN,NaN
660,NaN,NaN,NaN,QYT87255,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnhnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 407 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 407 from patent US 11034762,2022-03-15,NaN,NaN,NaN
661,NaN,NaN,NaN,QYT87254,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpvtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 406 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 406 from patent US 11034762,2022-03-15,NaN,NaN,NaN
662,NaN,NaN,NaN,QYT87253,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyslpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 405 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 405 from patent US 11034762,2022-03-15,NaN,NaN,NaN
663,NaN,NaN,NaN,QYT87252,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyhstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 404 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 404 from patent US 11034762,2022-03-15,NaN,NaN,NaN
664,NaN,NaN,NaN,QYT87251,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvfhssnnknhlawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 403 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 403 from patent US 11034762,2022-03-15,NaN,NaN,NaN
665,NaN,NaN,NaN,QYT87250,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasmresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 402 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 402 from patent US 11034762,2022-03-15,NaN,NaN,NaN
666,NaN,NaN,NaN,QYT87249,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastrefgvpdrfsgsgsgtdftltisslqaedvavyycqqyykipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 401 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 401 from patent US 11034762,2022-03-15,NaN,NaN,NaN
667,NaN,NaN,NaN,QYT87248,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyatpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 400 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 400 from patent US 11034762,2022-03-15,NaN,NaN,NaN
668,NaN,NaN,NaN,QYT87247,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyhtipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 399 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 399 from patent US 11034762,2022-03-15,NaN,NaN,NaN
669,NaN,NaN,NaN,QYT87246,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastraagvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 398 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 398 from patent US 11034762,2022-03-15,NaN,NaN,NaN
670,NaN,NaN,NaN,QYT87245,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqrvlyssnnlnylawyqqkpgqppklliywastrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 397 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 397 from patent US 11034762,2022-03-15,NaN,NaN,NaN
671,NaN,NaN,NaN,QYT87244,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaytrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 396 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 396 from patent US 11034762,2022-03-15,NaN,NaN,NaN
672,NaN,NaN,NaN,QYT87243,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasnrepgvpdrfsgsgsgtdftltisslqaedvavyfchqyystpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 395 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 395 from patent US 11034762,2022-03-15,NaN,NaN,NaN
673,NaN,NaN,NaN,QYT87242,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywasyresgvpdrfsgsgsgtdftltisslqaedvavyycqqyygfpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 394 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 394 from patent US 11034762,2022-03-15,NaN,NaN,NaN
674,NaN,NaN,NaN,QYT87241,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnlnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 393 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 393 from patent US 11034762,2022-03-15,NaN,NaN,NaN
675,NaN,NaN,NaN,QYT87240,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratincrssqtvlyrsnnynylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 392 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 392 from patent US 11034762,2022-03-15,NaN,NaN,NaN
676,NaN,NaN,NaN,QYT87239,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnknnylawyqqkpgqppklliywastrlsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 391 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 391 from patent US 11034762,2022-03-15,NaN,NaN,NaN
677,NaN,NaN,NaN,QYT87238,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaslreggvpdrfsgsgsgtdftltisslqaedvavyycqqyyyapwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 390 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 390 from patent US 11034762,2022-03-15,NaN,NaN,NaN
678,NaN,NaN,NaN,QYT87237,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnninylawyqqkpgqppklliywastrasgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 389 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 389 from patent US 11034762,2022-03-15,NaN,NaN,NaN
679,NaN,NaN,NaN,QYT87236,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 388 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 388 from patent US 11034762,2022-03-15,NaN,NaN,NaN
680,NaN,NaN,NaN,QYT87235,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 387 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 387 from patent US 11034762,2022-03-15,NaN,NaN,NaN
681,NaN,NaN,NaN,QYT87234,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastrdfgvpdrfsgsgsgtdftltisslqaedvavyycqqyyalpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 386 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 386 from patent US 11034762,2022-03-15,NaN,NaN,NaN
682,NaN,NaN,NaN,QYT87233,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratirctsslslqdrsnnknyltwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqhysapltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 385 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 385 from patent US 11034762,2022-03-15,NaN,NaN,NaN
683,NaN,NaN,NaN,QYT87232,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqnvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 384 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 384 from patent US 11034762,2022-03-15,NaN,NaN,NaN
684,NaN,NaN,NaN,QYT87231,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywaniresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 383 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 383 from patent US 11034762,2022-03-15,NaN,NaN,NaN
685,NaN,NaN,NaN,QYT87230,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliywgstrgsgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 382 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 382 from patent US 11034762,2022-03-15,NaN,NaN,NaN
686,NaN,NaN,NaN,QYT87229,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlytsnnnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 381 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 381 from patent US 11034762,2022-03-15,NaN,NaN,NaN
687,NaN,NaN,NaN,QYT87228,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 380 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 380 from patent US 11034762,2022-03-15,NaN,NaN,NaN
688,NaN,NaN,NaN,QYT87227,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 379 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 379 from patent US 11034762,2022-03-15,NaN,NaN,NaN
689,NaN,NaN,NaN,QYT87226,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliswastresgvpdrfsgsgsgtdftltisslqaedvavyycrqyystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from CR3022; US11034762-B1 378 15-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 378 from patent US 11034762,2022-03-15,NaN,NaN,NaN
690,NaN,NaN,QYS33726,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgiinprggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctreakpqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 208 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
691,NaN,NaN,QYS33717,NaN,SARS-CoV-2,Unknown.,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 199 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
692,NaN,NaN,QYS33686,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpngggtyyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 168 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 168 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
693,NaN,NaN,QYS33685,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 167 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 167 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
694,NaN,NaN,QYS33684,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregppqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 166 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 166 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
695,NaN,NaN,QYS33683,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfteyemhwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 165 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 165 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
696,NaN,NaN,QYS33682,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgmvdpnsgntyyaqkfqgrftmtrdtststvymelsslrsedtavyyctregipqllgtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 164 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 164 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
697,NaN,NaN,QYS33681,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfsdyymhwvrqapgqglewmgiidpsggsasyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 163 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 163 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
698,NaN,NaN,QYS33680,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgysftsyeihwvrqapgqglewmgiinpsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqvlrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 162 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 162 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
699,NaN,NaN,QYS33679,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvinpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrhldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 161 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 161 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
700,NaN,NaN,QYS33678,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiintsggytnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 160 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 160 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
701,NaN,NaN,QYS33677,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgminpsggytnyaqefqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 159 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 159 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
702,NaN,NaN,QYS33676,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpdggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 158 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 158 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
703,NaN,NaN,QYS33675,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgydfinyyihwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 157 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 157 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
704,NaN,NaN,QYS33674,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfasydvnwvrqapgqglewmgiinprsgdanyaqkfqgrvtmtrdtststvymelsslrsedtavyyctrerhpqllmpldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 156 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 156 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
705,NaN,NaN,QYS33673,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsysmhwvrqapgqglewmgaiypgnsdttyaqkfqgrvtmtrdtststvymelsslrsedtavyyctldgipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 155 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 155 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
706,NaN,NaN,QYS33672,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipwwlrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 154 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 154 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
707,NaN,NaN,QYS33671,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfgnyainwvrqapgqglewmgaiypgnsdttynqkfqgrvtmtrdtststvymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 153 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 153 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
708,NaN,NaN,QYS33670,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgyrftsyevnwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllwaldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 152 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 152 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
709,NaN,NaN,QYS33669,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 151 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 151 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
710,NaN,NaN,QYS33668,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 150 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 150 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
711,NaN,NaN,QYS33667,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgdiwrlhwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 149 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 149 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
712,NaN,NaN,QYS33666,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgntftgyymhwvrqapgqglewmgaiypggsdtsynqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlawtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 148 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 148 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
713,NaN,NaN,QYS33665,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgvvnpsggytsyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqllrsqdywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 147 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 147 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
714,NaN,NaN,QYS33664,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftshdinwvrqapgqglewmgminpsggytsyaqnfqgrvtmtrdtststvymelsslrsedtavyyctregipallrtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 146 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 146 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
715,NaN,NaN,QYS33663,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgvinpsgghtnyaqkfqgrvtmtrdtststvymelsslrsedtavyyctregipqlagtldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 145 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 145 from patent US 11028167,NaN,2022-03-15,NaN,NaN,NaN
716,NaN,NaN,NaN,QYS33727,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgidtylnwyqqkpgkapklliykasslesgvpsrfsgsgsgteftltinslqpediatyycqqydnlpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 209 from patent US 11028167,2022-03-15,NaN,NaN,NaN
717,NaN,NaN,NaN,QYS33718,SARS-CoV-2,Unknown.,NaN,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 200 from patent US 11028167,2022-03-15,NaN,NaN,NaN
718,NaN,NaN,NaN,QYS33710,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtysapytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 192 from patent US 11028167,2022-03-15,NaN,NaN,NaN
719,NaN,NaN,NaN,QYS33709,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnplhfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 191 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 191 from patent US 11028167,2022-03-15,NaN,NaN,NaN
720,NaN,NaN,NaN,QYS33708,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyhtsnletgvpsrfsgsgsgtdftltisslqpedfatyycqqsysfpattfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 190 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 190 from patent US 11028167,2022-03-15,NaN,NaN,NaN
721,NaN,NaN,NaN,QYS33707,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 189 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 189 from patent US 11028167,2022-03-15,NaN,NaN,NaN
722,NaN,NaN,NaN,QYS33706,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtkggdqt,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 188 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 188 from patent US 11028167,2022-03-15,NaN,NaN,NaN
723,NaN,NaN,NaN,QYS33705,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqvgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlavtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 187 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 187 from patent US 11028167,2022-03-15,NaN,NaN,NaN
724,NaN,NaN,NaN,QYS33704,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 186 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 186 from patent US 11028167,2022-03-15,NaN,NaN,NaN
725,NaN,NaN,NaN,QYS33703,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgswtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 185 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 185 from patent US 11028167,2022-03-15,NaN,NaN,NaN
726,NaN,NaN,NaN,QYS33702,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 184 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 184 from patent US 11028167,2022-03-15,NaN,NaN,NaN
727,NaN,NaN,NaN,QYS33701,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsiyrwlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyycqqsygnpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 183 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 183 from patent US 11028167,2022-03-15,NaN,NaN,NaN
728,NaN,NaN,NaN,QYS33700,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 182 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 182 from patent US 11028167,2022-03-15,NaN,NaN,NaN
729,NaN,NaN,NaN,QYS33699,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdisdslawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysrlawtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 181 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 181 from patent US 11028167,2022-03-15,NaN,NaN,NaN
730,NaN,NaN,NaN,QYS33698,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlesgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 180 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 180 from patent US 11028167,2022-03-15,NaN,NaN,NaN
731,NaN,NaN,NaN,QYS33697,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygvsslhsgvpsrfsgsgsgtdftltisslqpedfatyyclqyvsypwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 179 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 179 from patent US 11028167,2022-03-15,NaN,NaN,NaN
732,NaN,NaN,NaN,QYS33696,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpewtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 178 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 178 from patent US 11028167,2022-03-15,NaN,NaN,NaN
733,NaN,NaN,NaN,QYS33695,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqeisgylswyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyvsypwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 177 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 177 from patent US 11028167,2022-03-15,NaN,NaN,NaN
734,NaN,NaN,NaN,QYS33694,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 176 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 176 from patent US 11028167,2022-03-15,NaN,NaN,NaN
735,NaN,NaN,NaN,QYS33693,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsirtylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 175 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 175 from patent US 11028167,2022-03-15,NaN,NaN,NaN
736,NaN,NaN,NaN,QYS33692,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpsytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 174 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 174 from patent US 11028167,2022-03-15,NaN,NaN,NaN
737,NaN,NaN,NaN,QYS33691,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqeissylswyqqkpgkapklliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqynsypltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 173 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 173 from patent US 11028167,2022-03-15,NaN,NaN,NaN
738,NaN,NaN,NaN,QYS33690,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqpediatyycqqfgsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 172 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 172 from patent US 11028167,2022-03-15,NaN,NaN,NaN
739,NaN,NaN,NaN,QYS33689,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 171 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 171 from patent US 11028167,2022-03-15,NaN,NaN,NaN
740,NaN,NaN,NaN,QYS33688,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyttpytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 170 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 170 from patent US 11028167,2022-03-15,NaN,NaN,NaN
741,NaN,NaN,NaN,QYS33687,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisgylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgyttprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 3bgf; US11028167-B1 169 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 169 from patent US 11028167,2022-03-15,NaN,NaN,NaN
742,NaN,NaN,QYS31785,NaN,SARS-CoV-2,Unknown.,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 280 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 280 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
743,NaN,NaN,QYS31737,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggsfsrfpiswvrqapgqglewmggiipifgtanyaqrfqgrvtitadeststaymelsslrsedtavyycaletvmgglqvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 232 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 232 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
744,NaN,NaN,QYS31736,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftafyihwvrqapgqglewmggiipisgtanyaqkfqgratitadeststaymelsslrsedtavyycarevvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 231 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 231 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
745,NaN,NaN,QYS31735,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswmrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsnlrsedtavyycardtywggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 230 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 230 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
746,NaN,NaN,QYS31734,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssfaiiwvrqapgqglewmalinpssgttsyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 229 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 229 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
747,NaN,NaN,QYS31733,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgntfsmfainwvrqapgqglewvgvinpigstttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 228 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 228 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
748,NaN,NaN,QYS31732,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 227 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 227 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
749,NaN,NaN,QYS31731,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggmqmwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 226 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 226 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
750,NaN,NaN,QYS31730,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssfyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 225 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 225 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
751,NaN,NaN,QYS31729,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsdfylhwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 224 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 224 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
752,NaN,NaN,QYS31728,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyyvhwvrqapgqglewmggilpilgtphyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmtawgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 223 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 223 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
753,NaN,NaN,QYS31727,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsygiswvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycavetvmggftvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 222 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 222 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
754,NaN,NaN,QYS31726,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgiinpsggstsyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmgvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 221 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 221 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
755,NaN,NaN,QYS31725,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtakyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 220 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 220 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
756,NaN,NaN,QYS31724,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftgfymqwvrqapgqglewmggitpilgtanyaqkfqgrvtitadeststaymelsslrsedtavyycareivmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 219 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 219 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
757,NaN,NaN,QYS31723,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinyeihwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 218 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 218 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
758,NaN,NaN,QYS31722,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfnafyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 217 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 217 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
759,NaN,NaN,QYS31721,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsdfdinwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycgmdtvmggmtswgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 216 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 216 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
760,NaN,NaN,QYS31720,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdfhmhwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 215 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 215 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
761,NaN,NaN,QYS31719,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtffggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 214 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 214 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
762,NaN,NaN,QYS31718,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfinydinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 213 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 213 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
763,NaN,NaN,QYS31717,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgymftefymhwvrqapgqglewmggiipvsgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 212 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 212 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
764,NaN,NaN,QYS31716,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssyyihwvrqapgqglewmggiipifgeaeyahkfqgrvtitadeststaymelsslrsedtavyycametvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 211 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 211 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
765,NaN,NaN,QYS31715,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgstfsmfainwvrqapgqglewvgvinprgssttyaqkfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 210 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 210 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
766,NaN,NaN,QYS31714,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgyaftsyymhwvrqapgqglewmgvidpsegstsnarkfqgrvtitadeststaymelsslrsedtavyycvsdtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 209 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 209 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
767,NaN,NaN,QYS31713,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfgnypitwvrqapgqglewmgiiypgdsdaryrpsfqgrvtitadeststaymelsslrsedtavyycardfsmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 208 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 208 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
768,NaN,NaN,QYS31712,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnfaltwvrqapgqglewmglinpsggstsyaqrfqgrvtitadeststaymelsslrsedtavyycardsvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 207 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 207 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
769,NaN,NaN,QYS31711,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgypfssyeinwvrqapgqglewmggitpifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycadetvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 206 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 206 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
770,NaN,NaN,QYS31710,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdfyihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 205 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 205 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
771,NaN,NaN,QYS31709,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnytitwvrqapgqglewlgwisayngntdyaqklqgrvtitadeststaymelsslrsedtavyycardalmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 204 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 204 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
772,NaN,NaN,QYS31708,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsfdihwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycayetvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 203 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 203 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
773,NaN,NaN,QYS31707,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsnfaitwvrqapgqglewmgvinpgggsttyaqtfqgrvtitadeststaymelsslrsedtavyycardtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 202 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 202 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
774,NaN,NaN,QYS31706,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfsayymhwvrqapgqglewmggitplfgtpsyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggvgvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 201 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 201 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
775,NaN,NaN,QYS31705,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgynfinyylhwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaretvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 200 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 200 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
776,NaN,NaN,QYS31704,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfnrfamtwvrqapgqglewmgtinpsggstiytqrfqgrvtitadeststaymelsslrsedtavyycghdtvmggmgewgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 199 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 199 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
777,NaN,NaN,QYS31703,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgiidpiggttnyaqkfqgrvtitadeststaymelsslrsedtavyycardtvgfgmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 198 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 198 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
778,NaN,NaN,QYS31702,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfsrydinwvrqapgqglewmgiinpsggsttyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 197 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 197 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
779,NaN,NaN,QYS31701,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfssfhinwvrqapgqglewmggitpifgianyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 196 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 196 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
780,NaN,NaN,QYS31700,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgysfnnydlhwvrqapgqglewmggiipifdtanyaqkfqgrvtitadeststaymelsslrsedtavyycaletvmggmvkwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 195 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 195 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
781,NaN,NaN,QYS31699,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftsyymhwvrqapgqglewmglidpsggttsyaqkfqgrvtitadeststaymelsslrsedtavyycvwdtvmggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 194 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 194 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
782,NaN,NaN,QYS31698,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytfttydinwvrqapgqglewmgwinpnsggtnyaqkfqgrvtitadeststaymelsslrsedtavyycardtywggmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 193 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 193 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
783,NaN,NaN,QYS31697,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgctftrftmhwvrqapgqglewmggitpifgitnyaqkfqgrvtitadeststaymelsslrsedtavyycahdtvmggmeewgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 192 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 192 from patent US 11028150,NaN,2022-03-15,NaN,NaN,NaN
784,NaN,NaN,NaN,QYS31786,SARS-CoV-2,Unknown.,NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 281 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 281 from patent US 11028150,2022-03-15,NaN,NaN,NaN
785,NaN,NaN,NaN,QYS31778,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 273 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 273 from patent US 11028150,2022-03-15,NaN,NaN,NaN
786,NaN,NaN,NaN,QYS31777,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 272 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 272 from patent US 11028150,2022-03-15,NaN,NaN,NaN
787,NaN,NaN,NaN,QYS31776,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 271 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 271 from patent US 11028150,2022-03-15,NaN,NaN,NaN
788,NaN,NaN,NaN,QYS31775,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 270 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 270 from patent US 11028150,2022-03-15,NaN,NaN,NaN
789,NaN,NaN,NaN,QYS31774,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwvsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 269 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 269 from patent US 11028150,2022-03-15,NaN,NaN,NaN
790,NaN,NaN,NaN,QYS31773,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdshsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 268 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 268 from patent US 11028150,2022-03-15,NaN,NaN,NaN
791,NaN,NaN,NaN,QYS31772,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 267 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 267 from patent US 11028150,2022-03-15,NaN,NaN,NaN
792,NaN,NaN,NaN,QYS31771,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 266 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 266 from patent US 11028150,2022-03-15,NaN,NaN,NaN
793,NaN,NaN,NaN,QYS31770,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 265 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 265 from patent US 11028150,2022-03-15,NaN,NaN,NaN
794,NaN,NaN,NaN,QYS31769,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 264 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 264 from patent US 11028150,2022-03-15,NaN,NaN,NaN
795,NaN,NaN,NaN,QYS31768,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 263 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 263 from patent US 11028150,2022-03-15,NaN,NaN,NaN
796,NaN,NaN,NaN,QYS31767,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 262 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 262 from patent US 11028150,2022-03-15,NaN,NaN,NaN
797,NaN,NaN,NaN,QYS31766,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 261 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 261 from patent US 11028150,2022-03-15,NaN,NaN,NaN
798,NaN,NaN,NaN,QYS31765,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 260 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 260 from patent US 11028150,2022-03-15,NaN,NaN,NaN
799,NaN,NaN,NaN,QYS31764,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 259 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 259 from patent US 11028150,2022-03-15,NaN,NaN,NaN
800,NaN,NaN,NaN,QYS31763,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdgssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 258 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 258 from patent US 11028150,2022-03-15,NaN,NaN,NaN
801,NaN,NaN,NaN,QYS31762,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsshdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 257 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 257 from patent US 11028150,2022-03-15,NaN,NaN,NaN
802,NaN,NaN,NaN,QYS31761,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 256 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 256 from patent US 11028150,2022-03-15,NaN,NaN,NaN
803,NaN,NaN,NaN,QYS31760,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 255 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 255 from patent US 11028150,2022-03-15,NaN,NaN,NaN
804,NaN,NaN,NaN,QYS31759,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 254 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 254 from patent US 11028150,2022-03-15,NaN,NaN,NaN
805,NaN,NaN,NaN,QYS31758,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 253 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 253 from patent US 11028150,2022-03-15,NaN,NaN,NaN
806,NaN,NaN,NaN,QYS31757,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 252 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 252 from patent US 11028150,2022-03-15,NaN,NaN,NaN
807,NaN,NaN,NaN,QYS31756,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdrssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 251 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 251 from patent US 11028150,2022-03-15,NaN,NaN,NaN
808,NaN,NaN,NaN,QYS31755,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 250 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 250 from patent US 11028150,2022-03-15,NaN,NaN,NaN
809,NaN,NaN,NaN,QYS31754,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwddssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 249 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 249 from patent US 11028150,2022-03-15,NaN,NaN,NaN
810,NaN,NaN,NaN,QYS31753,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 248 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 248 from patent US 11028150,2022-03-15,NaN,NaN,NaN
811,NaN,NaN,NaN,QYS31752,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 247 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 247 from patent US 11028150,2022-03-15,NaN,NaN,NaN
812,NaN,NaN,NaN,QYS31751,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssshyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 246 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 246 from patent US 11028150,2022-03-15,NaN,NaN,NaN
813,NaN,NaN,NaN,QYS31750,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsrsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 245 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 245 from patent US 11028150,2022-03-15,NaN,NaN,NaN
814,NaN,NaN,NaN,QYS31749,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 244 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 244 from patent US 11028150,2022-03-15,NaN,NaN,NaN
815,NaN,NaN,NaN,QYS31748,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 243 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 243 from patent US 11028150,2022-03-15,NaN,NaN,NaN
816,NaN,NaN,NaN,QYS31747,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveavdeadyycqvwdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 242 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 242 from patent US 11028150,2022-03-15,NaN,NaN,NaN
817,NaN,NaN,NaN,QYS31746,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnkigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 241 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 241 from patent US 11028150,2022-03-15,NaN,NaN,NaN
818,NaN,NaN,NaN,QYS31745,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqstdsssdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 240 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 240 from patent US 11028150,2022-03-15,NaN,NaN,NaN
819,NaN,NaN,NaN,QYS31744,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 239 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 239 from patent US 11028150,2022-03-15,NaN,NaN,NaN
820,NaN,NaN,NaN,QYS31743,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 238 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 238 from patent US 11028150,2022-03-15,NaN,NaN,NaN
821,NaN,NaN,NaN,QYS31742,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqswdssgdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 237 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 237 from patent US 11028150,2022-03-15,NaN,NaN,NaN
822,NaN,NaN,NaN,QYS31741,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrieagdeadyycqvwdssgdyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 236 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 236 from patent US 11028150,2022-03-15,NaN,NaN,NaN
823,NaN,NaN,NaN,QYS31740,SARS-CoV-2,Unknown.,NaN,syvltqppsvsvapgktaaritcggnnigsksvhwyqqkpgqapvlviykdgerpsgiperfsgsnsrntatltisrveagdeadyycqvwdssslyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 235 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 235 from patent US 11028150,2022-03-15,NaN,NaN,NaN
824,NaN,NaN,NaN,QYS31739,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssfyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 234 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 234 from patent US 11028150,2022-03-15,NaN,NaN,NaN
825,NaN,NaN,NaN,QYS31738,SARS-CoV-2,Unknown.,NaN,ssyvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssndyvfgggtkltvla,"Glanville,J. et al.; Anti-SARS-CoV-2 antibodies derived from 2DD8; US11028150-B1 233 08-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 233 from patent US 11028150,2022-03-15,NaN,NaN,NaN
826,NaN,NaN,QYS20240,NaN,SARS-CoV-2,Unknown.,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 497 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 497 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
827,NaN,NaN,QYS20171,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 428 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 428 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
828,NaN,NaN,QYS20170,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 427 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 427 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
829,NaN,NaN,QYS20169,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsvisasggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 426 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 426 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
830,NaN,NaN,QYS20168,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 425 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 425 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
831,NaN,NaN,QYS20167,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfafssyalhwvrqapgkglewvsaisgsggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 424 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 424 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
832,NaN,NaN,QYS20166,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 423 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 423 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
833,NaN,NaN,QYS20165,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 422 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 422 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
834,NaN,NaN,QYS20164,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 421 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 421 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
835,NaN,NaN,QYS20163,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 420 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 420 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
836,NaN,NaN,QYS20162,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfpfslygmhwvrqapgkglewvavitsdgrskfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 419 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 419 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
837,NaN,NaN,QYS20161,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgitfnnyamtwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnsrntlylqmnslraedtavyycvtqrdnpvdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 418 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 418 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
838,NaN,NaN,QYS20160,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfddfgmhwyrqapgkglewvsatsgggsityyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 417 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 417 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
839,NaN,NaN,QYS20159,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfkfntyamhwvrqapgkglewvsaisitggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 416 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 416 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
840,NaN,NaN,QYS20158,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 415 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 415 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
841,NaN,NaN,QYS20157,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfrsygmhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnfdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 414 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 414 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
842,NaN,NaN,QYS20156,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 413 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 413 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
843,NaN,NaN,QYS20155,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfifndygmhwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 412 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 412 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
844,NaN,NaN,QYS20154,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 411 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 411 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
845,NaN,NaN,QYS20153,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsvitgdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 410 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 410 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
846,NaN,NaN,QYS20152,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisrsgdsayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 409 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 409 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
847,NaN,NaN,QYS20151,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 408 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 408 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
848,NaN,NaN,QYS20150,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfntyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 407 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 407 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
849,NaN,NaN,QYS20149,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 406 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 406 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
850,NaN,NaN,QYS20148,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsgvsasgggpyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 405 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 405 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
851,NaN,NaN,QYS20147,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsgissggsgthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 404 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 404 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
852,NaN,NaN,QYS20146,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfafsnygmhwirqapgkglewvsgidgsggtahyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 403 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 403 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
853,NaN,NaN,QYS20145,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfsrygmhwvrqapgkglewvsgisadggtayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 402 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 402 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
854,NaN,NaN,QYS20144,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygvhwvrqapgkglewvavishdgkkkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnvdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 401 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 401 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
855,NaN,NaN,QYS20143,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsgisgggagtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtyrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 400 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 400 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
856,NaN,NaN,QYS20142,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsgisgsgdrtyyadsvkgrftisrdnskntlylqmnslraedtavyycsmqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 399 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 399 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
857,NaN,NaN,QYS20141,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfhdyamhwvrqapgkglewvavtsydgntkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 398 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 398 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
858,NaN,NaN,QYS20140,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfgtsavswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 397 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 397 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
859,NaN,NaN,QYS20139,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvsaysgsggytyfadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 396 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 396 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
860,NaN,NaN,QYS20138,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavvsrsggstfyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 395 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 395 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
861,NaN,NaN,QYS20137,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvaaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 394 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 394 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
862,NaN,NaN,QYS20136,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaisassagayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 393 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 393 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
863,NaN,NaN,QYS20135,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsringdgsttgyadsvkgrftisrdnskntlylqmnslraedtavyycvttgdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 392 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 392 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
864,NaN,NaN,QYS20134,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsshtiawvrqapgkglewlshisssgsttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdmsphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 391 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 391 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
865,NaN,NaN,QYS20133,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvaaigasgestyyadsvkgrftisrdnskntlylqmnslraedtavyycvtqrdnsrdyfplwfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 390 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 390 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
866,NaN,NaN,QYS20132,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfstygmhwvrqapgkglewvstisgngvstsyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 389 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 389 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
867,NaN,NaN,QYS20131,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 388 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 388 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
868,NaN,NaN,QYS20130,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftftsygmhwvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 387 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 387 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
869,NaN,NaN,QYS20129,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfiftnyalhwvrqapgkglewvsaisgsggsthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 386 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 386 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
870,NaN,NaN,QYS20128,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfstyamhwvrqapgkglewvavisydgnyqyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 385 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 385 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
871,NaN,NaN,QYS20127,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfifssyamnwvrqapgkglewvsgisgsgggayyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 384 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 384 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
872,NaN,NaN,QYS20126,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfnnyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 383 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 383 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
873,NaN,NaN,QYS20125,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsavsssggspyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 382 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 382 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
874,NaN,NaN,QYS20124,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvavisssgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 381 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 381 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
875,NaN,NaN,QYS20123,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwirqapgkglewvsavsasgdrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 380 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 380 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
876,NaN,NaN,QYS20122,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavissdgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 379 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 379 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
877,NaN,NaN,QYS20121,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 378 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 378 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
878,NaN,NaN,QYS20120,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssyamhwvrqapgkglewvsavgdsgrstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnldnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 377 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 377 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
879,NaN,NaN,QYS20119,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 376 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 376 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
880,NaN,NaN,QYS20118,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfifssfgmhwvrqapgkglewvsaisdsgdatqyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 375 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 375 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
881,NaN,NaN,QYS20117,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsavsttggstyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 374 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 374 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
882,NaN,NaN,QYS20116,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrnyamhwvrqapgkglewvsaigtggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 373 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 373 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
883,NaN,NaN,QYS20115,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfrsyamhwvrqapgkglewvavishdasnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 372 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 372 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
884,NaN,NaN,QYS20114,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfsdhpmhwvrqapgkglewvavitgsgrnkfyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 371 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 371 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
885,NaN,NaN,QYS20113,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvsvisgsgrntyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 370 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 370 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
886,NaN,NaN,QYS20112,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnyamhwvrqapgkglewvsaigagggtyyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 369 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 369 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
887,NaN,NaN,QYS20111,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsdyalhwvrqapgkglewvsgvswngsrthyadsvkgrftisrdnskntlylqmnslraedtavyycvtnmdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 368 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 368 from patent US 11053304,NaN,2022-03-15,NaN,NaN,NaN
888,NaN,NaN,NaN,QYS20241,SARS-CoV-2,Unknown.,NaN,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 498 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 498 from patent US 11053304,2022-03-15,NaN,NaN,NaN
889,NaN,NaN,NaN,QYS20233,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 490 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 490 from patent US 11053304,2022-03-15,NaN,NaN,NaN
890,NaN,NaN,NaN,QYS20232,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 489 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 489 from patent US 11053304,2022-03-15,NaN,NaN,NaN
891,NaN,NaN,NaN,QYS20231,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssrsllhtnglnyidwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyctqalqtpisfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 488 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 488 from patent US 11053304,2022-03-15,NaN,NaN,NaN
892,NaN,NaN,NaN,QYS20230,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalrtptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 487 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 487 from patent US 11053304,2022-03-15,NaN,NaN,NaN
893,NaN,NaN,NaN,QYS20229,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhrngynyvdwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlrisrveaedvgvyycmqarqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 486 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 486 from patent US 11053304,2022-03-15,NaN,NaN,NaN
894,NaN,NaN,NaN,QYS20228,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrapgvpdrfsgsgsgtdftlkisrveaedvgvyycaqglqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 485 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 485 from patent US 11053304,2022-03-15,NaN,NaN,NaN
895,NaN,NaN,NaN,QYS20227,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqllislgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 484 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 484 from patent US 11053304,2022-03-15,NaN,NaN,NaN
896,NaN,NaN,NaN,QYS20226,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 483 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 483 from patent US 11053304,2022-03-15,NaN,NaN,NaN
897,NaN,NaN,NaN,QYS20225,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssesllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyciqalqtpftfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 482 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 482 from patent US 11053304,2022-03-15,NaN,NaN,NaN
898,NaN,NaN,NaN,QYS20224,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylssnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqspytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 481 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 481 from patent US 11053304,2022-03-15,NaN,NaN,NaN
899,NaN,NaN,NaN,QYS20223,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqvpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 480 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 480 from patent US 11053304,2022-03-15,NaN,NaN,NaN
900,NaN,NaN,NaN,QYS20222,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 479 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 479 from patent US 11053304,2022-03-15,NaN,NaN,NaN
901,NaN,NaN,NaN,QYS20221,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqaysfpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 478 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 478 from patent US 11053304,2022-03-15,NaN,NaN,NaN
902,NaN,NaN,NaN,QYS20220,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkitrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 477 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 477 from patent US 11053304,2022-03-15,NaN,NaN,NaN
903,NaN,NaN,NaN,QYS20219,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 476 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 476 from patent US 11053304,2022-03-15,NaN,NaN,NaN
904,NaN,NaN,NaN,QYS20218,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsirasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsqqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 475 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 475 from patent US 11053304,2022-03-15,NaN,NaN,NaN
905,NaN,NaN,NaN,QYS20217,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 474 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 474 from patent US 11053304,2022-03-15,NaN,NaN,NaN
906,NaN,NaN,NaN,QYS20216,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplgfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 473 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 473 from patent US 11053304,2022-03-15,NaN,NaN,NaN
907,NaN,NaN,NaN,QYS20215,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssksllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaaqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 472 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 472 from patent US 11053304,2022-03-15,NaN,NaN,NaN
908,NaN,NaN,NaN,QYS20214,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyyclqtlqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 471 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 471 from patent US 11053304,2022-03-15,NaN,NaN,NaN
909,NaN,NaN,NaN,QYS20213,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgtnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtppkfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 470 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 470 from patent US 11053304,2022-03-15,NaN,NaN,NaN
910,NaN,NaN,NaN,QYS20212,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrsshsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqlphtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 469 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 469 from patent US 11053304,2022-03-15,NaN,NaN,NaN
911,NaN,NaN,NaN,QYS20211,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylaanrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 468 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 468 from patent US 11053304,2022-03-15,NaN,NaN,NaN
912,NaN,NaN,NaN,QYS20210,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyfgsnrasgvpdrfsgsgsgtdftlkisrvetedvgvyycmqalqtpaltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 467 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 467 from patent US 11053304,2022-03-15,NaN,NaN,NaN
913,NaN,NaN,NaN,QYS20209,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliyqgsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 466 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 466 from patent US 11053304,2022-03-15,NaN,NaN,NaN
914,NaN,NaN,NaN,QYS20208,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaqqtpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 465 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 465 from patent US 11053304,2022-03-15,NaN,NaN,NaN
915,NaN,NaN,NaN,QYS20207,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllqsngdnyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqglhwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 464 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 464 from patent US 11053304,2022-03-15,NaN,NaN,NaN
916,NaN,NaN,NaN,QYS20206,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 463 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 463 from patent US 11053304,2022-03-15,NaN,NaN,NaN
917,NaN,NaN,NaN,QYS20205,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 462 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 462 from patent US 11053304,2022-03-15,NaN,NaN,NaN
918,NaN,NaN,NaN,QYS20204,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsvqtpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 461 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 461 from patent US 11053304,2022-03-15,NaN,NaN,NaN
919,NaN,NaN,NaN,QYS20203,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsvrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqgynmpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 460 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 460 from patent US 11053304,2022-03-15,NaN,NaN,NaN
920,NaN,NaN,NaN,QYS20202,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgletpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 459 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 459 from patent US 11053304,2022-03-15,NaN,NaN,NaN
921,NaN,NaN,NaN,QYS20201,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasisckssqsllhingfnyldwflqkpgqspqlliylgsnrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqslqnprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 458 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 458 from patent US 11053304,2022-03-15,NaN,NaN,NaN
922,NaN,NaN,NaN,QYS20200,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsystpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 457 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 457 from patent US 11053304,2022-03-15,NaN,NaN,NaN
923,NaN,NaN,NaN,QYS20199,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhingynyldwflqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqnprtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 456 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 456 from patent US 11053304,2022-03-15,NaN,NaN,NaN
924,NaN,NaN,NaN,QYS20197,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngnnyldwylqkpgqspqlliyggsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsytppptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 454 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 454 from patent US 11053304,2022-03-15,NaN,NaN,NaN
925,NaN,NaN,NaN,QYS20196,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyitpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 453 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 453 from patent US 11053304,2022-03-15,NaN,NaN,NaN
926,NaN,NaN,NaN,QYS20195,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslldsngfnyldwylqkpgqspqlliylgssrapgvpdrfsgsgsgtdftlkisrveaedvgvyycqqsyntpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 452 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 452 from patent US 11053304,2022-03-15,NaN,NaN,NaN
927,NaN,NaN,NaN,QYS20194,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsirapgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqtpwtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 451 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 451 from patent US 11053304,2022-03-15,NaN,NaN,NaN
928,NaN,NaN,NaN,QYS20193,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvysdgytylnwylqkpgqspqlliyqvsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpaltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 450 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 450 from patent US 11053304,2022-03-15,NaN,NaN,NaN
929,NaN,NaN,NaN,QYS20192,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsdgytylnwylqkpgqspqlliyvgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqasqwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 449 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 449 from patent US 11053304,2022-03-15,NaN,NaN,NaN
930,NaN,NaN,NaN,QYS20191,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllqsngynyldwylqkpgqspqlliylgynrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqapltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 448 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 448 from patent US 11053304,2022-03-15,NaN,NaN,NaN
931,NaN,NaN,NaN,QYS20190,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrpsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlqtpfsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 447 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 447 from patent US 11053304,2022-03-15,NaN,NaN,NaN
932,NaN,NaN,NaN,QYS20189,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaiqnrrtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 446 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 446 from patent US 11053304,2022-03-15,NaN,NaN,NaN
933,NaN,NaN,NaN,QYS20188,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllqsngynymdwylqkpgqspqlliyltsnraagvpdrfsgsgsgtdftlkisrveaedvgvyycqqsygppltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 445 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 445 from patent US 11053304,2022-03-15,NaN,NaN,NaN
934,NaN,NaN,NaN,QYS20187,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscssrqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycvqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 444 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 444 from patent US 11053304,2022-03-15,NaN,NaN,NaN
935,NaN,NaN,NaN,QYS20186,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqslvhsdgdnylnwylqkpgqspqlliysgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 443 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 443 from patent US 11053304,2022-03-15,NaN,NaN,NaN
936,NaN,NaN,NaN,QYS20185,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 442 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 442 from patent US 11053304,2022-03-15,NaN,NaN,NaN
937,NaN,NaN,NaN,QYS20184,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynrlawylqkpgqspqlliylgsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 441 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 441 from patent US 11053304,2022-03-15,NaN,NaN,NaN
938,NaN,NaN,NaN,QYS20183,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngnnymdwylqkpgqspqlliylasqrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqrpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 440 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 440 from patent US 11053304,2022-03-15,NaN,NaN,NaN
939,NaN,NaN,NaN,QYS20182,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlqtprfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 439 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 439 from patent US 11053304,2022-03-15,NaN,NaN,NaN
940,NaN,NaN,NaN,QYS20181,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 438 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 438 from patent US 11053304,2022-03-15,NaN,NaN,NaN
941,NaN,NaN,NaN,QYS20180,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngyndldwylqkpgqspqlliyggsngasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 437 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 437 from patent US 11053304,2022-03-15,NaN,NaN,NaN
942,NaN,NaN,NaN,QYS20179,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalhipytfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 436 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 436 from patent US 11053304,2022-03-15,NaN,NaN,NaN
943,NaN,NaN,NaN,QYS20178,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsdrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqtlhtpgtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 435 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 435 from patent US 11053304,2022-03-15,NaN,NaN,NaN
944,NaN,NaN,NaN,QYS20177,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngyiyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqvlrtpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 434 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 434 from patent US 11053304,2022-03-15,NaN,NaN,NaN
945,NaN,NaN,NaN,QYS20176,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrmeaedvgvyycmqtlqmpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 433 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 433 from patent US 11053304,2022-03-15,NaN,NaN,NaN
946,NaN,NaN,NaN,QYS20175,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllhrngynyldwylqkpgqspqlliygastratgvpdrfsgsgsgtdftlkisrveaedvgvyyctqslqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 432 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 432 from patent US 11053304,2022-03-15,NaN,NaN,NaN
947,NaN,NaN,NaN,QYS20174,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrpsqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqaahwpitfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 431 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 431 from patent US 11053304,2022-03-15,NaN,NaN,NaN
948,NaN,NaN,NaN,QYS20173,SARS-CoV-2,Unknown.,NaN,divmtqsplslpvtpgepasiscrssqsllysdgdtyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 430 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 430 from patent US 11053304,2022-03-15,NaN,NaN,NaN
949,NaN,NaN,NaN,QYS20172,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 6nb6; US11053304-B1 429 06-JUL-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 429 from patent US 11053304,2022-03-15,NaN,NaN,NaN
950,NaN,NaN,QYR87209,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 436 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 436 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
951,NaN,NaN,QYR87201,NaN,SARS-CoV-2,Unknown.,qmqlvqsgtevkkpgeslkisckgsgygfitywigwvrqmpgkglewmgiiypgdsetryspsfqgqvtisadksintaylqwsslkasdtaiyycaggsgistpmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 427 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 427 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
952,NaN,NaN,QYR87193,NaN,SARS-CoV-2,Unknown.,qvqlvesggalvqpgrslrlscaasgftfrnyamhwvrqapatglqwlavitsdgrnkfyadsvkgrftisredskntlylqmdslrgedtavyycvtqrdnsrdyfphyfhdmdvwgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 419 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 419 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
953,NaN,NaN,QYR87185,NaN,SARS-CoV-2,Unknown.,evqleesgtvlarpgasvkmsckasgytfttyrmhwikqrpgqglewigaiypgnsdttynqkfkdkakltavtstssaymelssltnedsavyfctregipqllrtldywgqgtsvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 411 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 411 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
954,NaN,NaN,QYR87177,NaN,SARS-CoV-2,Unknown.,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 403 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 403 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
955,NaN,NaN,QYR87169,NaN,SARS-CoV-2,Unknown.,qvqlqqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggitpilgianyaqkfqgrvtittdeststaymelsslrsedtavyycardtvmggmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 395 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 395 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
956,NaN,NaN,QYR87138,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvyvsckasgytftsygiswvrqapgqglewmggiipmfgttnyaqkfqgrvtitadkststaymelsslrsedtavyycardrgdtidywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 364 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 364 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
957,NaN,NaN,QYR87137,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyeinwvrqapgqglewmgiinpsdgsstyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgysydhdqiyyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 363 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 363 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
958,NaN,NaN,QYR87136,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgwmnsnsgstgyaqkfqgrvtmtrdtststvymelsslrsedtavyycargwmaydafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 362 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 362 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
959,NaN,NaN,QYR87135,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqapgqglewmgiidpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycatvtpgygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 361 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 361 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
960,NaN,NaN,QYR87134,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 360 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 360 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
961,NaN,NaN,QYR87133,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftryyihwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycakgaphdyiwgsyrpdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 359 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 359 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
962,NaN,NaN,QYR87132,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftnygiswvrqapgqglewmgwisarngntnyaqkfqgrvtmtrdtststvymelsslrsedtavyycttdpvlewfgysiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 358 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 358 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
963,NaN,NaN,QYR87131,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftgsyaiswvrqapgqglewmgwinpktgdtnyaqefqgrvtmtrdtststvymelsslrsedtavyycargssgyyfgwgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 357 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 357 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
964,NaN,NaN,QYR87130,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftgnyihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycakdvqnyygsgssfdywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 356 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 356 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
965,NaN,NaN,QYR87129,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 355 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 355 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
966,NaN,NaN,QYR87128,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardsgvdtatlryyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 354 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 354 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
967,NaN,NaN,QYR87127,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardlmdivvvpwlggmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 353 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 353 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
968,NaN,NaN,QYR87126,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftenemhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaktryggnsrsryyyygmdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 352 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 352 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
969,NaN,NaN,QYR87125,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftdyymqwvrqapgqglewmgwidphsgatnyahsfqgrvtmtrdtststvymelsslrsedtavyycarleggsywtgyfdlwgrgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 351 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 351 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
970,NaN,NaN,QYR87124,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgssvkvsckasgytftdyyiqwvrqapgqglewmgwinpnsggpnyaqkfqgrvtitadeststaymelsslrsedtavyycarvdygdygrledywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 350 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 350 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
971,NaN,NaN,QYR87123,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftdyhmhwvrqapgqglewmgwmnpnsgntsyaqkfqgrvtmtrdtststvymelsslrsedtavyycagmgmgrdgynsrafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 349 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 349 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
972,NaN,NaN,QYR87122,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinydinwvrqapgqglewmgvinpsagstsyahkfqgrvtmtrdtststvymelsslrsedtavyycasahssswysdwfdpwgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 348 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 348 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
973,NaN,NaN,QYR87121,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftsypihwvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycardrgsydtdafdiwgqgtmvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 347 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 347 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
974,NaN,NaN,QYR87120,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasggtftsyhmhwvrqapgqglewmgwmnpnsgntgyalkfqgrvtmtrdtststvymelsslrsedtavyycasferfgelvpetfdywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 346 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 346 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
975,NaN,NaN,QYR87119,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasggtfssyaiswvrqapgqglewmgivnpssgsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarvrgsaaiammdvwgqgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 345 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 345 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
976,NaN,NaN,QYR87118,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasggtfrstaiswvrqapgqglewmgwmnpnsgntgyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragyssssgyyyygmdvwgkgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 344 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 344 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
977,NaN,NaN,QYR87117,NaN,SARS-CoV-2,Unknown.,evqllesggglvqpggslrlscaasgftfsgsamhwvrqapgkgleyvsaisrnggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgtlitttldywgqgtlvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 343 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 343 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
978,NaN,NaN,QYR87116,NaN,SARS-CoV-2,Unknown.,evqllesggglvqpggslrlscaasgfsfsnydmhwvrqapgkglewvavisydggfklyadsvkgrftisrdnaknslylrmnslrsedtavyycargqvrgsgpqvvvmdvwgkgttvtvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 342 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 342 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
979,NaN,NaN,QYR87115,NaN,SARS-CoV-2,Unknown.,qvqlvqsgaevkkpgasvkvsckasgdtfsnygiswvrqapgqglewmgwmnpnsggtnyaqkfqgrvtmtrdtststvymelsslrsedtavyycaigttvvtpfgywgqgtlvnvss,NaN,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 341 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 341 from patent US 11021532,NaN,2022-03-15,NaN,NaN,NaN
980,NaN,NaN,NaN,QYR87210,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 437 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 437 from patent US 11021532,2022-03-15,NaN,NaN,NaN
981,NaN,NaN,NaN,QYR87202,SARS-CoV-2,Unknown.,NaN,diqltqspdslavslgeratinckssqsvlyssinknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 428 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 428 from patent US 11021532,2022-03-15,NaN,NaN,NaN
982,NaN,NaN,NaN,QYR87194,SARS-CoV-2,Unknown.,NaN,dvvltqsplslpvtlgqpasiscrssqslvysdgdtylnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgshwpptfgqgtkveik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 420 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 420 from patent US 11021532,2022-03-15,NaN,NaN,NaN
983,NaN,NaN,NaN,QYR87186,SARS-CoV-2,Unknown.,NaN,dilmtqspsslsaslgervsltcrasqeisgylswlqekpdgtikrliyaastldsgvpkrfsgsrsgsdysltisslesedfadyyclqyvsypwtfgggtkleik,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 412 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 412 from patent US 11021532,2022-03-15,NaN,NaN,NaN
984,NaN,NaN,NaN,QYR87178,SARS-CoV-2,Unknown.,NaN,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 404 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 404 from patent US 11021532,2022-03-15,NaN,NaN,NaN
985,NaN,NaN,NaN,QYR87170,SARS-CoV-2,Unknown.,NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdyvfgtgtkvtvl,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 396 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 396 from patent US 11021532,2022-03-15,NaN,NaN,NaN
986,NaN,NaN,NaN,QYR87162,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqgngfpltfgpgtkvdikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 388 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 388 from patent US 11021532,2022-03-15,NaN,NaN,NaN
987,NaN,NaN,NaN,QYR87161,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrvsqgissylnwyqqkpgkapklliyaasilqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpftfgpgtkvdikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 387 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 387 from patent US 11021532,2022-03-15,NaN,NaN,NaN
988,NaN,NaN,NaN,QYR87160,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqsiynylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 386 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 386 from patent US 11021532,2022-03-15,NaN,NaN,NaN
989,NaN,NaN,NaN,QYR87159,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqtiysylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftltisslqpedfatyycqqaisfpltfgggtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 385 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 385 from patent US 11021532,2022-03-15,NaN,NaN,NaN
990,NaN,NaN,NaN,QYR87158,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 384 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 384 from patent US 11021532,2022-03-15,NaN,NaN,NaN
991,NaN,NaN,NaN,QYR87157,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasenidswlawyqqkpgkapklliyeastlesgvpsrfsgsgsgtdftltisslqpedfatyychqylsspetfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 383 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 383 from patent US 11021532,2022-03-15,NaN,NaN,NaN
992,NaN,NaN,NaN,QYR87156,SARS-CoV-2,Unknown.,NaN,divmtqspdslavslgeratinckssqsvfsssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 382 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 382 from patent US 11021532,2022-03-15,NaN,NaN,NaN
993,NaN,NaN,NaN,QYR87155,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 381 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 381 from patent US 11021532,2022-03-15,NaN,NaN,NaN
994,NaN,NaN,NaN,QYR87154,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysppltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 380 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 380 from patent US 11021532,2022-03-15,NaN,NaN,NaN
995,NaN,NaN,NaN,QYR87153,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 379 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 379 from patent US 11021532,2022-03-15,NaN,NaN,NaN
996,NaN,NaN,NaN,QYR87152,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliygastlsdgvpsrfsgsgsgtdftltisslqpedfatyycqqgystpysfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 378 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 378 from patent US 11021532,2022-03-15,NaN,NaN,NaN
997,NaN,NaN,NaN,QYR87151,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqaitnylawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyysypptfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 377 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 377 from patent US 11021532,2022-03-15,NaN,NaN,NaN
998,NaN,NaN,NaN,QYR87150,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqhissylnwyqqkpgkapklliyaasalqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgygtpytfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 376 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 376 from patent US 11021532,2022-03-15,NaN,NaN,NaN
999,NaN,NaN,NaN,QYR87149,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnylawyqqkpgqaprlliyavssratgiparfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 375 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 375 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1000,NaN,NaN,NaN,QYR87148,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsiyswlawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypytfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 374 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 374 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1001,NaN,NaN,NaN,QYR87147,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysmpltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 373 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 373 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1002,NaN,NaN,NaN,QYR87146,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 372 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 372 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1003,NaN,NaN,NaN,QYR87145,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdisnylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpstfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 371 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 371 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1004,NaN,NaN,NaN,QYR87144,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgirndlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 370 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 370 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1005,NaN,NaN,NaN,QYR87143,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqdirnelgwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 369 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 369 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1006,NaN,NaN,NaN,QYR87142,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnnlnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqydtfpltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 368 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 368 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1007,NaN,NaN,NaN,QYR87141,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsigyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpltfgggtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 367 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 367 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1008,NaN,NaN,NaN,QYR87140,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgirndlgwyqqkpgkapklliydasrlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqyystppltfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 366 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 366 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1009,NaN,NaN,NaN,QYR87139,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasesvssrylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqgyknpptfgqgtkveikr,"Glanville,J. et al.; Superhuman anti-SARS-CoV-2 antibodies and uses thereof; US11021532-B1 365 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 365 from patent US 11021532,2022-03-15,NaN,NaN,NaN
1010,NaN,NaN,QYR85030,NaN,SARS-CoV-2,Unknown.,evqlvqsgggvvqpgkslrlscaasgfafssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 102 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 102 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1011,NaN,NaN,QYR85011,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 83 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 83 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1012,NaN,NaN,QYR85010,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 82 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 82 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1013,NaN,NaN,QYR85009,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamhwvrqapgkglewvaiiyeggsphyadsvkgrftisrdnskntlylqmnslraedtavyycardrsgyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 81 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 81 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1014,NaN,NaN,QYR85008,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsdhymswvrqapgkglewvsaistsgdstfyadsvkgrftisrdnskntlylqmnnlraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 80 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 80 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1015,NaN,NaN,QYR85007,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfsfssygmswvrqapgkglewvsamnrdgsyiyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyvgywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 79 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 79 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1016,NaN,NaN,QYR85006,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnsdmnwvrqapgkglewvsaisgtgdtteyadsvkgrftisrdnskntlylqmnslraedtavyycardrslmldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 78 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 78 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1017,NaN,NaN,QYR85005,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfsnhymswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 77 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 77 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1018,NaN,NaN,QYR85004,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftftnyamtwvrqapgkglewvstmsniggdtyyadsvkgrftisrdnskntlylqmnslraedtavyycardrrvyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 76 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 76 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1019,NaN,NaN,QYR85003,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfashamswvrqapgkglewvsgissdgsittyadsvkgrftisrdnskntlylqmnslraedtavyycardrgwyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 75 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 75 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1020,NaN,NaN,QYR85002,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasglsvtsnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 74 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 74 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1021,NaN,NaN,QYR85001,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsvvypggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsyyldywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 73 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 73 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1022,NaN,NaN,QYR85000,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgfrfsdaaihwvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsygidywgqgtlvtvss,NaN,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 72 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,Sequence 72 from patent US 11021531,NaN,2022-03-15,NaN,NaN,NaN
1023,NaN,NaN,NaN,QYR85031,SARS-CoV-2,Unknown.,NaN,ettltqspatlslspgeratlscrasqsvrsnlawyqqkpgqaprpliydastratgipdrfsgsgsgtdftltisrlepedfavyycqqrsnwpptfgqgtkvevk,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 103 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 103 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1024,NaN,NaN,NaN,QYR85023,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 95 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 95 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1025,NaN,NaN,NaN,QYR85022,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvsssylawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqasstpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 94 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 94 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1026,NaN,NaN,NaN,QYR85021,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliydastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 93 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 93 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1027,NaN,NaN,NaN,QYR85020,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqfgtsppglsfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 92 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 92 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1028,NaN,NaN,NaN,QYR85019,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 91 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 91 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1029,NaN,NaN,NaN,QYR85018,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqrnnwpptfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 90 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 90 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1030,NaN,NaN,NaN,QYR85017,SARS-CoV-2,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsigtylswyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqslslpvtfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 89 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 89 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1031,NaN,NaN,NaN,QYR85016,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgteftltisslqsedfavyycqqygsspltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 88 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 88 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1032,NaN,NaN,NaN,QYR85015,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 87 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 87 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1033,NaN,NaN,NaN,QYR85014,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 86 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 86 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1034,NaN,NaN,NaN,QYR85013,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 85 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 85 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1035,NaN,NaN,NaN,QYR85012,SARS-CoV-2,Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikr,"Glanville,J. et al.; Anti-SARS-Cov-2 antibodies derived from 2GHW; US11021531-B1 84 01-JUN-2021 Centivax, Inc.; South San Francisco, CA; 2021.",NaN,NaN,Sequence 84 from patent US 11021531,2022-03-15,NaN,NaN,NaN
1036,NaN,NaN,QXE98516,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1037,NaN,NaN,QXE98515,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1038,NaN,NaN,QXE98514,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1039,NaN,NaN,QXE98513,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsdtpfywgwirqppgkglewigsmyytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpssifrgtvftpyyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1040,NaN,NaN,QXE98512,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvnpggslrlscagsgftfsdyymgwirqapgkglevvsyisttgsyikdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgsfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1041,NaN,NaN,QXE98511,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglsqpggslrlscatsgfavrnncmnwvrqapgkglewvslicgdgityhsdsvkgrfiisrddsenalhlqmnslrvedtavyycvkasppggntgwpffhywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1042,NaN,NaN,QXE98510,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewlsyishtastiyyadsvkgrftisrdnaknslflqmnsltaedtavyycardrgsgvidpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1043,NaN,NaN,QXE98509,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrepgssvklscktsggpfsthafswvrqapgqrpewmggimpvfgeskdtqkfkgrvtftadasttttymelrslksddtaiyycvrdsdpytatsshnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1044,NaN,NaN,QXE98508,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggiiplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1045,NaN,NaN,QXE98507,NaN,SARS-CoV,Homo sapiens (human),evqlvqwgagllkpsetlslrcavyggsfngfywtwirqapgqglewiaeinhsgttnynpslksrvtisidtskkqfslslksvtaadtamyfcargtispivgvptpvvprrgrswfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1046,NaN,NaN,QXE98506,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgggvvqpgtslrlscaatgftfttypmhwvrqapgkglewvavisydgmnqyyadflkgrftisrdnskntlylqmnslraddtavyycarayggnyqnhfdhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1047,NaN,NaN,QXE98505,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvqpggslrlscadsgnafianpmhwvrqapgkglewlalistdgnnrhyadsvkgrftfsrdnsknslylqmdslrpedtgvyycaresrssgragcfdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1048,NaN,NaN,QXE98504,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsryamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlflqmsnvrpedtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1049,NaN,NaN,QXE98503,NaN,SARS-CoV,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsissnnlywgwirqppgkglewigsiyysgstyynpslksrviipvdtskdqfslrlssvtaadtavyycarhsqkdivlipaaqspifdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1050,NaN,NaN,QXE98502,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsshaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftvdestntaymeltslksedtaiyycvrdpdpytatvrhnhywhgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1051,NaN,NaN,QXE98501,NaN,SARS-CoV,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsinsqywnwirqspgkglewigyvyysgstnynpslksrvtmsvdtsknhfslnlrsvtaadtavyycarglvvryfdgfpsgpiigafdiwnqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1052,NaN,NaN,QXE98500,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1053,NaN,NaN,QXE98499,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcgvyggsfsgyfwswirqspgkglewigeinhsrsmsynpslksritmsvdtsknqfslnlnsvtaadtavyfcargkahrndfwsgyyphwfdpwgqgilvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1054,NaN,NaN,QXE98498,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgfywtwirqppgkglewigeinhsgssnydlslksrvtmsvdtsknqfslklssvtaadtavyycargmispriprttrqrwfdtwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1055,NaN,NaN,QXE98497,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyvrkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1056,NaN,NaN,QXE98496,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewlggilplfgtsesaqrfqarvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1057,NaN,NaN,QXE98495,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkmpgssvkvsckvsggrfsdyaiswlrqapleglewmggivphlnrkgysqkfqdrltftaddststaymelsgltsedtavyycardptflntgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1058,NaN,NaN,QXE98494,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmlsdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1059,NaN,NaN,QXE98493,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaaseftfstyamhwvrqapgkglewvalisydginkyyadsvkgrfaisrdnskntlylqvnslraddtavyycvrpysgsytnwfdlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1060,NaN,NaN,QXE98492,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscvasgftfsdfymswirqapgkglewvsyisgsgdtiyyadsvkgrftvsrdnaknslflqmsslgaedtamyycarematsfgyyfvldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1061,NaN,NaN,QXE98491,NaN,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgtslrlscavsgfmfknyaihwvrqapgkglewvavisfdgsdisytesvqgrftisrdnsenmlylqmnslraedtamyycarepdgigaagisgywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1062,NaN,NaN,QXE98490,NaN,SARS-CoV,Homo sapiens (human),evqllesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsehaqrfqarvkftadeststaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1063,NaN,NaN,QXE98489,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1064,NaN,NaN,QXE98488,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggevkkpgasvkvsckasgytlssypiswvrqapghglewmgwintyngrtnyeqmlqgrvtmttdtststaymelrslrsddtavyycarvvfrhgqyddssgrlafdiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1065,NaN,NaN,QXE98487,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvylqmnslrdedtavyfcareldsetyynynsldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1066,NaN,NaN,QXE98486,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkgpgasvkvsckvsgysfityditwvrqapgqglewmgwistksgdtryaqnvqgrvtmttdtstntaymelrnlksddtalyycarttprgweqwpvleywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1067,NaN,NaN,QXE98485,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgrglvkpsetlsltctvsggsitssryywgwirqppgrnlewigsihysgttsynpslwsrvaisvdtaqnqfslrlnsvtaadtavyycaapapsnheswsgtdwfdpwgqgilvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1068,NaN,NaN,QXE98484,NaN,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1069,NaN,NaN,QXE98483,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrepgssvklscktsggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrsnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1070,NaN,NaN,QXE98482,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlsceasgftfadypmhwvrqapgkglewvavisshgrsqgyaasvkgrftfsrdnsqsslflqlnslrvedtavyfcareaqssgragcldawgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1071,NaN,NaN,QXE98481,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscgasgftfsdyamswvrqapgkglewvstisgsgdktyyadslkgrftnsrdnskstlylqmtslraedtavyfcakdrycsggscfydafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1072,NaN,NaN,QXE98480,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1073,NaN,NaN,QXE98479,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggpfssfaiswvrqapgqglewlggimtvfgpahyaqksrdrisitadeststsylelssltsddtavyycaaeersgtnhnyygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1074,NaN,NaN,QXE98478,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsggdsvnpggslrlscagsgfsvrdvwmswvrqapgkglewigrikseadggssdyraslkdrfsiwrdaskntlylqvnglqtedtaiyfcswndvgwaftfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1075,NaN,NaN,QXE98477,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgdkkyypdsvrgrftisrdnskntlhlqmnslrledtavyycarsyggsystvgywgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1076,NaN,NaN,QXE98476,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavnggsfnnyywswirqppgkgpewigevvhsgsttynpslksrvtisidmsknqfalklnsvtaadtavyycargftftysdfltgqrtfeywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1077,NaN,NaN,QXE98475,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpggslrlscvasgfpfgryamhwvrqapgqglewltlisfdssnieysdsvqgrftisrdnsrntlflqmtslrpedtavyfcardlppldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1078,NaN,NaN,QXE98474,NaN,SARS-CoV,Homo sapiens (human),evqlvesgptlvkptqtltltctfsgfslntrelgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltltnmdpgdtatyycahtselpprrpyaafdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1079,NaN,NaN,QXE98473,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvkpggslrvscvgsgftfsdhymswirqapgkgleiisyistdgsyindadsvkgrfinsrdnaknsvylqlnslraedtavyycarmgpsgsgsldywgqgslvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1080,NaN,NaN,QXE98472,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1081,NaN,NaN,QXE98471,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsthaiswvrqapghgpewmggiiplfgtsesaqrfqarvrftadeststaymelssltsedtavyycvrdsdpytatsrnnhywydmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1082,NaN,NaN,QXE98470,NaN,SARS-CoV,Homo sapiens (human),evqlvqsggglvqpggslrlscaasgftfssysmswvrqapgkglewvsyitrssdniyyaesvkgrftisrdsaknslylhmnslrdedtavyycardpgleysgnyfsyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1083,NaN,NaN,QXE98469,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvtdnymswvrqapgkglewvsvlysggstyyadavqgrfsisrdnsknalylqmnslraedtavyycargfgngwsyyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1084,NaN,NaN,QXE98468,NaN,SARS-CoV,Homo sapiens (human),evqllesggglvkpggslrlsceasgftfsnynmnwvrqapgkglewvssisgsssyisyadsvkgrftisrdnaknslylqmnslrvedtavyycaradrdydfwsdpplidhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1085,NaN,NaN,QXE98467,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgaevkrpgasvkvsckasgyafsdyymhwvrqapgqgpewmgwinpnsgdtgypqkfrgwvtmtrdtsvstaymelkrlksddtavyycasgpnyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1086,NaN,NaN,QXE98466,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtlshyaiswvrqapgqglewmggimpvsgtvgyaqkfqgrvkftadeyastaymeltnlrsedsavyfcardpsivdsgphhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1087,NaN,NaN,QXE98465,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1088,NaN,NaN,QXE98464,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1089,NaN,NaN,QXE98463,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1090,NaN,NaN,QXE98462,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggilpafaasgspgyapifrgratfsadvststayleltnlkpedtavyycardpsilntgnhhwydldlwgqgtevtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1091,NaN,NaN,QXE98461,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfskfamhwvrqapgkglewvaiisydgshknyadsvkgrftisrdnskntvylqvdslraedtavyycallygsgsyynfvffgwkdgsdawgpgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1092,NaN,NaN,QXE98460,NaN,SARS-CoV,Homo sapiens (human),evqllesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1093,NaN,NaN,QXE98459,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfifsdyymswirqapgkglewvsyitgsgrtihyadsvkgrftisrdnaknsvylqmnslraedtavyycarghrflefplnyfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1094,NaN,NaN,QXE98458,NaN,SARS-CoV,Homo sapiens (human),evqlvesgghvvlpgkslrlscagsgfgfplyamqwvrrapgkglewvalvsydssniryadsvkgrftisrdnsqntlylqmdslrpedtamyycardnalqdgrpgyfdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1095,NaN,NaN,QXE98457,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvkvsckasggtfynsafswlrhapgqgpewmggitpslgrvgyserflarltitadeststvymeltslasedtavyycardasivgtgnhlwygldfwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1096,NaN,NaN,QXE98456,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqhfrgrlsitadesastaymeltglrsedtamyycardpsilntgnhhwydldlwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1097,NaN,NaN,QXE98455,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsaseftlrshamhwvrqapgkgleyvsgistdgsgrfyadsvkgrftisrdnsknklflqmsslrpedtavyycvrdwgssthydvfdlwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1098,NaN,NaN,QXE98454,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgatyknsafswarqapgqgfqwmggiiplfgvphyvqmfqgrvtitadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1099,NaN,NaN,QXE98453,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpifgspgyaeifqgrvtitadeskstvymeltslrsedtavyycardpsildtgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1100,NaN,NaN,QXE98452,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrlscaasgfifsghwmswvrqapgkglewvanikqdgrekhyvdsvkgrftisrdnaknsvslqmnslraedtavyycvrqnvaiqyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1101,NaN,NaN,QXE98451,NaN,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfnsyalfwvrqapgkglewvavvsydgnnkyyadsvkgrftisrdnskntlylqmnslktedtsvyycarprsgsyrqaidywglgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1102,NaN,NaN,QXE98450,NaN,SARS-CoV,Homo sapiens (human),evqlvesgaevknpgssvkisckssggtlgdyaiswvrqapglglewlggimplhgttgysqrfrprltitadesartaymeltalssedsaiyycardpsilntgnhhwydldlwgqgtevtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1103,NaN,NaN,QXE98449,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1104,NaN,NaN,QXE98448,NaN,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsetlslactvsggsisnyywnwvrqppgkglewigniyysgsttfnpslksrvtisvdtsrnqfslklssvtaadtavyycarqssswynpyyfdqwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1105,NaN,NaN,QXE98447,NaN,SARS-CoV,Homo sapiens (human),evqllesgaevkkpgssvkvscktsggtfnsytiswvrqapgqglewmggiipildtphyaqkfrgrvtitadkststafmdlssltsedtavyycairrdysdyrdfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1106,NaN,NaN,QXE98446,NaN,SARS-CoV,Homo sapiens (human),qvqllesggglvqpgrslrlsctasgfrfgdytmtwfrqapgkglewvgfirsiayggttehaasvegrfiisrddsksiaylqmnslkaedtgvyfctrgsgmfygsssgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1107,NaN,NaN,QXE98445,NaN,SARS-CoV,Homo sapiens (human),evqlqesgpglvkpsetlsltcavsggsvssdtdywgwirqppgkglewigsihdsertyydpslksrvtisvdtsknqfslrlssvtaadtalyfcasrhldllpigsfdvwgrgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1108,NaN,NaN,QXE98444,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgeslrlscaasgfnfspygmnwvrqapgkglewiayiisgsgtiyyadsvkgrftisrdnaqsslylqmnslraedtavyycarglldylhdafdiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1109,NaN,NaN,QXE98443,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqvpgrglewvsgiswnsgtinyadsvmgrftisrdnaknslylqmnslraedtalyycakdgrycsgiscrtgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1110,NaN,NaN,QXE98442,NaN,SARS-CoV,Homo sapiens (human),evqllesgpglvkpsqtlsltctvsngfissgeyywswirqspgkglewigyishsgstyynrslksrvtisldtsrnqfslnlssvtaadtavyycardlakwsygyyysgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1111,NaN,NaN,QXE98441,NaN,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgysstnygfswvrqapgqglewmgwisvhsgnanfaqkfqgritmttdtstttaymelrnlrsddtatyycatsassysryyfgldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1112,NaN,NaN,QXE98440,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsnynmvwvrqapgkglewisyissssstiyyadsvkgrfiisrdnaknslhlqmnslrdedtavyycvrdycnsvscytyyyigmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1113,NaN,NaN,QXE98439,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggsftsyvlswvrqapgqglewmgrivpnlgvanyaqkfqdrvtitadkstttaylelrslrsedtavyycardlyydnggynyldywgpgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1114,NaN,NaN,QXE98438,NaN,SARS-CoV,Homo sapiens (human),evqlvesgaevrkpgssvkvsckatggtfssygitwvrqapgqglewmgriiptlgrtnyaqkfqgrvtitadkststahmelsslrsedtavyycardlstlqpdaivnfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1115,NaN,NaN,QXE98437,NaN,SARS-CoV,Homo sapiens (human),evqllesgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1116,NaN,NaN,QXE98436,NaN,SARS-CoV,Homo sapiens (human),evqllesgaevkkpgssvkvsckasggtfssdaiswvrqapgqglewmggiipifgttnyaqkfqgrvtitadestntaymelsslrsedtavyycardgpydsggyhlnhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1117,NaN,NaN,QXE98435,NaN,SARS-CoV,Homo sapiens (human),evqlvesgaevkkpgasvilsckasgytvtnyyihwvrqapgqglewmgwidpdsgvtnfaekfqgrvtmtrdtsistaymelrwlesddtavyycakdlitvirglgggmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1118,NaN,NaN,QXE98434,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelgslrsddtavyycarvlagsshewqlthdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1119,NaN,NaN,QXE98433,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagvlkpsetlsltcavyggsfrgffwswirqppgkglewigqithsgstnynsslksrltisvdtsknqfslnlssvtaadtaiyycargqggydlrrvgygltswfdpwgqgilvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1120,NaN,NaN,QXE98432,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1121,NaN,NaN,QXE98431,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvqpgkslrlscvasgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgvyycvkdqssgdrllylgyfdlwgpgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1122,NaN,NaN,QXE98430,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgkslrlscvpsgfsfgtygmhwvrqapgkgpewlavmwydgitqyyadsvkgrftisrdnsketlylqmnsltaddtgiyycvkdqssgdrllylgyfdlwgpgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1123,NaN,NaN,QXE98429,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscktsgytftghyihwvrqapgqglewmgwinpasgdtnyaqkfqgrvtktrdtsittaymelnrlrsddtavyycarggplpwsdldivgtfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1124,NaN,NaN,QXE98428,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyyvhwvrqvpgqglewmgwispdsgdtiraqnfqgrvtmtrdtsmntaymevnrlrtddtaiyycardlisvirglgggmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1125,NaN,NaN,QXE98427,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsnyamtwvrqapgkglkwvsginpsgdatfytdsvkgqftisrdnsknilylqmnrlraddtaiyycakglsfygsgsdafdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1126,NaN,NaN,QXE98426,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssmkvsckasgvnfrsysfswvrqapgqglewmggvipyfptanyadkfrdrvtitadestgtvyldmsslrsedtavyfcaseyfdgrsyhsfcgldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1127,NaN,NaN,QXE98425,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckasgysftnywvgwvrqmpakglewmgiiwpddsdtryrpsfqgqvtisvdksistaylhwnslkasdngmyfcaraplascsggrcptynrfdlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1128,NaN,NaN,QXE98424,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgpglvrpsgtlsvtcavsgdsissdywctwvrqspgkglewigkishsgslnynpslksrvtmsvdksknhfslklasvtaadtavyycarvrigashhnfwsgyytdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1129,NaN,NaN,QXE98423,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsgrvywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1130,NaN,NaN,QXE98422,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgaevkkpgssvrvsckasggtfrksaiswvrqapgqgfewmggiiptldrrgfaqkfqdrltmtadeftstaymdlsdlrsddtavyycardasfpntgnhfwydfdlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1131,NaN,NaN,QXE98421,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscrvsggrfsdyafswlrqapvkglewmggiiprldrkgyshifqdrltftadeststtymelsgltsddtavyycardptflnsgnhfwydvdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1132,NaN,NaN,QXE98420,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvevsckvsggtfrdyaiswvrqapgqrlewmggimpglgspayaqifgdrvtisadtststaylqvtnlrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1133,NaN,NaN,QXE98419,NaN,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1134,NaN,NaN,QXE98418,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpgllkpsetlsltctvsnspissnywswirqpagkglewigriditgntnynpslksrvimsvdtsksqfslkmtsvtaadtavyycarsfisfdssghpyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1135,NaN,NaN,QXE98417,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlslicdvyggsfngfywswirqppgkglewigeishdgstnyspslksrvsisidtskkqfslklrsvtaadtamyycargmtspvvhlyssgrpsrwfdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1136,NaN,NaN,QXE98416,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfsnyamnwvrqapgqgpewmgwidtntgnptyaqgfigrfvfsldtsvntaylligsleaedtavyycareehydfssgyfrpaywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1137,NaN,NaN,QXE98415,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1138,NaN,NaN,QXE98414,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggifsthaiswvrqapgqrpewmggiipifgeskdtrkfqgrvtftadestttaymelrslksddtaiyycvldsdpytatfshnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1139,NaN,NaN,QXE98413,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscvtsgfdfrpyamqwvrqapgkglewvavishdgvhtgyadslkgrftisrdnskntlylqvdslrpddsalyycardnalqnaqigyldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1140,NaN,NaN,QXE98412,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1141,NaN,NaN,QXE98411,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1142,NaN,NaN,QXE98410,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmisdyaiswvrqapgqrlewmggimpafgspgyaqifrgratisadvstntayleltslnpddtavyycardpsilntgnhhwydldmwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1143,NaN,NaN,QXE98409,NaN,SARS-CoV,Homo sapiens (human),qvtlkesggglvqpggslrlscaasgftvnsygmswvrqapgkglewvsgfksrsdrpdyaesvkgrftisrdtskntvylemiglraedtatyycvrmdwmewmkyyfdswgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1144,NaN,NaN,QXE98408,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrpewmggimpglgspayaqifrgratisadlststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1145,NaN,NaN,QXE98407,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmftdyaiswvrqapgqrlewmggimpglgspayaqifrdratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1146,NaN,NaN,QXE98406,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1147,NaN,NaN,QXE98405,NaN,SARS-CoV,Homo sapiens (human),evqllesgpgllkpsetlsltctvsgdsvssgnfywswvrrppgkalewiayshytggtnsdpsfmgrvtmsidpsrnqfslrltsvaaadtavyycarttspltysghwplfdywgqgslvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1148,NaN,NaN,QXE98404,NaN,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgidggggssyyadsvrgrftvsrdnsknmlhlqmnslraddtavyfcakgdwiryfdwslpisffdywgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1149,NaN,NaN,QXE98403,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgadvkkpgasvkvsckasgytftsyymhwvrqapgqglewlgvihpsggsttfaqkfqgrvtmtrdtststvymelsslrsedtavyycarvlagsshewqlthdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1150,NaN,NaN,QXE98402,NaN,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1151,NaN,NaN,QXE98401,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgaevkkpgssvkisckisgdtfstnaiswlrqapgrepewmggivplvgpasyaqrpqgrltitadeftntaylelnslrsedtatyycardsdpytatrrhnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1152,NaN,NaN,QXE98400,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmnhyywswirqppgkglegigytyysgstnynpslksrvtisvdasknqfslrlssvtaadtavyycargsqidlrgglgatffdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1153,NaN,NaN,QXE98399,NaN,SARS-CoV,Homo sapiens (human),evqlvesggsvvqpgtslklscagsagltitryamhwvrqapgkglewvalvshdgihigysdsvrgrftisrdnsrntlylqmdglrpedtavyycvrddvlqhsrpsgpgyfvswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1154,NaN,NaN,QXE98398,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsitsrdwwswvrqppgkglewigevyhsgstsynpslksrvtisvdksknefslklssvtaadtavyycaragnivvmpaaqyyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1155,NaN,NaN,QXE98397,NaN,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalskvgyagkfqarltfsadelkttvymdlssltsedtavyycardpsflnagnhfyydfdvwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1156,NaN,NaN,QXE98396,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsafamhwvrqapgkglewvtiisydgsneyyadsvqgrfsisrdnskntlflqmsslrtedtaiyycaraggylsafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1157,NaN,NaN,QXE98395,NaN,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsatlsltctvsggsinnyywtwvrqsagkglewigrintsgstnynaslksrvtmsidtsknefslrlssvtaadtavyycarefgvrfldrslfgamdvwghgatvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1158,NaN,NaN,QXE98394,NaN,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssmrvscrvsggtfithamswvrqapgqgpewmggivplfgrasyaqpsqtrvqitadeststvylevpsltsedtavyycvrdsepytatrsqnhywydmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1159,NaN,NaN,QXE98393,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtlsdyaiswvrqapgqglewmggimpvfgspgyaeifqgrltitadesrstaymeltslrsedtavyycardpsilntgphhwydldiwgpgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1160,NaN,NaN,QXE98392,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgpevkkpgssvrvsckvsggpfssygvswarqapekglewmggvlpifgtvgyvhkfqgrvtitadeststvymalsslrsedtavyycvldttmshphnwygmdvwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1161,NaN,NaN,QXE98391,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftndgfvwvrqapgqvpewmgwisvhtgdtiyaqrfqgrvtmttdtstrtsymelmslrsddtavyycardygdgppdhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1162,NaN,NaN,QXE98390,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggslrdyaiswvrqapgqgpewmggimpifgtagyaqkfqgrvkftadesattaymeltglrsedsavyfcardpsilntgnhhwydldiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1163,NaN,NaN,QXE98389,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcgvygvsfsdyywswirqppgkglewigeinhsgitnynpslksrvtisvdtsknqfslklssvtaadtavyycarglisytlwlresyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1164,NaN,NaN,QXE98388,NaN,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgasvkisckasgyafrnnyinwirqapgqglewmgiinpsagtstyaqkfqgrvtmtrdtstntvymeitslrsedtatyfcarearrqvtqwfgefwgpynwfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1165,NaN,NaN,QXE98387,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvrpsetlsltctvsrgsisssywswirqppgkglewigfmyysgstnynpslksrvtisldtsknqfslklssvtaadtavyycakaqgiyyrgwsywfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1166,NaN,NaN,QXE98386,NaN,SARS-CoV,Homo sapiens (human),qvqlqqsggglvqpggslrlsceasgfnfnsysmswvrqapgkglewlsyissrsstikyassvqgrftvsrdnakksvflqmnslrdedtavyycareldsetyynynsldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1167,NaN,NaN,QXE98385,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrlscsasgftfntytmhwvrqapgkgleyvsaissngvvtyyadsvkgrftisrdnskntlylqmsslraedtavyycvkalyssswcpfdywgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1168,NaN,NaN,QXE98384,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgfilddyavhwvrlapgkglewvsgitwnsgylgyadsvkgrftisrdnaknslylqmnslrpedtalyycaklgtdhpigvdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1169,NaN,NaN,QXE98383,NaN,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdtgrdtyyaasvkgrftisrdnskntvylqmnslraedtavyycantnfldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1170,NaN,NaN,QXE98382,NaN,SARS-CoV,Homo sapiens (human),qvqlqesggglvqpggslrlsceasgfsfsdfvmhwvrqvpgkglewvsrishdgsitsyvdsvkgrftvsrdngkktlylqmnsprtedtavyycardlawtffdywghgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1171,NaN,NaN,QXE98381,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1172,NaN,NaN,QXE98380,NaN,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsgtlsltcavtgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1173,NaN,NaN,QXE98379,NaN,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsgtlsltcavsgasvssdhwwswvrqspgkglewigevyhsgstnynpslksrvtisldqsnnqfslkltsvtaadtaiyycatmwgglctasncygnpmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1174,NaN,NaN,QXE98378,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklscrasggtfhtytvnwvrqapgqglewlggiipifgtptyaqrfqgkvsitadsstntvfmeltsltsedtavyyctretgtdefdfwgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1175,NaN,NaN,QXE98377,NaN,SARS-CoV,Homo sapiens (human),evqlqesgpgllkpsetlsltctvsgspiasnywswvrqpagkglewigridtspttdynpslksrvimsvdtstsqfslkmssvtaadtavyyctrsfisfdssghpyyyyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1176,NaN,NaN,QXE98376,NaN,SARS-CoV,Homo sapiens (human),evqllesggglvqpggslrlscaasgfpfstdamnwvrqapgeglewvstisdsgrdtyyaasvrgrftisrdnskntvylqmnslrvedtavyycantnfldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1177,NaN,NaN,QXE98375,NaN,SARS-CoV,Homo sapiens (human),evqlvesgptlvkptqtltltctfsgfslttrrqgvgwlrrppgkalewlaliywdddkryspslksrltitkdtsknhvvlsltnvgpadtatyycahtselpprrpyaafdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1178,NaN,NaN,QXE98374,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifknepmnwirqfpgkglewisnirdngndvyyadsvkgrftvsrdnaknslylqmnslrdddtalyycvrdtdwafdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1179,NaN,NaN,QXE98373,NaN,SARS-CoV,Homo sapiens (human),evqlvqsgaemkkpgeslkisckgsgysfpnywigwvrqmpgkglewmaimwpsdsdtryspsfqgqvtisadtststvylqwgslkasdtamyycvrqrycsggscflfedafeiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1180,NaN,NaN,QXE98372,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrlscsasgftfntyamhwvrqapgkrleyvssitrdgagkfyadsvkgrftisrdnskntlyqqmsslrpedtavyycvregqqwlglyfdhwgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1181,NaN,NaN,QXE98371,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsggnvvqpggslrlscvgsefsitffamqwvrrtpgkglewvalvshdgsnirysdsvkgrfiisrdnakntlylqldsltpedtgiyycardhalqngrpgyfdswgqgsqvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1182,NaN,NaN,QXE98370,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvnpggsmrlscagsgftfsdhymgwirqapgkglevisyisssgsfirdadsvkgrftisrdnaknsvylqmnslraedtavyycarmgpygsgtfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1183,NaN,NaN,QXE98369,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfrgfywtwirqppgkglewigevshsgetnynpslksrvtisvdtsknqfslnlisvtaadtsvyycargytapiirevpitfrprwfdpwgqgtpvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1184,NaN,NaN,QXE98368,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmswvrqapgkglewvsghdggtthyadsvkgrftisrddsmntlslqmnslraedtavyycakerdlpgrggyfdhwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1185,NaN,NaN,QXE98367,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfsnyamywvrqapgkrpeyvsgissnggityyadsvegrftvsrdnskkslylqmsslrpedtavyycvkdlgatvtydvfdvwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1186,NaN,NaN,QXE98366,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1187,NaN,NaN,QXE98365,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgdemkkpgssvkvsckasgdtfsthaiswvrqapgqgpewmggiiplfgtasyaqtsqsrvkitadeststaymelssltsedtavyycvrdsdpytatsrnnhywygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1188,NaN,NaN,QXE98364,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscltsgfsfssywmiwvrqapgkglewvaniepdgneeyyvdsvkgrftisrdnaknslylqmnslraedtavyycargpirhfgldafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1189,NaN,NaN,QXE98363,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1190,NaN,NaN,QXE98362,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspayaqsfggrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1191,NaN,NaN,QXE98361,NaN,SARS-CoV,Homo sapiens (human),qvtlkesgaevkkpgssvkvscktsggtfsthaiswvrqapgqgpewmggiiplfgtsqhaqrfqarvkftadestntaymelssltpedtavyycvrdsdpytatsrnnhywygmdvwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1192,NaN,NaN,QXE98360,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggmfrdyaiswlrqapgqrlewmggimpafgapgyaqifrgratisadvstttayleltslmpddtavyycardpsilntgnhhwydldlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1193,NaN,NaN,QXE98359,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftlapygmqwvrqapgkglewvaflshdgshlgyvdsvkgrftisrdnskntlylemnslraedtatyycardnvvqqnadnvgyfdfwgqgslvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1194,NaN,NaN,QXE98358,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggmfsdyaiswvrqapgqrlewmggimpglgspayaqifrgrvtisadiststaylevtslrpedtavyycardpsilntgnhhwydldmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1195,NaN,NaN,QXE98357,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsggglvqpggslrvscsasgftfssfamhwvrqapgkgleyvagisdnghttmyadsvkgrftisrdnskntlylqlsslrpedtavyfcvkdnvilpgaivrpqfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1196,NaN,NaN,QXE98356,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytttfshnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1197,NaN,NaN,QXE98355,NaN,SARS-CoV,Homo sapiens (human),evqllesgggvvqpgtslrlscvasgftfstfamhwvrqapgkglewvalisfdstniryansvrgrftisrdnskntlylevdslriedtgvyycardlppldywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1198,NaN,NaN,QXE98354,NaN,SARS-CoV,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvaviysdgrneyyadsvkgrftisrdnskntlhlqmnslgaadtavyycardpgpitffdwspdksrksyydyngmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1199,NaN,NaN,QXE98353,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggdlvkpgrslrlsctasgftigdyamtwfrqapgkglecvavirsrafggtteyaasvkgrfivsrddsnsvaflqmnslktedtavyycsrdlrrgyydsnghqqfdlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1200,NaN,NaN,QXE98352,NaN,SARS-CoV,Homo sapiens (human),evqlqqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1201,NaN,NaN,QXE98351,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckvsggtfsnyaiswlrqapgqgpewmggiipalsrvgyarkfqarltisadeltttaymdlssltsedtavyycardpsflntgnhfwydfdmwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1202,NaN,NaN,QXE98350,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgpglvrpsgtlsltcavsgdsisgdywctwvrqtpgkglewigkishsgsinynpslksritmsvdksknqfslklnsvtaadtamyycarvrvgashhnfwsgyytdafdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1203,NaN,NaN,QXE98349,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgpelkkpgssvrvsckasggsissyaiswvrqapgqrlewmggvlpmmgrespvqkfkdrvtiaadeststaymelrslsaedtavyycvvdttmadphnwygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1204,NaN,NaN,QXE98348,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtladyaiswvrqapgqglewmggikplhgaagysqlfrgrlsitadesastaymeltgltsddtamyycardpsilntgnhhwydldlwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1205,NaN,NaN,QXE98347,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfslfhvhwvrqapgqglewmgwinphngdttfaerfqgrvaltrdtsintaymelsrltsddtavyfcardfgvryddsrqlmkycdswgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1206,NaN,NaN,QXE98346,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvtvsckvsggrfsdyaiswlrqapveglewmggiiphlnkkgysqkfqdritftadeststaymelsgltsedtaiyycardptflntgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1207,NaN,NaN,QXE98345,NaN,SARS-CoV,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckvsggrfsdyaiswlrqapvkglewmggiiprlnrkgysqdfqgrltftadeststaymelsgltsedtavyycardptflnsgnhfwyavdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1208,NaN,NaN,QXE98344,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtssthaiswvrqapgqglewmggiipifgttnyaqkfqdrvtitadeststaymelsslrsedtavyfcvrdgaydssgyystqwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1209,NaN,NaN,QXE98343,NaN,SARS-CoV,Homo sapiens (human),pgpactvwaevkkpgssvkvsckasggmfsdyaiswvrqapgqrlewmggimpglgspgyaqifrgratisadvststayleltslkpedtavyycardpsilntgnhhwydldiwgqgtqvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1210,NaN,NaN,QXE98342,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvnpggslrlscvgsgftfsdyymgwirqapgkglevisyisstgsyirdadsvkgrftisrdnaensvylqmnslrgedtavyycarmgpygsgsfdywglgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1211,NaN,NaN,QXE98341,NaN,SARS-CoV,Homo sapiens (human),evqlvesgpelkkpgssvrvsckasggsfsnfavswvrqapgqrlewmggviprfgrseyvqkfqgrvtitvdeaastaymelsslrsedtaiyycvldttsanphnwygmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1212,NaN,NaN,QXE98340,NaN,SARS-CoV,Homo sapiens (human),qvqlvqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslrlrsvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1213,NaN,NaN,QXE98339,NaN,SARS-CoV,Homo sapiens (human),evqlqesgpglvkpsgtlsltcgvsgvsisssswwswvrqppgrglewigeispsgstsynpsfrsrltmsvdksrnqlslklssvtaadtavyycartqsndfwsgyytaafdlwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1214,NaN,NaN,QXE98338,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssdwcswvrqppgkgpewiaeishsgstnynpslksrvtmsvdrsknqfslnlnsvtaadtavyycaarirgathydfwsgfwagpfdiwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1215,NaN,NaN,QXE98337,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaemrkpgssvkvsckasggtfsrycfswvrqapgqrlewmggimsilgahyaqkfqgrvtftadestntaymelisltsedtavyycareepsgtyhnyygldvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1216,NaN,NaN,QXE98336,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglsqpggslrlscaasgftvrtycmnwvrqapgkglewvslvcgdnidyypdsvkgrfsisrddskntlllhmdslrvedtavyycaratppgggtgwpyfdfwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1217,NaN,NaN,QXE98335,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslksddtaiyycvrdsdpytatvrnnhywyaldvwgpgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1218,NaN,NaN,QXE98334,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstsamswvrqapgkglewvsrigggggrtkyadsvkgrftisrdnskntlylqmnslraddtavyycakcdlvryfdwlgeennwfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1219,NaN,NaN,QXE98333,NaN,SARS-CoV,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsgasvtagssywgwirqppgkglewigymfssgntkynpslksrvtisadtsknqfslrlssvtaadtavyfcarvgwvryfdwskpyyyfdlwgrgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1220,NaN,NaN,QXE98332,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgfhwswirqppgkglewigevnhsgstkynpslksrvtvsvdtsknqfslrlssvtaadtaiyycargslsreydfltapqngpwfdswgqgalvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1221,NaN,NaN,QXE98331,NaN,SARS-CoV,Homo sapiens (human),qvqlqqwgagllkpsetlslscavyggsfsgfywswirqppgkglewigeinhsgsanynpslmsrvtismdtskkqfslqlrsvtaadtavyycargqespivgvtgrwfdpwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1222,NaN,NaN,QXE98330,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1223,NaN,NaN,QXE98329,NaN,SARS-CoV,Homo sapiens (human),evqlvesgaevrtpgssvklsckasggtfsthafswvrqapgqrpewmggiipifgeskdtqkfqgrvtftadestttvymelrslksddtaiyycvrdsdpytatyrnnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1224,NaN,NaN,QXE98328,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaelkkpgssvrvsckaaggtltnyaiswvrqapgqgfewmggimpvshtagyaqkfqgrvtftadesattaymdltslrpedtaiyycardpsihytgnhhwydldiwgqgtmvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1225,NaN,NaN,QXE98327,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsgypmhwvrqapgkglewvalisfdgdskyytdsvkarfaisrdnskntlflqmnslrvadtalyycarakggsysnafdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1226,NaN,NaN,QXE98326,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckisggtfknsafswarqvpgqgfqwmggiipmfgvphsvqmfqgrvtltadestsavymelsgltsddtavyycareeysgtvhnffgmdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1227,NaN,NaN,QXE98325,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevrkpgssvklsckasggtfsthaiswvrqapgqrpewmggimpifgeskdtqkfqgrvtftadestttaymelrslrsddtaiyycvrdsdpytatvtsnhywyamdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1228,NaN,NaN,QXE98324,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvqpgrslklscvvsgfsfshygmnwvrqapgkglewvavmsydgsdkyyadsvkgrftisrdiskntlylemnslrtedtavyycakkgspycgvdcykgyfdywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1229,NaN,NaN,QXE98323,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglsqpggslrlscaasgfvvknncmnwvrqapgkglewvalicadgityhsdsvtgrftiyrdesdntlhlqmdslriedtavyycvrasppggntgwpffedwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1230,NaN,NaN,QXE98322,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwmspntgdtgyahkfqgrvrmtsntsistaymelnsltsedtavyycarrgnnfgyyyyytvdvwgqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1231,NaN,NaN,QXE98321,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgssmklsckasginfrsysfswvrqapgqglewmggvipyfptanyaekfrgrvtatadestgtvylemsslrsedtavyycaseyfdgrsyhsfcgldvwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1232,NaN,NaN,QXE98320,NaN,SARS-CoV,Homo sapiens (human),evqllesggglsrpggslrlscaasgfiasrncmqwvrqapgkglewvsiicgdeityirdsvkgrftisrddskntlhlemnslraddtavyycaratppggttgwpyidlwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1233,NaN,NaN,QXE98319,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytfsgydinwvrqatgqglewmgwmnpnsgdtgyahkfqgrvtmtrnssistaymelssltsedtavyfcarekksfgpqyyygsgedwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1234,NaN,NaN,QXE98318,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpgrslrlscsasgfsfgdyamswfrqapgkglqwvgliktraygaatdyaasvqgrfiisrddsksiaylqmnslktedtavyfcaregtslgyyyyyamdvwghgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1235,NaN,NaN,QXE98317,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssissssymyyadsmkgrftisrdnaqnslylqmsslraedtavyycardfpgdtavagtgfnywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1236,NaN,NaN,QXE98316,NaN,SARS-CoV,Homo sapiens (human),qvqlqesgpglvrpsetlsltctvsgdsvsssdyhwgwirqppgkglewigsiyyggrshfnpslksrvaifvdtsnnqfslrlnsvtasdtavyfcagrhqellpmgsfdmwaqgttvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1237,NaN,NaN,QXE98315,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1238,NaN,NaN,QXE98314,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1239,NaN,NaN,NaN,QXE98313,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1240,NaN,NaN,NaN,QXE98312,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrnsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlytfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1241,NaN,NaN,NaN,QXE98311,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasenilhylawyqqkpgqaprlviydasrratgipgrfsgsgagtdftltinslepedfavyycqqranwpqnfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1242,NaN,NaN,NaN,QXE98310,SARS-CoV,Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvtsnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygraplytfglgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1243,NaN,NaN,NaN,QXE98309,SARS-CoV,Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydssnratgtpdrfsasgsgteftltitrlepedsavyyclqyssattfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1244,NaN,NaN,NaN,QXE98308,SARS-CoV,Homo sapiens (human),NaN,ettltqspailsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydasnratgvparfsgsgfgteftltisslqsedfavyycqqynnwppltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1245,NaN,NaN,NaN,QXE98307,SARS-CoV,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsishylnwyqqkpgkapklliyaasnlqsgvpsrfsgngsgtdftltisslqpedfatyfcqqsystpltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1246,NaN,NaN,NaN,QXE98306,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqvlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1247,NaN,NaN,NaN,QXE98305,SARS-CoV,Homo sapiens (human),NaN,divltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1248,NaN,NaN,NaN,QXE98304,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnigndyvswyqqlpgtapklliyenykrpsgipdrfsgsksgtsatlditglqtgdeadyycgtwdsslsvdnyvfgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1249,NaN,NaN,NaN,QXE98303,SARS-CoV,Homo sapiens (human),NaN,divltqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyytmwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1250,NaN,NaN,NaN,QXE98302,SARS-CoV,Homo sapiens (human),NaN,dirltqspsslsasvgdrvtitcrasqdisswlawyqqksgkapksliyaasslqngvpsrfsgsrsgtdftltisslqpedlgtyycqqydsypvtfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1251,NaN,NaN,NaN,QXE98301,SARS-CoV,Homo sapiens (human),NaN,dirvtqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1252,NaN,NaN,NaN,QXE98300,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsatpgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsrlsavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1253,NaN,NaN,NaN,QXE98299,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqaasiscrssqavvhsdgntylnwfqqrpgqpprrliykvsnrdsgvpdrfsgsgsgtvftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1254,NaN,NaN,NaN,QXE98298,SARS-CoV,Homo sapiens (human),NaN,ettltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydafnratgvparfsgsgsgtdftltisslepedfavyycqqrtstltfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1255,NaN,NaN,NaN,QXE98297,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1256,NaN,NaN,NaN,QXE98296,SARS-CoV,Homo sapiens (human),NaN,divltqspgtlslspgervtlscrasqsissnylawyqqkpgqaprllisdassratgipdrfsgsgsgadftliisrlepedfavyfchqyggspttfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1257,NaN,NaN,NaN,QXE98295,SARS-CoV,Homo sapiens (human),NaN,qpgltqpasvsgspgqsitisctgtsgdvgsdnlvswyqrhpgkapklmiyegskrpsgvshrfsgsnsgntasltisglqaeddadyyccsyagddtvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1258,NaN,NaN,NaN,QXE98294,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasisctssqtvvhtdrntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1259,NaN,NaN,NaN,QXE98293,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1260,NaN,NaN,NaN,QXE98292,SARS-CoV,Homo sapiens (human),NaN,dirltqsplslsvtlgqaasisctcsqsavhsdgttyfnwfhqrpgqsprrliykvsnrdsgvpdrfigsgsgthftlkisrveaedvgvyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1261,NaN,NaN,NaN,QXE98291,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1262,NaN,NaN,NaN,QXE98290,SARS-CoV,Homo sapiens (human),NaN,eivmtqspgtlssspgeratlscrasqsvssrylawyqqkpgqaprlliygtsnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1263,NaN,NaN,NaN,QXE98289,SARS-CoV,Homo sapiens (human),NaN,eivmtqtpsslsasvgdrvtitcrasqsisnyvnwyqqkpgrapnlliyaasslqsgvssrfsgsgsgtdftltisslqpedfatyycqqtystppegptfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1264,NaN,NaN,NaN,QXE98288,SARS-CoV,Homo sapiens (human),NaN,givltqspdslavsvgeratinckssqtvlyssknkhylawyqqkpgqppklltsspstrepgvpdrfsgsgsgtdftltisslqaedvavyycqqyyttpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1265,NaN,NaN,NaN,QXE98287,SARS-CoV,Homo sapiens (human),NaN,diqmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1266,NaN,NaN,NaN,QXE98286,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1267,NaN,NaN,NaN,QXE98285,SARS-CoV,Homo sapiens (human),NaN,eivmtqspsslsasvgdsvtitcrasqsisnylnwyqdkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysdswtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1268,NaN,NaN,NaN,QXE98284,SARS-CoV,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlrpedsatyyckqynsypytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1269,NaN,NaN,NaN,QXE98283,SARS-CoV,Homo sapiens (human),NaN,diqvtqspatlsvspgervtlscrasqsisntlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyychqynkwppitfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1270,NaN,NaN,NaN,QXE98282,SARS-CoV,Homo sapiens (human),NaN,eivmtqspaslsasvgdrvtitcragqsistnlcwyqqrqgkapklliyaasslrsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1271,NaN,NaN,NaN,QXE98281,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1272,NaN,NaN,NaN,QXE98280,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslavtlgqpasiscrsslglvhtngntylnwfqqrpgqsprrliyrvsnrdsgvpdrfsgsgsvtdftltisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1273,NaN,NaN,NaN,QXE98279,SARS-CoV,Homo sapiens (human),NaN,dirltqspsslsasvgdrvtitcrasqaiagwlawyqqkpgrapksliyrasslqsgvpsrfsgsgsgtdfsltisnlqpedsatyycqhydsyptafgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1274,NaN,NaN,NaN,QXE98278,SARS-CoV,Homo sapiens (human),NaN,ettltqspsslsasvgdrvnitcrasqsistyltwyqqkpgkapklliygasslhsgvpsrftgvgsgteftlsisslqpedfatyycqqsyntfftfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1275,NaN,NaN,NaN,QXE98277,SARS-CoV,Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1276,NaN,NaN,NaN,QXE98276,SARS-CoV,Homo sapiens (human),NaN,ettltqsplflpvtlgqpasiscrssqrlvhtngntylnwfqqrpghsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1277,NaN,NaN,NaN,QXE98275,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsgspgqsvsiscsgtssdfgnynriswyqqtpgtapkviiyevnsrpsgvpdrfsgsksgntasltitglqaedeadyyccsyrsdntyifgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1278,NaN,NaN,NaN,QXE98274,SARS-CoV,Homo sapiens (human),NaN,qsaliqprsvsgspgqsvtisctgtssdvggsnyvswyqqhpgkapkllvydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagtyifgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1279,NaN,NaN,NaN,QXE98273,SARS-CoV,Homo sapiens (human),NaN,qsaliqpasvsgspgqsitisctgtssdvgrynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssyisdiklvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1280,NaN,NaN,NaN,QXE98272,SARS-CoV,Homo sapiens (human),NaN,dirmtqspsslsasvgdrvtitcrasqgfgnkvawyqqkpgtapklliyetstlqsgvpsrfsgsgsgtefaftisslqpedgatyycqkynrapwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1281,NaN,NaN,NaN,QXE98271,SARS-CoV,Homo sapiens (human),NaN,syeltqppsvsgaprqkvtiscsgssaniasngvnwyqqlpgkapklliyyddlvssgvsdrfsgsksgtsaslaisglqsedeadyycatwddilngpvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1282,NaN,NaN,NaN,QXE98270,SARS-CoV,Homo sapiens (human),NaN,divmtqspgtlslspgeraalscrasqivtrsqlawyqhkpgqpprlliydsssratgtpdrfsgsgsgtdftltisrlepedsavyychqysgsatfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1283,NaN,NaN,NaN,QXE98269,SARS-CoV,Homo sapiens (human),NaN,dirltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1284,NaN,NaN,NaN,QXE98268,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqivvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1285,NaN,NaN,NaN,QXE98267,SARS-CoV,Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsisyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfiltisslqpediatyycqhsyssppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1286,NaN,NaN,NaN,QXE98266,SARS-CoV,Homo sapiens (human),NaN,divltqtpsslsasvgdrvtitcrasqtiatylswyqqkpgkapklliyavsslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsysipwtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1287,NaN,NaN,NaN,QXE98265,SARS-CoV,Homo sapiens (human),NaN,ettltqspatlslspgegatlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdytltisslepedfavyychqrsnwpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1288,NaN,NaN,NaN,QXE98264,SARS-CoV,Homo sapiens (human),NaN,syvltqppsvsvspgqtaritcsadglpkqysywyqqkpgqapvmviykdterpsgiperfsgsssgttatltisgvqaedeadyycqsadsndsspvfgggtqltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1289,NaN,NaN,NaN,QXE98263,SARS-CoV,Homo sapiens (human),NaN,dirmtqsplslpvtlgqpasiscrssqfvvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1290,NaN,NaN,NaN,QXE98262,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1291,NaN,NaN,NaN,QXE98261,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1292,NaN,NaN,NaN,QXE98260,SARS-CoV,Homo sapiens (human),NaN,diqltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1293,NaN,NaN,NaN,QXE98259,SARS-CoV,Homo sapiens (human),NaN,diqmtqsplslpvglgqsasiscrssqwvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1294,NaN,NaN,NaN,QXE98258,SARS-CoV,Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgttsdvggydyvswyqqrpgkapkliiydvinrpsgvsnrfsgsksgntasltisglqaddetdyycssytsggtlvfgtgtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1295,NaN,NaN,NaN,QXE98257,SARS-CoV,Homo sapiens (human),NaN,dirltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1296,NaN,NaN,NaN,QXE98256,SARS-CoV,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitiscavtssdvgsynlvswhqqhpgkapklmiyevnkrpsgvsnrfsgsksgntasltisglqaedeavyyccsyggrstsvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1297,NaN,NaN,NaN,QXE98255,SARS-CoV,Homo sapiens (human),NaN,ettltqspatlslspgeratlscrasqsindylgwyqhrpgqaprllihdastrapgipvrfsgsgsgtdftltisslepedsavyycqqrfswynfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1298,NaN,NaN,NaN,QXE98254,SARS-CoV,Homo sapiens (human),NaN,ettltqsplflpvtlgqpasisctssvhvvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtyftlkisrveaedvgvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1299,NaN,NaN,NaN,QXE98253,SARS-CoV,Homo sapiens (human),NaN,dirltqsplslpvtlgqaasiscksshfivhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftleisgveaedvgvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1300,NaN,NaN,NaN,QXE98252,SARS-CoV,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsiniylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystplitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1301,NaN,NaN,NaN,QXE98251,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvsrgqsasiscrsshsvvhsdgktyvnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgfdftlkisrveaedvgvyfcmqgtdwprsfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1302,NaN,NaN,NaN,QXE98250,SARS-CoV,Homo sapiens (human),NaN,eivmtqsplslpvslgqpasiscrssqsvihtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1303,NaN,NaN,NaN,QXE98249,SARS-CoV,Homo sapiens (human),NaN,ettltqspgtlsvspgeratlscrasqsvisnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltiaslqsedfavyycqqyhhwppytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1304,NaN,NaN,NaN,QXE98248,SARS-CoV,Homo sapiens (human),NaN,dirmtqspstlsasvgdrvtitcrasqtigswlawyqqkpgkapnlliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynslytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1305,NaN,NaN,NaN,QXE98247,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslsvtlgqaasiscrpnlglmhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfagsgsgthftleisgveaddvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1306,NaN,NaN,NaN,QXE98246,SARS-CoV,Homo sapiens (human),NaN,divltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1307,NaN,NaN,NaN,QXE98245,SARS-CoV,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiannyvqwlqqrpgsspttiiyednqrpsgvpdrfsgsidassnsasltisglktedeadyycqsydsssqvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1308,NaN,NaN,NaN,QXE98244,SARS-CoV,Homo sapiens (human),NaN,qpvltqspsasaslggsvkltctltsghstyaiawhqqqpekgprflmklnsdgshnkgdgipdrfsgsssgaeryltisslqsedeadyychtwgtdiqvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1309,NaN,NaN,NaN,QXE98243,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvgtylawyqqkhgqaprllisdvskratgiparfsgsgsgtdftltitslepedfavyycqqrtnwpgatfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1310,NaN,NaN,NaN,QXE98242,SARS-CoV,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqktgkapelliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyrfpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1311,NaN,NaN,NaN,QXE98241,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlsvspgeritlscrashsvssnlawyqqkpgqvprlliygasaratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1312,NaN,NaN,NaN,QXE98240,SARS-CoV,Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasrsissylnwyqqkpgkapnlliydastlqsgvpsrfsgsgsgtdfsltisslqpedfatyyclhtyttprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1313,NaN,NaN,NaN,QXE98239,SARS-CoV,Homo sapiens (human),NaN,qpvltqppsasgtpgqrvtiscsgsysnigtnpanwyqqlpgtapklliynndqrpsgvpdrfsgsksgtsaslaisglqsedetdyycatwddslngvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1314,NaN,NaN,NaN,QXE98238,SARS-CoV,Homo sapiens (human),NaN,dirmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgvtfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1315,NaN,NaN,NaN,QXE98237,SARS-CoV,Homo sapiens (human),NaN,diqltqspsamsasvgdrvtitcrasqgindnlawfqqkpgkvpkrliyaasnlqngvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1316,NaN,NaN,NaN,QXE98236,SARS-CoV,Homo sapiens (human),NaN,qpvltqsssasaslgssvkltctlrsghssyiiawhqqqpgkaprflmkvghsgsynkgsgvpdrfsgsrsgadhyltisnlqpddeadyyceawdnnnlgvfsggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1317,NaN,NaN,NaN,QXE98235,SARS-CoV,Homo sapiens (human),NaN,qpvltqsssasaslgssvkltctlssghssyilawhqqqpgkaprflmkfevggrynkgsgvpdrfsgsssgadryltisnlqsedeadyycetwdsnlkgvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1318,NaN,NaN,NaN,QXE98234,SARS-CoV,Homo sapiens (human),NaN,divmtqtpgtlsvspgeratlscrasqiinrsqlgwyqhkpgqpprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1319,NaN,NaN,NaN,QXE98233,SARS-CoV,Homo sapiens (human),NaN,diqltqspatlslspgeratlscranqsvsnflawyqqkpgqaprhliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1320,NaN,NaN,NaN,QXE98232,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvstylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyyclqrsdwhpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1321,NaN,NaN,NaN,QXE98231,SARS-CoV,Homo sapiens (human),NaN,dirvtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1322,NaN,NaN,NaN,QXE98230,SARS-CoV,Homo sapiens (human),NaN,qsvliqpasvsgspgqsitisctgsssdvgsynlvswyqqhpgkapklmiyegykrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagssavvvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1323,NaN,NaN,NaN,QXE98229,SARS-CoV,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtmatltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1324,NaN,NaN,NaN,QXE98228,SARS-CoV,Homo sapiens (human),NaN,divltqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvifgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1325,NaN,NaN,NaN,QXE98227,SARS-CoV,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvsiylawyqqkpgqaprlliydasnratgvparfsgsgsgtdftltinnlepedfaiyycqqrakwpprvtfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1326,NaN,NaN,NaN,QXE98226,SARS-CoV,Homo sapiens (human),NaN,diqvtqspsslsasvgdrvtitcrasqsissslnwyqqkpgkaptlliytasnlqsgvpsrfsgsgsgtdftltitslqpedfatyycqqsystpgfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1327,NaN,NaN,NaN,QXE98225,SARS-CoV,Homo sapiens (human),NaN,diqvtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqqrsdwhpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1328,NaN,NaN,NaN,QXE98224,SARS-CoV,Homo sapiens (human),NaN,diqltqspstlsasvgdsvtitcrasqsisswlawyqqkpgkapklliykassletgvpsrfsgsgsgteftltisslqpddfatyycqqyksplsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1329,NaN,NaN,NaN,QXE98223,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglvhtngnlylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1330,NaN,NaN,NaN,QXE98222,SARS-CoV,Homo sapiens (human),NaN,qpvltqppsvsaapgqkvtiscsgsssniennyvswyqqlpgaapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdfslsagvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1331,NaN,NaN,NaN,QXE98221,SARS-CoV,Homo sapiens (human),NaN,divvtqspgtlslspgeraalscrasqsvgnnylawyqqkpgqaprlliygatsratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1332,NaN,NaN,NaN,QXE98220,SARS-CoV,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1333,NaN,NaN,NaN,QXE98219,SARS-CoV,Homo sapiens (human),NaN,ettltqspvtlpvtlgqpasisctssrwlvhtngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlqisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1334,NaN,NaN,NaN,QXE98218,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkinrveaedvgiyycmqttdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1335,NaN,NaN,NaN,QXE98217,SARS-CoV,Homo sapiens (human),NaN,dirmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1336,NaN,NaN,NaN,QXE98216,SARS-CoV,Homo sapiens (human),NaN,ettltqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1337,NaN,NaN,NaN,QXE98215,SARS-CoV,Homo sapiens (human),NaN,eivltqspgtlslspgdrvtlfcrasqniannhlawyqqkpgqaprvliygasttatdipdrfsgrvsgtdftltisrldpedfavyychqygsspwtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1338,NaN,NaN,NaN,QXE98214,SARS-CoV,Homo sapiens (human),NaN,qpvltqpasvsgspgqsstlscsgtssdvgsydlvswyqqhpgkapklmiyegtkrpsgvsdrfsgstsgntasltisglqaedeanyyccsyagsgtwifgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1339,NaN,NaN,NaN,QXE98213,SARS-CoV,Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcraghtistylnwyqqkpgkapkilisgasslqsgvpsrfsgsgsgtdftltigslqpedfatyycqqsystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1340,NaN,NaN,NaN,QXE98212,SARS-CoV,Homo sapiens (human),NaN,dirvtqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1341,NaN,NaN,NaN,QXE98211,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1342,NaN,NaN,NaN,QXE98210,SARS-CoV,Homo sapiens (human),NaN,eivmtqspatlsvspgetatlscrasqsvgrfmgwyqqkpgqaprllifdasnrvtgvpdrfrgsgsgtdfiltinslepedsasyycqrrgdgynfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1343,NaN,NaN,NaN,QXE98209,SARS-CoV,Homo sapiens (human),NaN,qpvltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedqadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1344,NaN,NaN,NaN,QXE98208,SARS-CoV,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1345,NaN,NaN,NaN,QXE98207,SARS-CoV,Homo sapiens (human),NaN,diqvtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1346,NaN,NaN,NaN,QXE98206,SARS-CoV,Homo sapiens (human),NaN,ettltqspvtlsvspgeratlscrasqsvisnlawyqqkpgqaprllifgastratgvparfsgsgsgteftltisslqsedfavyycqqynnwpsltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1347,NaN,NaN,NaN,QXE98205,SARS-CoV,Homo sapiens (human),NaN,divltqsplslpvglgqsasiscrssqrvvhtdgntylhwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqgtewprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1348,NaN,NaN,NaN,QXE98204,SARS-CoV,Homo sapiens (human),NaN,diqltqsplslpvglgqsasiscrssqrvvhtdgntylnwyhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqstdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1349,NaN,NaN,NaN,QXE98203,SARS-CoV,Homo sapiens (human),NaN,divmtqtplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1350,NaN,NaN,NaN,QXE98202,SARS-CoV,Homo sapiens (human),NaN,diqltqspatlsvspgeratlscrasqsvtkhlawyqqkpgqaprlliygastratgvparfsgsgsdtefsltisslqsedfavyycqqyyswppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1351,NaN,NaN,NaN,QXE98201,SARS-CoV,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtnsdisnsysvswyqqypgkapklvifdvinrpsgvsnrfsgsksgntasltisglqaddeadyyccsytrtntpvlfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1352,NaN,NaN,NaN,QXE98200,SARS-CoV,Homo sapiens (human),NaN,dirmtqspdslavslgeratincrtsqsvlyssnnknylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1353,NaN,NaN,NaN,QXE98199,SARS-CoV,Homo sapiens (human),NaN,qsaliqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1354,NaN,NaN,NaN,QXE98198,SARS-CoV,Homo sapiens (human),NaN,dirltqtplslpvtlgqpasiscrssqiamhsdgntylswfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaedigtfycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1355,NaN,NaN,NaN,QXE98197,SARS-CoV,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapkltvydvrnrpsgvsnrfsgsksgntasltisglqaedeahyycssytstntvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1356,NaN,NaN,NaN,QXE98196,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvstflgwyqqrpgqpprlliydasyrapdipvrfsgsgsgtdftltinslepedsavyycqqrsdgynfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1357,NaN,NaN,NaN,QXE98195,SARS-CoV,Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasqdisnylawyqqkpgkapklliyaastlqsgvplrfsgsgsgtdftltisslqpedfatyyclqlhnyssfgggtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1358,NaN,NaN,NaN,QXE98194,SARS-CoV,Homo sapiens (human),NaN,dirltqsplslpvtlgqpasisctssqdvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedagiyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1359,NaN,NaN,NaN,QXE98193,SARS-CoV,Homo sapiens (human),NaN,dirltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsgwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1360,NaN,NaN,NaN,QXE98192,SARS-CoV,Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgsfnyvswyqqhpgkapklviydvynrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1361,NaN,NaN,NaN,QXE98191,SARS-CoV,Homo sapiens (human),NaN,diqmtqsplslsvtlgqsasiscrasqtvvhsvdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedigiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1362,NaN,NaN,NaN,QXE98190,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvslgqpasiscrssqsvvhtdgntylnwyqqrpgqsprrliykvsnrdsgvpdrfsgsgsvtdftlkisrveaedvavyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1363,NaN,NaN,NaN,QXE98189,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrsshslvhtngntylnwfqqrpgqpprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaddvgiyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1364,NaN,NaN,NaN,QXE98188,SARS-CoV,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlfssnnknylawyqqkpglppklliywastrksgvsdrfsgsgsgtdftltisslqaedvavyycqqyyttplftfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1365,NaN,NaN,NaN,QXE98187,SARS-CoV,Homo sapiens (human),NaN,eivmtqtplslpvtlgqpasiscrssqfvshtdgntylnwfqqrpgqsprrliykvskrdsgvpdrfsgsgsgtdftltisrveaedvgvyycmqatewprtfgqgtkveyq,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1366,NaN,NaN,NaN,QXE98186,SARS-CoV,Homo sapiens (human),NaN,dirvtqspdslavslgeratinckssqsvlyssnnknylawyqqkigqppklliywasiresgvpdrftgsgsgtdftltisslqaedvavyycqqyystpptfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1367,NaN,NaN,NaN,QXE98185,SARS-CoV,Homo sapiens (human),NaN,divltqsplslsvtpgqpasiscrssqslqhtdgktylywylqkpgqspqlliyelfnrfsgvperfsgsgsgtdftlkisrveaedvgiyycmqsiqtpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1368,NaN,NaN,NaN,QXE98184,SARS-CoV,Homo sapiens (human),NaN,qsvvtqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydsdkrpsgiperfsgsksatsatlgitglqtgdeadyycetwddslsavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1369,NaN,NaN,NaN,QXE98183,SARS-CoV,Homo sapiens (human),NaN,eivltqspsslsasvgdrvtiscrasqgistflawfqqrpgkapksliyaasklqsgvpsrfsgsdsgpdftltidnlqpedsatyyckqynsypytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1370,NaN,NaN,NaN,QXE98182,SARS-CoV,Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratniparfsgsgsgteftltisslqsedfavyycqqynlwpytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1371,NaN,NaN,NaN,QXE98181,SARS-CoV,Homo sapiens (human),NaN,divmtqsplalsvtpgqpasisckssqsllhsdgktyfywylqkpgqsphlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqvpitfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1372,NaN,NaN,NaN,QXE98180,SARS-CoV,Homo sapiens (human),NaN,eivmtqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1373,NaN,NaN,NaN,QXE98179,SARS-CoV,Homo sapiens (human),NaN,qsvltqpsslsaspgasasltctlhsgfnvgdhtinwyqqrpgsppryllkyksdsdkeqgsgvpirfsgskdasanagfllisglrsedeadyycmiwhdnavvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1374,NaN,NaN,NaN,QXE98178,SARS-CoV,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1375,NaN,NaN,NaN,QXE98177,SARS-CoV,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1376,NaN,NaN,NaN,QXE98176,SARS-CoV,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprryaywyqqrsgqapvlviyednkrpsgiperfsafssgtratltisgaqvedeadyycystdstanykvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1377,NaN,NaN,NaN,QXE98175,SARS-CoV,Homo sapiens (human),NaN,dirltqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliyeasnratgvparfsgsgsgtdftlaisslepedfavyycqhrsnwpprytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1378,NaN,NaN,NaN,QXE98174,SARS-CoV,Homo sapiens (human),NaN,eivmtqspgtlslspgervtlscratqsvsnnhlawyqqkpgqaprlliygasttatdipdrfsgrvagtdftltisrldpedfavyychqygsspwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1379,NaN,NaN,NaN,QXE98173,SARS-CoV,Homo sapiens (human),NaN,divltqsplslpvtlgqsasiscrssqglvhsdgniylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvglyycmqathwprafgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1380,NaN,NaN,NaN,QXE98172,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsgvprqkvtiscsgstaniasngvnwyqlvpgkaprllisyddlvpsgvsarfsgsksgtsaslaisglqaedeadyycatwddilngpvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1381,NaN,NaN,NaN,QXE98171,SARS-CoV,Homo sapiens (human),NaN,qpvltqprsvsgspgqsvtisctgssstfgtdnhiswyqqlpgkvpkliihavsqrpsvvpdrfsgsrsgntasltisglqaedeadyyccsspgtitwvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1382,NaN,NaN,NaN,QXE98170,SARS-CoV,Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqnvnnwlawyqqkpgkapklliyeastlksgvpsrfsgsgsgteftltisslqpddfatyycqqynsqytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1383,NaN,NaN,NaN,QXE98169,SARS-CoV,Homo sapiens (human),NaN,dirvtqspsslsasvgdrvtitcrasqtinnylnwyqqkpgkapnlliyaastlqngvpsrfsgsgsgtdftltissvqpedfatyycqqtyitptwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1384,NaN,NaN,NaN,QXE98168,SARS-CoV,Homo sapiens (human),NaN,diqltqspatlslspgeratlscraspsvftflawyqqrpgqpprllihdvsnrapgiparfsgsgsgtdftliisslepddsavyfcqqrsdgynfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1385,NaN,NaN,NaN,QXE98167,SARS-CoV,Homo sapiens (human),NaN,eivltqspgtlsvspgeratlscrasqiinrsqlgwyqhkpgqaprllifdsskratgtpdrfsasgsetdftltisgvepedsgvyyclqyslattfgpgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1386,NaN,NaN,NaN,QXE98166,SARS-CoV,Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgnynvvswyqqhpgkapqlfiyedtkrpsgvsdrfsgsksgitasltisrlqpedeadyyccsyavsgtvlfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1387,NaN,NaN,NaN,QXE98165,SARS-CoV,Homo sapiens (human),NaN,dirltqspdslalslgeratinckssqsvlfssnnnnylgwyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyltpwtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1388,NaN,NaN,NaN,QXE98164,SARS-CoV,Homo sapiens (human),NaN,dirvtqspsslsatvgdrvtitcrasqtitkylnwyqqkpgkapklllygasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitpgtfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1389,NaN,NaN,NaN,QXE98163,SARS-CoV,Homo sapiens (human),NaN,dirltqsplslpvdlgqsasiscrssqtvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1390,NaN,NaN,NaN,QXE98162,SARS-CoV,Homo sapiens (human),NaN,diqmtqsplslpvtlgqpasiscrasqtvvhtngntylnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlsisrveaedigvyycmqgtdwprtfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1391,NaN,NaN,NaN,QXE98161,SARS-CoV,Homo sapiens (human),NaN,qpgltqpasvsgspgqsitisctrtsgdvgdynsvswyvswyqqhpgrapklmlydvsnrpsgvsnrfsgsklgdtasltiselqaedeadyycstytststifgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1392,NaN,NaN,NaN,QXE98160,SARS-CoV,Homo sapiens (human),NaN,diqmtqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1393,NaN,NaN,NaN,QXE98159,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvdlgqsasiscrssqtavhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrinrveaedvgvyycmqatdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1394,NaN,NaN,NaN,QXE98158,SARS-CoV,Homo sapiens (human),NaN,eivmtqsplslpvtlgqpasiscrssqsvvhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1395,NaN,NaN,NaN,QXE98157,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1396,NaN,NaN,NaN,QXE98156,SARS-CoV,Homo sapiens (human),NaN,cirltqspatlslspgeratlscrasqsvtsylawyqqrpgqaprlliydtsnrvtgvpvrfsgsgygtdftltisslepedfavyycqqrgngytfgpgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1397,NaN,NaN,NaN,QXE98155,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvdlgqsasiscrssqrvvhtngntylhwfhqrpgqaprrliykvsnresgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1398,NaN,NaN,NaN,QXE98154,SARS-CoV,Homo sapiens (human),NaN,ettltqspasvsasvgdrvtiscrasqgigrwlawyqqkpgrapkllifsasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaesfpftfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1399,NaN,NaN,NaN,QXE98153,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqrlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1400,NaN,NaN,NaN,QXE98152,SARS-CoV,Homo sapiens (human),NaN,dirmtqspfslsasvgdrvtitcrasqgfgnrlawyqqkpgrapklliydastlqsgvpsrfsgsgsetdfaltisslqpedvatyycqkhdrdpwtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1401,NaN,NaN,NaN,QXE98151,SARS-CoV,Homo sapiens (human),NaN,qpgltqepsltvspggtvtltcgssagavtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeaeyfcflsyrgappvfgggthltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1402,NaN,NaN,NaN,QXE98150,SARS-CoV,Homo sapiens (human),NaN,dirltqspatlslspgeratlscrasqsigyylawfqqkpgqaprlliydaskratgiparfsgsgsgtdftltisslepedfavyycqhrtnwpytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1403,NaN,NaN,NaN,QXE98149,SARS-CoV,Homo sapiens (human),NaN,divltqtpatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1404,NaN,NaN,NaN,QXE98148,SARS-CoV,Homo sapiens (human),NaN,diqltqsplslpvtlgqpasisctssqnvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgshftlkisrveaedvgiyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1405,NaN,NaN,NaN,QXE98147,SARS-CoV,Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsvgnnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspvytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1406,NaN,NaN,NaN,QXE98146,SARS-CoV,Homo sapiens (human),NaN,eivmtqtplslpvtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliyqvshrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1407,NaN,NaN,NaN,QXE98145,SARS-CoV,Homo sapiens (human),NaN,diqmtqsplslpvtlgqaasiscrssqpiphtdgntylnwfhqrpgqsprrlihkvsnrdsgvpdrfsgsgsgldftleisgveaedvgiyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1408,NaN,NaN,NaN,QXE98144,SARS-CoV,Homo sapiens (human),NaN,nfmltqphsvsespgkaviisctrssgniasnfvqwyqqrpgssptpviyedklrpsgvpdrfsgsidrssnsasltisglktedeadyycqsydsgnlvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1409,NaN,NaN,NaN,QXE98143,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslsvtlgqaasisctcsqsavhsdgntyfnwfhqrpgqsprrliykvsnrdsgvperfsgsgsgthftliisrveaedvgvyycmqttdwprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1410,NaN,NaN,NaN,QXE98142,SARS-CoV,Homo sapiens (human),NaN,eivltqsplslsvtlgqaasisctcsqtavhsdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqttdwprtfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1411,NaN,NaN,NaN,QXE98141,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqpprlliydasnrasgiaarfsgrgsgtdftltisslepedfavyycqqrrnwppmytfgqgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1412,NaN,NaN,NaN,QXE98140,SARS-CoV,Homo sapiens (human),NaN,divmtqsplslpvglgqsasiscrssqrvvhtdgntylnwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlrisrveaedvgvyycmqatewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1413,NaN,NaN,NaN,QXE98139,SARS-CoV,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqtvtrsqlawyqhkpgqpprlliydsskratgspdrfsasgsgtdftltisglepedtgiyyclqysdattfgpgtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1414,NaN,NaN,NaN,QXE98138,SARS-CoV,Homo sapiens (human),NaN,divmtqtplslavtlgqpasiscrsshglvhtngntylnwfhqrpgqpprrliykisnrdsgvpdrfsgsgsgtdftlkisrveaddvgvyycmqgtdwprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1415,NaN,NaN,NaN,QXE98137,SARS-CoV,Homo sapiens (human),NaN,qpvltqppsvsaapgqkvtiscsgsssnigdnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdtslsvvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1416,NaN,NaN,NaN,QXE98136,SARS-CoV,Homo sapiens (human),NaN,eivltqspgtlslspgeraslscrasqsvsssylawyqhrpgqaprlliydassratgipdrfsgsgsgtdftltisrlesedfavyycqqygnsprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1417,NaN,NaN,NaN,QXE98135,SARS-CoV,Homo sapiens (human),NaN,ettltqspgtlslspgeratlscrasqsigssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsaplytfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1418,NaN,NaN,NaN,QXE98134,SARS-CoV,Homo sapiens (human),NaN,dirltqsplslpvtlgqpasiscrssqslvhsngntylnwfqqrpgqsprrliyevsnrdsgvpdrftgsgsgtdftlkisrveaedvgvyycmqgthwprsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1419,NaN,NaN,NaN,QXE98133,SARS-CoV,Homo sapiens (human),NaN,diqvtqspatvsvspgegaslscrasqsvrsnlawfqqkpgqaprllisdastrasgvparftgsgfgteftltisslqsedfaiyycqqyntwppltfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1420,NaN,NaN,NaN,QXE98132,SARS-CoV,Homo sapiens (human),NaN,diqltqsplslpvtlgqpasiscrssqhlvhsdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgidftlkisrveaedigvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1421,NaN,NaN,NaN,QXE98131,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpetapklliyangnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvlfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1422,NaN,NaN,NaN,QXE98130,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagyyvhwyqqlpgtapklliydnnnrpsgvpdrfsgsrsgtsaslaitglqaedegdyfcqsydsslsasfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1423,NaN,NaN,NaN,QXE98129,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnlgnnyvswyqqlpgtapklliydnhkrpsgipdrfsgsksgtsatlgitglqtgdeadyycetwdsslsvvvfgggtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1424,NaN,NaN,NaN,QXE98128,SARS-CoV,Homo sapiens (human),NaN,qpvltqpasvsgspgqsvtisctgtssdvgsysdvgnyvswyqhhpgkapklmiyevrtrpswvstrfsgsksgttasltisglqaedeadyyccsyagaspfvvfgggtkltvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1425,NaN,NaN,NaN,QXE98127,SARS-CoV,Homo sapiens (human),NaN,etgltqipfslpvtfgqpasiscrfsqrlvhtdgntnlnwflqrpgqfprgliykvfnrdsgvpdrfrgsgsgidftlkisrvevedvgiyygmqgtewlgtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1426,NaN,NaN,NaN,QXE98126,SARS-CoV,Homo sapiens (human),NaN,eivltqsplslpvtlgqpasiscrsslrlvhtdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1427,NaN,NaN,NaN,QXE98125,SARS-CoV,Homo sapiens (human),NaN,dirltqsplslpvtlgqpasiscrssqrivhtdgntylnwflqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgiyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1428,NaN,NaN,NaN,QXE98124,SARS-CoV,Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnenclawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqycstppytfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1429,NaN,NaN,NaN,QXE98123,SARS-CoV,Homo sapiens (human),NaN,dirmtqsplslpvtrgqpasiscrsshnvvhsdgktylnwfhqrpgqaprrliyqvskrdsgvpdrfsgsgsgsdftltisrveaedvgvyycmqgtdwprsfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1430,NaN,NaN,NaN,QXE98122,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglvhsngntyvnwfhqrpgqsprrliyevsnrdsgvpdrfsgsgsgtdftlkisrveaedigvyycmqgtewprtfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1431,NaN,NaN,NaN,QXE98121,SARS-CoV,Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdirkclnwyqhipgkapkllihdasslesgvpsrfsgsgsgtdfsftinslhpediatyycqqfedlpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1432,NaN,NaN,NaN,QXE98120,SARS-CoV,Homo sapiens (human),NaN,divltqtpatlsvspgegatlscrasqsvrsnlawfqqrpgqvprlliydastratgvparftgsgsgtyftltisslqsedfavyycqqynswppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1433,NaN,NaN,NaN,QXE98119,SARS-CoV,Homo sapiens (human),NaN,dirltqspsslsasvgdrvtiacrasqsvsnylnwyqqkpgkapklliyaasslqngvpsrfggsgsgtdftltisslqpedfatyycqqcysypptfghgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1434,NaN,NaN,NaN,QXE98118,SARS-CoV,Homo sapiens (human),NaN,ettltqsplslpvtlgqpasiscrssqglahsngntylnwfhqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtewprtfgqgtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1435,NaN,NaN,NaN,QXE98117,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlsvspgdgaslscrasqsvgsnlawyqqkpgqaprllisdasaratgvparftgsgsgtdftltisslqsedfavyychqyntwppltfgggtkleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1436,NaN,NaN,NaN,QXE98116,SARS-CoV,Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsisnylywyqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpynfgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1437,NaN,NaN,NaN,QXE98115,SARS-CoV,Homo sapiens (human),NaN,divltqtpsslsasvgdrvtitcrasqtisyylnwyqqkvgkapqllvyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysvpltlgqgtkvdik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1438,NaN,NaN,NaN,QXE98114,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqvpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1439,NaN,NaN,NaN,QXE98113,SARS-CoV,Homo sapiens (human),NaN,eivmtqspsslsasigdrvtiscrasqnigsylnwyqqrpgkapnllifvasslqsgvpsrfsgsgsgtdftltisslqaedfatyycqqsyttpitfgqgtrleik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1440,NaN,NaN,NaN,QXE98112,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlslspgeratlscraseniahylawyqqkpgqaprlviydassratgipgrfsgsgagtdftltinslepedfavyycqqrsnwpqnfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1441,NaN,NaN,NaN,QXE98111,SARS-CoV,Homo sapiens (human),NaN,qpvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlyvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1442,NaN,NaN,QXE98038,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycsggscfdgfdiwgqgtmvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1443,NaN,NaN,QXE98037,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsnvvcydgfdiwgqgtmvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1444,NaN,NaN,QXE98036,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyafhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraddtavyycardlaiavagtwhyyngmdvwgqgttvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1445,NaN,NaN,QXE98035,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftlssygmhwvrqapgkglewvavisydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycargwaywellpdyyygmdvwgqgttvtvss,NaN,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1446,NaN,NaN,NaN,QXE98042,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgfpdrfsgsgsgtdftltisrlepedfavyycqqygnspwtfgqgtkveir,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1447,NaN,NaN,NaN,QXE98041,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliysassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygtspwtfgqgtkveik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1448,NaN,NaN,NaN,QXE98040,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrviitcrasqgisswlawyqqkpgkapkvliydasslqsgvpsrfsgsgygtdftltisslqpedsatyycqqaksfpitfgqgtrleik,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1449,NaN,NaN,NaN,QXE98039,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqepsfsvspggtvtltcglssgsvstayfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgrgivvfgggtkltvl,"Wang,L. et al.; Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants; bioRxiv (2021); 2021.",10.1101/2021.02.25.432969,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
1450,NaN,NaN,QQP23469,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlhgdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1451,NaN,NaN,QQP23468,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1452,NaN,NaN,QQP23467,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1453,NaN,NaN,QQP23466,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1454,NaN,NaN,QQP23465,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmrsvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1455,NaN,NaN,QQP23464,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlhgdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1456,NaN,NaN,QQP23463,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1457,NaN,NaN,QQP23462,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlygdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1458,NaN,NaN,QQP23461,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1459,NaN,NaN,QQP23460,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1460,NaN,NaN,QQP23459,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1461,NaN,NaN,QQP23458,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1462,NaN,NaN,QQP23457,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1463,NaN,NaN,QQP23456,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1464,NaN,NaN,QQP23455,NaN,SARS-CoV,Homo sapiens (human),evqlvesggdlvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1465,NaN,NaN,QQP23454,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1466,NaN,NaN,QQP23453,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssisedgyntyypdslkgrftisrdsaknslylqmnslgaddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1467,NaN,NaN,QQP23452,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymnwvrqapgkglewvssisedgynpyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1468,NaN,NaN,QQP23451,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1469,NaN,NaN,QQP23450,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1470,NaN,NaN,QQP23449,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrddskntlflqmnnlrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1471,NaN,NaN,QQP23448,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlwgdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1472,NaN,NaN,QQP23447,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdskyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1473,NaN,NaN,QQP23446,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyttyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtasagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1474,NaN,NaN,QQP23445,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsayymnwvrqapgkglewvssissdgystyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtawagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1475,NaN,NaN,QQP23444,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitertygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1476,NaN,NaN,QQP23443,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfplrgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1477,NaN,NaN,QQP23442,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpflgtymtwvrqapgkglewvsiiysdgdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1478,NaN,NaN,QQP23441,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfkgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1479,NaN,NaN,QQP23440,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfpfsgtymtwvrqapgkglewvsiiysggdtyyadsvkgrftisrdnskntlflqmnslrvedtamyycardremaiitersygldvwgqgtmvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1480,NaN,NaN,QQP23439,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfsrfamhwvrqapgkgleyvsainlngdstyytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1481,NaN,NaN,QQP23438,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
1482,NaN,NaN,QXD47405,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 828 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 828 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1483,NaN,NaN,QXD47403,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 824 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 824 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1484,NaN,NaN,QXD47397,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 810 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 810 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1485,NaN,NaN,QXD47396,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 808 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 808 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1486,NaN,NaN,QXD47394,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 804 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 804 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1487,NaN,NaN,QXD47390,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 796 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 796 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1488,NaN,NaN,QXD47389,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 794 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 794 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1489,NaN,NaN,QXD47387,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 790 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 790 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1490,NaN,NaN,QXD47382,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 780 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 780 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1491,NaN,NaN,QXD47381,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 778 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 778 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1492,NaN,NaN,QXD47379,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 774 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 774 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1493,NaN,NaN,QXD47374,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 764 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 764 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1494,NaN,NaN,QXD47373,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 762 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 762 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1495,NaN,NaN,QXD47372,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 759 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 759 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1496,NaN,NaN,QXD47371,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 757 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 757 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1497,NaN,NaN,QXD47369,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 753 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 753 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1498,NaN,NaN,QXD47368,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 751 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 751 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1499,NaN,NaN,QXD47366,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 747 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 747 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1500,NaN,NaN,QXD47361,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 737 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 737 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1501,NaN,NaN,QXD47360,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 735 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 735 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1502,NaN,NaN,QXD47358,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 731 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 731 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1503,NaN,NaN,QXD47354,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 723 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 723 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1504,NaN,NaN,QXD47353,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 721 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 721 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1505,NaN,NaN,QXD47351,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 717 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 717 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1506,NaN,NaN,QXD47347,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 708 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 708 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1507,NaN,NaN,QXD47346,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 706 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 706 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1508,NaN,NaN,QXD47345,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 704 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 704 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1509,NaN,NaN,QXD47344,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 702 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 702 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1510,NaN,NaN,QXD47343,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 700 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 700 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1511,NaN,NaN,QXD47342,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 698 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 698 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1512,NaN,NaN,QXD47341,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 696 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 696 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1513,NaN,NaN,QXD47339,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 692 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 692 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1514,NaN,NaN,QXD47332,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 678 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 678 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1515,NaN,NaN,QXD47330,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 674 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 674 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1516,NaN,NaN,QXD47323,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 658 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 658 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1517,NaN,NaN,QXD47321,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 654 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 654 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1518,NaN,NaN,QXD47315,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 640 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 640 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1519,NaN,NaN,QXD47313,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 636 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 636 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1520,NaN,NaN,QXD47308,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 624 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 624 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1521,NaN,NaN,QXD47306,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 620 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 620 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1522,NaN,NaN,QXD47300,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 608 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 608 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1523,NaN,NaN,QXD47298,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 604 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 604 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1524,NaN,NaN,QXD47293,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 594 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 594 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1525,NaN,NaN,QXD47292,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 592 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 592 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1526,NaN,NaN,QXD47290,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 588 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 588 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1527,NaN,NaN,QXD47284,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 574 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 574 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1528,NaN,NaN,QXD47283,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 572 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 572 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1529,NaN,NaN,QXD47282,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 570 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 570 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1530,NaN,NaN,QXD47281,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 568 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 568 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1531,NaN,NaN,QXD47280,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 566 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 566 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1532,NaN,NaN,QXD47278,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 562 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 562 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1533,NaN,NaN,QXD47271,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 548 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 548 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1534,NaN,NaN,QXD47270,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 546 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 546 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1535,NaN,NaN,QXD47269,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 544 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 544 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1536,NaN,NaN,QXD47268,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 542 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 542 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1537,NaN,NaN,QXD47267,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 540 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 540 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1538,NaN,NaN,QXD47265,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 536 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 536 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1539,NaN,NaN,QXD47260,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 524 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 524 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1540,NaN,NaN,QXD47258,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 520 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 520 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1541,NaN,NaN,QXD47253,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 510 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 510 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1542,NaN,NaN,QXD47251,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 506 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 506 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1543,NaN,NaN,QXD47246,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 495 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 495 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1544,NaN,NaN,QXD47244,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 491 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 491 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1545,NaN,NaN,QXD47239,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 480 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 480 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1546,NaN,NaN,QXD47237,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 476 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 476 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1547,NaN,NaN,QXD47233,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 468 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 468 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1548,NaN,NaN,QXD47231,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 464 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 464 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1549,NaN,NaN,QXD47225,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 451 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 451 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1550,NaN,NaN,QXD47223,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 447 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 447 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1551,NaN,NaN,QXD47216,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 432 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 432 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1552,NaN,NaN,QXD47215,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 430 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 430 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1553,NaN,NaN,QXD47214,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 428 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 428 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1554,NaN,NaN,QXD47213,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 426 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 426 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1555,NaN,NaN,QXD47212,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 424 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 424 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1556,NaN,NaN,QXD47210,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 420 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 420 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1557,NaN,NaN,QXD47205,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 409 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 409 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1558,NaN,NaN,QXD47203,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 405 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 405 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1559,NaN,NaN,QXD47199,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 396 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 396 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1560,NaN,NaN,QXD47197,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 392 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 392 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1561,NaN,NaN,QXD47192,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 381 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 381 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1562,NaN,NaN,QXD47190,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 377 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 377 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1563,NaN,NaN,QXD47186,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 366 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 366 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1564,NaN,NaN,QXD47185,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 364 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 364 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1565,NaN,NaN,QXD47184,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 362 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 362 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1566,NaN,NaN,QXD47183,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 360 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 360 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1567,NaN,NaN,QXD47182,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 358 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 358 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1568,NaN,NaN,QXD47181,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 356 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 356 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1569,NaN,NaN,QXD47180,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 354 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 354 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1570,NaN,NaN,QXD47179,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 352 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 352 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1571,NaN,NaN,QXD47178,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 350 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 350 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1572,NaN,NaN,QXD47177,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 348 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 348 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1573,NaN,NaN,QXD47176,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 346 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 346 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1574,NaN,NaN,QXD47174,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 342 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 342 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1575,NaN,NaN,QXD47170,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 333 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 333 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1576,NaN,NaN,QXD47168,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 329 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 329 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1577,NaN,NaN,QXD47162,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 316 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 316 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1578,NaN,NaN,QXD47160,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 312 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 312 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1579,NaN,NaN,QXD47155,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 302 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 302 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1580,NaN,NaN,QXD47153,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 298 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 298 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1581,NaN,NaN,QXD47147,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 284 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 284 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1582,NaN,NaN,QXD47145,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 280 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 280 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1583,NaN,NaN,QXD47139,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 268 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 268 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1584,NaN,NaN,QXD47137,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 264 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 264 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1585,NaN,NaN,QXD47131,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 252 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 252 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1586,NaN,NaN,QXD47129,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 248 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 248 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1587,NaN,NaN,QXD47124,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 238 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 238 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1588,NaN,NaN,QXD47122,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 234 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 234 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1589,NaN,NaN,QXD47115,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 220 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 220 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1590,NaN,NaN,QXD47113,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 216 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 216 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1591,NaN,NaN,QXD47106,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 202 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 202 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1592,NaN,NaN,QXD47104,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 198 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 198 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1593,NaN,NaN,QXD47099,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 185 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 185 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1594,NaN,NaN,QXD47098,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 183 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 183 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1595,NaN,NaN,QXD47096,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 179 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 179 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1596,NaN,NaN,QXD47090,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 167 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 167 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1597,NaN,NaN,QXD47089,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 165 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 165 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1598,NaN,NaN,QXD47088,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 163 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 163 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1599,NaN,NaN,QXD47087,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 161 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 161 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1600,NaN,NaN,QXD47086,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 159 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 159 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1601,NaN,NaN,QXD47085,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 157 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 157 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1602,NaN,NaN,QXD47083,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 153 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 153 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1603,NaN,NaN,QXD47076,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 137 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 137 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1604,NaN,NaN,QXD47074,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 133 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 133 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1605,NaN,NaN,QXD47067,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 119 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 119 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1606,NaN,NaN,QXD47065,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 115 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 115 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1607,NaN,NaN,QXD47058,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 99 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 99 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1608,NaN,NaN,QXD47056,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 95 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 95 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1609,NaN,NaN,QXD47050,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 83 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 83 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1610,NaN,NaN,QXD47048,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 79 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 79 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1611,NaN,NaN,QXD47041,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 65 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 65 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1612,NaN,NaN,QXD47040,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 63 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 63 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1613,NaN,NaN,QXD47038,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 59 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 59 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1614,NaN,NaN,QXD47032,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 44 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 44 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1615,NaN,NaN,QXD47031,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 42 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 42 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1616,NaN,NaN,QXD47029,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 38 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 38 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1617,NaN,NaN,QXD47022,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 22 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 22 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1618,NaN,NaN,QXD47020,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 18 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 18 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1619,NaN,NaN,QXD47013,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 2 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 2 from patent US 10975139,NaN,2022-03-15,NaN,NaN,NaN
1620,NaN,NaN,NaN,QXD47404,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 826 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 826 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1621,NaN,NaN,NaN,QXD47401,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 818 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 818 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1622,NaN,NaN,NaN,QXD47395,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 806 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 806 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1623,NaN,NaN,NaN,QXD47392,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 800 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 800 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1624,NaN,NaN,NaN,QXD47388,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 792 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 792 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1625,NaN,NaN,NaN,QXD47385,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 786 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 786 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1626,NaN,NaN,NaN,QXD47380,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 776 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 776 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1627,NaN,NaN,NaN,QXD47377,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 770 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 770 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1628,NaN,NaN,NaN,QXD47367,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 749 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 749 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1629,NaN,NaN,NaN,QXD47363,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 741 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 741 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1630,NaN,NaN,NaN,QXD47359,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 733 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 733 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1631,NaN,NaN,NaN,QXD47356,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 727 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 727 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1632,NaN,NaN,NaN,QXD47352,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 719 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 719 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1633,NaN,NaN,NaN,QXD47349,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 713 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 713 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1634,NaN,NaN,NaN,QXD47340,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 694 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 694 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1635,NaN,NaN,NaN,QXD47336,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 686 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 686 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1636,NaN,NaN,NaN,QXD47331,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 676 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 676 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1637,NaN,NaN,NaN,QXD47327,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 666 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 666 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1638,NaN,NaN,NaN,QXD47322,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 656 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 656 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1639,NaN,NaN,NaN,QXD47318,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 646 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 646 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1640,NaN,NaN,NaN,QXD47314,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 638 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 638 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1641,NaN,NaN,NaN,QXD47311,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 630 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 630 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1642,NaN,NaN,NaN,QXD47307,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 622 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 622 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1643,NaN,NaN,NaN,QXD47303,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 614 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 614 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1644,NaN,NaN,NaN,QXD47299,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 606 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 606 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1645,NaN,NaN,NaN,QXD47296,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 600 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 600 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1646,NaN,NaN,NaN,QXD47291,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 590 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 590 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1647,NaN,NaN,NaN,QXD47287,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 580 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 580 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1648,NaN,NaN,NaN,QXD47279,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 564 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 564 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1649,NaN,NaN,NaN,QXD47275,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 556 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 556 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1650,NaN,NaN,NaN,QXD47266,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 538 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 538 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1651,NaN,NaN,NaN,QXD47262,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 530 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 530 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1652,NaN,NaN,NaN,QXD47259,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 522 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 522 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1653,NaN,NaN,NaN,QXD47255,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 514 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 514 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1654,NaN,NaN,NaN,QXD47252,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 508 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 508 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1655,NaN,NaN,NaN,QXD47250,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 503 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 503 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1656,NaN,NaN,NaN,QXD47245,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 493 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 493 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1657,NaN,NaN,NaN,QXD47242,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 487 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 487 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1658,NaN,NaN,NaN,QXD47238,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 478 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 478 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1659,NaN,NaN,NaN,QXD47235,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 472 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 472 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1660,NaN,NaN,NaN,QXD47232,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 466 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 466 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1661,NaN,NaN,NaN,QXD47228,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 457 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 457 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1662,NaN,NaN,NaN,QXD47224,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 449 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 449 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1663,NaN,NaN,NaN,QXD47220,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 440 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 440 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1664,NaN,NaN,NaN,QXD47211,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 422 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 422 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1665,NaN,NaN,NaN,QXD47208,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 416 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 416 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1666,NaN,NaN,NaN,QXD47204,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 407 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 407 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1667,NaN,NaN,NaN,QXD47201,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 401 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 401 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1668,NaN,NaN,NaN,QXD47198,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 394 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 394 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1669,NaN,NaN,NaN,QXD47195,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 387 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 387 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1670,NaN,NaN,NaN,QXD47191,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 379 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 379 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1671,NaN,NaN,NaN,QXD47188,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 372 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 372 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1672,NaN,NaN,NaN,QXD47175,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 344 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 344 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1673,NaN,NaN,NaN,QXD47172,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 338 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 338 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1674,NaN,NaN,NaN,QXD47169,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 331 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 331 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1675,NaN,NaN,NaN,QXD47165,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 323 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 323 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1676,NaN,NaN,NaN,QXD47161,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 314 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 314 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1677,NaN,NaN,NaN,QXD47157,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 306 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 306 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1678,NaN,NaN,NaN,QXD47154,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 300 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 300 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1679,NaN,NaN,NaN,QXD47150,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 290 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 290 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1680,NaN,NaN,NaN,QXD47146,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 282 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 282 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1681,NaN,NaN,NaN,QXD47143,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 276 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 276 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1682,NaN,NaN,NaN,QXD47138,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 266 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 266 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1683,NaN,NaN,NaN,QXD47135,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 260 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 260 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1684,NaN,NaN,NaN,QXD47130,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 250 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 250 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1685,NaN,NaN,NaN,QXD47126,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 242 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 242 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1686,NaN,NaN,NaN,QXD47123,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 236 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 236 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1687,NaN,NaN,NaN,QXD47119,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 228 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 228 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1688,NaN,NaN,NaN,QXD47114,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 218 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 218 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1689,NaN,NaN,NaN,QXD47110,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 210 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 210 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1690,NaN,NaN,NaN,QXD47105,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 200 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 200 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1691,NaN,NaN,NaN,QXD47102,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 191 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 191 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1692,NaN,NaN,NaN,QXD47097,"SARS-CoV-2, Spike protein",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 181 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 181 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1693,NaN,NaN,NaN,QXD47094,"SARS-CoV-2, Spike protein",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 175 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 175 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1694,NaN,NaN,NaN,QXD47084,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 155 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 155 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1695,NaN,NaN,NaN,QXD47080,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 145 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 145 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1696,NaN,NaN,NaN,QXD47075,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 135 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 135 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1697,NaN,NaN,NaN,QXD47071,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 127 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 127 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1698,NaN,NaN,NaN,QXD47066,"SARS-CoV-2, Spike protein",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 117 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 117 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1699,NaN,NaN,NaN,QXD47062,"SARS-CoV-2, Spike protein",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 107 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 107 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1700,NaN,NaN,NaN,QXD47057,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 97 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 97 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1701,NaN,NaN,NaN,QXD47053,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 89 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 89 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1702,NaN,NaN,NaN,QXD47049,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 81 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 81 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1703,NaN,NaN,NaN,QXD47045,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 73 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 73 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1704,NaN,NaN,NaN,QXD47039,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 61 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 61 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1705,NaN,NaN,NaN,QXD47035,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 51 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 51 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1706,NaN,NaN,NaN,QXD47030,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 40 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 40 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1707,NaN,NaN,NaN,QXD47026,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 30 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 30 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1708,NaN,NaN,NaN,QXD47021,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 20 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 20 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1709,NaN,NaN,NaN,QXD47017,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments; US10975139-B1 10 13-APR-2021 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 10 from patent US 10975139,2022-03-15,NaN,NaN,NaN
1710,NaN,NaN,QXC72641,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 828 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 828 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1711,NaN,NaN,QXC72639,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 824 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 824 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1712,NaN,NaN,QXC72633,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 810 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 810 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1713,NaN,NaN,QXC72632,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 808 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 808 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1714,NaN,NaN,QXC72630,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 804 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 804 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1715,NaN,NaN,QXC72626,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 796 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 796 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1716,NaN,NaN,QXC72625,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 794 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 794 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1717,NaN,NaN,QXC72623,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 790 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 790 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1718,NaN,NaN,QXC72618,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 780 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 780 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1719,NaN,NaN,QXC72617,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 778 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 778 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1720,NaN,NaN,QXC72615,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 774 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 774 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1721,NaN,NaN,QXC72610,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 764 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 764 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1722,NaN,NaN,QXC72609,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 762 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 762 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1723,NaN,NaN,QXC72608,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 759 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 759 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1724,NaN,NaN,QXC72607,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 757 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 757 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1725,NaN,NaN,QXC72605,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 753 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 753 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1726,NaN,NaN,QXC72604,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 751 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 751 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1727,NaN,NaN,QXC72602,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 747 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 747 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1728,NaN,NaN,QXC72597,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 737 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 737 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1729,NaN,NaN,QXC72596,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 735 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 735 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1730,NaN,NaN,QXC72594,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 731 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 731 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1731,NaN,NaN,QXC72590,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 723 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 723 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1732,NaN,NaN,QXC72589,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 721 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 721 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1733,NaN,NaN,QXC72587,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 717 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 717 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1734,NaN,NaN,QXC72583,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 708 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 708 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1735,NaN,NaN,QXC72582,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 706 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 706 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1736,NaN,NaN,QXC72581,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 704 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 704 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1737,NaN,NaN,QXC72580,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 702 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 702 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1738,NaN,NaN,QXC72579,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 700 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 700 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1739,NaN,NaN,QXC72578,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 698 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 698 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1740,NaN,NaN,QXC72577,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 696 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 696 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1741,NaN,NaN,QXC72575,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 692 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 692 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1742,NaN,NaN,QXC72568,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 678 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 678 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1743,NaN,NaN,QXC72566,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 674 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 674 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1744,NaN,NaN,QXC72559,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 658 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 658 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1745,NaN,NaN,QXC72557,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 654 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 654 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1746,NaN,NaN,QXC72551,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 640 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 640 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1747,NaN,NaN,QXC72549,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 636 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 636 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1748,NaN,NaN,QXC72544,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 624 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 624 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1749,NaN,NaN,QXC72542,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 620 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 620 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1750,NaN,NaN,QXC72536,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 608 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 608 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1751,NaN,NaN,QXC72534,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 604 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 604 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1752,NaN,NaN,QXC72529,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 594 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 594 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1753,NaN,NaN,QXC72528,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 592 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 592 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1754,NaN,NaN,QXC72526,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 588 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 588 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1755,NaN,NaN,QXC72520,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 574 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 574 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1756,NaN,NaN,QXC72519,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 572 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 572 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1757,NaN,NaN,QXC72518,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 570 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 570 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1758,NaN,NaN,QXC72517,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 568 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 568 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1759,NaN,NaN,QXC72516,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 566 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 566 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1760,NaN,NaN,QXC72514,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 562 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 562 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1761,NaN,NaN,QXC72507,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 548 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 548 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1762,NaN,NaN,QXC72506,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 546 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 546 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1763,NaN,NaN,QXC72505,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 544 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 544 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1764,NaN,NaN,QXC72504,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 542 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 542 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1765,NaN,NaN,QXC72503,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 540 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 540 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1766,NaN,NaN,QXC72501,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 536 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 536 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1767,NaN,NaN,QXC72496,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 524 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 524 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1768,NaN,NaN,QXC72494,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 520 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 520 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1769,NaN,NaN,QXC72489,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 510 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 510 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1770,NaN,NaN,QXC72487,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 506 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 506 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1771,NaN,NaN,QXC72482,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 495 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 495 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1772,NaN,NaN,QXC72480,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 491 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 491 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1773,NaN,NaN,QXC72475,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 480 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 480 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1774,NaN,NaN,QXC72473,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 476 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 476 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1775,NaN,NaN,QXC72469,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 468 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 468 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1776,NaN,NaN,QXC72467,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 464 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 464 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1777,NaN,NaN,QXC72461,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 451 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 451 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1778,NaN,NaN,QXC72459,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 447 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 447 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1779,NaN,NaN,QXC72452,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 432 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 432 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1780,NaN,NaN,QXC72451,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 430 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 430 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1781,NaN,NaN,QXC72450,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 428 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 428 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1782,NaN,NaN,QXC72449,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 426 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 426 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1783,NaN,NaN,QXC72448,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 424 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 424 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1784,NaN,NaN,QXC72446,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 420 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 420 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1785,NaN,NaN,QXC72441,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 409 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 409 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1786,NaN,NaN,QXC72439,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 405 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 405 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1787,NaN,NaN,QXC72435,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 396 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 396 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1788,NaN,NaN,QXC72433,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 392 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 392 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1789,NaN,NaN,QXC72428,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 381 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 381 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1790,NaN,NaN,QXC72426,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 377 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 377 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1791,NaN,NaN,QXC72422,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 366 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 366 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1792,NaN,NaN,QXC72421,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 364 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 364 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1793,NaN,NaN,QXC72420,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 362 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 362 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1794,NaN,NaN,QXC72419,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 360 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 360 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1795,NaN,NaN,QXC72418,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 358 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 358 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1796,NaN,NaN,QXC72417,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 356 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 356 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1797,NaN,NaN,QXC72416,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 354 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 354 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1798,NaN,NaN,QXC72415,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 352 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 352 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1799,NaN,NaN,QXC72414,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 350 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 350 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1800,NaN,NaN,QXC72413,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 348 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 348 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1801,NaN,NaN,QXC72412,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 346 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 346 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1802,NaN,NaN,QXC72410,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 342 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 342 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1803,NaN,NaN,QXC72406,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 333 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 333 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1804,NaN,NaN,QXC72404,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 329 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 329 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1805,NaN,NaN,QXC72398,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 316 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 316 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1806,NaN,NaN,QXC72396,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 312 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 312 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1807,NaN,NaN,QXC72391,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 302 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 302 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1808,NaN,NaN,QXC72389,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 298 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 298 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1809,NaN,NaN,QXC72383,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 284 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 284 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1810,NaN,NaN,QXC72381,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 280 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 280 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1811,NaN,NaN,QXC72375,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 268 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 268 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1812,NaN,NaN,QXC72373,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 264 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 264 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1813,NaN,NaN,QXC72367,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 252 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 252 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1814,NaN,NaN,QXC72365,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 248 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 248 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1815,NaN,NaN,QXC72360,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 238 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 238 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1816,NaN,NaN,QXC72358,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 234 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 234 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1817,NaN,NaN,QXC72351,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 220 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 220 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1818,NaN,NaN,QXC72349,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 216 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 216 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1819,NaN,NaN,QXC72342,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 202 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 202 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1820,NaN,NaN,QXC72340,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 198 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 198 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1821,NaN,NaN,QXC72335,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 185 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 185 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1822,NaN,NaN,QXC72334,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 183 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 183 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1823,NaN,NaN,QXC72332,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 179 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 179 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1824,NaN,NaN,QXC72326,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 167 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 167 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1825,NaN,NaN,QXC72325,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 165 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 165 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1826,NaN,NaN,QXC72324,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 163 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 163 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1827,NaN,NaN,QXC72323,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 161 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 161 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1828,NaN,NaN,QXC72322,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 159 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 159 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1829,NaN,NaN,QXC72321,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 157 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 157 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1830,NaN,NaN,QXC72319,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 153 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 153 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1831,NaN,NaN,QXC72312,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 137 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 137 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1832,NaN,NaN,QXC72310,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 133 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 133 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1833,NaN,NaN,QXC72303,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 119 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 119 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1834,NaN,NaN,QXC72301,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 115 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 115 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1835,NaN,NaN,QXC72294,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 99 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 99 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1836,NaN,NaN,QXC72292,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 95 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 95 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1837,NaN,NaN,QXC72286,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 83 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 83 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1838,NaN,NaN,QXC72284,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 79 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 79 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1839,NaN,NaN,QXC72277,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 65 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 65 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1840,NaN,NaN,QXC72276,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 63 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 63 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1841,NaN,NaN,QXC72274,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 59 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 59 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1842,NaN,NaN,QXC72268,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 44 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 44 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1843,NaN,NaN,QXC72267,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 42 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 42 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1844,NaN,NaN,QXC72265,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 38 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 38 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1845,NaN,NaN,QXC72258,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 22 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 22 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1846,NaN,NaN,QXC72256,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 18 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 18 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1847,NaN,NaN,QXC72249,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 2 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,Sequence 2 from patent US 10954289,NaN,2022-03-15,NaN,NaN,NaN
1848,NaN,NaN,QPY34286,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 828 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 828 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1849,NaN,NaN,QPY34284,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 824 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 824 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1850,NaN,NaN,QPY34278,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyycaidggtvttifdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 810 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 810 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1851,NaN,NaN,QPY34277,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 808 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 808 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1852,NaN,NaN,QPY34275,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 804 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 804 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1853,NaN,NaN,QPY34271,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnsentlylqmnslraedtavyycardlaaagtdywgqgalvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 796 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 796 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1854,NaN,NaN,QPY34270,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 794 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 794 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1855,NaN,NaN,QPY34268,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 790 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 790 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1856,NaN,NaN,QPY34263,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgfivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslkaedtavyycarelrgyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 780 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 780 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1857,NaN,NaN,QPY34262,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 778 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 778 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1858,NaN,NaN,QPY34260,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 774 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 774 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1859,NaN,NaN,QPY34255,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscvasgftfsiygmdwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycakdreaaadafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 764 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 764 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1860,NaN,NaN,QPY34254,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 762 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 762 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1861,NaN,NaN,QPY34253,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 759 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 759 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1862,NaN,NaN,QPY34252,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 757 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 757 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1863,NaN,NaN,QPY34250,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycaregygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 753 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 753 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1864,NaN,NaN,QPY34249,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 751 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 751 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1865,NaN,NaN,QPY34247,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 747 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 747 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1866,NaN,NaN,QPY34242,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvrgrftisrhnskntlylqmnslraedtavyycardgsaygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 737 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 737 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1867,NaN,NaN,QPY34241,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 735 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 735 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1868,NaN,NaN,QPY34239,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 731 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 731 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1869,NaN,NaN,QPY34235,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvhpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlflqmnslraedtavyycardrpitgttldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 723 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 723 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1870,NaN,NaN,QPY34234,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 721 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 721 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1871,NaN,NaN,QPY34232,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 717 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 717 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1872,NaN,NaN,QPY34228,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqmvesggglvqpggslrlscaasgftvssnymtwvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardgvsygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 708 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 708 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1873,NaN,NaN,QPY34227,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 706 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 706 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1874,NaN,NaN,QPY34226,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 704 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 704 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1875,NaN,NaN,QPY34225,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 702 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 702 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1876,NaN,NaN,QPY34224,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 700 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 700 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1877,NaN,NaN,QPY34223,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 698 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 698 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1878,NaN,NaN,QPY34222,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 696 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 696 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1879,NaN,NaN,QPY34220,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 692 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 692 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1880,NaN,NaN,QPY34213,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsgganyaqkfqgrvtltrdtsittvymelsrlrfddtavyycargsrydwnqnnwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 678 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 678 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1881,NaN,NaN,QPY34211,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 674 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 674 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1882,NaN,NaN,QPY34204,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlsctasgftfsnyemnwvrqapgkglewvsyissrsgstlhyadsvkgrftisrdnaknslylqmnslraedtavyycarrgdgtsslihhyyymdvwgkgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 658 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 658 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1883,NaN,NaN,QPY34202,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 654 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 654 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1884,NaN,NaN,QPY34196,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsnyamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrtedtavyycasgsdygdyllvywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 640 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 640 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1885,NaN,NaN,QPY34194,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 636 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 636 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1886,NaN,NaN,QPY34189,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaaseftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaralpygdlhfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 624 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 624 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1887,NaN,NaN,QPY34187,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 620 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 620 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1888,NaN,NaN,QPY34181,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnrgsigyadsvkgrftisrdnaknslylqmsslraedtalyycakdgerwdsvvvpsarngmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 608 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 608 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1889,NaN,NaN,QPY34179,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 604 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 604 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1890,NaN,NaN,QPY34174,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvnrnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrledtavyycargelgipygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 594 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 594 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1891,NaN,NaN,QPY34173,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 592 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 592 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1892,NaN,NaN,QPY34171,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 588 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 588 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1893,NaN,NaN,QPY34165,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggttyyadsvkgrftisrhnskntlslqmnslraedtavyycargeganyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 574 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 574 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1894,NaN,NaN,QPY34164,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 572 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 572 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1895,NaN,NaN,QPY34163,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 570 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 570 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1896,NaN,NaN,QPY34162,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 568 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 568 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1897,NaN,NaN,QPY34161,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 566 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 566 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1898,NaN,NaN,QPY34159,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 562 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 562 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1899,NaN,NaN,QPY34152,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmgriipmfgianyaqkfqgrvtitadkststaymevsslrsedtavyycartpfyydssgyyldywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 548 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 548 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1900,NaN,NaN,QPY34151,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 546 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 546 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1901,NaN,NaN,QPY34150,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 544 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 544 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1902,NaN,NaN,QPY34149,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 542 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 542 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1903,NaN,NaN,QPY34148,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 540 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 540 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1904,NaN,NaN,QPY34146,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 536 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 536 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1905,NaN,NaN,QPY34141,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfysdsvkgrfsisrdnskntlylqmnslraedtavyycardlyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 524 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 524 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1906,NaN,NaN,QPY34139,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 520 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 520 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1907,NaN,NaN,QPY34134,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnrlraddtavyycvrdpvgryyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 510 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 510 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1908,NaN,NaN,QPY34132,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 506 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 506 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1909,NaN,NaN,QPY34127,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgrtitmvrgviddafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 495 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 495 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1910,NaN,NaN,QPY34125,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 491 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 491 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1911,NaN,NaN,QPY34120,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardqrdfawgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 480 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 480 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1912,NaN,NaN,QPY34118,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 476 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 476 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1913,NaN,NaN,QPY34114,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycaregriaatgygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 468 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 468 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1914,NaN,NaN,QPY34112,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 464 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 464 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1915,NaN,NaN,QPY34106,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesgggliqpggslrlscaasvftvsynymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaralpgwggsfeyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 451 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 451 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1916,NaN,NaN,QPY34104,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 447 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 447 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1917,NaN,NaN,QPY34097,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsinnyywiwirqppgkglewigyiyhsgstnynpslksrvtisvdtsknqfslkvssvtaadtavyycanmvrgvyeddywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 432 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 432 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1918,NaN,NaN,QPY34096,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 430 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 430 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1919,NaN,NaN,QPY34095,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 428 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 428 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1920,NaN,NaN,QPY34094,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 426 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 426 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1921,NaN,NaN,QPY34093,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 424 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 424 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1922,NaN,NaN,QPY34091,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 420 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 420 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1923,NaN,NaN,QPY34086,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlflqmnslriedtavyycardlgpygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 409 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 409 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1924,NaN,NaN,QPY34084,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 405 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 405 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1925,NaN,NaN,QPY34080,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlikygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 396 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 396 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1926,NaN,NaN,QPY34078,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 392 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 392 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1927,NaN,NaN,QPY34073,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrvscaasgftvsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtaiyycaryiprfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 381 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 381 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1928,NaN,NaN,QPY34071,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 377 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 377 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1929,NaN,NaN,QPY34067,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslrvedtavyycardhgmaaagynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 366 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 366 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1930,NaN,NaN,QPY34066,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 364 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 364 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1931,NaN,NaN,QPY34065,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 362 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 362 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1932,NaN,NaN,QPY34064,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 360 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 360 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1933,NaN,NaN,QPY34063,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 358 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 358 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1934,NaN,NaN,QPY34062,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 356 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 356 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1935,NaN,NaN,QPY34061,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 354 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 354 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1936,NaN,NaN,QPY34060,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 352 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 352 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1937,NaN,NaN,QPY34059,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 350 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 350 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1938,NaN,NaN,QPY34058,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 348 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 348 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1939,NaN,NaN,QPY34057,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 346 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 346 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1940,NaN,NaN,QPY34055,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 342 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 342 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1941,NaN,NaN,QPY34051,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymtwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnnlraedtavyycvrdlevrggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 333 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 333 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1942,NaN,NaN,QPY34049,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 329 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 329 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1943,NaN,NaN,QPY34043,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgltvssnymnwvrqvpgkglewvsviysggskfyvdsvkgrftisrhnskntlylqmnslrpedtavyyctrdaqyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 316 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 316 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1944,NaN,NaN,QPY34041,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 312 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 312 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1945,NaN,NaN,QPY34036,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscavsgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareggysydynywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 302 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 302 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1946,NaN,NaN,QPY34034,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 298 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 298 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1947,NaN,NaN,QPY34028,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgvswnsgtidyadsvkgrftiirdnaknslylqmnslraedtalyycskdmgrldyysgldvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 284 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 284 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1948,NaN,NaN,QPY34026,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 280 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 280 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1949,NaN,NaN,QPY34020,NaN,"SARS-CoV-2, Spike protein",Unknown.,qitlkesgptlvkptqtltltctfsgfslstnvvgvgwirqppgkalewlaliywnddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahgptgdyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 268 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 268 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1950,NaN,NaN,QPY34018,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 264 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 264 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1951,NaN,NaN,QPY34012,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglewvsviwydgsnryyadsvkgrftisrdtskntlylqmnslraedtavyycardppitgttggdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 252 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 252 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1952,NaN,NaN,QPY34010,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 248 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 248 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1953,NaN,NaN,QPY34005,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslrsedtavyycarvplgdyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 238 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 238 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1954,NaN,NaN,QPY34003,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 234 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 234 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1955,NaN,NaN,QPY33996,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvkpggslrlscaasgitfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttarwdwyfdlwgrgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 220 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 220 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1956,NaN,NaN,QPY33994,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 216 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 216 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1957,NaN,NaN,QPY33987,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitysgstiyyadsvkgrftisrdnaksslylqmnslraedtavyycardrgttmvpfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 202 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 202 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1958,NaN,NaN,QPY33985,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 198 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 198 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1959,NaN,NaN,QPY33980,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqsggslrlscaasgltvssnymswvrqapgkglewvsviysggstfysdsvkgrftisrhnskntlylqmnslraedtavyycarargdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 185 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 185 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1960,NaN,NaN,QPY33979,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 183 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 183 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1961,NaN,NaN,QPY33977,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 179 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 179 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1962,NaN,NaN,QPY33971,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpgrslrlscaasgftfddyamywvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraadtalyycakdkdwnsrgyyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 167 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 167 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1963,NaN,NaN,QPY33970,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 165 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 165 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1964,NaN,NaN,QPY33969,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 163 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 163 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1965,NaN,NaN,QPY33968,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 161 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 161 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1966,NaN,NaN,QPY33967,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 159 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 159 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1967,NaN,NaN,QPY33966,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 157 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 157 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1968,NaN,NaN,QPY33964,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 153 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 153 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1969,NaN,NaN,QPY33957,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycardpllidywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 137 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 137 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1970,NaN,NaN,QPY33955,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 133 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 133 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1971,NaN,NaN,QPY33948,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvqsgaevkkpgasvkvsckasgytfinyyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycaiitifgvvtwfdpwgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 119 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 119 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1972,NaN,NaN,QPY33946,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 115 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 115 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1973,NaN,NaN,QPY33939,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfsiyemnwvrqapgkglewvsyitssgttiyyadsvkgrftisrdnaknslylqmnslraedtavyycasssssgyyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 99 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 99 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1974,NaN,NaN,QPY33937,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 95 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 95 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1975,NaN,NaN,QPY33931,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycarernfdafdiwgqgtmvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 83 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 83 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1976,NaN,NaN,QPY33929,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 79 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 79 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1977,NaN,NaN,QPY33922,NaN,"SARS-CoV-2, Spike protein",Unknown.,qvqlvesgggvvqpgrslrlscaasgftfsyygmhwvrqapgkglewvaviwydgsnkfyadsvkgrftisrdnskntlylqmnslraedtavyycaaarpgyyygmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 65 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 65 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1978,NaN,NaN,QPY33921,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 63 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 63 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1979,NaN,NaN,QPY33919,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 59 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 59 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1980,NaN,NaN,QPY33913,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasglivsrnymiwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgtggmdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 44 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 44 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1981,NaN,NaN,QPY33912,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapggggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 42 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 42 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1982,NaN,NaN,QPY33910,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 38 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 38 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1983,NaN,NaN,QPY33903,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycardlggyfdywgqgtlvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 22 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 22 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1984,NaN,NaN,QPY33901,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 18 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 18 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1985,NaN,NaN,QPY33894,NaN,"SARS-CoV-2, Spike protein",Unknown.,evqlvesggglvqpggslrlscaasgftfrnyemnwvrqapgkglewvsyitssgstmyyadsvkgrftisrdnaknslylqmnslraedtavyycardgfyyyyamdvwgqgttvtvss,NaN,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 2 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,Sequence 2 from patent US 10787501,NaN,2022-03-15,NaN,NaN,NaN
1986,NaN,NaN,NaN,QXC72640,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 826 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 826 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1987,NaN,NaN,NaN,QXC72637,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 818 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 818 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1988,NaN,NaN,NaN,QXC72631,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 806 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 806 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1989,NaN,NaN,NaN,QXC72628,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 800 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 800 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1990,NaN,NaN,NaN,QXC72624,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 792 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 792 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1991,NaN,NaN,NaN,QXC72621,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 786 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 786 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1992,NaN,NaN,NaN,QXC72616,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 776 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 776 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1993,NaN,NaN,NaN,QXC72613,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 770 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 770 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1994,NaN,NaN,NaN,QXC72603,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 749 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 749 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1995,NaN,NaN,NaN,QXC72599,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 741 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 741 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1996,NaN,NaN,NaN,QXC72595,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 733 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 733 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1997,NaN,NaN,NaN,QXC72592,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 727 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 727 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1998,NaN,NaN,NaN,QXC72588,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 719 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 719 from patent US 10954289,2022-03-15,NaN,NaN,NaN
1999,NaN,NaN,NaN,QXC72585,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 713 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 713 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2000,NaN,NaN,NaN,QXC72576,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 694 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 694 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2001,NaN,NaN,NaN,QXC72572,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 686 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 686 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2002,NaN,NaN,NaN,QXC72567,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 676 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 676 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2003,NaN,NaN,NaN,QXC72563,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 666 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 666 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2004,NaN,NaN,NaN,QXC72558,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 656 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 656 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2005,NaN,NaN,NaN,QXC72554,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 646 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 646 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2006,NaN,NaN,NaN,QXC72550,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 638 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 638 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2007,NaN,NaN,NaN,QXC72547,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 630 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 630 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2008,NaN,NaN,NaN,QXC72543,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 622 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 622 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2009,NaN,NaN,NaN,QXC72539,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 614 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 614 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2010,NaN,NaN,NaN,QXC72535,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 606 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 606 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2011,NaN,NaN,NaN,QXC72532,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 600 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 600 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2012,NaN,NaN,NaN,QXC72527,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 590 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 590 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2013,NaN,NaN,NaN,QXC72523,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 580 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 580 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2014,NaN,NaN,NaN,QXC72515,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 564 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 564 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2015,NaN,NaN,NaN,QXC72511,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 556 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 556 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2016,NaN,NaN,NaN,QXC72502,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 538 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 538 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2017,NaN,NaN,NaN,QXC72498,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 530 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 530 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2018,NaN,NaN,NaN,QXC72495,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 522 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 522 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2019,NaN,NaN,NaN,QXC72491,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 514 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 514 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2020,NaN,NaN,NaN,QXC72488,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 508 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 508 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2021,NaN,NaN,NaN,QXC72486,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 503 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 503 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2022,NaN,NaN,NaN,QXC72481,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 493 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 493 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2023,NaN,NaN,NaN,QXC72478,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 487 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 487 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2024,NaN,NaN,NaN,QXC72474,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 478 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 478 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2025,NaN,NaN,NaN,QXC72471,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 472 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 472 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2026,NaN,NaN,NaN,QXC72468,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 466 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 466 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2027,NaN,NaN,NaN,QXC72464,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 457 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 457 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2028,NaN,NaN,NaN,QXC72460,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 449 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 449 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2029,NaN,NaN,NaN,QXC72456,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 440 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 440 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2030,NaN,NaN,NaN,QXC72447,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 422 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 422 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2031,NaN,NaN,NaN,QXC72444,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 416 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 416 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2032,NaN,NaN,NaN,QXC72440,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 407 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 407 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2033,NaN,NaN,NaN,QXC72437,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 401 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 401 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2034,NaN,NaN,NaN,QXC72434,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 394 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 394 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2035,NaN,NaN,NaN,QXC72431,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 387 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 387 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2036,NaN,NaN,NaN,QXC72427,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 379 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 379 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2037,NaN,NaN,NaN,QXC72424,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 372 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 372 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2038,NaN,NaN,NaN,QXC72411,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 344 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 344 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2039,NaN,NaN,NaN,QXC72408,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 338 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 338 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2040,NaN,NaN,NaN,QXC72405,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 331 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 331 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2041,NaN,NaN,NaN,QXC72401,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 323 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 323 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2042,NaN,NaN,NaN,QXC72397,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 314 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 314 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2043,NaN,NaN,NaN,QXC72393,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 306 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 306 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2044,NaN,NaN,NaN,QXC72390,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 300 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 300 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2045,NaN,NaN,NaN,QXC72386,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 290 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 290 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2046,NaN,NaN,NaN,QXC72382,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 282 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 282 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2047,NaN,NaN,NaN,QXC72379,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 276 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 276 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2048,NaN,NaN,NaN,QXC72374,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 266 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 266 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2049,NaN,NaN,NaN,QXC72371,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 260 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 260 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2050,NaN,NaN,NaN,QXC72366,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 250 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 250 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2051,NaN,NaN,NaN,QXC72362,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 242 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 242 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2052,NaN,NaN,NaN,QXC72359,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 236 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 236 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2053,NaN,NaN,NaN,QXC72355,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 228 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 228 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2054,NaN,NaN,NaN,QXC72350,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 218 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 218 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2055,NaN,NaN,NaN,QXC72346,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 210 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 210 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2056,NaN,NaN,NaN,QXC72341,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 200 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 200 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2057,NaN,NaN,NaN,QXC72338,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 191 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 191 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2058,NaN,NaN,NaN,QXC72333,"SARS-CoV-2, Spike protein",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 181 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 181 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2059,NaN,NaN,NaN,QXC72330,"SARS-CoV-2, Spike protein",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 175 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 175 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2060,NaN,NaN,NaN,QXC72320,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 155 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 155 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2061,NaN,NaN,NaN,QXC72316,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 145 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 145 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2062,NaN,NaN,NaN,QXC72311,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 135 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 135 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2063,NaN,NaN,NaN,QXC72307,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 127 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 127 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2064,NaN,NaN,NaN,QXC72302,"SARS-CoV-2, Spike protein",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 117 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 117 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2065,NaN,NaN,NaN,QXC72298,"SARS-CoV-2, Spike protein",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 107 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 107 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2066,NaN,NaN,NaN,QXC72293,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 97 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 97 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2067,NaN,NaN,NaN,QXC72289,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 89 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 89 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2068,NaN,NaN,NaN,QXC72285,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 81 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 81 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2069,NaN,NaN,NaN,QXC72281,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 73 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 73 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2070,NaN,NaN,NaN,QXC72275,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 61 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 61 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2071,NaN,NaN,NaN,QXC72271,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 51 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 51 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2072,NaN,NaN,NaN,QXC72266,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 40 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 40 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2073,NaN,NaN,NaN,QXC72262,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 30 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 30 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2074,NaN,NaN,NaN,QXC72257,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 20 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 20 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2075,NaN,NaN,NaN,QXC72253,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10954289-B1 10 23-MAR-2021 Regeneren Pharmaceuticals, Inc.; Tarrytown, NY; 2021.",NaN,NaN,Sequence 10 from patent US 10954289,2022-03-15,NaN,NaN,NaN
2076,NaN,NaN,NaN,QPY34285,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 826 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 826 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2077,NaN,NaN,NaN,QPY34282,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 818 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 818 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2078,NaN,NaN,NaN,QPY34276,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 806 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 806 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2079,NaN,NaN,NaN,QPY34273,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpddfatyycqhlnsylytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 800 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 800 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2080,NaN,NaN,NaN,QPY34269,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 792 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 792 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2081,NaN,NaN,NaN,QPY34266,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsypytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 786 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 786 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2082,NaN,NaN,NaN,QPY34261,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 776 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 776 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2083,NaN,NaN,NaN,QPY34258,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfrltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 770 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 770 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2084,NaN,NaN,NaN,QPY34248,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 749 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 749 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2085,NaN,NaN,NaN,QPY34244,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 741 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 741 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2086,NaN,NaN,NaN,QPY34240,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 733 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 733 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2087,NaN,NaN,NaN,QPY34237,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslfasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfafyycqqtystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 727 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 727 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2088,NaN,NaN,NaN,QPY34233,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 719 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 719 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2089,NaN,NaN,NaN,QPY34230,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 713 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 713 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2090,NaN,NaN,NaN,QPY34221,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 694 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 694 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2091,NaN,NaN,NaN,QPY34217,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmifdvsnrpsgvsdrfsgsksgntasltisglqaedeadyycssfttsstvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 686 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 686 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2092,NaN,NaN,NaN,QPY34212,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 676 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 676 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2093,NaN,NaN,NaN,QPY34208,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 666 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 666 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2094,NaN,NaN,NaN,QPY34203,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 656 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 656 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2095,NaN,NaN,NaN,QPY34199,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqsedeadyycnsltsistwvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 646 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 646 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2096,NaN,NaN,NaN,QPY34195,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 638 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 638 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2097,NaN,NaN,NaN,QPY34192,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 630 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 630 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2098,NaN,NaN,NaN,QPY34188,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 622 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 622 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2099,NaN,NaN,NaN,QPY34184,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsyvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 614 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 614 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2100,NaN,NaN,NaN,QPY34180,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 606 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 606 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2101,NaN,NaN,NaN,QPY34177,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 600 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 600 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2102,NaN,NaN,NaN,QPY34172,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 590 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 590 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2103,NaN,NaN,NaN,QPY34168,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsgapgqrvtisctgsssnigtgydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvvfgggtkltvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 580 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 580 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2104,NaN,NaN,NaN,QPY34160,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 564 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 564 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2105,NaN,NaN,NaN,QPY34156,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqspgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyvrsprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 556 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 556 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2106,NaN,NaN,NaN,QPY34147,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 538 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 538 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2107,NaN,NaN,NaN,QPY34143,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqldsypgltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 530 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 530 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2108,NaN,NaN,NaN,QPY34140,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 522 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 522 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2109,NaN,NaN,NaN,QPY34136,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 514 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 514 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2110,NaN,NaN,NaN,QPY34133,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 508 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 508 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2111,NaN,NaN,NaN,QPY34131,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 503 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 503 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2112,NaN,NaN,NaN,QPY34126,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 493 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 493 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2113,NaN,NaN,NaN,QPY34123,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpptfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 487 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 487 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2114,NaN,NaN,NaN,QPY34119,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 478 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 478 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2115,NaN,NaN,NaN,QPY34116,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlgtgvpsrfsgsrsgtdftftisslqpediatyychqydnlpqtfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 472 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 472 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2116,NaN,NaN,NaN,QPY34113,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 466 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 466 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2117,NaN,NaN,NaN,QPY34109,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvssrfsgsgsgteftltisslqpddfatyycqqynsysvtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 457 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 457 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2118,NaN,NaN,NaN,QPY34105,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 449 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 449 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2119,NaN,NaN,NaN,QPY34101,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapkllifaasslrsgvpsrfsgsgsgtdftltisslhpedfatyycqqnyntpltfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 440 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 440 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2120,NaN,NaN,NaN,QPY34092,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 422 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 422 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2121,NaN,NaN,NaN,QPY34089,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtqfiltisslqpedfatyycqqlnsypgftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 416 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 416 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2122,NaN,NaN,NaN,QPY34085,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 407 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 407 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2123,NaN,NaN,NaN,QPY34082,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpphfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 401 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 401 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2124,NaN,NaN,NaN,QPY34079,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 394 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 394 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2125,NaN,NaN,NaN,QPY34076,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwfqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 387 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 387 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2126,NaN,NaN,NaN,QPY34072,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 379 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 379 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2127,NaN,NaN,NaN,QPY34069,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftinslqpedfatyfcqqydnlppafgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 372 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 372 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2128,NaN,NaN,NaN,QPY34056,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 344 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 344 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2129,NaN,NaN,NaN,QPY34053,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsfsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 338 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 338 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2130,NaN,NaN,NaN,QPY34050,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 331 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 331 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2131,NaN,NaN,NaN,QPY34046,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsistylhwyqqkpgeapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeifgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 323 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 323 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2132,NaN,NaN,NaN,QPY34042,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 314 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 314 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2133,NaN,NaN,NaN,QPY34038,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgigsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 306 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 306 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2134,NaN,NaN,NaN,QPY34035,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 300 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 300 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2135,NaN,NaN,NaN,QPY34031,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssdfawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 290 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 290 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2136,NaN,NaN,NaN,QPY34027,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 282 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 282 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2137,NaN,NaN,NaN,QPY34024,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystlmytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 276 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 276 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2138,NaN,NaN,NaN,QPY34019,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 266 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 266 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2139,NaN,NaN,NaN,QPY34016,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkaphlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 260 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 260 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2140,NaN,NaN,NaN,QPY34011,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 250 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 250 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2141,NaN,NaN,NaN,QPY34007,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqsdnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 242 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 242 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2142,NaN,NaN,NaN,QPY34004,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 236 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 236 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2143,NaN,NaN,NaN,QPY34000,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqdiwnyinwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqhddlpptfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 228 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 228 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2144,NaN,NaN,NaN,QPY33995,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 218 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 218 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2145,NaN,NaN,NaN,QPY33991,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisglqpediatyycqqydnlpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 210 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 210 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2146,NaN,NaN,NaN,QPY33986,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 200 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 200 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2147,NaN,NaN,NaN,QPY33983,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcqasqgisnylnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlrfftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 191 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 191 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2148,NaN,NaN,NaN,QPY33978,"SARS-CoV-2, Spike protein",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 181 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 181 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2149,NaN,NaN,NaN,QPY33975,"SARS-CoV-2, Spike protein",Unknown.,NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyitpytfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 175 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 175 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2150,NaN,NaN,NaN,QPY33965,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 155 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 155 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2151,NaN,NaN,NaN,QPY33961,"SARS-CoV-2, Spike protein",Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 145 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 145 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2152,NaN,NaN,NaN,QPY33956,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 135 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 135 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2153,NaN,NaN,NaN,QPY33952,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 127 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 127 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2154,NaN,NaN,NaN,QPY33947,"SARS-CoV-2, Spike protein",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 117 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 117 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2155,NaN,NaN,NaN,QPY33943,"SARS-CoV-2, Spike protein",Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpptfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 107 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 107 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2156,NaN,NaN,NaN,QPY33938,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 97 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 97 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2157,NaN,NaN,NaN,QPY33934,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfplftfgpgtkvdik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 89 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 89 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2158,NaN,NaN,NaN,QPY33930,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 81 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 81 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2159,NaN,NaN,NaN,QPY33926,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapnsliyaasslqrgvpskfsgsgsgtdftltisslqpedfatyycqqynsyprtfgqgtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 73 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 73 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2160,NaN,NaN,NaN,QPY33920,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 61 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 61 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2161,NaN,NaN,NaN,QPY33916,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqltqspsflsasvgdrvtitcwasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 51 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 51 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2162,NaN,NaN,NaN,QPY33911,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 40 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 40 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2163,NaN,NaN,NaN,QPY33907,"SARS-CoV-2, Spike protein",Unknown.,NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyytfgqgtkleik,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 30 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 30 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2164,NaN,NaN,NaN,QPY33902,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 20 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 20 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2165,NaN,NaN,NaN,QPY33898,"SARS-CoV-2, Spike protein",Unknown.,NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvgrvfgtgtkvtvl,"Babb,R. et al.; Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments; US10787501-B1 10 29-SEP-2020 Regeneron Pharmaceuticals, Inc.; Tarrytown, NY; 2020.",NaN,NaN,Sequence 10 from patent US 10787501,2022-03-15,NaN,NaN,NaN
2166,NaN,NaN,QUX33762,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvassgnrreidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2167,NaN,NaN,QUX33761,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqdntamsyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2168,NaN,NaN,QUX33760,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2169,NaN,NaN,QUX33759,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrtgtteyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2170,NaN,NaN,QUX33758,NaN,SARS-CoV-2,Homo sapiens (human),ecrllesggglvqpggslrlscaasgftfsiypmtwvrqapgkglewvsaitagggstyytdsvkgrftisrdnskntlylqmnslraedtaiyycakngdcdstscppdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2171,NaN,NaN,QUX33757,NaN,SARS-CoV-2,Homo sapiens (human),eaqllesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardivvatartagdyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2172,NaN,NaN,QUX33756,NaN,SARS-CoV-2,Homo sapiens (human),qcrlvesggglvkpggslrlscaasgftfsdfymswirqapgkglewisyisrsggtiyyadsvkgrftisrdnaknslylqmnslraedtavyycargvsgydygsrfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2173,NaN,NaN,QUX33755,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqexgpglvkpsqtlsltctvxggsissgdxywswxrqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslkxssvtaadtavyycarvdcggdcypdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2174,NaN,NaN,QUX33754,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggdlvkpggslrlscaasgfrfsntwmnwvrqapgrglewvgriktlgeggitdyaapvkgrftisrddskqtlylqmnslkiedtavyycttdlptafdsyygmaawgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2175,NaN,NaN,QUX33753,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftftnarmtwvrqapgkglewvgriktktqggtidygapvrgrftisrddlkntldlqmnslktedtavyycaaiddgldhwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2176,NaN,NaN,QUX33752,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdfyanyspsfqghvtisadksistaylqwsslkasdtamyycarqtgycsstscyaggpfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2177,NaN,NaN,QUX33751,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesgsglvkpsqtlsltcavsggsissggyswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsknqfslklssvtaadtavyycarspydssgaidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2178,NaN,NaN,QUX33750,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhtdcsggscylggafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2179,NaN,NaN,QUX33749,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyyccffdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2180,NaN,NaN,QUX33748,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgggetyvryyfdfwgqgglvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2181,NaN,NaN,QUX33747,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdmtpyydilteaygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2182,NaN,NaN,QUX33746,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftftnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylemnslktedtavyycttrrycsstrcylgewsyfdcwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2183,NaN,NaN,QUX33745,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycasgwylswfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2184,NaN,NaN,QUX33744,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvsdyglfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2185,NaN,NaN,QUX33743,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgpyydssgyfdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2186,NaN,NaN,QUX33742,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarggdlfgellgatgyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2187,NaN,NaN,QUX33741,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycatcsggschpyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2188,NaN,NaN,QUX33740,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardfsrggydspsgyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2189,NaN,NaN,QUX33739,NaN,SARS-CoV-2,Homo sapiens (human),evqlvefggglvqpgrslrlscaafgftfddyamhwvrqapgkglewvsgiswnsgsigyadfvkgrftisrdnaknslylqmnslraedtalyycaksriaaavfyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2190,NaN,NaN,QUX33738,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssytmnwvrqapgkglewvsyitsdsstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarnkamddywgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2191,NaN,NaN,QUX33737,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscavsgftfssswmfwvrqapgkglvwvsrisadgytatyaesvegrftisrdnakntlylqmnslraedtalyycarglthdywgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2192,NaN,NaN,QUX33736,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaadlnyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2193,NaN,NaN,QUX33735,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2194,NaN,NaN,QUX33734,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmnwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdlgrfrayyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2195,NaN,NaN,QUX33733,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaktmmgyyyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2196,NaN,NaN,QUX33732,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarangdydlpyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2197,NaN,NaN,QUX33731,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycatdadniatgfwsgyyseyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2198,NaN,NaN,QUX33730,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycareardpfyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2199,NaN,NaN,QUX33729,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsshwmhwvrqapgkglvwvsriigdgseityadsvkgrftisrdnvkntlyleinslraedtavyyclrghvsgstrhfdywgqgtlltvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2200,NaN,NaN,QUX33728,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyycardlfpeyssswyrplyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2201,NaN,NaN,QUX33727,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrssswhyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2202,NaN,NaN,QTI96706,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssytiyyadsvkgrftisrdnaknslylqmnslrdedtavyycardpsdssswypiywyfdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2203,NaN,NaN,QTI96705,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarspyydfwsgyhyyfdywgqgtlvavss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2204,NaN,NaN,QTI96704,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2205,NaN,NaN,QTI96703,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyysgstkynpslnrrvtmsvdtsknqfslklnsvtaadtavyycaryivptspppyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2206,NaN,NaN,QTI96702,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaralssyydfwsaplswdrdnyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2207,NaN,NaN,QTI96701,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctasggsiasnsyywgwirqspgkgldwigsiyysgitysnsslksrvtisvdtsknqfslklssvtaadtavyhcaryssgwahddgfdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2208,NaN,NaN,QTI96700,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevrkpgasvkvsckasgytfsnyaiiwvrqapgqglewmgwisayngktdyseklqdrvtmttdtstntaymelknlrsddtavyycardmffrewfgelihyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2209,NaN,NaN,QTI96699,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsinngdyywswirqhpgkglewigyiyysgntyynpslksrvtisldtsknqfslklssvtaadtalyycargplgyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2210,NaN,NaN,QTI96698,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnyaihwvrqapgkglewvafisydgsikyytdsvkgrftisrdsskntlflqmnnlrpedtavyyctrgavagnnafdvwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2211,NaN,NaN,QTI96697,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyyctagfmaqgliitsifdfwgqgtqvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2212,NaN,NaN,QTI96696,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgaevkkpgasvkvsckisgyrltelsihwvrqapakglewmggfdpddgetmysqrfqgrvtmtedtstdtaymelrnlnsedtaiyycttgfmaqgliitsifdfwgqgtqvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2213,NaN,NaN,QTI96695,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyidnsgstyynpslksrvtisvdtsknqfslnlrsvtaadaavyycarerdlaaagidswgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2214,NaN,NaN,QTI96694,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltctvsggsvnsdsyywswirqppgkglewigyiyysgstncnpslksrltisadtsknqfslklnsvtaadtavyycarveapeggsdywgqgtlvtvsp,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2215,NaN,NaN,QTI96693,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsdtlsltctvsggsissssyywgwirqppgkglewigsisysgstyynpslksrvtisgdtsknqlslklssvtaadtavyycarhtyyydssgylalapdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2216,NaN,NaN,QTI96692,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarsreskdwsygggfyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2217,NaN,NaN,QTI96691,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggnlvqpggslrlscvvsgftfssysmnwvrqapgkglewvsvisgsgdttyyadsvkgrftisrdnskntlylqmnslraedtaiyycakdcdyeiltgyhsncfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2218,NaN,NaN,QTI96690,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsrggsyhdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2219,NaN,NaN,QTI96689,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggnyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2220,NaN,NaN,QTI96688,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcivsggsissssyywgwirqppgkglewigiiyfsgspyynpslksrvtisvdtsknqfslrlssvtaadtalyycarhnyltryyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2221,NaN,NaN,QTI96687,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfdnyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdwggvyygsgtyytnwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2222,NaN,NaN,QTI96686,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigslyysgstyynpslksrvsisvdtsknqfslklssvtaadtavyycatlyyvwgsyrglegnfdnwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2223,NaN,NaN,QTI96685,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpgvllwfgellspwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2224,NaN,NaN,QTI96684,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarawgsyysafdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2225,NaN,NaN,QTI96683,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvgvyydfwsgyyggdnggfwldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2226,NaN,NaN,QTI96682,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckisgytlielsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtgymelsslrsedtavyycvtgppysgsywfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2227,NaN,NaN,QTI96681,NaN,SARS-CoV-2,Homo sapiens (human),evqlqesgpglvkpsqtlsltctvsgdsisrgsyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycaregsfwywfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2228,NaN,NaN,QTI96680,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardysycsstscytsifdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2229,NaN,NaN,QTI96679,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqspgkglewigeinhsgstnyspslksrvtisldtsknqlslkvtsvtaadtgvyfcardsrtsgwhkiyyyyamdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2230,NaN,NaN,QTI96678,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltcavsgasisssgyywgwirqppgkglewignifyigsthynpslksrvtisldtsknqlslklrsvtaadtavyycarptndyggfyfdywgqgilvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2231,NaN,NaN,QTI96677,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaaafsnyeyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2232,NaN,NaN,QTI96676,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardskeyyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2233,NaN,NaN,QTI96675,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscvvsgftfsnysmnwvrqapgkglewvssissvssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvlrryydfwsgyypdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2234,NaN,NaN,QTI96674,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssyywswirqppgkglewigyfyfsgatkynpslnrrvtmsvdtsknqfslklqsvtaadtavyycaryivptspppyyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2235,NaN,NaN,QTI96673,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsisssdyywgwirqppgkglewigsmyysgstyynpslnsrvtisvdtsknqfslnlnsvtaadtavyycarargycsivgcytslyyfdylgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2236,NaN,NaN,QTI96672,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrfaisrdnaknslylqmnslraedtalyycardivpyssswlyyygmdvwgqgttvsvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2237,NaN,NaN,QTI96671,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisnyywswirqppgkglewigyifysgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycardrgyssgwpdafdmwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2238,NaN,NaN,QTI96670,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisssywswirqtpgkglewigyidysgstnynpslksritmsvdtsknqfslklssvtaadtavyycarspnfdwllntggyygldvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2239,NaN,NaN,QTI96669,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrsvrlscaasgftfsscamywvrqapgkglewvavisydvinkyyedsvkgrftisrdnskntlylqmnslraedtavyycasqppairafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2240,NaN,NaN,QTI96668,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgggvvqpgrslrlscassgftfstyamhwvrqapgkglewvafisydgskkyyadslkgrftisrdnskntlylqtnslraedtavyycakvrrwlqfpetdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2241,NaN,NaN,QTI96667,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvrvsckasggpfsnyaifwvrqapgqglewmggiipvfgttnyaqkfqgrvtitadeststaymemsslrsedtavfycaglvastpwpdfwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2242,NaN,NaN,QTI96666,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglelvsyisssgsiiyyadsvkgrftisrdnaknslslqmnslraedtavyycardaniwfgelrglstgymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2243,NaN,NaN,QTI96665,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardshiyrhdswetaitifgvviidafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2244,NaN,NaN,QTI96664,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakrenrllwfgelllghdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2245,NaN,NaN,QTI96663,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrsltlscaasgftfssygvhwvrqapgkglewvslisyegsitqyadpvrgrftisrdnskntlylqmnslktedtavyycargavagndafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2246,NaN,NaN,QTI96662,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisgnsgntkyaqkvqgrvtmttdtststaymelrslrsddtamyycardiiellwfgdyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2247,NaN,NaN,QTI96661,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaakmglwfgelwwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2248,NaN,NaN,QTI96660,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsintaflqwsslkasdtamyycarqrfsgslyfyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin gamma, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2249,NaN,NaN,QSI99137,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyvyysgstnynpslksrvtisvdtsknefslklssvtaadtavyycassqrpdgnlyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2250,NaN,NaN,QSI99136,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaslqwsslkasdtamyycarqkrdgttwafdywgqgtlvtass,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2251,NaN,NaN,QSI99135,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnykyslksrvtisvdtsknqfslklssvtaadtavyycarekggtewefndafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2252,NaN,NaN,QSI99134,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvstnymswvrqapgkglewvsviysggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycastnsgsyshvfdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2253,NaN,NaN,QSI99133,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglgqpggslrlscaasgftfsnyamswvrqapgkglewvsvisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakagavgyydsngyyydvdyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2254,NaN,NaN,QSI99132,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrltitaddststaymelsslksedtavyycarfraydssgygpdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2255,NaN,NaN,QSI99131,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslklscaasgftfnsyamtwvrqapgkglewlstisgsggrtyyadsvkgrfaisrdnskntvflqmstlraedtavyfcardfyglesfypgidswgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2256,NaN,NaN,QSI99130,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhiaglewlfraaavlnwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2257,NaN,NaN,QSI99129,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycagtyydfwsgstnyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2258,NaN,NaN,QSI99128,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvhhcsggscygyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2259,NaN,NaN,QSI99127,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycaredsygsgstgafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2260,NaN,NaN,QSI99126,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlsgifgvviipgffdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2261,NaN,NaN,QSI99125,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardptavtgpfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2262,NaN,NaN,QSI99124,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvprppwddfwsgylyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2263,NaN,NaN,QSI99123,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpseslslaffvyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargggysygaidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2264,NaN,NaN,QSI99122,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2265,NaN,NaN,QSI99121,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptvttvtnwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2266,NaN,NaN,QSI99120,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilditnyaqkfqgrvtitadkststaymelsslrsedtavyycarglwrssiaglhvpygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2267,NaN,NaN,QSI99119,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgynfisygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2268,NaN,NaN,QSI99118,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgnslrlscvasgfkfsssamhwvrqapgkglewvaiiwfhgntkfygdfvkgrftvsrdnsnntlhlqmnslraedtavyhcarassdyggafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2269,NaN,NaN,QSI99117,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraltgnyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2270,NaN,NaN,QSI99116,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmggiipifgtanyaqnfqgrvtitadeststaymelsslrsedtavyycarvsyydssgyytdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2271,NaN,NaN,QSI99115,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtftsyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2272,NaN,NaN,QSI99114,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadsvkgrftisrdsskntlylqmnslraedtavyycarggvgyqllfgndwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2273,NaN,NaN,QSI99113,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnqyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptifgvvlqiprfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2274,NaN,NaN,QSI99112,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpelvkpsetlsltcsvsggsissyywswirqppgkglewigyiyysgstnynpslsgstnynpslksrvtvsvdtsknqfslkvssvtaadtavyycargfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2275,NaN,NaN,QSI99111,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigniyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarqlwgyydssgyyafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2276,NaN,NaN,QSI99110,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymelsslrsedtavfycvsriaaaadfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2277,NaN,NaN,QSI99109,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrlydyvwgsyrfghtwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2278,NaN,NaN,QSI99108,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntldlqmnslraedtavyycarayggnyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2279,NaN,NaN,QSI99107,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfisygiswvrqapgqglewmgwisgyngntnyaqkfqgrvtmttdtststaymelrslrsddtavyycarvrifgvviivdtamvldywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2280,NaN,NaN,QSI99106,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraysydssgyspdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2281,NaN,NaN,QSI99105,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardrrgsgwswdyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2282,NaN,NaN,QSI99104,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtstnqfslklssvtaadtavyycarrvhydiltgfyggalitrafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2283,NaN,NaN,QSI99103,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissrssytnyadsvkgrftisrdnaknslylqmnslraedtavyycargydssgyhyslwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2284,NaN,NaN,QSI99102,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsgissnggstyyadsvkgritisrdnskktlylqmsslraedtavyycvksssrgyywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2285,NaN,NaN,QSI99101,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasarfitmvrgviniyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2286,NaN,NaN,QSI99100,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvscrasgytftnfgiswvrqapglglewmgwistyngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarasgpyllglywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2287,NaN,NaN,QSI99099,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycatnsnypywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2288,NaN,NaN,QSI99098,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsncwmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarmgntawyfdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2289,NaN,NaN,QSI99097,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasrftfstyamhwvrqapgkglewvtvisydgdnkyyadsvkgrftisrdnskntlylqmnslrtedtavyyctragsgsylsyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2290,NaN,NaN,QSI99096,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarissydssgysmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2291,NaN,NaN,QSI99095,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctmvwqqlhdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2292,NaN,NaN,QSI99094,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadestntaymelssltsedtavyycakigdydssgyyfdywaqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2293,NaN,NaN,QSI99093,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarayggsyfygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2294,NaN,NaN,QSI99092,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsvssnayywgwirqppgkglewigsvnyrgstyyiptlksritisvntsknqfslkltsvtaadtavyycarrgvalvtityfdfwgqgalvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2295,NaN,NaN,QSI99091,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglefigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycatqevvlvrpynyngmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2296,NaN,NaN,QSI99090,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaaagfifssyamnwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlnlqmnslraedtavyycargngyiiidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2297,NaN,NaN,QSI99089,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgkidpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarqfggellgwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2298,NaN,NaN,QSI99088,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisstsnyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarvspnydfwsgyypdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2299,NaN,NaN,QSI99087,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnsfamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardrsggyscfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2300,NaN,NaN,QSI99086,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycaseivsfigssedywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2301,NaN,NaN,QSI99085,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckafgytftknginwvrqapgqglewmgwispnngytnfaqkfqgratmtsdtststaymelrslrsddtavyycarvrvdydssgydayyyhldvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2302,NaN,NaN,QSI99084,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmardtsistaymelsrlrsddtavyycardqvspycggdcpdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2303,NaN,NaN,QSI99083,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntlylqmnslrvedtavyycarpgggsyygpfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2304,NaN,NaN,QSI99082,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgyyqdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2305,NaN,NaN,QSI99081,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvstistnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvlgycsstscqhfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2306,NaN,NaN,QSI99080,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssfafiwvrqapgqglewmggiipifgtakytqkfqgrvtitadeststaymelsslrsedtavyycarvsyydssgfytdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2307,NaN,NaN,QSI99079,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsggifssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasysgfddyghyrnywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2308,NaN,NaN,QSI99078,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfalhwvrqapgkglewvavvsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarsmggnyadyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2309,NaN,NaN,QSI99077,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylemnslraedtavyycastsdsgsyyihwyfdlwgrgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2310,NaN,NaN,QSI99076,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylhmnslraedtavyycarpnsgsyhsyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2311,NaN,NaN,QSI99075,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssrsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycasnpaadpntyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2312,NaN,NaN,QSI99074,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsissstwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycarsasnyfgyyyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2313,NaN,NaN,QSI99073,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymtwvrqapgkglewvsiiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaagyydsinwgqgtlvtvps,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2314,NaN,NaN,QSI99072,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscgasgfifssyamhwvrqapgkglewvavisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpysgtyfsafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2315,NaN,NaN,QSI99071,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgnsftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhrnydiltgyryyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2316,NaN,NaN,QSI99070,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlflqmnslrtedtavyycaramggnyfhafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2317,NaN,NaN,QSI99069,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnnaqkfqgrvtltadestsaaymelsslrsedtavyycariepyastgytfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2318,NaN,NaN,QSI99068,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaitwvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycvrvalydssgyspdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2319,NaN,NaN,QSI99067,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissstyywgwirqppgkglewigniyytgstyynpslksrvtisvdtsknhfslrlssvtaadtavyycarhnrfwsedtpfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2320,NaN,NaN,QSI99066,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglaqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggntyyadslkgrftisrdnskstlylqmnslraedtavyycakgpmwqwlvrlslvgdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2321,NaN,NaN,QSI99065,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycarpysgsyyayfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2322,NaN,NaN,QSI99036,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssdnyywswirqppgkglewigyiyysgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargfvatyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2323,NaN,NaN,QSI99035,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfsvssnymnwvrqaprkglewvsviysggstyyadsvkgrftisrdnskntlylqmntlraedtavyycargygdsqrwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2324,NaN,NaN,QSI99034,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpgqvkpsetlsltctvsgysissgyfwgwvrqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycardhgsydfwsgysrdafdiwgqgtmvtfss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2325,NaN,NaN,QSI99033,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvscktsgyiftdyfmhwvrqapgqglewmgwinpnsgganyaqkfqgrvtmtrdtsittvymelsrlriddtamyycareaslnrsryyssggtvyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2326,NaN,NaN,QSI99032,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvglsswyfeywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2327,NaN,NaN,QSI99031,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgpglvkpsetlsltctvsggsirsyshywgwirqppgkglewigtiyysgstyynpslksritisvdtsksqfslklssvtaadtavyfcastiptyddiltgyqfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2328,NaN,NaN,QSI99030,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyaiywvrqapgkglewvavisydgsnkyyadsvrgrftisrdnskntlylqmnslraedtavyycarggggyntffdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2329,NaN,NaN,QSI99029,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdgavatgpgyfyfymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2330,NaN,NaN,QSI99028,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgfpfrnyamhwvrqapgkglehisvissrgdttyyansvkgrftisrdnsqntlylqmdslraddmavyycarvqsgfsygygfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2331,NaN,NaN,QSI99027,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisadtsknqfslklssvtaadtavyycarapgatyssgwyyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2332,NaN,NaN,QSI99026,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgytftrywigwvrqmpgkglewmgiiypgdsdtryspsfqghvtisadksistaylqwnslkasdtamyycarlpqycsngvcqrwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2333,NaN,NaN,QSI99025,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydginkyyadsvkgrftssrdnskntlylqmnslraedtavyfcarmysgsylgyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2334,NaN,NaN,QSI99024,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlsltctvsgdsissyywswirqppgkglewigyiyytgstnynpslksrvtisvdtsknqfslklssvtaadtavyycanlgynsgwyggyfeywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2335,NaN,NaN,QSI99023,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfifsrysmnwvrqapgkglewvssissstsfiyyadsvrgrftisrdnaknslylqmnslraedtavyycarwiggdssgyypdafdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2336,NaN,NaN,QSI99022,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgpglvkpsetlsltctvsgdsisnyywswirqppekglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtamyycardfslwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2337,NaN,NaN,QSI99021,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscavsgftfsnygmhwvrqapgkglewvavilydgsnryyadsvkgrftvsrdnskntlylqmnslraedtavyycakgggpycgggscwahyfdywgqgtlvsvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2338,NaN,NaN,QSI99020,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvaggsissgtyywswirqpagkglewigriytsgsanynpslksrvtisvdtsknqfslrlssvtaedtavyycareysssyyyfyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2339,NaN,NaN,QSI99019,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissgnyywswirqpagkglewigriytsgstnynpslksrvtisvdtsknqfslklssvtaadtalyycardayydflsgyiptynwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2340,NaN,NaN,QSI99018,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpgrslrlsctasgftfgdyamiwfrqapgkglewvgfirskayggtteyaasmkgrftisrddsksiaylqmnslktedtavyyctrdldyydssgyyptyidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2341,NaN,NaN,QSI99017,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsyyalswvrqapgkglewvsatygsgsntyyadsvkgrftisrdnskntlylqmsnlraddtavyycakdqrnaydsfdfwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2342,NaN,NaN,QSI99016,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiyaihwvrqapgqglewvavisydgsnkyyadsvrgrftisrdnskntlylqmntlraedtavyycargptysymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2343,NaN,NaN,QSI99015,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdksknmvylqmnslraedtalyycakdleyytsgsyslfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2344,NaN,NaN,QSI99014,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcgfyggslnnyfwswirqppgkglewigdinhsgstnynpslksrvtvsvdtsknqfslnlnsvtaadtavyycarglflvyygsglggfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2345,NaN,NaN,QSI99013,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssygmswvrqapgkglewvsginnhggstyygdsvkgrftisrdnskntlylqmnslraedtavyycaksdtamvpynwfdpwgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2346,NaN,NaN,QSI99012,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqgsgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycarhptfsgyeyyfdhwgqgtlitvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2347,NaN,NaN,QSI99011,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssyalswvrqapgkglewvsaisgsggsiyyadsvkgrftisrdnskstlylqmnslkaedtavyycakddstsayyyyyymdvwgkgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2348,NaN,NaN,QSI99010,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyigssgssihyadsvkgrftisrdnaknslylqmnslraedtavyycardgsygdyvrgywgqgalvivss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2349,NaN,NaN,QSI99009,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpevkkpgtsvkvpckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapscsggrcydgfdiwgqgtmvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2350,NaN,NaN,NaN,QUX33798,SARS-CoV-2,Homo sapiens (human),NaN,qavvtqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2351,NaN,NaN,NaN,QUX33797,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2352,NaN,NaN,NaN,QUX33796,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigshpvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslsgrvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2353,NaN,NaN,NaN,QUX33795,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqepsltvspggtvtltcgsstgavtsghwpywfqqkpgqtprtliydtsnkqswtparfsgsllggkaaltlsgaqpedeaeyyclllysdgrvfgggtkltvq,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2354,NaN,NaN,NaN,QUX33794,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2355,NaN,NaN,NaN,QUX33793,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2356,NaN,NaN,NaN,QUX33792,SARS-CoV-2,Homo sapiens (human),NaN,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2357,NaN,NaN,NaN,QUX33791,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2358,NaN,NaN,NaN,QUX33790,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2359,NaN,NaN,NaN,QUX33789,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqepsltvspggtvtltcasstgvvtsghypywfqqkpgqaprtliydtnnkyswtparfsgsllggkaaltlsgaqpedeadyyclitysgrevfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2360,NaN,NaN,NaN,QUX33788,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyravvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2361,NaN,NaN,NaN,QUX33787,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2362,NaN,NaN,NaN,QUX33786,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqepslavspggtvtltcasstgtvtsgsypnwfqqkpgqppraliydtsnkhswtparfsgfllggkatlalsgaqpedeaeyycllynggvwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2363,NaN,NaN,NaN,QUX33785,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvrtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2364,NaN,NaN,NaN,QUX33784,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppatfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2365,NaN,NaN,NaN,QUX33783,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvssnflawyqrkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2366,NaN,NaN,NaN,QUX33782,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplflvatatgvhseivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2367,NaN,NaN,NaN,QUX33781,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2368,NaN,NaN,NaN,QUX33780,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsvsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsywtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2369,NaN,NaN,NaN,QUX33779,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystlaltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2370,NaN,NaN,NaN,QUX33778,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvwtfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2371,NaN,NaN,NaN,QUX33777,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2372,NaN,NaN,NaN,QUX33776,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlfsfnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqynstpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2373,NaN,NaN,NaN,QUX33775,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvaayycqqyystpptfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2374,NaN,NaN,NaN,QUX33774,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2375,NaN,NaN,NaN,QUX33773,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2376,NaN,NaN,NaN,QUX33772,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpmtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2377,NaN,NaN,NaN,QUX33771,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppntfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2378,NaN,NaN,NaN,QUX33770,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrlmykvskrdsgvpdrfsgsgsgtdftlkisrveaedagiyycmqgthwppytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2379,NaN,NaN,NaN,QUX33769,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2380,NaN,NaN,NaN,QUX33768,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2381,NaN,NaN,NaN,QUX33767,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqtvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyntpptfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2382,NaN,NaN,NaN,QUX33766,SARS-CoV-2,Homo sapiens (human),NaN,eilmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgrtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2383,NaN,NaN,NaN,QUX33765,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2384,NaN,NaN,NaN,QUX33764,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtpsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2385,NaN,NaN,NaN,QUX33763,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltvsslepedfavyycqqrsnwppitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2386,NaN,NaN,NaN,QTI96751,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2387,NaN,NaN,NaN,QTI96750,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsrsgtsatlgitglqtgdeadyycgtwdsslsawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2388,NaN,NaN,NaN,QTI96749,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssniesntvqwyqqlpgtapkliihnnskrpsgvpdrfsasksgtsaslaisglqsqddgdyycaawddslnawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2389,NaN,NaN,NaN,QTI96748,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvapgktasiicggnnignknvhwyqqkpgqapvlvisydsgrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsgsdlmvfgggtkltal,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2390,NaN,NaN,NaN,QTI96747,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhrgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2391,NaN,NaN,NaN,QTI96746,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsylsgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2392,NaN,NaN,NaN,QTI96745,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2393,NaN,NaN,NaN,QTI96744,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgnryacwyqqkpgqspvlviyqnnkrpsgiperfsgsnsgnsatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2394,NaN,NaN,NaN,QTI96743,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstlvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2395,NaN,NaN,NaN,QTI96742,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqprsvsgspglsvtisctgsssdvggynyvswyqqhpgkapklmiydvsrrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytyvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2396,NaN,NaN,NaN,QTI96741,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgdkyaswyqqksgqspvlviyqdsrrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2397,NaN,NaN,NaN,QTI96740,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnawvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2398,NaN,NaN,NaN,QTI96739,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasatpgqrvtiscsgsssnigsnyvywyqqfpgtapklliygnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddspsvhwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2399,NaN,NaN,NaN,QTI96738,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvapgktaritcggnnigtksvhwyqqkpgqapvlviyydtdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggakltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2400,NaN,NaN,NaN,QTI96737,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2401,NaN,NaN,NaN,QTI96736,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsmsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydngkrpsgipdrfsasksgtsatlgitglqtgdeadyycgtwdsslstwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2402,NaN,NaN,NaN,QTI96735,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycsssassttlhgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2403,NaN,NaN,NaN,QTI96734,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqppsmsvspgqtasitcsgdklgnkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsestatltisgtlamdeadyycqawdsstegvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2404,NaN,NaN,NaN,QTI96733,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsvspgqtasiicsgdklgdkyacwyqqkpgqspllviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyfcqawdsstavvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2405,NaN,NaN,NaN,QTI96732,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgfvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2406,NaN,NaN,NaN,QTI96731,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtnsdvgaynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2407,NaN,NaN,NaN,QTI96730,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslesedfvvyycqqrsnwpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2408,NaN,NaN,NaN,QTI96729,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspssvsasvgdrvtitcrasqdisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqaksfppptfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2409,NaN,NaN,NaN,QTI96728,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtpgtlslspgeratlscrasqsvsnnylawyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygnswtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2410,NaN,NaN,NaN,QTI96727,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqssstpsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2411,NaN,NaN,NaN,QTI96726,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2412,NaN,NaN,NaN,QTI96725,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpftfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2413,NaN,NaN,NaN,QTI96724,SARS-CoV-2,Homo sapiens (human),NaN,airmtqsplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsasgagtdftlkisrveaedvgvyycmqatqfpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2414,NaN,NaN,NaN,QTI96723,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrviitcrasqsiagylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2415,NaN,NaN,NaN,QTI96722,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2416,NaN,NaN,NaN,QTI96721,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2417,NaN,NaN,NaN,QTI96720,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2418,NaN,NaN,NaN,QTI96719,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspmytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2419,NaN,NaN,NaN,QTI96718,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpqtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2420,NaN,NaN,NaN,QTI96717,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2421,NaN,NaN,NaN,QTI96716,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2422,NaN,NaN,NaN,QTI96715,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfsftisslqpediatyycqqydnlpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2423,NaN,NaN,NaN,QTI96714,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtpsslstsvgdrvtitcrtsqsigsflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystpytfgqgtkmeik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2424,NaN,NaN,NaN,QTI96713,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasiratgiparfsgsgsgtdftltisslepedfavyycqyrsnwpprltfgggtrveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2425,NaN,NaN,NaN,QTI96712,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkagqaprlliygastratgiparfsgsgsgteftltisslqsedfaiyycqqynnwpprtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2426,NaN,NaN,NaN,QTI96711,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2427,NaN,NaN,NaN,QTI96710,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2428,NaN,NaN,NaN,QTI96709,SARS-CoV-2,Homo sapiens (human),NaN,airmtqsplslpvtlgqpasiscrssqslvysdgntyliwfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlnisrveaedvgvyycmqgthwpltfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2429,NaN,NaN,NaN,QTI96708,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2430,NaN,NaN,NaN,QTI96707,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2431,NaN,NaN,NaN,QSI99210,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgqtaritcggnnigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2432,NaN,NaN,NaN,QSI99209,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2433,NaN,NaN,NaN,QSI99208,SARS-CoV-2,Homo sapiens (human),NaN,syeltqpssvsvfpgqtaritcsgdvlekkyarwfqqkpgqapllviykdserpsgiperffgsssgttvtltisgaqvedeadyycysaadnnrgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2434,NaN,NaN,NaN,QSI99207,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2435,NaN,NaN,NaN,QSI99206,SARS-CoV-2,Homo sapiens (human),NaN,syeltqplsvsvalgqtaritcggnnigsknvhwyqqkpgqapvlviyrdsnrpsgiperfsgsnsgntatltisraqagdeadyfcqvwdsstvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2436,NaN,NaN,NaN,QSI99205,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigtnyvywyqqlpgtapklliyrntqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaswddshvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2437,NaN,NaN,NaN,QSI99204,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2438,NaN,NaN,NaN,QSI99203,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaevfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2439,NaN,NaN,NaN,QSI99202,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapqlliydnnkrpsripdrfsgsksgtsatlgitglqtgdeavyycgtwdsslsavvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2440,NaN,NaN,NaN,QSI99201,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedesdyycssyttsstlyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2441,NaN,NaN,NaN,QSI99200,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeaayyccsyvgsstyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2442,NaN,NaN,NaN,QSI99199,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeahyycgtwdsslsagvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2443,NaN,NaN,NaN,QSI99198,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytnsrtldvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2444,NaN,NaN,NaN,QSI99197,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstllfgggtklrs,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2445,NaN,NaN,NaN,QSI99196,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2446,NaN,NaN,NaN,QSI99195,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqatdeadyycqawdsstgvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2447,NaN,NaN,NaN,QSI99194,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyswvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2448,NaN,NaN,NaN,QSI99193,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtitctgsssnigsgydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeahyycqsydssvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2449,NaN,NaN,NaN,QSI99192,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitlsctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistlvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2450,NaN,NaN,NaN,QSI99191,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmkfnsdgthskgdgipdrfsgsssgaersltisslqsedeadyycqtwgtggvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2451,NaN,NaN,NaN,QSI99190,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyccystdssdnhrrvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2452,NaN,NaN,NaN,QSI99189,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigrntvnwfqqlpgtapklliysnyqrpsgvpdrlsgsksgtsaslairglqsedeadyycaawddslhgwvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2453,NaN,NaN,NaN,QSI99188,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2454,NaN,NaN,NaN,QSI99187,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltlsglqaedeadyycssytssstlyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2455,NaN,NaN,NaN,QSI99186,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2456,NaN,NaN,NaN,QSI99185,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyyccshagsstsyifgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2457,NaN,NaN,NaN,QSI99184,SARS-CoV-2,Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2458,NaN,NaN,NaN,QSI99183,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgqtaritcggnnigskgvhwyqqkpgqapvlvvfddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdstsdhpgyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2459,NaN,NaN,NaN,QSI99182,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2460,NaN,NaN,NaN,QSI99181,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysaprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2461,NaN,NaN,NaN,QSI99180,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2462,NaN,NaN,NaN,QSI99179,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2463,NaN,NaN,NaN,QSI99178,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgkratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqxygsspntfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2464,NaN,NaN,NaN,QSI99177,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2465,NaN,NaN,NaN,QSI99176,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwvtfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2466,NaN,NaN,NaN,QSI99175,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyslltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2467,NaN,NaN,NaN,QSI99174,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappgftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2468,NaN,NaN,NaN,QSI99173,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2469,NaN,NaN,NaN,QSI99172,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvslgeratlscrasqsvtsslawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqynnwppwtfgqgtkvevt,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2470,NaN,NaN,NaN,QSI99171,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2471,NaN,NaN,NaN,QSI99170,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltinslepedfavyycqqrsnwppeytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2472,NaN,NaN,NaN,QSI99169,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2473,NaN,NaN,NaN,QSI99168,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2474,NaN,NaN,NaN,QSI99167,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2475,NaN,NaN,NaN,QSI99166,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsissylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpplltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2476,NaN,NaN,NaN,QSI99165,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2477,NaN,NaN,NaN,QSI99164,SARS-CoV-2,Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2478,NaN,NaN,NaN,QSI99163,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppkltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2479,NaN,NaN,NaN,QSI99162,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2480,NaN,NaN,NaN,QSI99161,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystlhtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2481,NaN,NaN,NaN,QSI99160,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2482,NaN,NaN,NaN,QSI99159,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsyrpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2483,NaN,NaN,NaN,QSI99158,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyychhygsspplftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2484,NaN,NaN,NaN,QSI99157,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2485,NaN,NaN,NaN,QSI99156,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2486,NaN,NaN,NaN,QSI99155,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2487,NaN,NaN,NaN,QSI99154,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsapftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2488,NaN,NaN,NaN,QSI99153,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprllifgastratgiparfsgsgsgteftltisslqsedfavyychqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2489,NaN,NaN,NaN,QSI99152,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssklawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2490,NaN,NaN,NaN,QSI99151,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppvitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2491,NaN,NaN,NaN,QSI99150,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppeytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2492,NaN,NaN,NaN,QSI99149,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtpatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrynwppeltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2493,NaN,NaN,NaN,QSI99148,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvtnylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpntfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2494,NaN,NaN,NaN,QSI99147,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscgasqsvsssylawyqqkpglaprlviydassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2495,NaN,NaN,NaN,QSI99146,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssqlawyqqkpgqaprllisdasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2496,NaN,NaN,NaN,QSI99145,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasnlesgvpsrfsgsgsgteftltisslqpddfatyycqqyytyswtfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2497,NaN,NaN,NaN,QSI99144,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqlqpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiptfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2498,NaN,NaN,NaN,QSI99143,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2499,NaN,NaN,NaN,QSI99142,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqrkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavfycqqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2500,NaN,NaN,NaN,QSI99141,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppritfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2501,NaN,NaN,NaN,QSI99140,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsnflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwppgitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2502,NaN,NaN,NaN,QSI99139,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2503,NaN,NaN,NaN,QSI99138,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwlaltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2504,NaN,NaN,NaN,QSI99064,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasigdrvtitcrasqsinnylnwyqqkpgkapelliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyspytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2505,NaN,NaN,NaN,QSI99063,SARS-CoV-2,Homo sapiens (human),NaN,digmtqspstlsasvgdrvtitcrasqsisswlawyqhkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysftfgpgtkvdpk,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2506,NaN,NaN,NaN,QSI99062,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqynsyprtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2507,NaN,NaN,NaN,QSI99061,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdisnflnwyqqkpgkapklliydasnletrvpsrfsgsgsgtdftftisslqpediatyycqhyttfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2508,NaN,NaN,NaN,QSI99060,SARS-CoV-2,Homo sapiens (human),NaN,airmtqtpdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyfcqqyystpltfgggtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2509,NaN,NaN,NaN,QSI99059,SARS-CoV-2,Homo sapiens (human),NaN,eivltqsplslpvtpgepasiscrssqsllhingynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2510,NaN,NaN,NaN,QSI99058,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2511,NaN,NaN,NaN,QSI99057,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpytfgqgtnleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2512,NaN,NaN,NaN,QSI99056,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwppitfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2513,NaN,NaN,NaN,QSI99055,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdfiltirrlepedfavyycqqygsslytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2514,NaN,NaN,NaN,QSI99054,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspvslsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwppwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2515,NaN,NaN,NaN,QSI99053,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliystssravgipdrfsgggsgtdftltisrlepedfavyychqygsspwtfgqgtkveik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2516,NaN,NaN,NaN,QSI99052,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslstsvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpttfgqgtrleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2517,NaN,NaN,NaN,QSI99051,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyvasnletgvpsrfsgsgfgtdftftisslqpediatyycqqfdnlpytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2518,NaN,NaN,NaN,QSI99050,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylncyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqynnlpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekh,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2519,NaN,NaN,NaN,QSI99049,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpaqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppltfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslss,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2520,NaN,NaN,NaN,QSI99048,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqdissalawyqqkpgktpkiliydasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqfnnypltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlska,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2521,NaN,NaN,NaN,QSI99047,SARS-CoV-2,Homo sapiens (human),NaN,eixltqspatlsvspgeratlscrasqsvrsnlawyqqkpgqaprlliygastratgtparfsgsgsgteftltisslqsedfavyycqqynywppytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdsty,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2522,NaN,NaN,NaN,QSI99046,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvnnylawyqqkpgqaprlliydashratdiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2523,NaN,NaN,NaN,QSI99045,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqspklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyynsytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsst,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2524,NaN,NaN,NaN,QSI99044,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspstlsasvgdrvtitcrasqtisswlawyqqkpgkapnlliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2525,NaN,NaN,NaN,QSI99043,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvtextartap,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2526,NaN,NaN,NaN,QSI99042,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgsssdvggydfvswyqqhpgkapkvviydvtnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2527,NaN,NaN,NaN,QSI99041,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgdkyvcwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdsstgvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2528,NaN,NaN,NaN,QSI99040,SARS-CoV-2,Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstsyvvfgggtkltvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2529,NaN,NaN,NaN,QSI99039,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsgsnigagydvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaddeadyycqsydsslsgpvvigggtkltvlsqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltp,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2530,NaN,NaN,NaN,QSI99038,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsvvlfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwksh,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2531,NaN,NaN,NaN,QSI99037,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynvvswyqqhpgkapqlmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstswvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwks,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2532,NaN,NaN,QTX15864,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqptgqdlewvsaigtagdtyypdsvkgrftisrenaknssylqmnslragdtavyycarasfdssgylnyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2533,NaN,NaN,QTX15863,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtsnnqfslklssvtaadtavyycarhvqwlvlyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2534,NaN,NaN,QTX15862,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartrggsyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2535,NaN,NaN,QTX15861,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaemkepgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqdrvtitadeststaylelsslrsedtavyycaresttifgvviltsygmdvwgqgttitiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2536,NaN,NaN,QTX15860,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgggliqpggslrlscaasvfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrddskntlylqmnslraedtavyycarsrggpldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2537,NaN,NaN,QTX15859,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkepgasvkvsckasgytftsygiswvrqapgqglewmgwisaydgntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregsdyydssgfhdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2538,NaN,NaN,QTX15858,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkgltwighisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycarqlwlrapfdywgqgalvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2539,NaN,NaN,QTX15857,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpgrslrltcaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrpedtalyycakddssswyfysraklgqyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2540,NaN,NaN,QTX15856,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgsglvkpsqtlsltcavsggsidsggdswswirqppgkglewigyiyhsgstyynpslksrvtisvdrsnnqfslklssvtaadtavyycarhsgydlggafdiwgqgtmvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2541,NaN,NaN,QTX15855,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewlggfdpedaetiyaqkfqgrvtmtedtstdtaymglssltsedtavyycatgvavagtqknysyyygldvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2542,NaN,NaN,QTX15854,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvasgggvvqpgrslrlscaasgfiitsygmhwvrqapgkglewvaaiwydgsnkyyadsvkgrftisrdnskntlylqmnspraedtavyycarddptpdgdafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2543,NaN,NaN,QTX15853,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvkpggslrlscaasgftfstysmnwvrqapgkglewvssisssstdihyadsmkgrftisrdnaknslylqmnslraedtavyycardfhrgwydhsayifdfwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2544,NaN,NaN,QTX15852,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsviswhsgsidyadsvkgrftisrdnaknslylqmnslraedtalyhcakgtgysygyavdggfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2545,NaN,NaN,QTX15851,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyisssgstkyygdsvkgrftisrdnaknslylqlnslrdedtavyycartiysydssgyygteryfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2546,NaN,NaN,QTX15850,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgysftnswiawvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdsamyycarlgswyvyyyyyaldvwgqgplvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2547,NaN,NaN,QTX15849,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgfyihwvrqapgqglewmgwinpnsggsncaqkfqgrvtmtrdtsistaymevsrlrsddtavyycarysnyyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2548,NaN,NaN,QTX15848,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavygesfsgyywswirqppgkglewigeiihsgstnynpplksrvtisvdtsksqfslklssvtaadtavyycaremsvavvdhwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2549,NaN,NaN,QTX15847,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgtevkkpgasvkvsctasgytftvcyihwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvarhyydrsgnlhsadyfqhwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2550,NaN,NaN,QTX15846,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsggtdyvqkfqgrvtmtrdtsistaymelsrlrsddtavyycaslsaagplndvfdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2551,NaN,NaN,QTX15845,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitspgsaiyyadsvkgrftisrdnaknslylqmnslraedtalyyctrdgvipprfdywgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2552,NaN,NaN,QTX15844,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasefivsrnymnwvrqapgkglewvsliysggttyyadavkgrftisrdnskntlylqmnslraedtavyycargfgdrrldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2553,NaN,NaN,QTX15843,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygihwvrqapgkglewvavisydgstkyyadsvkgrftisrdnskntlylqmnslraedtavyfcakdrgtliegmdvwgkgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2554,NaN,NaN,QTX15842,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpggslrlscaasglifshygmhwvrqapgkglewvafirndgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdggyyyessgwfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2555,NaN,NaN,QTX15841,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsshamnwvrqapgkglewvsgisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaksmfgydssgyfygedfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2556,NaN,NaN,QTX15840,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggstsssfhywgwirqppgkglewigniyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlgsgsyytadywgqgtrvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2557,NaN,NaN,QTX15839,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfisyamhwvrqapgkglewvavisydgnnkyysdsvkgrftisrdnskntlhlqmnslraedtavyycakdlsggysywdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2558,NaN,NaN,QTX15838,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtftsydvnwvrqatgqglewmgwmdpnsgntgyaqnfqgrvtmtrstsigtaymelsslrsedtavyycarskergyynrtgyyypgdwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2559,NaN,NaN,QTX15837,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgdsisnnyaywgwirqppgkglewignlyysgstyynpslksrvtisvdtsenqfslrlssvtaadtavyycarlpygydyveafdiwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2560,NaN,NaN,QTX15836,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvafisydgsnqystdpvkgrftfardnskdtlylqmnslrgddtavyycaksrggnyfdafdmwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2561,NaN,NaN,QTX15835,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvtanymswvrqapgkglewvstiysggstfyadsvkgrftisrdnsrntlylqmnslraedtavyycarergakafdpwgqgalvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2562,NaN,NaN,QTX15834,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsgygmhwvrqapgrglewvavisydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakpysgsywsyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2563,NaN,NaN,QTX15833,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissygkywswirqhpgkglewigyiyysgstqynpslksrvtisvdtsknqfslklnsvtaadtavyycardsaaghfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2564,NaN,NaN,QTX15832,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgnthyaqkfqervtitrdmststaymelsslrsedtavyycaapyctttrchdgfdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2565,NaN,NaN,QTX15831,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsdkyyadsvkgrltifrdnskntlylqmnslraedtavyycaregadrsgwwgsfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2566,NaN,NaN,QTX15830,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmhslraedtavyycardrfgrindywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2567,NaN,NaN,QTX15829,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckafgysftsfnlnwvrqapgqglewmgwisayngntsyaqkfqgrvtmttdtstttvymelrslrsddtavyycaralenyydrngnyyvgafdywgqgslvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2568,NaN,NaN,QTX15828,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsrtscqdgfdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2569,NaN,NaN,QTX15827,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfsiywmhwvrqapgkglvwvsrinsdgsstsnadsvkgrftisrdnakntlylqmnslraedtavyycardhvvaatpgmdvwgqgttitvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2570,NaN,NaN,QTX15826,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfvaedgetiyaqkfqgrvsmtedtstdtaymelsslrsedtavyycatdrarldyfasgsyyghfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2571,NaN,NaN,QTX15825,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfmfssynmnwvrqapgkglewvssisssssyiyyedsvkgrftisrdnaknslylqmislsaedtavyycarmayfdssgyypnafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2572,NaN,NaN,QTX15824,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifssydmhwvrqatgkglewvsgignagdthypgavkgrftisrenaknslylqmnslragdtavyycarahrgyydrsgyyhnpdafdiwgqgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2573,NaN,NaN,QTX15823,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgysftsygiswvrqapgqglewmgwisafnnnanyvqkfqgrvtmttdtststaylelrslrsddaavyycardddnydttgyylywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2574,NaN,NaN,QTX15822,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgdtfrsysiswvrqapgqglewmgriipilgipnyaqkfqgrvtitadkstntaymelsslrsedtavyycarespycssttclsdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2575,NaN,NaN,QTX15821,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglewigsmyysgntyynpplqsrvtisvdtsknqvslslssvtaadtalyycarhpdicdfwsgypgwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2576,NaN,NaN,QTX15820,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgkslrlscaasgltfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakegwgysygsyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2577,NaN,NaN,QTX15819,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycastprgdsygggaywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2578,NaN,NaN,QTX15818,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggalvqpggslrlsceasefivsrnymnwvrqapgkglewvsviysggstfyadsvkgrfiisrdnskntlylqmnslraedtavyycarelvgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2579,NaN,NaN,QTX15817,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyytdsvkgrftisrdnskntlylqmnslrpedravyycakdaadsritmfgvviishfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2580,NaN,NaN,QTX15816,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewassissnssciyyadsvkgrftisrdnaknslylqmnslraedtavyycasgehnyyyyygmdvwgqgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2581,NaN,NaN,QTX15815,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqqsgaevkkpgasvkdsckasgytftsygiswvrqapgqglewvgwisayngntnyglklqgrvtmttdtststaymelrslrsddtavyycarahpfydsggysdywgqgslvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2582,NaN,NaN,QTX15814,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrltcaasgfifssygmhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnslraedtavyyctkadyydfwsgyqktyyyymdvwgkgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2583,NaN,NaN,QTX15813,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvetgggliqpggslrlscaasgltvsanymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrvedtavyycarniyddafdvwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2584,NaN,NaN,QTX15812,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgfsfssysmnwvrqapgkglewvssissnsnyiyyadsmkgrftisrdnaknslylqmnslraedtavyycasnrspydssnyyfdywgqgtrvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2585,NaN,NaN,QTX15811,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnggiidyadsvkgrftisrdnaknslylhmrslraedtafyycakdigpfeaarpggnyyyyamdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2586,NaN,NaN,QTX15810,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvtsnnyywgwirqppgeglewigsiyytgstfynpslksrvtisvdasknqfslklssvtaadtavyyctrqlvlvrgyfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2587,NaN,NaN,QTX15809,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgpglvkpsqtlsltctvsggsissgsyfwswirqpagkglewigriftsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycargpdivvvpaadprnwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2588,NaN,NaN,QTX15808,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvetgggliqpggslrlscatsgftvssnymtwvrqapgkglewvstiysggstyyadsvkgrfsisrdsskntlylqmnslraedtavyycargpyphfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2589,NaN,NaN,QTX15807,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyycakdiksfgifgvvtafdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2590,NaN,NaN,QTX15806,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2591,NaN,NaN,QTX15805,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycaresygmdvwgqgttitvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2592,NaN,NaN,QTX15804,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgfifddyaihwvrqgpgkglewvsgiswnsgsigygdsvkgrftisrdnaknslylqmnslraedtafyycakggrraamllnyfdywgqgtlvtvsa,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2593,NaN,NaN,QTX15803,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvrgrftisrdnaknslflqmnslraedtalyycardpfsrwerpegwfdpwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2594,NaN,NaN,QTX15802,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgrifpilgianyaqkfqnrvtitadrststafmelsslrsedtavyycardqdsgyiwwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2595,NaN,NaN,QTX15801,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslrvedtavyycakkgysygyfdyyfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2596,NaN,NaN,QTX15800,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlteismhwvrqapgkglewmggfdpeegetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsevvvpgairhkaayyynymdvwgkgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2597,NaN,NaN,QTX15799,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstnamhwvrqapgkglewvalisydgsnkyyavsakgrfiisrdnskntlhlqmsslraedtavyycvkglggnyyyfgfwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2598,NaN,NaN,QTX15798,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmvgqycsggncylgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2599,NaN,NaN,QTX15797,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyissttsytnyadsakgrftisrdnaknslylqmnslraedtavyycardvayyydsgsyyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2600,NaN,NaN,QTX15796,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakmmgqycsggdcysgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2601,NaN,NaN,QTX15795,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsfiypggstyyvdsvkgrftisrdnskntlylqmnslraedtavyycarsygdyyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2602,NaN,NaN,QTX15794,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlslsctvsggsispyywswirqlpgkglewigyiyytgstnynpslkgrvtmsadmsknqfslnlssvtaadtamyycargydfwsrgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2603,NaN,NaN,QTX15793,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgitwnsgtigyadsvkgrftiskdnaknslylqmnrlraedtafyycakdltgwgltfggvitnwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2604,NaN,NaN,QTX15792,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslksedtavyycateehpfagraklhhldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2605,NaN,NaN,QTX15791,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftiyymhwvrqapgqglewmgiinpgggsrsyaqrfqgrvtmtrdtststvymelsslrsedtavyycargrycsssscyigldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2606,NaN,NaN,QTX15790,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqprgslrlscaasgftfstywmtwvrqapgkglewvanigqdgseryfvdsvkgrftisrdnannslylqmnslraedsavyycardytddygdyggyfdlwgrgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2607,NaN,NaN,QTX15789,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsgdsissshwwswvrqppgkglewigeiyhsgstnynpslksrvtisveksknqfslklssvtaadtavyycarrrlgpssnnsgyfywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2608,NaN,NaN,QTX15788,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfifsnyrmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardsvpryyyhyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2609,NaN,NaN,QTX15787,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfniyvmhwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslraedtavyycakgrsgsyfnpldywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2610,NaN,NaN,QTX15786,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgtnkyyadsvngrftisrdnskntlylqmdslragdtavyycarpnsgsyssyldywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2611,NaN,NaN,QTX15785,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvhpggslrlscaasgftfssywmswvrqapgkglewvanikedgrekyyvdyvkgrftisrdnaknslylqmnslraedtavyycardsvhyyydssgyhysygmdvwgqgttvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2612,NaN,NaN,QTX15784,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcaahggsfsgynwswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqlslklssvtaadtavyycarggtigttgiydiltgydpffdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2613,NaN,NaN,QTX15783,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakgnwndvlshyyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2614,NaN,NaN,QTX15782,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlsctgsgftfgdyamswfrqapgkglewvgfirsedhggtteyaasvkgrftisrddsksiaylqmnslktedtavyycsrpltyyydssgyyypyyfdywgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2615,NaN,NaN,QTX15781,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakgwggynthfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2616,NaN,NaN,QTX15780,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftiywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrtltttygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2617,NaN,NaN,QTX15779,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakshsgsyfssgdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2618,NaN,NaN,QTX15778,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarenydfwsgyfngwfdpwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2619,NaN,NaN,QTX15777,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrhdskntlylqmnslktedtavyycttasnpdywgqgtrvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2620,NaN,NaN,QTX15776,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardtrgrgghdafdiwgqgtmvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2621,NaN,NaN,QTX15775,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygthwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarpdsgsywgafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2622,NaN,NaN,QTX15774,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdladgetiyaqefqgrvtmtedtstdtaymalsslrsedtavyycatgpltiavagqwfdpwgqgtlvtiss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2623,NaN,NaN,QTX15773,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftiprdnskntlylqmnslraedtavyycakggsgyryyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2624,NaN,NaN,QTX15772,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksafgsyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2625,NaN,NaN,QTX15771,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgqvgatsgidywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2626,NaN,NaN,QTX15770,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycashpyydssgyypnygmdawgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2627,NaN,NaN,QTX15769,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnrlrdedtavyycardrcgdcygpyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2628,NaN,NaN,QTX15768,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardldivvvpaarsyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2629,NaN,NaN,QTX15767,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdptivvvavnptfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2630,NaN,NaN,QTX15766,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymnwvrqapgkglewvsviysggstyygdsvkgrftisrdnskntlylqmnslraedtavyycardfregafdiwgqgtmvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2631,NaN,NaN,QTX15765,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssywmhwvrqapgkglvwvsriniygsstsyadsvkgrftisrdnakntlylqmnslraedtavyycardlhydssgwdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2632,NaN,NaN,QTX15764,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsgtlsltcavsggfisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrycsggscgyfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2633,NaN,NaN,QTX15763,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslraedtavyycaraqyssgwylrfdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2634,NaN,NaN,QTX15762,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargaasvlrflewlldywgqgalvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2635,NaN,NaN,QTX15761,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevknpgasvkvsctasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycalvgatdywgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2636,NaN,NaN,QTX15760,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycakafkgnyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2637,NaN,NaN,QTX15759,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycardrppivvvttyyyygmdvwgqgttvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2638,NaN,NaN,QTX15758,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgpglvkssqtlpltctvsgasinsnnyywnwirqpagkglewigrihssgntnyspslrsrltisvdtsknqfsleltsvtaadtavyycarddwttaldcwgqgtlvtvss,NaN,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2639,NaN,NaN,NaN,QTX15757,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipdwtfgpgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2640,NaN,NaN,NaN,QTX15756,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynsvswyqhhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagrytlvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2641,NaN,NaN,NaN,QTX15755,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftptisslqpedfatyycqqsystppytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2642,NaN,NaN,NaN,QTX15754,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsirswlawyqqkpgkapkvliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynyysvtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2643,NaN,NaN,NaN,QTX15753,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcrasqsirnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsygipxwtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2644,NaN,NaN,NaN,QTX15752,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyvtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2645,NaN,NaN,NaN,QTX15751,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgisgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2646,NaN,NaN,NaN,QTX15750,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvnnylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedlavyycqqcsnwppsltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2647,NaN,NaN,NaN,QTX15749,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmisevskrpsgvpdrfsgsksgntasltvsglqaedeadyycnsyagsnnwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2648,NaN,NaN,NaN,QTX15748,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgvyycmqatqfpitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2649,NaN,NaN,NaN,QTX15747,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qlvltqppsvsvapgqtaritcggnsigsktvhwyqqkpgqapvlvvyddsdrpsgiperfsgsksgntatltisrveagdeadyycqvwhissdhlwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2650,NaN,NaN,NaN,QTX15746,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysftfgpgtkkdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2651,NaN,NaN,NaN,QTX15745,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsytvnwyqhlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2652,NaN,NaN,NaN,QTX15744,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspatlslspgeratlscrasqsvssylawyqhkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2653,NaN,NaN,NaN,QTX15743,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvsrnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynngrgtfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2654,NaN,NaN,NaN,QTX15742,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqtplslpvtpgepasiscrsgqslldsddgntyldwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqriefpwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2655,NaN,NaN,NaN,QTX15741,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvtnrpsgvsnrfsgsksgntasltisglqaedeatyycnsytssstyvlfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2656,NaN,NaN,NaN,QTX15740,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnflnwyqekpgkapkllisdasnletgvpsrfsgsgsgtdftftitslqpediatyycqqydnllitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2657,NaN,NaN,NaN,QTX15739,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qlvltqpptvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperisgsssgtmatltisgaqvedgadyycysidssgnhyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2658,NaN,NaN,NaN,QTX15738,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdiskylnwyqrkpgtaptlliydasnletgvpsrfsgsgsgtdftftisslqpedigtyycqqydnlptfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2659,NaN,NaN,NaN,QTX15737,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqfgewftfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2660,NaN,NaN,NaN,QTX15736,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qlvltqppsvseaprqrvtiscsgsssnignnpvnwyqqlpgkapkpliyyddllpsgvsdrfsgsrsatsaslaisglqsedeadyyctawdgslngyvfgsgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2661,NaN,NaN,NaN,QTX15735,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqksgqaprlliygassratgipdrfsgsgsgtdftltisrlqpedfavyycqqygsspmytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2662,NaN,NaN,NaN,QTX15734,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysipptfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2663,NaN,NaN,NaN,QTX15733,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgteftftitslqpediatyycqqydtlpptfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2664,NaN,NaN,NaN,QTX15732,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgggsgtdftltisslepedfavyycqqrsnwrtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2665,NaN,NaN,NaN,QTX15731,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspatlslspgeratlscrasqsvssslawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslgpedfavyycqqrsnwpptwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2666,NaN,NaN,NaN,QTX15730,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspsslsasvgdgvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgggsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2667,NaN,NaN,NaN,QTX15729,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2668,NaN,NaN,NaN,QTX15728,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdirnylnwyqqtpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyychqydnlpqsfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2669,NaN,NaN,NaN,QTX15727,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlhssnnknyvawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyhcqqyystpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2670,NaN,NaN,NaN,QTX15726,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgagtyftftisslqpediatyycqqydnlpplftfgpgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2671,NaN,NaN,NaN,QTX15725,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrasqsvsrsylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsllftfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2672,NaN,NaN,NaN,QTX15724,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspdslavslgeratinckssqsvlhnsknksylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyggrwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2673,NaN,NaN,NaN,QTX15723,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgrapklliydasnletgvpsrfsgsgsgtdftftisslqpedvatyycqqydnlpgtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2674,NaN,NaN,NaN,QTX15722,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrashnissthlvwyqqkpgqaprlliygasnratgipdrfsgggsgtdftltisrlepedfavyfcqqfgsspqtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2675,NaN,NaN,NaN,QTX15721,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvssshlawyqqksgqaprlfiygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppwtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2676,NaN,NaN,NaN,QTX15720,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspeqtasitcsgdklgdkyacwyqqkagqspvlviyedgkrpsgiperfsgsnsgntatltisgtqtmdeadyycqawdrttavfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2677,NaN,NaN,NaN,QTX15719,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgirsylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlntyaltfgggtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2678,NaN,NaN,NaN,QTX15718,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhyynwppwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2679,NaN,NaN,NaN,QTX15717,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgtssdvgvydyvswyqqhpgkapklmiyevsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2680,NaN,NaN,NaN,QTX15716,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisrwlawyqqipgkapnlliyqtsslqsgvpsrfsgsgsgteftltisslqpddfatyycqqyysypltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2681,NaN,NaN,NaN,QTX15715,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqfpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssridvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2682,NaN,NaN,NaN,QTX15714,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qavvtqppsvsgapgqrvtisctgsssnigagydihwyqqlpgtapklliynnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2683,NaN,NaN,NaN,QTX15713,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyhqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2684,NaN,NaN,NaN,QTX15712,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghssnaiawhqqqpekgprylmklnidgshrkgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgpnwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2685,NaN,NaN,NaN,QTX15711,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgygsgteftltisslqpedfatyycqhlnsyprytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2686,NaN,NaN,NaN,QTX15710,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsafvgdrvtiicrasqsisswlawyqqkpgkapklliykasslesgvpstfsgsgsgteftltisslqpddfatyfcqqynsypytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2687,NaN,NaN,NaN,QTX15709,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslavtpgepasiscrssqsllhsdgynyldwylqkpgqspqlltylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtsitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2688,NaN,NaN,NaN,QTX15708,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqqpgkapklllyaasrlasgvpsrfsgsgsgtdytltisslqpedfatyycqqyysapptfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2689,NaN,NaN,NaN,QTX15707,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygtssratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2690,NaN,NaN,NaN,QTX15706,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcrasqgvssylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppgtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2691,NaN,NaN,NaN,QTX15705,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqhhdslpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2692,NaN,NaN,NaN,QTX15704,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qtvvtqapsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysdnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnvvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2693,NaN,NaN,NaN,QTX15703,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qavvtqprsvsgspgqsvtisctgtssdvgaynfvswyqqhpgkapklmtydvtkrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsfyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2694,NaN,NaN,NaN,QTX15702,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgegatlscrasqsvgrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2695,NaN,NaN,NaN,QTX15701,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqsediatyycqqydnlpitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2696,NaN,NaN,NaN,QTX15700,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqpwrltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2697,NaN,NaN,NaN,QTX15699,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2698,NaN,NaN,NaN,QTX15698,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsisstylawyqqkpgqaprllihgassratgisdrisgsgsgtdfiltisrlepedfavyycqqygsspgtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2699,NaN,NaN,NaN,QTX15697,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspatlsvslgeratlscrasqsvssnlawyqqkpgraprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppsitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2700,NaN,NaN,NaN,QTX15696,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspssvsasvgdrvtitcrasqgissglawyrqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpytfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2701,NaN,NaN,NaN,QTX15695,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qtvvtqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssligsvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2702,NaN,NaN,NaN,QTX15694,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqrpgqppqlliyevsdrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpvtfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2703,NaN,NaN,NaN,QTX15693,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgqapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpadfatyycqqsysifrtsgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2704,NaN,NaN,NaN,QTX15692,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgegatlscrasqsvssylawyqrkpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqersswppafgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2705,NaN,NaN,NaN,QTX15691,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspsslsasegdrvtitcqasqdinnylnwyqqkpgkapklliydasnleagvpsrfsgsgsgtdftftisslqpediatyycqqydnlppafgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2706,NaN,NaN,NaN,QTX15690,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynkwprtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2707,NaN,NaN,NaN,QTX15689,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsrtdftftisslqpddiatyycqqydkppvtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2708,NaN,NaN,NaN,QTX15688,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlssspgeratlscrasqgvsssylawyqqklgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhsrtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2709,NaN,NaN,NaN,QTX15687,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtspwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2710,NaN,NaN,NaN,QTX15686,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnniggksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2711,NaN,NaN,NaN,QTX15685,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkfliydasnletgvpsrfsgsgsgtdftftisslqpedfatyfcqqyddlpytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2712,NaN,NaN,NaN,QTX15684,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftistlqpediatyycqqydnllsltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2713,NaN,NaN,NaN,QTX15683,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsastgdrvtitcrasqgirtylvwyqqkpgqapnlliyaasslqsgvpsrfsgsgsgtdftltisglqsedfatyycqqyysypltfgggtkvevk,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2714,NaN,NaN,NaN,QTX15682,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsissnlawhqqkpgqaprllisdastratgiparfsgsgsgteftltidslqsediavyycqqynnwpptitfgqgtrleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2715,NaN,NaN,NaN,QTX15681,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,slsqlvltqgrlgpgqtaritcegnniggksvlwyqqkpgqapvlvvyddsdrpsgiperfsasnsgntatltisrveagdeadyycqvwdtssdhagvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2716,NaN,NaN,NaN,QTX15680,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspstvsasvgdrvtitcrasqsistwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisrlqpddfatyycqqynsylfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2717,NaN,NaN,NaN,QTX15679,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftlttsslqpddfatyycqqystyspltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2718,NaN,NaN,NaN,QTX15678,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspstlsasvgdrvtitcrasqsfsswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylktfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2719,NaN,NaN,NaN,QTX15677,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsvsgapgqrvtisctgsssnigadydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqssdsslsgsrvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2720,NaN,NaN,NaN,QTX15676,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2721,NaN,NaN,NaN,QTX15675,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnryplytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2722,NaN,NaN,NaN,QTX15674,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppptfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2723,NaN,NaN,NaN,QTX15673,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapelpiyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2724,NaN,NaN,NaN,QTX15672,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nivmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2725,NaN,NaN,NaN,QTX15671,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystprtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2726,NaN,NaN,NaN,QTX15670,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2727,NaN,NaN,NaN,QTX15669,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2728,NaN,NaN,NaN,QTX15668,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssftfgpgtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2729,NaN,NaN,NaN,QTX15667,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliymgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspynlgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2730,NaN,NaN,NaN,QTX15666,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2731,NaN,NaN,NaN,QTX15665,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsaphtfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2732,NaN,NaN,NaN,QTX15664,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedegdyycystdssgnkrvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2733,NaN,NaN,NaN,QTX15663,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlarfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2734,NaN,NaN,NaN,QTX15662,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2735,NaN,NaN,NaN,QTX15661,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyhvvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2736,NaN,NaN,NaN,QTX15660,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytfgyvfgtgtkvtvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2737,NaN,NaN,NaN,QTX15659,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsytltfgggtkvdik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2738,NaN,NaN,NaN,QTX15658,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2739,NaN,NaN,NaN,QTX15657,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2740,NaN,NaN,NaN,QTX15656,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssqytfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2741,NaN,NaN,NaN,QTX15655,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2742,NaN,NaN,NaN,QTX15654,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwptfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2743,NaN,NaN,NaN,QTX15653,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsissylnwyqqepgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpftfgpgtkleik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2744,NaN,NaN,NaN,QTX15652,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltissmqsedfavyycqqynnwppgdtfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2745,NaN,NaN,NaN,QTX15651,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyfcqqygssrntfgqgtkveik,"Graham,C. et al.; Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.03.023,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2746,NaN,NaN,QRG26522,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgnnkyyadsvkgrftissdnskntlylqmnslraedtavyycakdlaawgpycsstncytggmdvwgqgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2747,NaN,NaN,QRG26521,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyyctteepgagslyyyyymdvwgkgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2748,NaN,NaN,QRG26520,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedggtiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatglqaarrdyyyygmdvwgqgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2749,NaN,NaN,QRG26519,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdpyypgsvkgrftisrenaknslylqmnslragdtavyycargggryydfwsgyygdyyhyymdvwgkgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2750,NaN,NaN,QRG26518,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifdttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvgdydssgyysdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2751,NaN,NaN,QRG26517,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyitsssgyrnyadsvkgrftisrdnaknslylqmsslraedtavyycardsaldergyssgwhpphwgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2752,NaN,NaN,QRG26516,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskttlylqmnslktedtavyycsrsillyyyastgyhheldywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2753,NaN,NaN,QRG26515,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftlssyamywvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlflqmnslraedtavyycarpysgsyreyfqhwgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2754,NaN,NaN,QRG26514,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyaihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarglggnyyavdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2755,NaN,NaN,QRG26513,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmntlraedtavyycarsstyytgfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2756,NaN,NaN,QRG26512,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvqpggslrlscsasgftfssyamhwvrqapgkgleyvsaissnggstyyadsvkgrftisrdnskntlylqmsslraedtavyycvkdwavliqmpfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2757,NaN,NaN,QRG26511,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlsctasgftlraydmiwvrqapgkglewvsysgrshsayyadsvkgrftisrddaenslylhmntlragdtalyycardrtycssgscyaydffygmdvwgqgttvtiss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2758,NaN,NaN,QRG26510,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregivgattgfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2759,NaN,NaN,QRG26509,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqsegygenymdvwgkgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2760,NaN,NaN,QRG26508,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargksptvvtpwfdywgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2761,NaN,NaN,NaN,QRG26537,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddgdrpsgiperfsgsnsgntatlaisrveagdeadyycqvwdssshwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2762,NaN,NaN,NaN,QRG26536,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwprtfgqgtkvdik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2763,NaN,NaN,NaN,QRG26535,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllifdasiratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgqgtkleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2764,NaN,NaN,NaN,QRG26534,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgihlqvgitfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2765,NaN,NaN,NaN,QRG26533,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppavtfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2766,NaN,NaN,NaN,QRG26532,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspstlsasvgdrvtiscrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsrsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2767,NaN,NaN,NaN,QRG26531,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytiistlgvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2768,NaN,NaN,NaN,QRG26530,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2769,NaN,NaN,NaN,QRG26529,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqqgtfgqgtkleik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2770,NaN,NaN,NaN,QRG26528,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydgsnhqvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2771,NaN,NaN,NaN,QRG26527,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qavvtpepsltvspggtvtltcgssigavtgghfpywfqqkpgqaprtliydtsnkhswtparfsgsllggkaaltlsgaqpededeyycllsnsgarpvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2772,NaN,NaN,NaN,QRG26526,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgrssnigdnyvswyqhlpgaapklliyennkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtsdsslsaggvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2773,NaN,NaN,NaN,QRG26525,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnpsfgtgtkvtvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2774,NaN,NaN,NaN,QRG26524,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqaaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssdtwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2775,NaN,NaN,NaN,QRG26523,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsalwvfgggtkltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; Unpublished; 2021.",NaN,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2776,NaN,NaN,QQY97159,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsirsdfwswirqfpgkglewigyiyysgstnynpslesrvtisvdtsknefslklnyvtaadtaiyycaretrwnwldswgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2777,NaN,NaN,QQY97158,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscvapgftlggygmhwvrqapgkglewvglisydgsvqkygssvkgrftiskdnskntlylemnslraddtavyfcvkgaslgdnwgqgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2778,NaN,NaN,QQY97157,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyvmtwarqapgkglewvsaisgtgytyyadsvkgrftvsrdnskntlflqmsslraedtavyycaitmapvvwgqgttvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2779,NaN,NaN,QQY97156,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpgrslrlscvasgftfsnygmhwvrqapgkglewvavmsydgsvtyygdsvrgrftisrdnskntlylqmsslrtddtgvyycakgqplddiwglgtlvtvss,NaN,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,"cross-reactive anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2780,NaN,NaN,NaN,QQY97164,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgerasinckssqtisyisnnknylawyqqkpgqpprlliywastresgvpdrfsgggfgtdftltisslqaedvavyycqqyfntpwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2781,NaN,NaN,NaN,QQY97163,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdfgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2782,NaN,NaN,NaN,QQY97162,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqsplslpvtlgqpasiscrssqslvysdgdtymswfhqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwpytfgpgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2783,NaN,NaN,NaN,QQY97161,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkryaywyqqksgqapilviyedkkrpsgiperlsgsksgtvatltisgaqvedeadyycystdssgnhavfgggtqltvl,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2784,NaN,NaN,NaN,QQY97160,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqsplslpvslgqsasiscrssqslvhtdgitylswfqqrpgqsprrllykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyyclqgtywpwtfgqgtkveik,"Song,G. et al.; Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection; bioRxiv (2020); 2021.",10.1101/2020.09.22.308965,NaN,"cross-reactive anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2785,NaN,NaN,QRW39016,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfsfssywmswvrqapgkglewvgnikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdpywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2786,NaN,NaN,QRW39015,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsistaylqisslkaedtavyycarvgpssswpswgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2787,NaN,NaN,QRW39014,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggwysskwyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2788,NaN,NaN,QRW39013,NaN,SARS-CoV-2,Homo sapiens (human),qvhlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipifdianyaqkfqgrvtmtadkstttaymeltslrsedtamyycarteysydsgssraysmdvwgkgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2789,NaN,NaN,QRW39012,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsavgtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycargfdtttgfyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2790,NaN,NaN,QRW39011,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakaagggysyiywggdywgqgtlvtsph,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2791,NaN,NaN,QRW39010,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgrglewigsiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycariprhlgqdhyyyvmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2792,NaN,NaN,QRW39009,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkplewlaliywdddkryspslksrltitkdtsknqvvlrmtnmdpvdtatyycahspdhryfdvltgyfnserfyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2793,NaN,NaN,QRW39008,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsfstyywswirqppgkglewighisysgsthynpslkgrvtisldtsknqfslnlssvtaadtavyycarggyyygpprdfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2794,NaN,NaN,QRW39007,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardlgvlwfgdllfssqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2795,NaN,NaN,QRW39006,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwddakyystsletrltiskdtsnnqvvltltnmdpvdtatyycarevagavhldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2796,NaN,NaN,QRW39005,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssssytnyadsvkgrftisrdnaknslylqmnslraedtavyfcardgsavagpmsyfdywgqgtpvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2797,NaN,NaN,QRW39004,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasghtftsylihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardppsgnydnidewtrsenhynygmdawgqgttvtvlt,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2798,NaN,NaN,QRW39003,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2799,NaN,NaN,QRW39002,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglewigyiyysgstnynpsltsrvtlsvdtsknqfslklssvtaadtavyycareyfvslpaaqtlyyygidvwgqwttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2800,NaN,NaN,QRW39001,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsgisdsggspyyadsvkgrftisrdnskntlylqmnslrvedtavyycaesssltgnfnywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2801,NaN,NaN,QRW39000,NaN,SARS-CoV-2,Homo sapiens (human),qvrlvesgggvvqpgrslrlscaasgftfssfgmhwvrqapgkglewvallsydgtnkyyadsvkgrftisrdnskstlflqmhslraedtavyfcakgggyisawstryyamdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2802,NaN,NaN,QRW38999,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyqsgstyynlslksrvtilvdtsknqlslklssvtaadtavyycarvgvatilgvdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2803,NaN,NaN,QRW38998,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqhpgkglewigyifysgstyynpslksrviisvdtsknqfslklssvtaadtavyycarvsrytmvrgvifdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2804,NaN,NaN,QRW38997,NaN,SARS-CoV-2,Homo sapiens (human),qvqlmesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgtnekyadsvkgrftisrdnskntlylqvnslraedtavyycakngysyayprqyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2805,NaN,NaN,QRW38996,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaseiivssnymswvrqapgmglewvsvvysggstfyadsvkgrftisrhnskntlylqmnslrtedtavyycareapnsrgsgtnfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2806,NaN,NaN,QRW38995,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrydmhwvrqttgkslewvsaigtagdtyypdsvkgrfiisrenansslylqmnslragdtavyycargsdtvttafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2807,NaN,NaN,QRW38994,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasrgtfssyaiswvrqapgqglewmggiipifttpnyaqnfqgrvtitadkststaymelnsltsedtavyycavlplhssynwyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2808,NaN,NaN,QRW38993,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsifamswvrqapgkglewvsgingsgdntyyadsvkgrftisrdnsrntlylqmnslrpedtavyycakqtdygvgwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2809,NaN,NaN,QRW38992,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckrsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasqaaagyyyymdvwgkgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2810,NaN,NaN,QRW38991,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstyynpslksrvtisvdksknqfslklssvtaadtavyycarvqglidywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2811,NaN,NaN,QRW38990,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycardlgplgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2812,NaN,NaN,QRW38989,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgkslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgnigyadsvkgrftisrdnandslflqmnslraedtalyycakdirsgdyvgvfdywgqgalvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2813,NaN,NaN,QRW38988,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrvscaasgfavsnnymtwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmkslraedtavyycardlvvagidywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2814,NaN,NaN,QRW38987,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggdlvqpggslrlscaasgitvssnymnwvrqapgkglewisviysggstyyadsvkgrftisrdnskntlflqmnslraedtavyycardldiagafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2815,NaN,NaN,QRW38986,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaagftfstydmhwvrqvtgkglewvsalgtsgdtyyadsvkgrftisrenaknslylqmnslragdtavyycvrgdhssgwygtyyyymdvwgkgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2816,NaN,NaN,QRW38985,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygitwvrqapgqglewmgwisvyngnthyaqklqgrvtmttgtststaymelrslrsddtavyycavldycsggssssgyynygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2817,NaN,NaN,QRW38984,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqnlqgrvtmttdtststaymelrslrsddtavyycaregagliiaydywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2818,NaN,NaN,QRW38983,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvtviwydgsnkyyadsvkgrftisrdnskntvylqmnslraedtavyycakggnygdylrgfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2819,NaN,NaN,QRW38982,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryrpsfqgqvtisadksistaylqwsslkasdtamyycalavgrgiptsyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2820,NaN,NaN,QRW38981,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgasissyfwswirqppgkgldwigyiyyngstnynpslksrvtisvdtsknqfslklssvtaadtavyfcastywdssgyyygvdywghgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2821,NaN,NaN,QRW38980,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarekirsiaaagtvyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2822,NaN,NaN,QRW38979,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaglfwyggyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2823,NaN,NaN,QRW38978,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgsstyyadsvkgrftisrdtskntlylqmnslraedtavyycarglqyyydtsgyykdsyyygvdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2824,NaN,NaN,QRW38977,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgasvkvsckasgytftsyyvhwvrqapghglewmaiinpdagstsfaqrfqgrltmttdtststvymglnslrsedtavyycargglvpavmpaldywgqgalvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2825,NaN,NaN,QRW38976,NaN,SARS-CoV-2,Homo sapiens (human),qvqliqsgaevkkpgasvkvscttsgytftsyflhwvrqapgqglewmgiinpsdgtttyaqkfqgrvtmtrdtstgtvsmelsslryedtavyycardgalysnsptefdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2826,NaN,NaN,QRW38975,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsintaymelsrltsddtavyycardslfsrvdwyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2827,NaN,NaN,QRW38974,NaN,SARS-CoV-2,Homo sapiens (human),qvllqesgpglvkpsqtlsltctvsggsisngsyywswirqhpgkglewigyiyysgstyynpslrsrvtisldtsmnqfslklssvtaadtavyycariyrgtmvvvfsdlhwyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2828,NaN,NaN,QRW38973,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevrkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpeansttyaqkfqgrvtmtsdtststvyldlsslrsedtavyycartgflipskgggmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2829,NaN,NaN,QRW38972,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgselkkpgasvkvsckasgysftdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqistlkaedtavyycastvgrgsgtyyygnyysysmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2830,NaN,NaN,QRW38971,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksittaylqwsslkasdtaiyycarlpphfgsgsyygnafdiwglgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2831,NaN,NaN,QRW38970,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslmtrltiskdtsknqvvltmtnmdpvdtatyycariqrgiaadywgqgilvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2832,NaN,NaN,QRW38969,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaaskftfsnyamnwvrqapgkglewvsaisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakgellwfgellenwfdpwgqgtrvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2833,NaN,NaN,QRW38968,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2834,NaN,NaN,QRW38967,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddddryspslksrltitkdtsknqvvltmtnmdpvdtatyycahslpskysysygsfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2835,NaN,NaN,QRW38966,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsiifsggttyyadsvkgrftisrdnsrntlylqmsslraedtavyycaetgwdgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2836,NaN,NaN,QRW38965,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkgldwigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardyggnsnyfhywgqgtlvtvsp,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2837,NaN,NaN,QRW38964,NaN,SARS-CoV-2,Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvatisydgsdkfyadsvkgrftisrdnsrntlyvqmnslrpedtalyycakggwygdirvdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2838,NaN,NaN,QRW38963,NaN,SARS-CoV-2,Homo sapiens (human),dvqlvesggglvqpggslrlscaasefivssnymswvrqapgrglewisviysggstfyadsvkgrftisrdsskntlylqmnslraedtavyycardlplhgdyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2839,NaN,NaN,QRW38962,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkgldwvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarelgpvggtdqwgqgtlvsvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2840,NaN,NaN,QRW38961,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkasetlsltctvsggsissssyywgwirqppgkglewigsihdsgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaryygpgtyydafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2841,NaN,NaN,QRW38960,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsfysihwvrqapgkglewvavisydgsykfyadsvkgrftisrdnskdtvylqmnslraedtavyycardwvhygsgsyppdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2842,NaN,NaN,QRW38959,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgdsfpsywiewvrqmpgkglewmgliypgdsdtryspsfqgqvtisadksistaylqlsslkasdtamyfcarhpvlrgnidywgqgtlvivss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2843,NaN,NaN,QRW38958,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasglivsrnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlenggldvwgqgttvtvfs,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2844,NaN,NaN,QRW38957,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggflqpggslrlscaasgftfssddmhwvrqvtgkglewvsaigtsgdtyysgsvkgrftisrenaknslylqmnslrvgdtavyycargslrggilsgyafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2845,NaN,NaN,QRW38956,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymiwirqapgkglewvsyisssgatiyyadsvkgrftisrdnaknslylqmtslraedtavyycaspllshnygsgsyynvywyfelwgrgtlvsvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2846,NaN,NaN,QRW38955,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsiityywswirqppgkglewigyidysgstnynpslksrvtisvdtsknqfslelssvtaadtavyycartlgayydiltgfrtpggwfapwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2847,NaN,NaN,QRW38954,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisasgdstyyadfvkgrftisrdnskntvylqmnslraedtaiyycakepsfglwfgelsgwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2848,NaN,NaN,QRW38953,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2849,NaN,NaN,QRW38952,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2850,NaN,NaN,QRW38951,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaviywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahttwyyygsgwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2851,NaN,NaN,QRW38950,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2852,NaN,NaN,QRW38949,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycaritphlvydywsqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2853,NaN,NaN,QRW38948,NaN,SARS-CoV-2,Homo sapiens (human),qvqivqsgaevkkpgasvkvsckasgytftsyaihwvrqapgqrlewmgwintgngntkysqnfqdrvtitrdtsattaymelssltpedtavyycaragwelnywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2854,NaN,NaN,QRW38947,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasrftfsnyamtwvrqapgkglewvsaisgsagsiyyadsvkgrftisrdnskntlylqmnslraddtavyfcakgqrgspdffdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2855,NaN,NaN,QRW38946,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpksvytgyaqkfqgrvtmtrntsirtaymelsslrsedtavyycarglwfgdltrtkynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2856,NaN,NaN,QRW38945,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftrywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarieyyndssgyyqfwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2857,NaN,NaN,QRW38944,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgfsfsnawmswvrqapgkglewvgrikfttdggtsdyaapvrgrftisrddskntlylqmnslrtedtavyycsttndygdysanywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2858,NaN,NaN,QRW38943,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2859,NaN,NaN,QRW38942,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissfywswirqpagkglewigrmsasgstnynpslksrvtmsvdtsenqislklgsvtaadtavyycageqhivttiidywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2860,NaN,NaN,QRW38941,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggdvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycakdptslycsggscynnwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2861,NaN,NaN,QRW38940,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggdlvqpggslrlscaasgftvssnymtwvrqapgkglewvsliysggstfyadsvkgrftisrlsskntlylqmnslrvedtavyycargpypssswawgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2862,NaN,NaN,QRW38939,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasmtvsckasgytfstyyihwvrqapgqglewmgiinpsagstsyaqkfqgrvtmttdtststvymelsslrsedtavyycardysritmirgagdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2863,NaN,NaN,QRW38938,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyvmhwvrqapgkglewvavisydgsskyyadsvkgrstisrdnskntlylqmnslraedtavyycakrggtycsggicyggyfdywgqgmlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2864,NaN,NaN,QRW38937,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfstyamhwvrqapgkglvwvafisydesnkyytdsvkgrftvsrdnskntlylqmnslraedtavyycagggvlvtsdpdafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2865,NaN,NaN,QRW38936,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycareeaagtkldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2866,NaN,NaN,QRW38935,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslntsgmcvswirqppgkalewlaridwddekyystslqtrltiskdtsknqvvltmtnmdpvdtatyycarmipipaldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2867,NaN,NaN,QRW38934,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslntsgmsvswirqppgkalewlaridwdddkyystslktrlsiskdtsknqvvltmtnvdpvdtatyyctrtatvvkdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2868,NaN,NaN,QRW38933,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssfamswvrqapgkglewvsvisssgdytsyadsvkgrftisrdnskntlylqmnslraedtavyycakdvgsrliydvfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2869,NaN,NaN,QRW38932,NaN,SARS-CoV-2,Homo sapiens (human),rgpgngvwaevkkpgssvkvscktsggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycasfgslwdlrdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2870,NaN,NaN,QRW38931,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlslictvsggsitsyywtwirqppgkglewigyiyyngssnynpslesrvtisvdasknqfslklssvtaadtavyycatdyydssgyrygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2871,NaN,NaN,QRW38930,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfnsygiswvrqapgqglewmgwissyngntnyaqklqgrvtmttdtststaymelrsltsddtavyycatddpdivlvpaamsldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2872,NaN,NaN,QRW38929,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardygdyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2873,NaN,NaN,QRW38928,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycakdgsgsyynsgaldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2874,NaN,NaN,QRW38927,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscagsgftfshygmhwvrqapgkglewvavilydgsnnyyadsvkgrftvsrdnskntlylqmnslrtedtavyycgkgagpycgggscyptkvdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2875,NaN,NaN,QRW38926,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggalvqpggslrlscaasgftfssydmhwvrqatakglewvstigtagdtyypgsvkgrftisrenaknslylqmnnlragdtavyycarvgydssgyywyldlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2876,NaN,NaN,QRW38925,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvnwirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycartrlgitafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2877,NaN,NaN,QRW38924,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvnsnymswvrqapgkglewvsviyngvttyyadsvkgrftisrdiskntvylqmnslraedtavyycaragwlrgrfdpwgqgtlvivss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2878,NaN,NaN,QRW38923,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslqisckgsgysfisnwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylrwsslkasdtamyycarigdwigfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2879,NaN,NaN,QRW38922,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycardleergamdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2880,NaN,NaN,QRW38921,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfstywigwvrqmpgkglewmgiiypydsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycarqesgwsfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2881,NaN,NaN,QRW38920,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslriscaasgftvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmntlrvedtavyycardavgsyyygmevwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2882,NaN,NaN,QRW38919,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvrptqtltltctfagfslrthgmcvswirqppgkalewlaridwdgdkyystslktrltiskdtskdqvvltmtnmdpvdtatyycarflvggfkawfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2883,NaN,NaN,QRW38918,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysgdntyyadsvkgrftisrdnskntlylqmnslraedtavyycakmlwlrgwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2884,NaN,NaN,QRW38917,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgdtfsshyihwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvylelsslrsedtavyycardqafivatlgpdywgqgilvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2885,NaN,NaN,QRW38916,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamnwvrqapgkglewvslisgdgdspsysgsvkgrftisrdnsknslylqmislrtedtalyycarespkltgyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2886,NaN,NaN,QRW38915,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaaagftfsnydmhwvrqatgkglewvsvigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarayydtsgyynyfdhwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2887,NaN,NaN,QRW38914,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymnwvrqapgkglewvsviysgdnthyadsvkgrftisrdnskntlylqmnslraedtavyycargygsgsygwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2888,NaN,NaN,QRW38913,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvaviwydgsdkyyadsvkgrftisrdnskntlylqmsslgvedtavyycakggfgyasgwyyldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2889,NaN,NaN,QRW38912,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgiivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglvgttltfdywgqgslvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2890,NaN,NaN,QRW38911,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasagtfssyavswvrqapgqglewmgriipivsitkyaqkfqgrvtmtadkststaymelsslrsedtavyycargrytygtegyfdnwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2891,NaN,NaN,QRW38910,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsviysggstfyadsvkgrftisrhnskntlylqmnslraedtavyycareglgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2892,NaN,NaN,QRW38909,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsnntlylqmnslraedtavyycardpmrpgmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2893,NaN,NaN,QRW38908,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssytlhwvrqapgkglewvavissdgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppgnmgsmaqhlvllvvfdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2894,NaN,NaN,QRW38907,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtftsyafswvrqapgqglewmggiipifgtsnyaqkfqgrvtisadessstaymelsslrsedtavyycargpayvsgtyywnafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2895,NaN,NaN,QRW38906,NaN,SARS-CoV-2,Homo sapiens (human),emqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyissstnsiyyagsvqgrftisrgnaknslylqmnslraedtavyycargrddygdyrggdfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2896,NaN,NaN,QRW38905,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkiscegsgysfisywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsistaylqwsslkasdtamyycvrsdgdyvighdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2897,NaN,NaN,QRW38904,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycatdggggsyyyahyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2898,NaN,NaN,QRW38903,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtalyycakdlssgwdlfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2899,NaN,NaN,QRW38902,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvisnymswvrqapgkglewvsviyrggstyfadsvkgrftisrdnskntlylqmnslraedtavyycarlasdgsgsyldyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2900,NaN,NaN,QRW38901,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckasgyrftnywtvwvrqmpgkglewmgiiypgdseirysppfqgqvtisadksistaylqwsslkasdtamyycarhpsnfydsggdyyamdvwgqgtpvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2901,NaN,NaN,QRW38900,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswssgsivyadsvkgrftvsrdnaknslylqmnslrvedtafyycakdmvagphyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2902,NaN,NaN,QRW38899,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystslrtrltiskdtsknlvvltmtnmdpvdtatyycalgragtmdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2903,NaN,NaN,QRW38898,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsnydmhwvrqgtgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtalyycarvgyygsgsyplywyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2904,NaN,NaN,QRW38897,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycatgrytygygyyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2905,NaN,NaN,QRW38896,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywitwvrqmpgkglecmgridpsdsyskyspsfqghvtisadksistaflqwsslkasdtamyycarlpfcdsascgrahyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2906,NaN,NaN,QRW38895,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftlsrywmswvrqapgkglewvanikqdgsekkyvdsvkgrftisrdntknslylqmnslraedtavyycarlmyyygnfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2907,NaN,NaN,QRW38894,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasglivsrnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlniaggfdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2908,NaN,NaN,QRW38893,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsavgvgwirqppgkalewlaliywnddkryspslknrltitkdpsknqvvltmtnmdpvdtatyycahrlapdydfltgyyngddafdvwgpgtmvtiss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2909,NaN,NaN,QRW38892,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvsvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahsmvrgvlfgadfdywgqgtlvavss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2910,NaN,NaN,QRW38891,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysiswvrqapgqglewmgriipilgvaddaqkfqgrvtitadkststaymelsslrsedtavyycareagttdwyfdlwgrgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2911,NaN,NaN,QRW38890,NaN,SARS-CoV-2,Homo sapiens (human),rilltqsgaevkkpgasakvsckvsgyslsespmhwvrqapgkglewmggfdpedgeiinvqkfkgrvtmtedtssdtaymeltsltsedtavyfcaitslarglkgyfdswgqgtllivss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2912,NaN,NaN,QRW38889,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrwdgvgfdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2913,NaN,NaN,QRW38888,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfnnywmtwvrqapgkglewvanikldgsekyyvdsvkgrftisrdnaknslylqvnslraedtavyycarsphyyggfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2914,NaN,NaN,QRW38887,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywtwirqapgkglewigyiynsgstnynpslrgrvtisvdtsknqfslnlssvtaadtavyycardqgyssgwndafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2915,NaN,NaN,QRW38886,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggfissyywswirqppgkglewigyiyysgttnynpslksrvtisvdtsknqfslklssvtaadtavyycarrsmgycsggncysgfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2916,NaN,NaN,QRW38885,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2917,NaN,NaN,QRW38884,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryglhwvrqapgkglewvgvilydgsdehyadsvkgrftisrdnskntldlqmnslrpedtavyycakqaspycsggscysgnfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2918,NaN,NaN,QRW38883,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissntfywgwirqppgkglewigsihytgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarfitdgyssgsdswgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2919,NaN,NaN,QRW38882,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgiyywswirqppgkglewigyvfysgstnynpslksrvtisvdtsknqfslklrsvtaadtavyycamtyydyiwgrvdpqfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2920,NaN,NaN,QRW38881,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisstshywgwirqppgkglewigsihysgstyynpslksrvtisvdtskkqfslklrsvtaadtavyycarfitdgyssgsdswgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2921,NaN,NaN,QRW38880,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2922,NaN,NaN,QRW38879,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfttsavqwvrqargqrlewigwivvgsdntnyaqkfqervtitrdmstrtaymelsslrsedtavyycaadrmrivggkgyyygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2923,NaN,NaN,QRW38878,NaN,SARS-CoV-2,Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalqwlaridwdddkyystslktrltiskdtsknqvvltvtnvdpvdtgtyycarvqvaaagspydywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2924,NaN,NaN,QRW38877,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsgkhyadsvkgqftisrdnskntlylqmnslraedtavyycardgvdfgmvtlfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2925,NaN,NaN,QRW38876,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytfttyglswvrqapgqglewmgwvsayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardygwfgelstegqfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2926,NaN,NaN,QRW38875,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqapgkglewvsgiswnsgsfgyadsvkgrftisrdnaknslylqmnslrpedtalyycakdigcsstscsyyhyygmdvwglgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2927,NaN,NaN,QRW38874,NaN,SARS-CoV-2,Homo sapiens (human),evmlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsliysggstfyadsvkgrftisrdnskntlylqmnslgaedtavyycarfrygdypdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2928,NaN,NaN,QRW38873,NaN,SARS-CoV-2,Homo sapiens (human),evqlvgsggglvqpggslrlscaasgftvssnymswvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlflqmnslrpedtavyycardgravagtdwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2929,NaN,NaN,QRW38872,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycgvpycsssscyryygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2930,NaN,NaN,QRW38871,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2931,NaN,NaN,QRW38870,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavygrsfsgnswswirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslklnsvtaadtavyycargwtvpplwvlnwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2932,NaN,NaN,QRW38869,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipilgvanyaqkfqgrvtitadkststaymelsslrsedtavyycaregttiteyfqqwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2933,NaN,NaN,QRW38868,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywddnkryspslksrltitkdtsknqvvltmttmdpvdtatyycahrplfsgpfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2934,NaN,NaN,QRW38867,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvrpsetlsltctvsggsissssyfwgwirqppgkglewigsiyysgtthynpslksritisvdtsknqfslkltsvtaadtavyycatlewlrapfdnwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2935,NaN,NaN,QRW38866,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsggtnfvqkfqgrvtmtrdtsistaymelsrlksddtavyycargtppdsvvvpaaihpynwfdpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2936,NaN,NaN,QRW38865,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasevtvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardglvgatlafdfwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2937,NaN,NaN,QRW38864,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgtevkkpgasvkvsckastytftnfglswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvqefwldpwgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2938,NaN,NaN,QRW38863,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakd,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2939,NaN,NaN,QRW38862,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgysfinygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrfddtavyycarvqwlrldywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2940,NaN,NaN,QRW38861,NaN,SARS-CoV-2,Homo sapiens (human),vqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsgiysggstyyadsvkgrftisrdkskntlylqmnslraedtavyycardggysaytlfysdfafdiwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2941,NaN,NaN,QRW38860,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyyihwvrqapgqglewmgifnpgagttnypqkfqgrvtmtrdtststvymelsslrsedtavyycardgspwgndydiygmdvwgqgttvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2942,NaN,NaN,QRW38859,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftlsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdkgplffwsgyytdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2943,NaN,NaN,QRW38858,NaN,SARS-CoV-2,Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslktrltitkdtsknqvvltltnmdpvdtatyycahrpagfwsahfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2944,NaN,NaN,QRW38857,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggfiryyywtwirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslnlssvtaadtavyycarrgkygsgspddafdvwgqgtmvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2945,NaN,NaN,QRW38856,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfnsyaihwvrqtpgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtalyycardgrifylsfyfdywgqgtlvtvss,NaN,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
2946,NaN,NaN,NaN,QRW39177,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdgvtitcrasqgisnslawyqqkpgkapklllyaastvesgvpsrfsgrgsgtdytltissllpedfatyycqqyysaprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2947,NaN,NaN,NaN,QRW39176,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2948,NaN,NaN,NaN,QRW39175,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspvslpvtpgepasmscrssqsllhsngyiyldwyvqkpgqspqllfylgsnrapgvpvrfsasgsgtdftlkisrveaedvgvyycmqalqmgtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2949,NaN,NaN,NaN,QRW39174,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtisnylnwyqqkpgkapelliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqthstprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2950,NaN,NaN,NaN,QRW39173,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgitnslawyqqkpgkapklllyaasrlqsgvpsrfsgsgsgtdytltisslqpedfavyycqqdynfpwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2951,NaN,NaN,NaN,QRW39172,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnlwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2952,NaN,NaN,NaN,QRW39171,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsdrfsgsksgntasltisglqaedeadyyccsyagifvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2953,NaN,NaN,NaN,QRW39170,SARS-CoV-2,Homo sapiens (human),NaN,rsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapkvliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2954,NaN,NaN,NaN,QRW39169,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqgvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsspqytfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2955,NaN,NaN,NaN,QRW39168,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnslawyqqkpgtapklllyaastlesgvpsrfsgsgsgtdftltisslqpedfatyycqqyysdpprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2956,NaN,NaN,NaN,QRW39167,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslpasvgdrvtitcrasqsirryinwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedsaiyycqqsfstprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2957,NaN,NaN,NaN,QRW39166,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqppsslsasvgdrvtitcrasqdisnslawyqqkpgkapklllyaasrlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyysiprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2958,NaN,NaN,NaN,QRW39165,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvrsflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpyltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2959,NaN,NaN,NaN,QRW39164,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeraalscrasqgvtstylawyqqkpgqaprlliygvstratgipdrfsgsgsgtdftltisrlepedfavyychqydsspltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2960,NaN,NaN,NaN,QRW39163,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspvtlsvspgeratlscrasqsvssnlawyqqkpgqgprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqyknwppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2961,NaN,NaN,NaN,QRW39162,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqrpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdtawvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2962,NaN,NaN,NaN,QRW39161,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgnapklmiydvnnrpsgvsdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2963,NaN,NaN,NaN,QRW39160,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktviisctrssgsiasnyvqwyqqrpgsapttviyedslrpsgvphrfsgsidsssnsasltisglmtedeadyycqsydsswvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2964,NaN,NaN,NaN,QRW39159,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitlsctgtssdvgsydlvswyqhhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyycclyaghstyvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2965,NaN,NaN,NaN,QRW39158,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisndlnwyqqkpgkapkllisdasnletgvpsrfsgsgsgtdftftisslqpediatyycqhydnlkvtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2966,NaN,NaN,NaN,QRW39157,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqsystppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2967,NaN,NaN,NaN,QRW39156,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttpgltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2968,NaN,NaN,NaN,QRW39155,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissleaedfavyycqqrsnwppgmytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2969,NaN,NaN,NaN,QRW39154,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnfsltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2970,NaN,NaN,NaN,QRW39153,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsynilwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2971,NaN,NaN,NaN,QRW39152,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgignslawyqqkpgkapklllyaastlesgvpsrfsgsgsgtdytltisslqpedfatyycqqyystpprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2972,NaN,NaN,NaN,QRW39151,SARS-CoV-2,Homo sapiens (human),NaN,divltqspgtlslspgeratlscrasqsvsssslawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfgvyycqqygssplfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2973,NaN,NaN,NaN,QRW39150,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgipasfsgsgsgteftltisslqsedfavyycqqyndwppmytfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2974,NaN,NaN,NaN,QRW39149,SARS-CoV-2,Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgisnylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqllnsdsptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2975,NaN,NaN,NaN,QRW39148,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnsfpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2976,NaN,NaN,NaN,QRW39147,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapklliygasslqsgvpsrfsgsgsgtdftltisslqpediatyycqqsyssppwtfgqgakveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2977,NaN,NaN,NaN,QRW39146,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgerttlscrasqsvrgsylawyqqkpgqaprlliygastratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2978,NaN,NaN,NaN,QRW39145,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspdfqsvtpkekvtitcrasqsiasslhwyqqkpdqspkllikyasqsfsgvpsrfsgsgsgtdftltinslepedaatyychqssslpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2979,NaN,NaN,NaN,QRW39144,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapkvliydasnletgvpsrfsgsgsgtdftfaisslqpediatyycqqyhnvppafgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2980,NaN,NaN,NaN,QRW39143,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatfycqqyhnlpitfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2981,NaN,NaN,NaN,QRW39142,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastlqsgvpsrfsgsgsgthftltisslqpedfatyycqqansfrltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2982,NaN,NaN,NaN,QRW39141,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtefthtisslqsedfavyycqqynnwppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2983,NaN,NaN,NaN,QRW39140,SARS-CoV-2,Homo sapiens (human),NaN,vltqppsvsgapgqrvtisctgsssnigagagydvhwyqqfpgtapklliygnnnrpsgvpdrfsgsksgtsasltitglqaedeadyycqsydrslsvlyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2984,NaN,NaN,NaN,QRW39139,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2985,NaN,NaN,NaN,QRW39138,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvsdrfsgsksgtsaslaisglrsedeadyycaawddslsgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2986,NaN,NaN,NaN,QRW39137,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycttwdasrggwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2987,NaN,NaN,NaN,QRW39136,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgntvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2988,NaN,NaN,NaN,QRW39135,SARS-CoV-2,Homo sapiens (human),NaN,syvvtqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvmyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssadhyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2989,NaN,NaN,NaN,QRW39134,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspeqsitisctgtssdvgvynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssslqifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2990,NaN,NaN,NaN,QRW39133,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgtynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadfyctsytgsstsvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2991,NaN,NaN,NaN,QRW39132,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrsnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycatwddsltgpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2992,NaN,NaN,NaN,QRW39131,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtissylnwfqqkpgkapklliyvasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2993,NaN,NaN,NaN,QRW39130,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqadsfpwtfgqgtrveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2994,NaN,NaN,NaN,QRW39129,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2995,NaN,NaN,NaN,QRW39128,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsinyylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysapytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2996,NaN,NaN,NaN,QRW39127,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpgtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2997,NaN,NaN,NaN,QRW39126,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdiskylswyqqkpgkapklliydasnletgvpsrfsgsgsgadftftisslqpediatyycqqydtlpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2998,NaN,NaN,NaN,QRW39125,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgttftftisslqpadiatyycqhynnlpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
2999,NaN,NaN,NaN,QRW39124,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3000,NaN,NaN,NaN,QRW39123,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkqgkapnlliyaasslqsgvpsrfsgsgsgtdftltitslqvedfatyycqqshstpytfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3001,NaN,NaN,NaN,QRW39122,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasmsgspgqsitisctgttsdvgaynyvswyqqhpgkapklmisnvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3002,NaN,NaN,NaN,QRW39121,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtiscagtssdvgsynrvswyqqppgtaprlmiyevgnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3003,NaN,NaN,NaN,QRW39120,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctasssnigadydvhwyqqlpgtvpklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslrgsvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3004,NaN,NaN,NaN,QRW39119,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgiskwvawyqqkpgkapkiliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3005,NaN,NaN,NaN,QRW39118,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdtvtitcrasqiinsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyssppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3006,NaN,NaN,NaN,QRW39117,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprllifdasnratgiparfsgsgsgtdftltisslepedfavyycqqlgtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3007,NaN,NaN,NaN,QRW39116,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscragqsvsssylawyqqkpgqaprvliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3008,NaN,NaN,NaN,QRW39115,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqslsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3009,NaN,NaN,NaN,QRW39114,SARS-CoV-2,Homo sapiens (human),NaN,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3010,NaN,NaN,NaN,QRW39113,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgktasitcggnnigsksvhwyqqrpgqapvlviyydtdrpsgiperfsgsnsvntatltisrveagdeadyycqvwdsssdhplfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3011,NaN,NaN,NaN,QRW39112,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnnvnwyqqlpgtapkvliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslnghvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3012,NaN,NaN,NaN,QRW39111,SARS-CoV-2,Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyscnsrdssgnhwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3013,NaN,NaN,NaN,QRW39110,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapksliyvasslqsgvpsrfsgsgsgtnftltisslqpedfatyycqqsysiprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3014,NaN,NaN,NaN,QRW39109,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysfwafgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3015,NaN,NaN,NaN,QRW39108,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliydssslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyspltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3016,NaN,NaN,NaN,QRW39107,SARS-CoV-2,Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissalawyqqkpgkapklliydasslesgvpsrfngsgsgtdftltisslqpedfatyycqqfnnflltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3017,NaN,NaN,NaN,QRW39106,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsswtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3018,NaN,NaN,NaN,QRW39105,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3019,NaN,NaN,NaN,QRW39104,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqksgkapklliydasnletgvpsrfsgsgsgadftftisslqpedigtyycqqsdnvpvtfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3020,NaN,NaN,NaN,QRW39103,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqplsasgtpgqrvtiscsgkssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3021,NaN,NaN,NaN,QRW39102,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3022,NaN,NaN,NaN,QRW39101,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvterpsgvsnrfsgsksgntasltisglqaedeadyycssftssstpyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3023,NaN,NaN,NaN,QRW39100,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsaqvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3024,NaN,NaN,NaN,QRW39099,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtvsctgsssnigagydvqwyqhlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdwgvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3025,NaN,NaN,NaN,QRW39098,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnsvnwyqqlpgtapkffmysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3026,NaN,NaN,NaN,QRW39097,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrtsqsirvylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3027,NaN,NaN,NaN,QRW39096,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslstsvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtnftltisslqpedfatfycqqsystphtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3028,NaN,NaN,NaN,QRW39095,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtisrylnwyqqrpgkapklliyiasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3029,NaN,NaN,NaN,QRW39094,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkllmyaasslqsgvpsrfsgsgsgtdftltinslqpedfatyycqqsystppysfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3030,NaN,NaN,NaN,QRW39093,SARS-CoV-2,Homo sapiens (human),NaN,esvltqspgtlslspgeratlscrasqsvssnylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygtsrtfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3031,NaN,NaN,NaN,QRW39092,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsaslgdrvtitcrasqgisgwlawyqqkpgkapmlliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqansfpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3032,NaN,NaN,NaN,QRW39091,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqhedfatyycqqsyntlalsfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3033,NaN,NaN,NaN,QRW39090,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3034,NaN,NaN,NaN,QRW39089,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqktgkapkpliydasileagvpsrfsgsgsgtdftftitslqpediatyycqqydnlppytfgqgtnleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3035,NaN,NaN,NaN,QRW39088,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnclnwyqqkpgkaptlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllwtfgpgtkmeik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3036,NaN,NaN,NaN,QRW39087,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcraslsigrylnwyqqkpgkapkllisaastlqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsyttplftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3037,NaN,NaN,NaN,QRW39086,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniktylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3038,NaN,NaN,NaN,QRW39085,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdeadyycqvwdsttdlphwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3039,NaN,NaN,NaN,QRW39084,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgqtasitcggsnigsknvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatliinrveagdesdyycqvwdsttdlphwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3040,NaN,NaN,NaN,QRW39083,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsslwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3041,NaN,NaN,NaN,QRW39082,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqninkylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3042,NaN,NaN,NaN,QRW39081,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3043,NaN,NaN,NaN,QRW39080,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgiapelliydnnkrpsgipgrfsgsrsgtsatlditglqtgdeadyycgtwdtslnvwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3044,NaN,NaN,NaN,QRW39079,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssdsasltisglktedeadyycqsydtsnhwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3045,NaN,NaN,NaN,QRW39078,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqepsfsvspggtvtltcglssgsvstsyyaswyqqtpgqaprtliystntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgiwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3046,NaN,NaN,NaN,QRW39077,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgqtagitcggddigsknvhwyqqkpgqapvlvvyddhdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3047,NaN,NaN,NaN,QRW39076,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3048,NaN,NaN,NaN,QRW39075,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3049,NaN,NaN,NaN,QRW39074,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnslnwyqqkpgkapklliydasdletgvpsrfsgsgsgtdftftisslqpediatyycqqygnlppiafgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3050,NaN,NaN,NaN,QRW39073,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgdsylnwfqqrpgqsprrliykvsnwdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwppgtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3051,NaN,NaN,NaN,QRW39072,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsistwlawyqqkpgkapklliydasslesgvpsrfsgsgsgteftltisslqpddfatyhcqqynnlytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3052,NaN,NaN,NaN,QRW39071,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3053,NaN,NaN,NaN,QRW39070,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdfiftisslqpediatyycqqydnlprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3054,NaN,NaN,NaN,QRW39069,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttlaltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3055,NaN,NaN,NaN,QRW39068,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqhynnwplytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3056,NaN,NaN,NaN,QRW39067,SARS-CoV-2,Homo sapiens (human),NaN,qivltqspatlslspgeratlscrasqsvttylawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgpgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3057,NaN,NaN,NaN,QRW39066,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssniggntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycatwddslngrvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3058,NaN,NaN,NaN,QRW39065,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqepsfsvspggtvtltcglssgsvptsyfpswyqqtpgqaprtliygtntrssgvpdrfsgsilgnkaaltitgaqaddesdyycvlymgsgivvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3059,NaN,NaN,NaN,QRW39064,SARS-CoV-2,Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatlsisrveagdeagyycqvwdtsgdplvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3060,NaN,NaN,NaN,QRW39063,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigadydvhwyqqfpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgswvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3061,NaN,NaN,NaN,QRW39062,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssnvgnydlvswyqqhpgkapklmiyevnkrpsgvsdrfsgsksgntasltisglqaedeadfyccsyagssswvfgggtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3062,NaN,NaN,NaN,QRW39061,SARS-CoV-2,Homo sapiens (human),NaN,rsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyscaawddslngwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3063,NaN,NaN,NaN,QRW39060,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsirsylnwyqqkpgkapkvliyaasslqsgvpsrfsgsgsgtdftltisslqpgdfatyycqqsysppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3064,NaN,NaN,NaN,QRW39059,SARS-CoV-2,Homo sapiens (human),NaN,diqmtpspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgteftltisslqpedfatyfcqqsysappwtfgqgtrveir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3065,NaN,NaN,NaN,QRW39058,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3066,NaN,NaN,NaN,QRW39057,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpetfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3067,NaN,NaN,NaN,QRW39056,SARS-CoV-2,Homo sapiens (human),NaN,airitqspsslsastgdrvtitcrasqgissylawyqqkpgkapnlliyaastlqsgvpsrfsgsgsgtdftltisrlhsedfatyycqqyygyptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3068,NaN,NaN,NaN,QRW39055,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnidpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3069,NaN,NaN,NaN,QRW39054,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslpasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisnlqpedfatyycqqsyntlalsfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3070,NaN,NaN,NaN,QRW39053,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnighnavnwyqqipgkapklliyyddlvpsgvsdrfsgsksgtsaslaisglqsedeaeyycaawddslngpvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3071,NaN,NaN,NaN,QRW39052,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliydntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3072,NaN,NaN,NaN,QRW39051,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvniscsgsssnlgnnfvywyqqlpgtapkllsyldsrrpsgvpdrfsgsksgtsasldisglrsedeadyycaawddslsgvifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3073,NaN,NaN,NaN,QRW39050,SARS-CoV-2,Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvlviydknnrpsdipdrfsgsssgntasltitgaqaedeadyycnsrdssinhyvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3074,NaN,NaN,NaN,QRW39049,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsvasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsyhnsvwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3075,NaN,NaN,NaN,QRW39048,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyhccsyagsrfwvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3076,NaN,NaN,NaN,QRW39047,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapelliyaasslqsgvpsrfsgsesgtdftltisslqpedfatyycqqsystpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3077,NaN,NaN,NaN,QRW39046,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliyaassratgipdrfsgsgsgtdftltisrlepedfavyychqyassprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3078,NaN,NaN,NaN,QRW39045,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqanqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqhdnvpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3079,NaN,NaN,NaN,QRW39044,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqspvslpvtlgqpasiscrssqslvhsdgntylnwfqqrpgqsprrliykvsyrhsgvpdrfsgsgsgtdftleisrveaedvgvyycmqgthwpmytfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3080,NaN,NaN,NaN,QRW39043,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvggvyycmqgthwpptfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3081,NaN,NaN,NaN,QRW39042,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsvssylnwyqqnpgkapklliyaastlqsgvpsrfsgsgsgtdftltistlqpedfatyfcqqsystprltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3082,NaN,NaN,NaN,QRW39041,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqhisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyfcqqakgfpltfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3083,NaN,NaN,NaN,QRW39040,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsitswlawyqqkpgkapklliykastlergvpsrfsgsgsgpeftltisslqpddfatyycqqynsyspgdtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3084,NaN,NaN,NaN,QRW39039,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapnlliyaaaslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3085,NaN,NaN,NaN,QRW39038,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntppwtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3086,NaN,NaN,NaN,QRW39037,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsrylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfalyycqqrrdftfgpgtrvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3087,NaN,NaN,NaN,QRW39036,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtptfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3088,NaN,NaN,NaN,QRW39035,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisiylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediaiyycqqydnlpsftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3089,NaN,NaN,NaN,QRW39034,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpvdiatyychqydnlprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3090,NaN,NaN,NaN,QRW39033,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypqatfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3091,NaN,NaN,NaN,QRW39032,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpawtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3092,NaN,NaN,NaN,QRW39031,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlviylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgggtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3093,NaN,NaN,NaN,QRW39030,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksdtsaslaitglqaedeadyycqsydssltgsvfgggtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3094,NaN,NaN,NaN,QRW39029,SARS-CoV-2,Homo sapiens (human),NaN,sfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttliyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsstiifgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3095,NaN,NaN,NaN,QRW39028,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnvvfgggtkltvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3096,NaN,NaN,NaN,QRW39027,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtlsctgsssnigagydvhwyqqlpgtapkvliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgnfvfgtgtkvtvl,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3097,NaN,NaN,NaN,QRW39026,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3098,NaN,NaN,NaN,QRW39025,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3099,NaN,NaN,NaN,QRW39024,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtnftltisslqpedfathycqqsystpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3100,NaN,NaN,NaN,QRW39023,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplslsvtpgqpasiscksrqsllhsdgktylywylqkpgqspqlliydvssrfsgvpdrfsgsgsgtdftlkisrveaedvgvyfcmqgihlptfgqgtrldik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3101,NaN,NaN,NaN,QRW39022,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcragqnissylnwyqqkpgkapklliyatsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysspprtfgqgtkveik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3102,NaN,NaN,NaN,QRW39021,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratvnckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftlnisslqaedvavyycqqyystpytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3103,NaN,NaN,NaN,QRW39020,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssprtfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3104,NaN,NaN,NaN,QRW39019,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsigynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqspytfgqgtkleik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3105,NaN,NaN,NaN,QRW39018,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqhkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkleir,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3106,NaN,NaN,NaN,QRW39017,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvnsnyltwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqsdnspftfgpgtkvdik,"Li,H. et al.; Direct Submission; Submitted (09-FEB-2021) Chongqing Medical University, 1st Yixueyuan Road, Yuzhong District, Chongqing 400000, China; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3107,NaN,NaN,QRN77621,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmgglipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycanfigdgynyeedymdvwgkgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3108,NaN,NaN,QRN77620,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasakvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqrfqgrvtmtedastdtaymelsslrsedtavyycttvgfpdyydssvylrhfdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3109,NaN,NaN,QRN77619,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgftftnyyihwvrqapgqglewmgiinpsggstiyaqkfqgrvtmtrdtstrtvymelsslrsedtavyycadllldywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3110,NaN,NaN,QRN77618,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgkslrlscadsgftfssyamhwvrqapgkglewvavisfdgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwlnwafdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3111,NaN,NaN,QRN77617,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkdrftisrdnskntlylqmnslraedtavyycvrdlysygmdvwgqgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3112,NaN,NaN,QRN77616,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgyslielsmhwvrqapgkglewmggfdpedvetiyaqnlqgrvtmtedtstdtaymelsslrsedtavyycatffavrgalnwfdswgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3113,NaN,NaN,QRN77615,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggitpifhtanyaqkfqgrvtitadeststvymelsslssedtavyycaretgdqgvtapfdlwgrgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3114,NaN,NaN,QRN77614,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlfcaasgftfsdyymswfrqapgkglewvsyisssgsniyyadsvkgrftvsrdnaknslylqmnslraedtavyfcargrlwgwfdpwgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3115,NaN,NaN,QRN77613,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqtpgkglewmggfdpadaetiyaqklqgrvtmtedtstdtaymelsslrsedtavyycatalpitmvrgvqyyyygmdvwgpgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3116,NaN,NaN,QRN77612,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlslqmnslraadtavyycatgtydfwsdnhyldywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3117,NaN,NaN,QRN77611,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgpsvkvsckasggtfssytinwvrqapgqglewmgriipmlgiakyaqkfqgrvtitadkststaymelsslrsedtavyycargivgatpgyfdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3118,NaN,NaN,QRN77610,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsinymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaapllwadsyymdvwgkgttvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3119,NaN,NaN,QRN77609,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntdyvqkfqgrvtitrdmststaymelsslrsedtavyycaapycssttchdgfdiwgqgtmvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3120,NaN,NaN,QRN77608,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytiswvrqapgqglewmgriipildrvmyaqkfqgrvtitadkststaymelsslrsedtavyycarraidsdtyveqshfdywgqgtlvtvssas,NaN,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3121,NaN,NaN,NaN,QRN77635,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppftfgpgtkvdikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3122,NaN,NaN,NaN,QRN77634,SARS-CoV-2,Homo sapiens (human),NaN,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyprtfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3123,NaN,NaN,NaN,QRN77633,SARS-CoV-2,Homo sapiens (human),NaN,aiqmtqspsslsasvgdrvtitcrasqginnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypftfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3124,NaN,NaN,NaN,QRN77632,SARS-CoV-2,Homo sapiens (human),NaN,aiqmtqspsslsasvgdrvtitcragqsissylnwyqqkpgkapklliylastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3125,NaN,NaN,NaN,QRN77631,SARS-CoV-2,Homo sapiens (human),NaN,aiqmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqvnsyptfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3126,NaN,NaN,NaN,QRN77630,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratglparfsgsgsgteftltisslqsedfavyycqqynnwppltfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3127,NaN,NaN,NaN,QRN77629,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqlrgnwppwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3128,NaN,NaN,NaN,QRN77628,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatyycqqydhllitfgqgtrleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3129,NaN,NaN,NaN,QRN77627,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplsspvtlgqpasiscrssqslvhsdgntylswlqqrpgqpprlliykisnrfsgvpdrfsgsgagtdftlkisrveaedvgiyycmqvtqfpytfgqgtkleikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3130,NaN,NaN,NaN,QRN77626,SARS-CoV-2,Homo sapiens (human),NaN,aiqmtqspsflsasvgdrvtitcrasqgissslawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypsttfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3131,NaN,NaN,NaN,QRN77625,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspaalsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgswsgteftltisslqsedlavyycqqynnwltfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3132,NaN,NaN,NaN,QRN77624,SARS-CoV-2,Homo sapiens (human),NaN,aiqmtqspsslsasvgdrvtitcrasqdirnnlgwfqqkpgkapkrliyaastlqrgvpsrfsgsgsgteftltisslqpedfatyyclqhnsylwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3133,NaN,NaN,NaN,QRN77623,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspgtlslapgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3134,NaN,NaN,NaN,QRN77622,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqapslliydasnratgiparfsgsgsgtdftltisslepedfavyycqqpltfgggtkveikrt,"Andreano,E. et al.; Extremely potent human monoclonal antibodies from COVID-19 convalescent patients; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3135,NaN,NaN,QRL72470,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 71 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 71 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3136,NaN,NaN,QRL72469,NaN,SARS-CoV,Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 70 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 70 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3137,NaN,NaN,QRL72468,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 69 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 69 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3138,NaN,NaN,QRL72467,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 68 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 68 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3139,NaN,NaN,QRL72432,NaN,SARS-CoV,Unknown.,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 26 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 26 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3140,NaN,NaN,QRL72430,NaN,SARS-CoV,Unknown.,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 22 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 22 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3141,NaN,NaN,QRL72428,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 18 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 18 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3142,NaN,NaN,QRL72426,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 14 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 14 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3143,NaN,NaN,QRL72424,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 10 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 10 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3144,NaN,NaN,QRL72422,NaN,SARS-CoV,Unknown.,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 6 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 6 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3145,NaN,NaN,QRL72420,NaN,SARS-CoV,Unknown.,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 2 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,Sequence 2 from patent US 10851155,NaN,2022-03-15,NaN,NaN,NaN
3146,NaN,NaN,AZK34220,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 71 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 71 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3147,NaN,NaN,AZK34219,NaN,SARS-CoV,Unknown.,qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 70 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 70 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3148,NaN,NaN,AZK34218,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 69 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 69 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3149,NaN,NaN,AZK34217,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyyc,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 68 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 68 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3150,NaN,NaN,AZK34182,NaN,SARS-CoV,Unknown.,evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgianyaqkfqgrvtitadkststaymelsslrsedtavyycassnyygsgsyyprsafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 26 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 26 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3151,NaN,NaN,AZK34180,NaN,SARS-CoV,Unknown.,evqlvqsgaevkkpgasvkvsckasgytfnvyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycardyygsgargfdywgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 22 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 22 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3152,NaN,NaN,AZK34178,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarasycsttscasgafdiwgqgtlvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 18 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 18 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3153,NaN,NaN,AZK34176,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvgycsstschigafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 14 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 14 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3154,NaN,NaN,AZK34174,NaN,SARS-CoV,Unknown.,qvqlvqsgaevkkpgssvkvsckasggtfssyavswvrqapgqglewvgriipifgkanyaqkfqgrvtitadkststaymelsslrpedtavyycardqgisanfkdafdiwgqgttvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 10 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 10 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3155,NaN,NaN,AZK34172,NaN,SARS-CoV,Unknown.,evqlvqsgaevkepgssvkvsckasggtfgsyainwvrqapgqrlewmgwidaangntkysqkfqgrvtitgdtsastaymelsslrsedtavyycardrwmttrafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 6 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 6 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3156,NaN,NaN,AZK34170,NaN,SARS-CoV,Unknown.,qvqlvqsgggvvqpgrslrlscvaseftfntygmhwvrqapgkglewvaaisydgtkkfyadslkgrftisrdnskntlylqmnslrsedtavyycarsgdsdafdiwgqgtmvtvss,NaN,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 2 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,Sequence 2 from patent US 10131704,NaN,2022-03-15,NaN,NaN,NaN
3157,NaN,NaN,NaN,QRL72476,SARS-CoV,Unknown.,NaN,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 77 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 77 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3158,NaN,NaN,NaN,QRL72475,SARS-CoV,Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 76 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 76 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3159,NaN,NaN,NaN,QRL72474,SARS-CoV,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 75 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 75 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3160,NaN,NaN,NaN,QRL72473,SARS-CoV,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 74 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 74 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3161,NaN,NaN,NaN,QRL72472,SARS-CoV,Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 73 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 73 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3162,NaN,NaN,NaN,QRL72471,SARS-CoV,Unknown.,NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 72 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 72 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3163,NaN,NaN,NaN,QRL72433,SARS-CoV,Unknown.,NaN,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 28 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 28 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3164,NaN,NaN,NaN,QRL72431,SARS-CoV,Unknown.,NaN,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 24 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 24 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3165,NaN,NaN,NaN,QRL72429,SARS-CoV,Unknown.,NaN,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 20 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 20 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3166,NaN,NaN,NaN,QRL72427,SARS-CoV,Unknown.,NaN,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 16 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 16 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3167,NaN,NaN,NaN,QRL72425,SARS-CoV,Unknown.,NaN,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 12 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 12 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3168,NaN,NaN,NaN,QRL72423,SARS-CoV,Unknown.,NaN,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 8 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 8 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3169,NaN,NaN,NaN,QRL72421,SARS-CoV,Unknown.,NaN,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10851155-B2 4 01-DEC-2020 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2021.",NaN,NaN,Sequence 4 from patent US 10851155,2022-03-15,NaN,NaN,NaN
3170,NaN,NaN,NaN,AZK34226,SARS-CoV,Unknown.,NaN,qagltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsyrnnnrpsgiserlsasrsgntasltitglqpedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 77 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 77 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3171,NaN,NaN,NaN,AZK34225,SARS-CoV,Unknown.,NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 76 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 76 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3172,NaN,NaN,NaN,AZK34224,SARS-CoV,Unknown.,NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 75 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 75 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3173,NaN,NaN,NaN,AZK34223,SARS-CoV,Unknown.,NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 74 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 74 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3174,NaN,NaN,NaN,AZK34222,SARS-CoV,Unknown.,NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 73 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 73 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3175,NaN,NaN,NaN,AZK34221,SARS-CoV,Unknown.,NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyyc,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 72 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 72 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3176,NaN,NaN,NaN,AZK34183,SARS-CoV,Unknown.,NaN,ettltqspatlsvspgerailscrasqsisndlawyqqkpgqaprlliygassratgipdrfsgsgsgtdftftisrlesedfavyycqqygvspltfgggtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 28 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 28 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3177,NaN,NaN,NaN,AZK34181,SARS-CoV,Unknown.,NaN,qpgltqppsvskglrqtatltctgnsnnvgnqgaawlqqhqghppkllsytnnnrpsgiserlsasrsgntaslaitglqpedeadyycaswdsslsvwvigggtkltvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 24 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 24 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3178,NaN,NaN,NaN,AZK34179,SARS-CoV,Unknown.,NaN,diqmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywasaresgvpdrfsgsgsgtdftltisslqpedvaiyycqqyysvpftfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 20 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 20 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3179,NaN,NaN,NaN,AZK34177,SARS-CoV,Unknown.,NaN,ettltqspgtlslspgeratlscrasqsvsssiawyqqkpgqaprllmfdsstratgipdrfsgsgsgtdftlnisslepedfavyycqqyssspytfgqgtkleik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 16 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 16 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3180,NaN,NaN,NaN,AZK34175,SARS-CoV,Unknown.,NaN,ettltqspatlsvspgeratlscrasesvgsnlawyqqkpgqapslliygastratgipdrfsgsgsgtdftltisslqsedfaayycqqynnwpltfgpgtkveik,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 12 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 12 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3181,NaN,NaN,NaN,AZK34173,SARS-CoV,Unknown.,NaN,qpvltqppsasgtpgqrvtiscsgsssnigsnyvfwyqqlpgmapkllisrnnqrpsgvpdrfsgsksgtsaslaisgpqsedeadyycaawddslrgpvfgggtrvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 8 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 8 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3182,NaN,NaN,NaN,AZK34171,SARS-CoV,Unknown.,NaN,syeltqppsvsvspgqtatitcsgdelgdkfafwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsnsyvfgtgtkvtvl,"Marasco,W.A. et al.; Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof; US10131704-B2 4 20-NOV-2018 DANA-FARBER CANCER INSTITUTE, INC.; Boston, MA; 2018.",NaN,NaN,Sequence 4 from patent US 10131704,2022-03-15,NaN,NaN,NaN
3183,NaN,NaN,QRJ89103,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,NaN,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 96 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",NaN,Sequence 96 from patent US 10822379,NaN,2022-03-15,NaN,NaN,NaN
3184,NaN,NaN,QRJ89017,NaN,SARS-CoV-2,Unknown.,evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrhnskntlylqmnslraedtavyycargygdyyfdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepksc,NaN,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 8 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",NaN,Sequence 8 from patent US 10822379,NaN,2022-03-15,NaN,NaN,NaN
3185,NaN,NaN,NaN,QRJ89025,SARS-CoV-2,Unknown.,NaN,dvvmtqspatlslspgekatlscrasqsvssylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqygsspltfgggtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Dimitrov,D.S. et al.; Molecules that bind to SARS-CoV-2; US10822379-B1 16 03-NOV-2020 University of Pittsburgh-of the Commonwealth System of Higher Education; Pittsburgh, PA; 2021.",NaN,NaN,Sequence 16 from patent US 10822379,2022-03-15,NaN,NaN,NaN
3186,NaN,NaN,QQX23548,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaraywgrgptifgvvsnttryygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3187,NaN,NaN,QQX23547,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrhssgwdnwyfdlwgrgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3188,NaN,NaN,QQX23546,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3189,NaN,NaN,QQX23545,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3190,NaN,NaN,QQX23544,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgsgsyywgsldywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3191,NaN,NaN,QQX23543,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvgplmvrgviipwgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3192,NaN,NaN,QQX23542,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardgspsggwytldywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3193,NaN,NaN,QQX23541,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3194,NaN,NaN,QQX23540,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpglvkpsetlsltctvsggsissyywswirqppgkglewigniyysgstdynpslksrvtisvdtsknqfslrlssvtaadtavyycareqfsggdyegfdfwgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3195,NaN,NaN,QQX23539,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsnyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelgslrsedtavyycaragwsvsplkynwfdpwgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3196,NaN,NaN,QQX23538,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraaygpyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3197,NaN,NaN,QQX23537,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgfifssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardlrgptgwtfdywgqgtlvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3198,NaN,NaN,QQX23536,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttegamvrrviygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3199,NaN,NaN,QQX23535,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwvicsstscytkysyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3200,NaN,NaN,QQX23534,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgggvvqpgrslrlscaasgftfsfyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarewfgetwegmdawgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3201,NaN,NaN,QQX23533,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarggwrssgyhdysyygmdvwgqgttvtvss,NaN,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3202,NaN,NaN,NaN,QQX23532,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygngnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3203,NaN,NaN,NaN,QQX23531,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdssliarlfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3204,NaN,NaN,NaN,QQX23530,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslnvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3205,NaN,NaN,NaN,QQX23529,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqepsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3206,NaN,NaN,NaN,QQX23528,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvsiscsgstssigrntvswfqqlpgtapklliyrdnqrpsgvpdrfsgsksgtsaslaisglrsedeaeyycsawhdtlngvvfgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3207,NaN,NaN,NaN,QQX23527,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsisnigsahvswyqqvpgtapklliydnserpsgiparfsafkygtsatlditglqtgdeadyycaswdislsagifgggtkltvl,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3208,NaN,NaN,NaN,QQX23526,SARS-CoV-2,Homo sapiens (human),NaN,envltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystllgtfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3209,NaN,NaN,NaN,QQX23525,SARS-CoV-2,Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3210,NaN,NaN,NaN,QQX23524,SARS-CoV-2,Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliygasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpwtfgqgtkvei,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3211,NaN,NaN,NaN,QQX23523,SARS-CoV-2,Homo sapiens (human),NaN,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrwtfgqgtkveik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3212,NaN,NaN,NaN,QQX23522,SARS-CoV-2,Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnpitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3213,NaN,NaN,NaN,QQX23521,SARS-CoV-2,Homo sapiens (human),NaN,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspiftfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3214,NaN,NaN,NaN,QQX23520,SARS-CoV-2,Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvsnylawyqqrpgqaprlliydssnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwkitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3215,NaN,NaN,NaN,QQX23519,SARS-CoV-2,Homo sapiens (human),NaN,envltqspgtlslspgeratlscrarqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspitfgqgtrleik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3216,NaN,NaN,NaN,QQX23518,SARS-CoV-2,Homo sapiens (human),NaN,envltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwplltfgggtkveik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3217,NaN,NaN,NaN,QQX23517,SARS-CoV-2,Homo sapiens (human),NaN,envltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprgvtfgpgtkvdik,"Zhang,L. et al.; Development of Patient-Derived Human Monoclonal Antibodies Against Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus 2 for Coronavirus Disease 2019 Diagnosis; Front Immunol 11, 595970 (2020); 2021.",10.3389/fimmu.2020.595970,NaN,"anti-SARS-CoV-2 nucleocapsid monoclonal antibody kappa chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3218,NaN,NaN,QQO74752,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgisgsggstyyadsmkgrftisrdnskntlylqmnslraedtavyycakdltrdyydssgyqtgafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3219,NaN,NaN,QQO74751,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgiggsgdstyyadsvkgrftisrdnskntlylqinslraedtavyycakgaapyyyyyygmdvwgqgttvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3220,NaN,NaN,QQO74750,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvrsnymswvrqapgkglewvsliysggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3221,NaN,NaN,QQO74749,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3222,NaN,NaN,QQO74748,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggrtyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivvvitgdafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3223,NaN,NaN,QQO74747,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyfihwvrqapgqglewmgminpsvgsttyaqnfqgrvtmtrdtststvymelsslrsedtaiyycarthvaqlweiwyfdiwgrgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3224,NaN,NaN,QQO74746,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctlsggairsgsyywgwirqtpgkglewigsifhignafynpslksrvtisadkaknqislnvrsvtaadtavyycvrpnnehggfffdywgqgilvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3225,NaN,NaN,QQO74745,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlfcaasgftfssfamswvrqapgkglewvstisgsggrtyyadsvkgrftifrdnskntlylqmnslraedtalyycakdmdivvvitgdafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3226,NaN,NaN,QQO74744,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwistyngntnyaqrlqgrvtmttdtstgtahmelrslrsddtaiyycareeplycsggscyefqhwgqgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3227,NaN,NaN,NaN,QQO74743,SARS-CoV-2,Homo sapiens (human),NaN,syelnqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwggvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3228,NaN,NaN,NaN,QQO74742,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggydyvswyqqhpgkapklmiyevsdrpsgvsnrfsgsksgstasltisglqaedeadyycssytsssalyvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3229,NaN,NaN,NaN,QQO74741,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtefkltisslqpedfatyycqqlnnyppvtfgqgtrleik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3230,NaN,NaN,NaN,QQO74740,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3231,NaN,NaN,NaN,QQO74739,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprhysywyqqkpgqapvlliykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgigtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3232,NaN,NaN,NaN,QQO74738,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgstsnigsnavnwyqqlpgtapklliysdnhrpsgvpdrfsgsrsgtsaslaisrlqsedeadyycaawddslkgvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3233,NaN,NaN,NaN,QQO74737,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppslsvapgktariscggnnigsrsvhwyqqkpgqapvvvisydtdrpseiperfsgsksgntatltisrveagdeadyycqvwvstfdhvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3234,NaN,NaN,NaN,QQO74736,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3235,NaN,NaN,NaN,QQO74735,SARS-CoV-2,Homo sapiens (human),NaN,eivltqsparlslspgeratlscrasqsvssdlawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrinwppiftfgpgtkvdik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3236,NaN,NaN,QNS17516,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtlvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3237,NaN,NaN,QNS17515,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgtyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3238,NaN,NaN,QNS17514,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesgggsveaggslrlscaasgvtldyyaigwfrqapgkeregvscisssdgstyyadsvkgrfttsrdnakntvylqmnslkpedtadyycaavpstyysgtyyynchpgamhywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3239,NaN,NaN,QNS17513,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftisrdnakntvylqmnslkpddtavyycaaalseggytidgsswcyhsvygmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3240,NaN,NaN,QNS17512,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscitnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycasfpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3241,NaN,NaN,QNS17511,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsggstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3242,NaN,NaN,QNS17510,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtlvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3243,NaN,NaN,QNS17509,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqsggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3244,NaN,NaN,QNS17508,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgftldyyaigwfrqapgkeregvscisnsdgstyyadsvkgrfttsrdnakntvylqmnslkpedtavyycaavpstyysgsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3245,NaN,NaN,QNS17507,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvacisssdgttyyadsvkgrftisrdnakntvylqmnslkpedtavyycatrpltyysgsyyttcsdygmdywgkgtlvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3246,NaN,NaN,QNS17506,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscaasgltldyytigwfrqapgkeregvscisssddstyyadsvkgrftisrdnakntvylqmnslkpedtavyycatapgtyykgsyypmchyygmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3247,NaN,NaN,QNS17505,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggglvqpggslrlscavsgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyysgtyyynchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3248,NaN,NaN,QNS17504,NaN,SARS-CoV-2,Lama glama (llama),dvqlqesggdlvqpggslrlscaasgftldyyaigwfrqapgkeregvscisssdgstyyadsvkgrftssrdnakntvylqmnslkpedtavyycaavpstyyngsyyytchpggmdywgkgtqvtvss,NaN,"Esparza,T.J. et al.; Direct Submission; Submitted (08-SEP-2020) National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive, Building 10 5C100, Bethesda, MD 20892, USA; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Lama glama]",NaN,2022-03-15,NaN,NaN,NaN
3249,VHAB8,NaN,QNN25877,NaN,SARS-CoV-2,synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,NaN,"Li,W. et al.; High potency of a bivalent human VH domain in SARS-CoV-2 animal models; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.007,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region VHab8, partial [synthetic construct]",NaN,2022-03-15,NaN,NaN,NaN
3250,RBD-SPECIFIC,NaN,QLR06781,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvss,NaN,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; Nat Commun 11 (1) (2020) In press; 2020.",10.1038/s41467-020-18174-5,"SARS-CoV-2 RBD-specific neutralizing immunoglobulin heavy chain, partial [Vicugna pacos]",NaN,2022-03-15,NaN,NaN,NaN
3251,NaN,NaN,QMI58173,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgltfssyvmhwvrqapgkgldwvgviwydgskkyyadsvkgrftisrdnskntlylqmnslraedtavyycardprdyydfwsgydyyygldvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3252,NaN,NaN,QMI58172,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycakdsgynygyswfdpwgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3253,NaN,NaN,QMI58171,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvaaisydgnnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsilygggmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3254,NaN,NaN,QMI58170,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyyctragwelrldafdiwgqgtmvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3255,NaN,NaN,QMI58169,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evhlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddaknslylqmnslktedtavyycarvhrwaycingvcfgaysdywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3256,NaN,NaN,QMI58168,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardlfyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3257,NaN,NaN,QMI58167,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahhkierifdywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3258,NaN,NaN,QMI58166,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvsssnyywswirqppgkglewigymyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycarevyyydrsgyyasdgfdiwgqgtmvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3259,NaN,NaN,QMI58165,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsisnyywswirqspgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarsakhwlappgdyyyymdvwgkgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3260,NaN,NaN,QMI58164,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedvetiyaqqfqgrvtmtedtstdtaymelsslrsedtavyycatgwaykstwyfgywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3261,NaN,NaN,QMI58163,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgiavigpppstyyyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3262,NaN,NaN,QMI58162,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsmhwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgwavagssdvwyyyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3263,NaN,NaN,QMI58161,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqllqsgaevkkpgasvkvsckasgysftsyymhwvrqapgqglewmgiinpsgggttyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpgggsyqefdywgqgtlvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3264,NaN,NaN,QMI58160,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgvinpsggstsyaekfrgrvtmtrdtststvymelsslrsedtavyycardrephsdssgywdslkyyyyyaldvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3265,NaN,NaN,QMI58159,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnytqmfqgrvtmtrdtsistaymevsrlrsddtavyycardrswavvyyymdvwgkgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3266,NaN,NaN,QMI58158,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckasgytftgyymhwvrqapgqglewmgwinpisdgtnyaqkfqgwvtmtrdtsistvymelsrlrsddtavyycarggsrcsggncygwaydafdiwgqgtmitvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3267,NaN,NaN,QMI58157,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsittaymelrrlrsddtavyycarglgvgcsggncyldyyymdvwgkgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3268,NaN,NaN,QMI58156,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggnipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargvgyrgviplnwfdpwgqgtvvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3269,NaN,NaN,QMI58155,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkagssvkvsckasggtfsshtitwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycaslqtvdtaiekyygmdvwgqgttvtvss,NaN,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3270,NaN,NaN,NaN,QMI58192,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssdlawyqhkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqynnwppftfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3271,NaN,NaN,NaN,QMI58191,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkllisaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyntlqvtfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3272,NaN,NaN,NaN,QMI58190,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalakqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdnsgtypnwvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3273,NaN,NaN,NaN,QMI58189,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrssyaswyqqkpgqapilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgilfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3274,NaN,NaN,NaN,QMI58188,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3275,NaN,NaN,NaN,QMI58187,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspstfgqgtkleik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3276,NaN,NaN,NaN,QMI58186,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgilslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssgaltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3277,NaN,NaN,NaN,QMI58185,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3278,NaN,NaN,NaN,QMI58184,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgqapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlnsypltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3279,NaN,NaN,NaN,QMI58183,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypcfgpgtkvdik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3280,NaN,NaN,NaN,QMI58182,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyltfgggtkveik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3281,NaN,NaN,NaN,QMI58181,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,aiqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapelliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqlntypftfgpgtkvdik,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3282,NaN,NaN,NaN,QMI58180,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsrmgfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3283,NaN,NaN,NaN,QMI58179,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3284,NaN,NaN,NaN,QMI58178,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsalaqpasvsgspgqsitisctgtssdvgaynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssyttsstvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3285,NaN,NaN,NaN,QMI58177,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3286,NaN,NaN,NaN,QMI58176,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssstyvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3287,NaN,NaN,NaN,QMI58175,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadcycssytssstfvfgtgtkvtvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3288,NaN,NaN,NaN,QMI58174,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedegdyycssytssstwvfgggtkltvl,"Liu,L. et al.; Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike; Nature (2020) In press; 2020.",10.1038/s41586-020-2571-7,NaN,"immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3289,NaN,NaN,QLI62517,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsssaiswvrqapgqglewmggiipilditnyaqkfqgrvtitadkststafmelsslrsedtavyycalrnqwdllvywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3290,NaN,NaN,QLI62516,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiafagsvkgrftisrdnaknslylqmnslraedtalyycakdqgysygnyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3291,NaN,NaN,QLI62515,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvscmasgytftsyymhwvrqapgqglewmgiispsgggtsyaqkfqgrvtltrdtststvymelsslrsedtavyycarwydstgsidywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3292,NaN,NaN,QLI62514,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsiyaitwvrqapgqglewmggiipiigtanyaqkfqgrvtitadkststaymelsslrsedtavyycardfrycsstrcyfwfdpwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3293,NaN,NaN,QLI62513,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfatyalnwvrqapgqglewmgwvntntgsptyaqgftgrfvfsfdtsvstaylqirtlkaedtavyycavyyydsgspgwfdpwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3294,NaN,NaN,QLI62512,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnyamtwvrqapgkglewvsaissgsgstyyadsvkgrftisrdnskntvylqmnslraedtaiyycakankysssefdfwgqgtlvtiss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3295,NaN,NaN,QLI62511,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfigyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistvymelsrlrsddtavyycarempaamgyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3296,NaN,NaN,QLI62510,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtvsadksistaylqwsslkasdtamyycarvnyydssgypsfhfdywgqgtlvtvs,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3297,NaN,NaN,QLI62509,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdryyefwsgysnwfdpwgqgtlvtiss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3298,NaN,NaN,QLI62508,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscsasgftfsiygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrtgnyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3299,NaN,NaN,QLI62507,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarqgdcsttscaydywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3300,NaN,NaN,QLI62506,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgfaqnmvlltpywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3301,NaN,NaN,QLI62505,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymdlsslrsedtavyycatafsifgvvppdywgqgtlvtvs,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3302,NaN,NaN,QLI62504,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslrgedtavyycakdqayydiltgylnppknyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3303,NaN,NaN,QLI62503,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakgsgsgsypnyyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3304,NaN,NaN,QLI62502,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarlhcggdcyldywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3305,NaN,NaN,QLI62501,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfrnygmhwvrqapgkglegvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakssgsyyyyyygmdvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3306,NaN,NaN,QLI62500,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaliwydgsnknyadsvkgrftisrdnskntldlqmnslraedtavyycardpfpgavagtgylqywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3307,NaN,NaN,QLI62499,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstyemnwvrqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmsslraedtaiyycardrrrryctngvcyrpeeidywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3308,NaN,NaN,QLI62498,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfnyysmnwvrqapgkglewissistsssfvyyadsvkgrftisrdnaktslylqmnslraedtavyfcarggycsdgscyvqdrliyyysgldvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3309,NaN,NaN,QLI62497,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardpygyssiwdgqgghwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3310,NaN,NaN,QLI62496,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3311,NaN,NaN,QLI62495,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3312,NaN,NaN,QLI62494,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiysgyfmhwvrqapgqglewmgwispdsgganyaqtfqgrvtmtrdtstttahmelsrlrsddtavyycargprysgthfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3313,NaN,NaN,QLI62493,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqnfqgrvtmtrdtsistgymelsrlrsddtamyycargprysgtyfdywgqgvlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3314,NaN,NaN,QLI62492,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyythwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittayvelsglrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3315,NaN,NaN,QLI62491,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvtcktsgyifsgyymhwvrqvpgqglewmgwispdsgatnyaqkfqgrvtmtrdtsittsyveltwlksddtavyycargprysgtyfdfwgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3316,NaN,NaN,QLI62490,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyifsgyymhwvrqapgqglewmgwispdsggtnyaqkfqgrvtmtrdtsittgymelsglrsddtavyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3317,NaN,NaN,QLI62489,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgyiysgyymhwvrqapgqglewmgwispdsggtnyaqrfqgrvtmtrdtstttaymelsrlrsddtamyycargprysgtyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3318,NaN,NaN,QLI62488,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwispnsggtnyaqkfqgwvtmtrdtsvstaymelsrlrfddtavyycateswvygsgsyssgafdiwgqgtmvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3319,NaN,NaN,QLI62487,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskstlylqmnslrvedtavyycardfgdfyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3320,NaN,NaN,QLI62486,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsvfysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardygdlyfdywgqgtlvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3321,NaN,NaN,QLI62485,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3322,NaN,NaN,NaN,QLI62550,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3323,NaN,NaN,NaN,QLI62549,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqppsvsvapgktaritcggnnigsksvywyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpyvfgsgtkvtvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3324,NaN,NaN,NaN,QLI62548,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypiltfgggtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3325,NaN,NaN,NaN,QLI62547,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqeagkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3326,NaN,NaN,NaN,QLI62546,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqtassylnwyqqkpgkapnlliyaasslqsgvpsrfsgsgsvtdftltisslqpedfatyycqqsystpptfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3327,NaN,NaN,NaN,QLI62545,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgaapklliyrndqrpsgvpdrfsgsksgtsvslaisglrsedeadyycaawddslsgwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3328,NaN,NaN,NaN,QLI62544,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstfvfvfgtgtkvivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3329,NaN,NaN,NaN,QLI62543,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcvsstgavtsgyypnwfqqkpgqapraliystskkhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggaqrwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3330,NaN,NaN,NaN,QLI62542,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkvlvysndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3331,NaN,NaN,NaN,QLI62541,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasnlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3332,NaN,NaN,NaN,QLI62540,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttatltisgvqaedeadyycqsadssgtylvvfgggtklavl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3333,NaN,NaN,NaN,QLI62539,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppitfgqgtrleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3334,NaN,NaN,NaN,QLI62538,SARS-CoV-2,Homo sapiens (human),NaN,qavvtqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3335,NaN,NaN,NaN,QLI62537,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasstpgqrvtiscsgsssnigsnyvywyqqlpgtapklliytnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsgrvvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3336,NaN,NaN,NaN,QLI62536,SARS-CoV-2,Homo sapiens (human),NaN,syeltqspsvsvapgqtaritcggnnigsksvhwyqrkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdnnsdhlvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3337,NaN,NaN,NaN,QLI62535,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiannyvkwyqqrpgsspttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnheeiwvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3338,NaN,NaN,NaN,QLI62534,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddtdrpsgiperfsgsssgntatltisrveagdeadyycqvwdsssdhpvvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3339,NaN,NaN,NaN,QLI62533,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpwvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3340,NaN,NaN,NaN,QLI62532,SARS-CoV-2,Homo sapiens (human),NaN,qavltqppsvsgapgqrvtisctgsssnieagydvhwyqqlpgtapklliyvnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgvvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3341,NaN,NaN,NaN,QLI62531,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvfycmqgthwpptfgqgtkvdik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3342,NaN,NaN,NaN,QLI62530,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnfatgvpsrfsgtgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3343,NaN,NaN,NaN,QLI62529,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsgstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3344,NaN,NaN,NaN,QLI62528,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3345,NaN,NaN,NaN,QLI62527,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsltisctgtssdvggynyvswyqqhpdkapklmiydvnnrpsgvsnrfsgsksgstasltisglqaedeadyycssyagsstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3346,NaN,NaN,NaN,QLI62526,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkvpklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3347,NaN,NaN,NaN,QLI62525,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynhvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssaqlfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3348,NaN,NaN,NaN,QLI62524,SARS-CoV-2,Homo sapiens (human),NaN,qpvltqpasvsgspgqsltisctgtssdiggfnyvswyqqhpgkapklmifdvskrpsgvpnrfsgsksgntasltisglqaedegdyycssytissaqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3349,NaN,NaN,NaN,QLI62523,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqptsvsgspgqsitisctgtssdvggynyvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytvsstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3350,NaN,NaN,NaN,QLI62522,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpdkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeaayycssytssstqvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3351,NaN,NaN,NaN,QLI62521,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgspgqsvtisctgtssdvggydyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvpglqaedeadyyctsyagsnnfvfgggtklivl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3352,NaN,NaN,NaN,QLI62520,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3353,NaN,NaN,NaN,QLI62519,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsetdftltisrlepeefavyycqqygssprtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3354,NaN,NaN,NaN,QLI62518,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsyppkftfgpgtkveik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3355,NaN,NaN,QLI33947,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3356,NaN,NaN,QLI33945,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3357,NaN,NaN,NaN,QLI33948,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3358,NaN,NaN,NaN,QLI33946,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; Nat. Med. (2020) In press; 2020.",10.1038/s41591-020-0998-x,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3359,NaN,NaN,QKY76702,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntdyaqkfqervtitrdvststaymelsslrsedtavyycaaprcsggscydgfdiwgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3360,NaN,NaN,QKY76701,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkisckasgyifinyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtslstaylqissleaedtavyycakigsrnslgvwgqgtlvtvsa,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3361,NaN,NaN,QKY76700,NaN,SARS-CoV-2,Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3362,NaN,NaN,QKY76699,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggilgyadsvkgrftisrdnaknslylqmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3363,NaN,NaN,QKY76698,NaN,SARS-CoV-2,Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3364,NaN,NaN,QKY76697,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgghlvqpgrslrlscaasgftfddyamhwvrqvpgkglewvsgiswnggildyadsvkgrftisrdnaknslylhmrslrtddtalyycakdlrrqdyyadwyfdlwgrgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3365,NaN,NaN,QKY76696,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssntryytdsvmgrftisrdnaknslflqmnslraedtavyycasskgfcsggscsdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3366,NaN,NaN,QKY76695,NaN,SARS-CoV-2,Homo sapiens (human),qlqvqesgpglvkpsetlsltctvsgasissnhyfwgwirqppgkglawigsmhysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycargvnyydrngyyrndgfdirgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3367,NaN,NaN,QKY76694,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfsrytiiwvrqapgqglewmgriipildianyaqkfqgrvtitadkststaymelsslrsedtavyycareggldyfgsrnsgwtytwfdpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3368,NaN,NaN,QKY76693,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycatgarfgespfdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3369,NaN,NaN,QKY76692,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgrglewvsviysggstfyadsvkgrftisrdnskntlylqmnslrpedtavyycatgarfgespfdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3370,NaN,NaN,QKY76691,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfrnyamtwvrqapgkglewvsgisdsgdrtynadsvkgrfsisrdnskntlhlqmnslraedtavyycalasgsyfgganywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3371,NaN,NaN,QKY76690,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtglyycakdinydsggyhknyfdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3372,NaN,NaN,QKY76689,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqgrvtitrdmstrtaymelsslrsedtamyycaapycsstrcydafdiwgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3373,NaN,NaN,QKY76688,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardygdyffdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3374,NaN,NaN,QKY76687,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardfgdfffdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3375,NaN,NaN,QKY76686,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaatgftfrrygmhwvrqapgkglewvagilfdgsnkyyvdsvkgrftisrdssrntlylqlnslrredtavyycakggdyewelleswgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3376,NaN,NaN,QKY76685,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcssticydgfdiwgqgtmvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3377,NaN,NaN,QKY76684,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgrnkyyvdsvkgrftisrdnskntlylqisslraedtavyycaraarrpvvtdtmayymdvwgkgttvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3378,NaN,NaN,QKY76683,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3379,NaN,NaN,QKY76682,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytflrfamnwlrqapgqglewmgwidtntgtptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarslrganlvpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3380,NaN,NaN,QKY76681,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarattdcsstscwsldfwsgyytggrekifdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3381,NaN,NaN,QKY76680,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdapirtaymelsglgsddtavyycarasvatitdfdywgqgtlvavss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3382,NaN,NaN,QKY76679,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevknpgasvkvsckasgyiftnyyihwvrqapgqglewvgwihslsggtsyaqkfqgrvtltrdasirtaymelsrlgsddtalyycarasvstitdfdywgqgtlvavss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3383,NaN,NaN,QKY76678,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksivylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3384,NaN,NaN,QKY76677,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamswfrqapgkglewvgfirskayggtteyaasvkgrftisrddsksiaylqmnslktedtavyyctrvrrlwfgsyyygmdvwgqgttvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3385,NaN,NaN,QKY76676,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardgellgwfdpwgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3386,NaN,NaN,QKY76675,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycarvsgydssgywgdywgqgtlvtvss,NaN,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3387,NaN,NaN,NaN,QKY76730,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqhkpgqaprllicgassratgipdrfsgsgsgtgftltisrlepedfavyycqqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3388,NaN,NaN,NaN,QKY76729,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrashsvdrsylawyqqkpglaprlliygassratgipdrfsgsgsgtdftltisrlepedfalyycqhfgtssvtfgrgtrleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3389,NaN,NaN,NaN,QKY76728,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3390,NaN,NaN,NaN,QKY76727,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtkvdv,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3391,NaN,NaN,NaN,QKY76726,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3392,NaN,NaN,NaN,QKY76725,SARS-CoV-2,Homo sapiens (human),NaN,diqmiqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaastllsavpsrfsgsgsgtdftltisslqpedfatyycqqgnsfpftfgpgtivdv,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3393,NaN,NaN,NaN,QKY76724,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfvvyychqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3394,NaN,NaN,NaN,QKY76723,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyeqkpgkapkrliyaasslesgvpsrfsgsgsgteftltisslqpedfatyyclqhntypftfgpgtrvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3395,NaN,NaN,NaN,QKY76722,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnissylnwyqqkpgkapnlliyaasslqsgvpprfsgsgsgtdftltisslqpedfatyycqqsystlysfgqgtkleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3396,NaN,NaN,NaN,QKY76721,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3397,NaN,NaN,NaN,QKY76720,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3398,NaN,NaN,NaN,QKY76719,SARS-CoV-2,Homo sapiens (human),NaN,qavvtqepsltvspggtvtltcgsstgpvtsdhypywfqqkpgqapttliydtnnkhswtparfsgsllggkaaltlsgaqpedeaeyycllsytgarvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3399,NaN,NaN,NaN,QKY76718,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdratitcrasqsissylnwyqekpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3400,NaN,NaN,NaN,QKY76717,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspwtfgqgtkvei,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3401,NaN,NaN,NaN,QKY76716,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprllisgassraagipdrfsgsgsgtdftltinrlepedfavyycqqygssprtfgqgtkleik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3402,NaN,NaN,NaN,QKY76715,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssylawyqqkpgqaprlliygvssratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3403,NaN,NaN,NaN,QKY76714,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstvsasvgdrvtitcrasqsidnwlawyqekpgkapkvliykasslesgvpsrfsgrgsgteftltisslqpgdfatyycqhyhsfpltfgggtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3404,NaN,NaN,NaN,QKY76713,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrvepedfavyycqqygsspwtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3405,NaN,NaN,NaN,QKY76712,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscraslslssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpptwtfgqgtkaeik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3406,NaN,NaN,NaN,QKY76711,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3407,NaN,NaN,NaN,QKY76710,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdvsnylnwyqqqpgkapklliydafnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3408,NaN,NaN,NaN,QKY76709,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3409,NaN,NaN,NaN,QKY76708,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtsgdigsynlvswyqqypgkapkliiyeaskrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3410,NaN,NaN,NaN,QKY76707,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtsgdvgsynlvswyqqhpgkapklviyeatkrpsgvsnrffasksgntasltisglqaedeadyyccsyagvrtvvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3411,NaN,NaN,NaN,QKY76706,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3412,NaN,NaN,NaN,QKY76705,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpgtfgpgtkvdik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3413,NaN,NaN,NaN,QKY76704,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3414,NaN,NaN,NaN,QKY76703,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppaltfgggtkveik,"Kreer,C. et al.; Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients; Cell (2020) In press; 2020.",10.1016/j.cell.2020.06.044,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3415,NaN,NaN,QKY76674,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3416,NaN,NaN,QKY76673,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3417,NaN,NaN,QKY76672,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3418,NaN,NaN,QKY76671,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3419,NaN,NaN,QKY76670,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3420,NaN,NaN,QKY76669,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3421,NaN,NaN,QKY76668,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3422,NaN,NaN,QKY76667,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3423,NaN,NaN,QKY76666,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3424,NaN,NaN,QKY76665,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfstywmtwvrqapgkglewvanikqdgsekyyvdsvkyrftisrdnaknslylqmnslraedtavyycarvgssswyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3425,NaN,NaN,QKY76664,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3426,NaN,NaN,QKY76663,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3427,NaN,NaN,QKY76662,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydmnwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarggiyylvrgfiigyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3428,NaN,NaN,QKY76661,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3429,NaN,NaN,QKY76660,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvagisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaradtmvrgtyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3430,NaN,NaN,QKY76659,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgskkdyadsvkgrftisrdnskntlylqmnslraedtavyycardqsqgayiltgyrgygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3431,NaN,NaN,QKY76658,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsdnigyadsvkgrftisrdiaknslylqmnslraedtalyycakgiyydifmplldwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3432,NaN,NaN,QKY76657,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3433,NaN,NaN,QKY76656,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaityyydssgywwddwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3434,NaN,NaN,QKY76655,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3435,NaN,NaN,QKY76654,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgaanyaqnfqgrvtitadeststgymqlsslrfedtavyycartshydssgsyfeywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3436,NaN,NaN,QKY76653,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3437,NaN,NaN,QKY76652,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscatsgftfssfalhwvrqapgkglewvtvisddgnnkyyvdsvkgrftisrdnskntlflqmnslrvedtaiyycarasynsnwsigeyfrdwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3438,NaN,NaN,QKY76651,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtvisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaksyngnyydafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3439,NaN,NaN,QKY76650,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigrvyiyssgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargaasfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3440,NaN,NaN,QKY76649,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissgsyywswirqpagkglewigriytsgsttynpslksrvtisvntsknqfslnlssvtaadtavyycarvggispyyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3441,NaN,NaN,QKY76648,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssydinwvrqatgqglewmgwvnpnsghtgyaqkfqgrvtmtrntsvstaymelsslrsedtavfycargrvgyvgsgsrgyyyyydmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3442,NaN,NaN,QKY76647,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiylsgttnynpsltsrvtisvdksknqfslklnsvtaadtaiyycarptagaggafdiwgqgtvvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3443,NaN,NaN,QKY76646,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfgsyviswvrqapgqglqwmggiipifgkpnyaqkfqgrvtitadeststaymelsslrsedtavyycargwfgellkgtywfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3444,NaN,NaN,QKY76645,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgssyyspslksrvtisadtsknqfslnlrsvtaadtavyycasgppymatfsyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3445,NaN,NaN,QKY76644,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3446,NaN,NaN,QKY76643,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdlvqpggslrltcaasgftfsshwmtwvrqapgkglewvanikedgrekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarvvvevatnkgihgvdyyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3447,NaN,NaN,QKY76642,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgynkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3448,NaN,NaN,QKY76641,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgttnyaqkfqgrvtitadeststayvelsslrsedtavyycarighfdssgyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3449,NaN,NaN,QKY76640,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscadsaftfssfwmswvrqapgkglewvanikqdgsekfyldsvkgrftisrdnaknslylqmnslraedtavyycarlgrsswnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3450,NaN,NaN,QKY76639,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstyamhwvrqapgkglewvavisydgdnkyyadsvkgrftisrdnskntlylemnslraedtavyycarprggsyqtcfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3451,NaN,NaN,QKY76638,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvtlisydggnkyyadsvkgrftisrdnskntlylqmnslraedaavyfcarghtgnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3452,NaN,NaN,QKY76637,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqleesgpglvkpsetlsltctvsggsisshywswirqppgkglewigyiqdsgstnynpslksrvtisvdtsknqfslrlssvttadtavyycvrgamawfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3453,NaN,NaN,QKY76636,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgfsfrnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3454,NaN,NaN,QKY76635,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgsyywswirqpagkglewigriftsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarggllwfggagnymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3455,NaN,NaN,QKY76634,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtamyycakdgsiaaadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3456,NaN,NaN,QKY76633,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3457,NaN,NaN,QKY76632,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydginkyyadavkgrftisrdnskntlylqmnslraedtavyycarprsgsyyayfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3458,NaN,NaN,QKY76631,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssfamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaayycarelmsvgwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3459,NaN,NaN,QKY76630,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygmhwvrqapgqrlewmgwinvgngntkysqrfqgrvtitrdtsastaymelsslrsedtavyycamgpsafswldpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3460,NaN,NaN,QKY76629,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmtwvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslslqmnslrvedtavyycvrlgvsswyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3461,NaN,NaN,QKY76628,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3462,NaN,NaN,QKY76627,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltcavsgasissgsyywswirqpagkglewigriytsgntnynpslksrvtisvdtsknqfslklssvtaadtavyycatgyigtyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3463,NaN,NaN,QKY76626,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcvvsggsisssnwgwvrqppgkglewigeiyhsgttnynpslrsrvtisvdksknqlslklnsvtaadtaiyycarptagaggafdtwgqgtmvtvsa,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3464,NaN,NaN,QKY76625,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3465,NaN,NaN,QKY76624,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvasgftfsfywmswvrqapgkglewvanikqdggekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlsgsswdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3466,NaN,NaN,QKY76623,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3467,NaN,NaN,QKY76622,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfilsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3468,NaN,NaN,QKY76621,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnpkntlylqmnslraedtavyycardtatyvllwsgdfnldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3469,NaN,NaN,QKY76620,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrhamhwvrqapgkglewvavisydgsnkyyadsvkgrfaisrdnskntlylqmnslrpedtavyycardpsplvlitsidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3470,NaN,NaN,QKY76619,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsiywmswvrqapgkglqwvanikqdasekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarlggsswhfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3471,NaN,NaN,QKY76618,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyyailwfrqapgkglewvaiisydgsnkyyadsvkgrftisrdnskntlylqmnslrpedtavyycarpqsggyyapldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3472,NaN,NaN,QKY76617,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqvvqsgaevkkpgasvkvsckasgytfknygiswvrqapgqglewmgwisaytgntnyaqkfqgrmtmttdtstgtgymelrslrsddtavyycarvqrrrldywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3473,NaN,NaN,QKY76616,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikedgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardvggysgydlgfdyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3474,NaN,NaN,QKY76615,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvelvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqggnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3475,NaN,NaN,QKY76614,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3476,NaN,NaN,QKY76613,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamywvrqapgkglewvavisydginkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvnsgsyysyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3477,NaN,NaN,QKY76612,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgsalkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycargrsyglslgywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3478,NaN,NaN,QKY76611,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqdftgrfvfsldtsvstaylqisslkaedtavyycarglvgridpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3479,NaN,NaN,QKY76610,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3480,NaN,NaN,QKY76609,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigtiyysgstyynpslksrvtisvdtskkqfslklssvtaadtavyycageevrgvklyyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3481,NaN,NaN,QKY76608,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3482,NaN,NaN,QKY76607,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgttnyaqklqgrvtisadeststaymevsslrsedtavyycarvsgygdygaysdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3483,NaN,NaN,QKY76606,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3484,NaN,NaN,QKY76605,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmsslraedtavfycargdgdvynfllvrnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3485,NaN,NaN,QKY76604,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevrkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipvfgtanyaqkfqgrvtitadkststafmelnslrsedtavyycarigsypeyfqhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3486,NaN,NaN,QKY76603,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsfisgtgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdqarvqdyiwgsyrsygmdvwglgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3487,NaN,NaN,QKY76602,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsyypmhwlwvrqapgkglewvavtsydgtnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarggatnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3488,NaN,NaN,QKY76601,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnyamhwvrqapgkgldwvavisydgsnryyaasvkgrftisrdnskntlylqmnslrtedtavyfcargdgyrsqfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3489,NaN,NaN,QKY76600,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfttygiswvrqapgqglewmgwisayngnsnygkkfqgrvtmtadtststaymelrslrsddtavyycardlpikvvvpaadynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3490,NaN,NaN,QKY76599,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyalfwvrqapgkglewvavisydgnnkyyadsvrgrftisrdnskntlylqmnslrpedtavyycarpytgsyksymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3491,NaN,NaN,QKY76598,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3492,NaN,NaN,QKY76597,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqlvesggglvqpgrslrlscaasgftfddsamhwvrqapgkglewvsgiswnsgnvgyadsvkgrftisrdnaknslylqmnslraedtalyyctkasrycssticywnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3493,NaN,NaN,QKY76596,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaylqisslkaedtavyycararllgycsstscytigwgafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3494,NaN,NaN,QKY76595,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglawvalisydgynkyyadsvrgrftisrinskntlslqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3495,NaN,NaN,QKY76594,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisgdennkfyansvkgrftisrdnskntlslqmnslrpedtaryycakggdssgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3496,NaN,NaN,QKY76593,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyfvdsvkgrftisrdnaknslylqmnslraedaavyycarlvttvttanglyyysyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3497,NaN,NaN,QKY76592,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarestqwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3498,NaN,NaN,QKY76591,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfafsnyaihwvrqapgkglewvavisydgnnkdyadsvkgrftisrdnskntlylqmnslraedtavyycarvpvmvrgvyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3499,NaN,NaN,QKY76590,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdltivvipaapnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3500,NaN,NaN,QKY76589,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlsctasgfifgdyamgwvrqapgkglewvgfirgkaydgtteyaasvkgrftisrddskyiahlqmnslktedtavyycirdydfwggyyyhplrafdiwgrgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3501,NaN,NaN,QKY76588,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavissdgsnkyyagsvkgrftisrdnskntlylqmnslraedtavyycakdmveplfshyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3502,NaN,NaN,QKY76587,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgtyywswirqpagkglewigrfytsgstnynpslksrvtisvdasknqfslklssvtaadtavyycararpdyyyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3503,NaN,NaN,QKY76586,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvqvsceasgytfttyymhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtststvymdlsslrsedtavyycardrlgdgsylgggyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3504,NaN,NaN,QKY76585,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3505,NaN,NaN,QKY76584,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggavqpgrslrlscaasgftfstyamywvrqapgkglewvavisydgsnryyadsvkgrftisrdnskntlylqmnslrpedtavyycardrsgnyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3506,NaN,NaN,QKY76583,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsvyyigstyynpslksrvtmsvdtsknqfslklssvtaadtavyycarapfqlldkyyffyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3507,NaN,NaN,QKY76582,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3508,NaN,NaN,QKY76581,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydeinkyyadsvkgrftisrdnskttldlqmnslraedtavyycaragggsyrgpfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3509,NaN,NaN,QKY76580,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisydgtnkyyadsvkgrftisrdnskntlylqmnslraddtavyycakgrgnyltffdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3510,NaN,NaN,QKY76579,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsfyaihwvrqapgqglewaaaissdgtykyyadsvkgrftisrdnskntsylqmnslraedtavyycaralnkgfdpwgqgtlltvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3511,NaN,NaN,QKY76578,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvsp,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3512,NaN,NaN,QKY76577,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3513,NaN,NaN,QKY76576,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggrlvlpggslrlscaasgftfsvyemnwvrqapgkglewlsyigtsgspiyyadsvkgrftvsrdnaknslylqmnslrvedtalyycardrgwnygldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3514,NaN,NaN,QKY76575,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3515,NaN,NaN,QKY76574,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarpdyssgwfsywyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3516,NaN,NaN,QKY76573,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3517,NaN,NaN,QKY76572,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvsgnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnspraedtavyycardpsayydiltgysgdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3518,NaN,NaN,QKY76571,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysagstyyadsvkgrfsisrdkskntlylqmnslraedtavyycakeggsgslryyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3519,NaN,NaN,QKY76570,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftshwigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycasalrergvqlwsvwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3520,NaN,NaN,QKY76569,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgpplvepkqtltltctfsgfslttsgeavgwirqppgkalewlaliywdddkhyspslrnrltitrdtsknqvvltltnvdpadtgtyycahravilnfdhwgqgflvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3521,NaN,NaN,QKY76568,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrvscaasgftfsshgmhwvrqapgkglewvsviwydgsnkyyadsvkgrftisrdnskntlslqmnslraedtavyycaresadissrldywgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3522,NaN,NaN,QKY76567,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsppasyynpstgyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3523,NaN,NaN,QKY76566,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftrhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycvreygsghplpiwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3524,NaN,NaN,QKY76565,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfsdywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarltfggsgsyyfyyngmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3525,NaN,NaN,QKY76564,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyviswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardqgptyyygsgsphygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3526,NaN,NaN,QKY76563,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnaknslylqmnslraedtavyycargsagnyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3527,NaN,NaN,QKY76562,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgrnkyyadsvkgrftisrdnskntlylqmsslraedtavyycakegewelrgnaldiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3528,NaN,NaN,QKY76561,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctvsgfslstsgvgvgcirqppgkalewlaliywdddkryspslksrltitrdtsknqvvltmtnmdpvdtgtyfcvhrhvsgafdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3529,NaN,NaN,QKY76560,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfifstygmhwvrqapgkglewvavisydgsnkynadsvkgrftisrdnskntlylqmnslrvedtavyycaiygyyyygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3530,NaN,NaN,QKY76559,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknhfslkmnsvtaadtavyycarcrqmgnfyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3531,NaN,NaN,QKY76558,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qgqlvqsggdvvqpgkslrlscaasgftftnyamhwvrqapgkglewvavisndgsnekyvdsvkgrfslsrdnskntvyldmhslrpedtaiyycardrsnlerlvmtfggiiagafdiwgqgarvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3532,NaN,NaN,QKY76557,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitfkesgptlvkptetltltctfsgfsvstsgegvgwirqppgkalewlaviywdddkryspslksrltitrdtsknqvvltmtnmdpvdtatyycahrlwfrdafdiwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3533,NaN,NaN,QKY76556,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfsdyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarglislfrgaifhyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3534,NaN,NaN,QKY76555,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgrikgktdggttdyaapvkgrftiskddskntlylqmsslntedtavywcttltyyydssaylndafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3535,NaN,NaN,QKY76554,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsisssnyywgwirqppgkglewigtihysgisyynpslksrvtisvdtsnnkfslelssvtaadtavyfcarrtyydlwsaysstayycmdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3536,NaN,NaN,QKY76553,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisndgrnkyyadsvkgrltisrdnskntlylqmnslraedtavyycarpsnwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3537,NaN,NaN,QKY76552,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstkynpslksrvtisvdtsknqfslklssvtaadtavyycardggnayssgwyryyyhmdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3538,NaN,NaN,QKY76551,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfhnyaiswvrqapgqglewmggfipilgttnyaqkfqgrvtitadeststaymelsslrsedtavyycarvegegvdsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3539,NaN,NaN,QKY76550,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqiqqwgagvlkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstkynpslksrvtisvdtsknqfslklssvtaadtavyycargppvttffvfsllfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3540,NaN,NaN,QKY76549,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgkslrlscaasgftfssygmhwvrqapgkglewvaviwydgnnkfyvdsvkgrftisrdnskntlymemnslraedtavyycarkgplwrfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3541,NaN,NaN,QKY76548,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapdkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqwpnqafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3542,NaN,NaN,QKY76547,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadkststaylqwsslkasdtamyycarrgeaagiwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3543,NaN,NaN,QKY76546,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckaseytftsyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycarpgkaaafdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3544,NaN,NaN,QKY76545,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaregqgtyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3545,NaN,NaN,QKY76544,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavvsydgsnkyytdsvkgrftisrdnskntlflqmiglreedtavyycaqgrggyyspfddwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3546,NaN,NaN,QKY76543,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslntngvavgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrrgiltedafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3547,NaN,NaN,QKY76542,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvaviwydgnkkycadsvkgrctisrdnskntlylqmnslraedtavyycaregpfgdreasgafdvwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3548,NaN,NaN,QKY76541,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstyyadsvkgrftisgdnskntlylqmnslrvddtavyycardpgsrysggwydyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3549,NaN,NaN,QKY76540,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssnywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardprvvvtarmynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3550,NaN,NaN,QKY76539,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwtwvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycasrwgdyfdssgaydswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3551,NaN,NaN,QKY76538,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssylmhwvrqapgkglewvaviwangnryyadsvkgrftisrdiskntlylqmnslraedtamyycardycngvtcnsnywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3552,NaN,NaN,QKY76537,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttatvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3553,NaN,NaN,QKY76536,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgsgsyygwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3554,NaN,NaN,QKY76535,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlacaasgftfssygmhwvrqapgkglewvavisydgnnkyyadslkgrftisrddskntlylqmnslraedtavyycakdrtavflffglgdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3555,NaN,NaN,QKY76534,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwfdgsnkhyadsvkgrftisrdnskntlylqmnslraedtavyycaregdfwsgyytgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3556,NaN,NaN,QKY76533,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydggnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3557,NaN,NaN,QKY76532,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnswigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtaiyycathrcsggfcylaywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3558,NaN,NaN,QKY76531,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3559,NaN,NaN,QKY76530,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycaradpyqllgqhyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3560,NaN,NaN,QKY76529,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtalyycarearyfdwifegsdyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3561,NaN,NaN,QKY76528,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3562,NaN,NaN,QKY76527,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklnsvtaadtavyycasrwgdyfdssgaydswgqgtlltvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3563,NaN,NaN,QKY76526,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvadisydgsekyyadsvkgrftiyrdnskntlylqmnslraedtavyycakdfggdntamveyffdfwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3564,NaN,NaN,QKY76525,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3565,NaN,NaN,QKY76524,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiayadsvkgrftisrdnaknslylqmnslraedtalyfcakvgwelsidafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3566,NaN,NaN,QKY76523,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviyydgsnkyyadsvkgrftisrdnskntlylqihslraedtavyycaregqmaattgidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3567,NaN,NaN,QKY76522,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavisndefnkfyansvkgrftisrdnskntvylqlnslrtedtaryycakggdgsgwawdgdnpptdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3568,NaN,NaN,QKY76521,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evalvesggglvkpggslrlscaasgfifsnawmtwvrqapgkglewvgrikskseggtpeyaapvkgrfiisrddstnslhlqmnylriedtavyycttggyssyaasdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3569,NaN,NaN,QKY76520,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarstsgsyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3570,NaN,NaN,QKY76519,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftfddygmswvrqapgkglewvsainwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcarrrsssryssgwymyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3571,NaN,NaN,QKY76518,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahnrfqycssttcytllpfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3572,NaN,NaN,QKY76517,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycvrdlalfevviqqgvwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3573,NaN,NaN,QKY76516,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrrggigieygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3574,NaN,NaN,QKY76515,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscavsgftfssywmhwvrqapgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylqmnslraedtavyycareveqlahmvdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3575,NaN,NaN,QKY76514,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtgdtststvymelsslrsedtavyycardlagvpaalgcwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3576,NaN,NaN,QKY76513,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3577,NaN,NaN,QKY76512,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysfptywigwvrqmpgkglewmgiiypgdsdtrygpsfqgqvtisadksistaylqwsslkasdtamyycarrdtdfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3578,NaN,NaN,QKY76511,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evrllesggglvqpggslrlscaasgftfsdyamnwvrqapgkglewvsaisatggstfyadsvkgrfsisrdnsknslvlqmnslraedtavyycakpygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3579,NaN,NaN,QKY76510,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygihwvrqapgqglewvagiwydgsnkyyvdsvkgrftisrdnskntlylqmnslraedtavyycagssgegglyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3580,NaN,NaN,QKY76509,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfdsygvhwvrqapgkglewvavisydgsnkhyadsvkgrftisrdnskntlyvqmnslrtedtavyycardsggnygdsyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3581,NaN,NaN,QKY76508,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytfttyamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvntaflhigslkaedtavyycardqdsgyptyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3582,NaN,NaN,QKY76507,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsyamswvrqapgkglewvsgisisggstyyaasvkgrftisrdnskntlylqmnslraedtavyycakdsrsgiagvdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3583,NaN,NaN,QKY76506,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3584,NaN,NaN,QKY76505,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3585,NaN,NaN,QKY76504,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3586,NaN,NaN,QKY76503,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisvdksknqfslklssvtaadtavyycargwyfdywgqgtlvtvsa,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3587,NaN,NaN,QKY76502,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggslssyywswirqppgkglewigyiydsggasrstnynpslksrvtisvdtsrnqlslklssvtaadtavyycardqrqfqllgrfgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3588,NaN,NaN,QKY76501,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewigeinhsgssnynpslksrvtisvdtsknqfslklssvtaadtavyycargwgwgavagraeyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3589,NaN,NaN,QKY76500,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3590,NaN,NaN,QKY76499,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslkltsvtaadtavyycareandsgsfyngpfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3591,NaN,NaN,QKY76498,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3592,NaN,NaN,QKY76497,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evrllesggglvqpggslrlscaasgftftsyamswvrqapgkglqwvstisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdpasgivgpthfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3593,NaN,NaN,QKY76496,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaavkkpgssvkvsckasggtfssyaiswvrqapgqglewmggivpifgtanyaqkfqgrvtitadestttaymelnslrsedtavyycaredyygsgslvdpyyyyrmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3594,NaN,NaN,QKY76495,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmnwvrqapgkglewvaninqdggekyyvdsvrgrftisrdnaknslylqmnslraedtavyycardpydlygdyggtfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3595,NaN,NaN,QKY76494,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3596,NaN,NaN,QKY76493,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissgtyycgwirqppgkglewigstyyggstlynpslrgrvtisvdtsknqfslklssvtaadtavyycarrgnyydsknwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3597,NaN,NaN,QKY76492,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3598,NaN,NaN,QKY76491,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsyamnwvrqapgkglewvsaisvsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdfgsgivgatgfdfwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3599,NaN,NaN,QKY76490,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftftsygmswvrqapgkglewvsaisisggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakllgsgitldndafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3600,NaN,NaN,QKY76489,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsfyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyscaslwfgdlysfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3601,NaN,NaN,QKY76488,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3602,NaN,NaN,QKY76487,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifsgdeksystslksrltiskdtsksqvvltmtnmdpldtatyycarttwgtwiqawyfdiwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3603,NaN,NaN,QKY76486,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3604,NaN,NaN,QKY76485,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggpisssryywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklnsvtaadtavyycarhdgsgemdtitwgpiyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3605,NaN,NaN,QKY76484,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlsctasgftfssyamhwvrqapgkglewvalisydgnnkyyadsakgrftisrdnskntlylqmnslrsedtavyycardlgrgldpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3606,NaN,NaN,QKY76483,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsirsssyywgwirqppgkglewiasiyysgstyynsslksrvtisvdtsknqfslkvnsmtaadtavyycailwrgsswadrhyyyysmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3607,NaN,NaN,QKY76482,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllqsggglvqpggslrlscaasgftfrnyamswvrqapgkglewvsaisgsggttyyadsvkgrftisrdnskntlylqmnslraedtavyycakneritmlvvvtlfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3608,NaN,NaN,QKY76481,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3609,NaN,NaN,QKY76480,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvhpggslrlscaasgftfssyalswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnrlraedtavyycaqmgplgstssaadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3610,NaN,NaN,QKY76479,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsinsgnyywswirqpagkglewigrmftsgstnynpsltsrvtmsidtsknqfslnlnsvtaadtamyycarghvaawescyywgqgilvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3611,NaN,NaN,QKY76478,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltcavsgfslsnakmgvswirqppgkalewlahifsndekaystslktrltiskdtsksqvvltvtnmdpvdtatyycarivlgasgtypspgfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3612,NaN,NaN,QKY76477,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsghywswirqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarppqaarihyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3613,NaN,NaN,QKY76476,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdmsknqfslklrsvtaadtavyycaraprerlqwgeyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3614,NaN,NaN,QKY76475,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwlqlrsdyyyfgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3615,NaN,NaN,QKY76474,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisnsnsfiyyadsmkgrftisrdnaknslylqmnslraedtavyycarvngnsnwnfgsyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3616,NaN,NaN,QKY76473,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslrvedtavyycardqewfrelflfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3617,NaN,NaN,QKY76472,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqqfqgrvtmtedtstdtaymelsslksedtalyycatgfavfgraavpywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3618,NaN,NaN,QKY76471,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyemnwvrqapgkglewvsyisssgsaiyyadsvkgrftisrdnaknslylqmnslrvedtavyycarearsryfdwlpsyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3619,NaN,NaN,QKY76470,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmiglraedtavyycardwaptyydmpsafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3620,NaN,NaN,QKY76469,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlsceasgftfssseinwvrqapgkglewvshisssgsiiyyadsvkgrftisrdnaknslylqmnslraedtavyycarrsyrsswyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3621,NaN,NaN,QKY76468,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedgetvyaqkfqgrvtmtedtssdtaymelsslrsedtavyycatsfpirgdpsyyyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3622,NaN,NaN,QKY76467,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytlielsihwvrqapgkglewmggfdpedvetiyaqkfqgrvtmtedtstdtaymelssltsedravyycatqpaaiggtppyywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3623,NaN,NaN,QKY76466,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsihwvrqapgkglewmggfdpedaetiyaqnfqgrvtmtedtstdtaymelsslrsedtalyycaaapavmtagwfdpwgqgtlvsvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3624,NaN,NaN,QKY76465,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3625,NaN,NaN,QKY76464,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3626,NaN,NaN,QKY76463,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3627,NaN,NaN,QKY76462,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvawirqppgkalewlaliywdddkryspslksrltitkdtsknqvvltmtnmdpvdtatyycahrlptpqllpsfenwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3628,NaN,NaN,QKY76461,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgseltkpgasvkvsckasgytftsyamnwvrqapgqglewmgwintdtgnptyaqgftgrfvfsldtsvstaylqisslkaedtavyycardpsycsstrcytvgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3629,NaN,NaN,QKY76460,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslntsgvgvgwirqppgkalewlaliywdddkrynpslksrltitkdtsknqvvltmtnmdpvdtatyycahrppsyhgwcyfdywgqgnlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3630,NaN,NaN,QKY76459,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfstygmhwvrqapgkglewvavilydgsnryyadsvkgrftisrdnskntlylqmnslraedtavyycakqgglycsgtncwggyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3631,NaN,NaN,QKY76458,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsrygmhwvrqapgkglewvgiisydasdktyaesvkgrftisrdnskntlylqmnslraedtavyycakvsatyyyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3632,NaN,NaN,QKY76457,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywvgwvrqmpgkglewmgiiypgdsdtrdspsfqgqvtisadksistaylqwsslkasdtamyycarlgseskidyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3633,NaN,NaN,QKY76456,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglecvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpirdgvwglnendywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3634,NaN,NaN,QKY76455,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftshymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtsdtststvymelsslrsedtamyycardvfwvpaassfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3635,NaN,NaN,QKY76454,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstkrvgvgwirqppgkalewlaliywdddqryspslksrltitkdtsknqvvltmtnmdpvdtatyycahsgppdlspvlsqgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3636,NaN,NaN,QKY76453,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgitiyyadsvkgrftisrdnaknslylqmnslraedtavyyctgvvaapaeyfqhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3637,NaN,NaN,QKY76452,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyfwswirqhpgkglewigsiyysgstyynpslrsritisvdtsknqfslklssvtaadtavyycarggsgsyslfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3638,NaN,NaN,QKY76451,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywnwlrqppgkglewigeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarvggyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3639,NaN,NaN,QKY76450,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevktpgasvkvsckasgytftsydinwvrqatgqgpewmgwmnpnsgntgyahkfqgrvtmtrntsistaymelsslrsedtavyycargpsiltgfynpldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3640,NaN,NaN,QKY76449,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3641,NaN,NaN,QKY76448,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytftsydinwvrqatgqglewmgwmnpnsghtgyaqkfqgrvtmtrntsistaymelsslryedtavyycargygltyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3642,NaN,NaN,QKY76447,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3643,NaN,NaN,QKY76446,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfssyylhwvrqapgqglqwmgisnpsggsttyaqkfqgrvtmtgdtststvymelsslrsedtavyycargglvpaarnafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3644,NaN,NaN,QKY76445,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiqpgdsdtryspsfqgqvtmsadkststaylqwsslkasdtamyycardliiestiaarpgyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3645,NaN,NaN,QKY76444,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvstigtagdtyypdsvkgrftisrenaknslflqmnslragdtavyycarvdfdiltgyysnwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3646,NaN,NaN,QKY76443,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvrlvqsgaevkkpgssvkvsckasggtfsdyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeftitaymelsslrsedtavyycarlsgsgwlgyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3647,NaN,NaN,QKY76442,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3648,NaN,NaN,QKY76441,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvalisydgrneyyadsvkgrftisrdnskntlylqmnslragdsavyycardlayhpyrdygdddyyyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3649,NaN,NaN,QKY76440,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3650,NaN,NaN,QKY76439,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyfadsvkgrftisrdnskntlylqmnslraedtavyycardqgtvvthfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3651,NaN,NaN,QKY76438,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhggstdynpslksrvtisvdksknqfslkltsvtaadtavyycarvdhvnvrdywgpgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3652,NaN,NaN,QKY76437,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscvasgftfssygmhwvrqapgkglewvavisfdgsnkyyadsvkgrftisrdnskntlylqmnslraedtavfycakdlppyasgwyeggfdywgrgtqvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3653,NaN,NaN,QKY76436,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3654,NaN,NaN,QKY76435,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3655,NaN,NaN,QKY76434,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3656,NaN,NaN,QKY76433,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqlvesggglvqpggslrlsceasgfifssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarvndgrpnpleyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3657,NaN,NaN,QKY76432,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqsggslrlscaasgftfstygmhwvrqapgkglewvaiisydginkyyadsvkgrftisrdnskntvylqmnslrtedtamyycakgdgsylmdyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3658,NaN,NaN,QKY76431,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycargltgssaykdeiyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3659,NaN,NaN,QKY76430,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesggglvqpggslrlscaasgftfnnyamswvrqapgkglewvsaiggsggstyyadsvkgrftvsrdnsentlylqmsslraedtavyycarvegdwllggpyyhyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3660,NaN,NaN,QKY76429,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlkesgpvlvkptetltltctvsgfslsnarmgvswirqppgkalewlahifwndensystslktrltiskdtsksqvvlnmtnmdpvdtatyycartewllsdnwfdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3661,NaN,NaN,QKY76428,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfrrygmywvrqapgkglewvavisydgtdkyytdsvkgrftisrdnskntlylqmnslraedtavyycakkggpycgggncyagyfdywgqgilvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3662,NaN,NaN,QKY76427,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypdsvkgrftisrenaknslylqmnslragdtavyycarggdsgydlgawyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3663,NaN,NaN,QKY76426,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3664,NaN,NaN,QKY76425,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgnglewigsiyysgstyynpslkgrvsisvdtsknqfslklssvtaadtavyycarilviftlnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3665,NaN,NaN,QKY76424,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfrsydmhwvrqvtgkglewvstigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarvfetkvirggryyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3666,NaN,NaN,QKY76423,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyymhwvrqapgqglewmgilnpgagstsyaqkfqgrvtmtsdtstntvymqlsslksedtavyycardqqivphadgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3667,NaN,NaN,QKY76422,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamnwvrqppgkglewvsgiswnsdsigyadsvkgrftisrdnaknslylqmnslraedtamyycakgrgagytsymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3668,NaN,NaN,QKY76421,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvssitsllgyyfdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3669,NaN,NaN,QKY76420,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3670,NaN,NaN,QKY76419,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsssdlhwvrqatgkglewvsaigtagdtyylgsvkgrftisrengknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3671,NaN,NaN,QKY76418,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfddyamhwvrqapgkglewvslisgdggntyyadsvkgrftisrdnsknslylqmnslrtedtalyycakdemayppshhyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3672,NaN,NaN,QKY76417,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyylhwvrqapgqglewmgiinpsggsttyaqkfqgrvtmtrdtstsavymelrslrsedtavyycarendygdyveprdyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3673,NaN,NaN,QKY76416,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3674,NaN,NaN,QKY76415,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyisysgstyynpslksrltisvdtsknqfslklssvtaadtavyycardlgdgynlrvpayfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3675,NaN,NaN,QKY76414,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3676,NaN,NaN,QKY76413,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdlvkpgrslrlscsasgftfgdytmswfrqapgkglewvafirskayggtteyaasvigrftisrddsksiaylqmnslksedtavyycsrvrgsfygsvgknygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3677,NaN,NaN,QKY76412,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3678,NaN,NaN,QKY76411,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktaggtsssyaiswvrqapgqglewmgriipilgvaiyaqkfqgrvtitadkststaymelnslrsedtavyyctttqggdygdnlyyldywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3679,NaN,NaN,QKY76410,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3680,NaN,NaN,QKY76409,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgilvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3681,NaN,NaN,QKY76408,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3682,NaN,NaN,QKY76407,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqvvesggglvqpgrslrlscaasgftfedyamhwvrqapgkglewvsgvswnsgiigyadsvkgrftisrdnaknslylqmnslraedtalyycakldvggydfvsghyyafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3683,NaN,NaN,QKY76406,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsnygmhwvrqapgkglewvavmsydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaknlgpycsggtcyslvgdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3684,NaN,NaN,QKY76405,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsdyamhwvrqapgkglewvadisfdgsnkyyadsvkgrftisrdssentlylqmdslraddtavyycardlsttwylemwgpdafdiwgqgtvvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3685,NaN,NaN,QKY76404,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmhwvrqvpgkglvwvsrinsdgsstsyadsvkgrftisrdnakntlylemnslraqdtavyycagspwlrgdidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3686,NaN,NaN,QKY76403,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvhlvqsgaevkkpgasvklsckasgytftnyllhwvrqapgqglewmgnvnpsrgtatypqklddrvtmtsdksastiymelsglrsedtaiyycarersgtyffdywgqgtlltvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3687,NaN,NaN,QKY76402,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkrpgasmnisckasgynfnnnyiywvrqapgqglewmgvvnptgggtayaqgfqdrvtitsdtprntvylgvtglhsedtavyfcarggewrivpggrdyfdywgqgtlvtvsa,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3688,NaN,NaN,QKY76401,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3689,NaN,NaN,QKY76400,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3690,NaN,NaN,QKY76399,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3691,NaN,NaN,QKY76398,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3692,NaN,NaN,QKY76397,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3693,NaN,NaN,QKY76396,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3694,NaN,NaN,QKY76395,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissrsstikyadsvkgrftisrdnaknslylqmnslrdedtavyycarvdyygsgsvywyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3695,NaN,NaN,QKY76394,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3696,NaN,NaN,QKY76393,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyaesvkgrftisrdnskntlylqmnslraedtavyycardlhqdwvvvvaanvygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3697,NaN,NaN,QKY76392,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3698,NaN,NaN,QKY76391,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsagstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargtlipahrgafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3699,NaN,NaN,QKY76390,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrsltlscaasgftfddytmhwvrqapgkglewvsgidwnggtigyadsvkgrftisrdnaknslylqmnslraedtalyycakagyyayvwgsyrfeyfdnwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3700,NaN,NaN,QKY76389,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3701,NaN,NaN,QKY76388,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsglcvswirqppgkalewlaridwdddkyyntslrtrltiskdtsknqvvltmtnmdpvdtatyycarattffygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3702,NaN,NaN,QKY76387,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqvvesggglvqpgrslrlscvssgfifddyvmhwvrqrpgkglewvagitynggilgygdsvkgrfiiardnvrgflslqmgdlrtedtalyycardycssttcpaetyyymdvwgkgtavtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3703,NaN,NaN,QKY76386,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggdliqpggslrlscaasgltvssnymswvrqapgkglewvsiiysggstyyadsvkgrfsisrdnsnntlylqmnslraedtavyfcarhipawgykwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3704,NaN,NaN,QKY76385,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarddnspqgsgwyfyyyyamdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3705,NaN,NaN,QKY76384,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqvvqsgpglvkpsetlsltctvsgdpvintnyywgwirqppgkglewigtlsysggthynpslssrvtiavdsskkrfsltlrsvtaadtaiyycarhpvdgynygysdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3706,NaN,NaN,QKY76383,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3707,NaN,NaN,QKY76382,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3708,NaN,NaN,QKY76381,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsvssgsyywswirqppgkglecigyiyysgssnynpslksrvtisvdtsknqfslkmssvtaadtavyycagspvpptivgasywgqgtlvtdss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3709,NaN,NaN,QKY76380,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqagaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycargaavpaagefdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3710,NaN,NaN,QKY76379,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytftgyvvhwvrqapgqdlewmgwintgygntkysqkfqgrvtiswdtsattaymelsnlksedkavyycasmtrmseqtyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3711,NaN,NaN,QKY76378,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3712,NaN,NaN,QKY76377,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3713,NaN,NaN,QKY76376,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissgryywswirqhpgkglewigfvyysgstyynpslksrvtisvdtsknqfslrlssvtaadtavyycaretysayemppyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3714,NaN,NaN,QKY76375,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgdtfttyyihwvrqapgqglewmgiinpsggsrsyaqkfqgrismtsdtststvymelsslrsedtavyycargygfvpnvlyyfdywgqgtlvtvst,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3715,NaN,NaN,QKY76374,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkrpgssvkvsckasggtfssytiswvrqapgqglewmgriipilavanyaqkfqgrvtitadkststaymelsslrsedtavyycardhsgyydstslmspffdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3716,NaN,NaN,QKY76373,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlpltctvsggsissssyywgwirqppgkglqwigniyysgstyynsslksrvtisvdtsknqfslklssvtaadtavyycarqsrgysyawsfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3717,NaN,NaN,QKY76372,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3718,NaN,NaN,QKY76371,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmspnsgntgyaqkfqgrvtmtrdtsistaymelnslrsedtavyycarmrsgwpthgrpddhwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3719,NaN,NaN,QKY76370,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgeslrlscaasgitvssnymswvrqapgkglewvsviysggstfyadsvkgrfiisrhnskntlylqmnslraedtavyycardlnehgldvwgqgttvsvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3720,NaN,NaN,QKY76369,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltcsvsggsirsyfwnwvrqppgkglewigyiyysgstnykpsfksrvtisldtsknqislklssvtaadtavyycaratwlrdafgiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3721,NaN,NaN,QKY76368,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscvaseftfssywmswfrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslktedtavyycasvitfggvivrsywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3722,NaN,NaN,QKY76367,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqvslklssvtaadtavyycarfrrsygsgsyynisfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3723,NaN,NaN,QKY76366,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3724,NaN,NaN,QKY76365,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgityynpslksrvtisvdtsknqfslklssvtaadtavyycarhqrycsssschvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3725,NaN,NaN,QKY76364,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvscqasgytftsydinwvrqatgqglewmgwmksnsgntgyaqkfqgrvtmtrntsistaymeltslrsedtavyycarmrsgwpthgrpddlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3726,NaN,NaN,QKY76363,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3727,NaN,NaN,QKY76362,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmcvswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtatyycariqyqlngmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3728,NaN,NaN,QKY76361,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3729,NaN,NaN,QKY76360,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3730,NaN,NaN,QKY76359,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),eaqllesggalvqpggslrlscaasgftfsccamgwvrqapgrglewvssihddgvgtfyavsvkgrfsisrdnskntvylqmnglraedtgvyycakwagpivmkyylqywgqgalvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3731,NaN,NaN,QKY76358,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgfsvstnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardyrdwiwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3732,NaN,NaN,QKY76357,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycasaklvatisyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3733,NaN,NaN,QKY76356,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgnagygqkfqgrvtmtrntsistaymelsslrsedtavyycarmrsgwpthgrpddywgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3734,NaN,NaN,QKY76355,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakvgytisrqwlvgefdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3735,NaN,NaN,QKY76354,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftnywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycartptlynwfhpwgqgtpvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3736,NaN,NaN,QKY76353,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3737,NaN,NaN,QKY76352,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvrvsckapgytfttyyihwvrqapgqglewmgiinpsagsttyaqkfqgrvtmtrdtststvymelsslrsedtavyycargfhvpaalrnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3738,NaN,NaN,QKY76351,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgtigyadsvkgrfiisrdnaknslylqmnslrpedtalyycakdiirqgedgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3739,NaN,NaN,QKY76350,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3740,NaN,NaN,QKY76349,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3741,NaN,NaN,QKY76348,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnpnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrsgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3742,NaN,NaN,QKY76347,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpgggsttyaqkfqgrvtmtsdtststvymelsslrsedtamyycargaippnsraeidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3743,NaN,NaN,QKY76346,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3744,NaN,NaN,QKY76345,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3745,NaN,NaN,QKY76344,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgselkkpgasvkvsckasgytftshtmnwvrqapgqglewmgwintntgnpmyaqgftgrfvfsldtsgstaylqisslkaedtavyycarwgpdygdyasndywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3746,NaN,NaN,QKY76343,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3747,NaN,NaN,QKY76342,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalissdggnkfyadsvkgrftisrdnskntlylqmnslraedtavyycardvpttvtaftvftywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3748,NaN,NaN,QKY76341,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqatgkglewvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycararggynwnfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3749,NaN,NaN,QKY76340,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtlsltctfsgfslgtsgmcvswirqppgkalewlaridwdddkyystslktrltiskdtsknqvvltmtnmdpvdtatyycargvvtydywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3750,NaN,NaN,QKY76339,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdttynpsfqgqvtisadkslttaflhwsslkasdtaiyycarrfygpssfdywgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3751,NaN,NaN,QKY76338,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfsfssyvmnwvrqapgkglewvavisydgsskyyadsvkgrftisrdnskntlylqmnslraedtavyycardidsgydptpvfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3752,NaN,NaN,QKY76337,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssysitwvrqapgqglewmgriipvlgianyaqkfqdrvtitadkststaymelsslrsedtavyycarvgvsgfksgsnwyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3753,NaN,NaN,QKY76336,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvscisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycardpvwvdgellsggipfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3754,NaN,NaN,QKY76335,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasgdtfssytinwvrqapgqglewmgriipilgipnyaqkfqgrvtitadkststafmelsslrsedtavyycargrgysnygasyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3755,NaN,NaN,QKY76334,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),nvqlvesggglvqpggslrlscaasgftfhhyamhwvrqapgkglewvsgisgssdyrayadslkgrftisrdyaknslwlqmnsltsedtafyycakgvdyggklayfdswgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3756,NaN,NaN,QKY76333,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlresgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavfycarmsrgynyaytfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3757,NaN,NaN,QKY76332,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3758,NaN,NaN,QKY76331,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsayywswirqppgkglewigeinhsgstnynpslrsrvtisvdtsknqfslklssvtaadtavyycarvgysqgyyyyymdvwgkgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3759,NaN,NaN,QKY76330,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3760,NaN,NaN,QKY76329,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsiaytdsvkgrftisrdnaknslylqmnslraedtalyycakahstghqyyygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3761,NaN,NaN,QKY76328,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3762,NaN,NaN,QKY76327,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydlhwvrqgtgkrlewvsaigtagdtyylgsvkgrftisrenaknslylqmnslragdtavyycarvlydssgfynwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3763,NaN,NaN,QKY76326,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissttyywgwirqppgkglewiasiyysgstyynpslksrltvsvdtsknqfslklssvtaadtavyycarqwkwfgeawyfdlwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3764,NaN,NaN,QKY76325,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmggiipifgtanyaqkfqgrvtftadeststaymevsslrsedtavyycarscgdcysadldfwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3765,NaN,NaN,QKY76324,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgaevkkpgeslkisckgfgynftnywigwvrqmpgkglewmgiiypgdsetrnspsfqgqvtisadksmstaylqwsslkasdtamyycarlgvskycsggrclsggsnwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3766,NaN,NaN,QKY76323,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdysmnwvrqapgkglewvssissggsyiyyadsvkgrftisrdnaknslylqmnslraedtavyycarggsilwwlidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3767,NaN,NaN,QKY76322,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsrhwmtwvrqapgkglewvanikqdgsekyyvdsvkgrltisrdnaknslylqmnslraedtavyycarlgfyyggadywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3768,NaN,NaN,QKY76321,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsmyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarllwlrghfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3769,NaN,NaN,QKY76320,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evhlvgsgggliqpggslrlscaasgftvssnfmswvrqapgkglewvsiihnggdsyytdsvkgrftisrdnskntlylqmnnlraedtavyycassswlrgafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3770,NaN,NaN,QKY76319,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslstsgmclswirqppgkalewlaridwdddkyystsletrltiskdtsknqvvltmtnmdpvdtgtyycartmatinafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3771,NaN,NaN,QKY76318,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewighiyytgssyynpslksrvtisldtsknqfslklnsvtaadtavyycarlrwlrggidfwgqgtlvivss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3772,NaN,NaN,QKY76317,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3773,NaN,NaN,QKY76316,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiistsggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3774,NaN,NaN,QKY76315,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3775,NaN,NaN,QKY76314,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgftlddyglswvrhapgkglewvsginwnggrtayadsvkgrftisrdnaknslylqmnslraedtalyhcarargpseqyydlltgyydafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3776,NaN,NaN,QKY76313,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvtlresgpalvkptqtltltctfsgfslttsgmcvswirqppgkalewlaridwdddkyystslqtrltiskdtsknqvvltmtnmdpvdtatyycaretpvtaidywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3777,NaN,NaN,QKY76312,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslrtedtalyycamgpfgellpyyfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3778,NaN,NaN,QKY76311,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasgitvssnymswvrqapgkglewvsviyaggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardalyyngpgrdgmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3779,NaN,NaN,QKY76310,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviypggsafyadsvkgrftisrhnsnntlclqmnslrtedtavyycarsydiltgyrdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3780,NaN,NaN,QKY76309,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqqwgagllkpsetlsrtcavygasfsnyywswirqppgkglewigeinhsentnynpslksrvtisvdtsknqfslrlssvtaadtavyycarlrysssgghifdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3781,NaN,NaN,QKY76308,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqllesgggliqpggslrlscaasgftfsnyamswvrqapgkglewvsgiisssggatynadsvrgrfttsrdnsknilylqmnslrgedtavyycvkglfdwfplwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3782,NaN,NaN,QKY76307,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qitlkesgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryspslksrlsitkdtsknqvvltmtnmdpvdtgtyycarhqivvlfdmwgqgtrvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3783,NaN,NaN,QKY76306,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgvtvssnymswvrqapgkglewvsliysggstfyadsvkgrftisrhnskntlylqmnslrpedtavyycargpepdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3784,NaN,NaN,QKY76305,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggliqpggslrlscaasevtvssnymswvrqapgkglewvsliysggttyyadsvkgrftisrdnskntlylqmnslraedtavyycardflrwhdlwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3785,NaN,NaN,QKY76304,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaagytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtststaymelssltsddtavyycarmrtgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3786,NaN,NaN,QKY76303,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvrsnymtwvrqtpgkglewvsviysggstfyadsvkgrftisrdnskntvylqmnslraedtavyycardlvtygldvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3787,NaN,NaN,QKY76302,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlaqsgaevkkpgasvkvsckaggytftsydinwvrqatgqglewmgwmnsnsgnagyaqkfqgrvtmtrdtsistaymelsslrsedtavyycarmrtgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3788,NaN,NaN,QKY76301,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsgiswnggntgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwaggafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3789,NaN,NaN,QKY76300,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvgsnymnwvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqlnslraedtavyycarevvgyfdcwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3790,NaN,NaN,QKY76299,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesgggvvrpggslrlscaasgfifddydmtwvrqapgkglewvsginwnggstgyadsvkgrftisrdnaknslylqmnslraedtalyhcavimspiprysgydwagdafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3791,NaN,NaN,QKY76298,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfvtsgihwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakggpnkevlyfgelldygmdvwgqgttvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3792,NaN,NaN,QKY76297,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsgdsissagyywswirqhpgkglewigyiyysgrtyynpslksrvtmsvdtsknqfslrlrsvtaadtavyycarvvptrgpvawfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3793,NaN,NaN,QKY76296,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfrdvwmswvrqapgkglewvgrikskidggttdyaapvkgrftisrddskntlylqmnslktedtavyycttagsyyydtvgpglpegkfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3794,NaN,NaN,QKY76295,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftdyymhwvrqapgqglewmgwinpnsrgtnyaqkfqgrvtmtrdtsistvymelsrltsddtavyycarvvvlgygrpnnyydgrnvwdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3795,NaN,NaN,QKY76294,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvesggglvqpggslrlscaasgltvssnymswvrqapgkglecvsviyaggntyyadsvkgrftisrdnskntlylqmnslraedtavyycargdggyyspfdywgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3796,NaN,NaN,QKY76293,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfgsfdinwvrqatgqglewmgrmnsnsgntayaqkfqgrvtmtrdtstntaymelsslrsedtamyycarmrsgwpthgrpddfwgrgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3797,NaN,NaN,QKY76292,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qvqlvqsgaevkkpgssvkvscktsgdtsssytvgwvrqapgqglewmgriipilgiaysaqkfqgrltitadkststsymelsslrsedtavyycargvvaatpgwfdpwgqgtlvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3798,NaN,NaN,QKY76291,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssavqwvrqargqrlewigwiavgsgntnyaqkfqervsitrdmststaymelsslrsedtavyycaapycsrtschdafdiwgqgtkvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3799,NaN,NaN,QKY76290,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftfmssavqwvrqargqrlewigwivigsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapycssiscndgfdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3800,NaN,NaN,QKY76289,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsvssrsyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhtvdcggdcfpndafdiwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3801,NaN,NaN,QKY76288,NaN,"SARS-CoV-2, Spike protein",Homo sapiens (human),qmqlvqsgpevkkpgtsvkvscktsgftftssaiqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaaphcnrtscydafdlwgqgtmvtvss,NaN,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,"anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
3802,NaN,NaN,NaN,QKY76287,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3803,NaN,NaN,NaN,QKY76286,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3804,NaN,NaN,NaN,QKY76285,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3805,NaN,NaN,NaN,QKY76284,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3806,NaN,NaN,NaN,QKY76283,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3807,NaN,NaN,NaN,QKY76282,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3808,NaN,NaN,NaN,QKY76281,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3809,NaN,NaN,NaN,QKY76280,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3810,NaN,NaN,NaN,QKY76279,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3811,NaN,NaN,NaN,QKY76278,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvvviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3812,NaN,NaN,NaN,QKY76277,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3813,NaN,NaN,NaN,QKY76276,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3814,NaN,NaN,NaN,QKY76275,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3815,NaN,NaN,NaN,QKY76274,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3816,NaN,NaN,NaN,QKY76273,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyccssytssravlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3817,NaN,NaN,NaN,QKY76272,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqfliylgsnrasgvpdrfsgsgsgtdfilkisrveaedvgvyycmqalqtpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3818,NaN,NaN,NaN,QKY76271,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsstflawyqqkpgqaprllifgassratgipdrfsgsgsgtdftltisrlepedfavyychqygtspytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3819,NaN,NaN,NaN,QKY76270,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3820,NaN,NaN,NaN,QKY76269,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3821,NaN,NaN,NaN,QKY76268,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3822,NaN,NaN,NaN,QKY76267,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltissldpedfavyychkrsnwppsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3823,NaN,NaN,NaN,QKY76266,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3824,NaN,NaN,NaN,QKY76265,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsllytsnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3825,NaN,NaN,NaN,QKY76264,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscragqtvsssylawyqhkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3826,NaN,NaN,NaN,QKY76263,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsdgytyldwylqkpgqspqlliylgskrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3827,NaN,NaN,NaN,QKY76262,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapkllmyaastlqsgvpsrfsgsgsgteftltintlqpedfatyycqqlnsypitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3828,NaN,NaN,NaN,QKY76261,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkprqapvliisgnnnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnhlrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3829,NaN,NaN,NaN,QKY76260,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrffgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfv,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3830,NaN,NaN,NaN,QKY76259,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpgfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3831,NaN,NaN,NaN,QKY76258,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswfqhhpdkaprlmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpfvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3832,NaN,NaN,NaN,QKY76257,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3833,NaN,NaN,NaN,QKY76256,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapvvviygknnrpsgipdrfsgsssgnkasltitgaqagdeadyycnsrdnsgnlnwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3834,NaN,NaN,NaN,QKY76255,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigtkgvhwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3835,NaN,NaN,NaN,QKY76254,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnrptgiparftgsgsgtdftltisslepedfavyycqhrtnwpplftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3836,NaN,NaN,NaN,QKY76253,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkfvcwyqqkpgqspvlviyqdnkrpsgiperfsgsnsgntatltisgtqaldeadyycqawdsstgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3837,NaN,NaN,NaN,QKY76252,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3838,NaN,NaN,NaN,QKY76251,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,itcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfggsasgtdftltisslqpedfatyycqqsystftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3839,NaN,NaN,NaN,QKY76250,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagynvhwyqqlpgtapklliygnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsfdsslsgsdvfgtgtkvsvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3840,NaN,NaN,NaN,QKY76249,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3841,NaN,NaN,NaN,QKY76248,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystppytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3842,NaN,NaN,NaN,QKY76247,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlhssnnkdslvwyqqkpgqppklliywassresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3843,NaN,NaN,NaN,QKY76246,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3844,NaN,NaN,NaN,QKY76245,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgisnylawfqqkpgkapksliyaasslqsgvpskfsgsgsgtdftltisslqpedvatyycqqynshpptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3845,NaN,NaN,NaN,QKY76244,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigarydvhwyqqlpgtapkllmygnnnrpsgvpdrfsgsksgtsvslaitglqaedeadyycqsydsslsgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3846,NaN,NaN,NaN,QKY76243,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqhlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgwsvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3847,NaN,NaN,NaN,QKY76242,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgssrgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3848,NaN,NaN,NaN,QKY76241,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3849,NaN,NaN,NaN,QKY76240,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyhcqqsystltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3850,NaN,NaN,NaN,QKY76239,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnskigsysvnwyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycsvwddslngplfgggtkltfl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3851,NaN,NaN,NaN,QKY76238,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3852,NaN,NaN,NaN,QKY76237,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstgvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3853,NaN,NaN,NaN,QKY76236,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3854,NaN,NaN,NaN,QKY76235,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqyygsspfgfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3855,NaN,NaN,NaN,QKY76234,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtsgdvgaynyvswyqqhpvkapklmiydvskrpsgvsnrfsgsksgntasltisglqtedeadyycssytssstlwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3856,NaN,NaN,NaN,QKY76233,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprqytywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadtigtywvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3857,NaN,NaN,NaN,QKY76232,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkysswyqqkpgqspvlviyedtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawssstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3858,NaN,NaN,NaN,QKY76231,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3859,NaN,NaN,NaN,QKY76230,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divvtqtplslsvtpgqpasisckssetllhsdgktylswylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkigrveaedvglyycmqsiqlafgqgtrleie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3860,NaN,NaN,NaN,QKY76229,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyanwyqqkpgqapvvvifgknnrpsgipdrfsgsnsgntasltitgaqaedeadyycnsrdssgyiwgwmfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3861,NaN,NaN,NaN,QKY76228,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvkvvyhdgdrpsgiperfsgsnsgntatltinrveagdeadyscqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3862,NaN,NaN,NaN,QKY76227,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3863,NaN,NaN,NaN,QKY76226,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3864,NaN,NaN,NaN,QKY76225,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliyaasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllqftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3865,NaN,NaN,NaN,QKY76224,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnslswyqqkpgkapklliydasnlktgvpsrfsgsgsgtdftftisslqpediatyycqqydnlllftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3866,NaN,NaN,NaN,QKY76223,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3867,NaN,NaN,NaN,QKY76222,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3868,NaN,NaN,NaN,QKY76221,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3869,NaN,NaN,NaN,QKY76220,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvsrflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3870,NaN,NaN,NaN,QKY76219,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3871,NaN,NaN,NaN,QKY76218,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvgnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3872,NaN,NaN,NaN,QKY76217,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyychyrsnwppvltfgggtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3873,NaN,NaN,NaN,QKY76216,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqsphlliylgsnrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3874,NaN,NaN,NaN,QKY76215,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktanitcggnnigrksvhwyqqksgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhpewvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3875,NaN,NaN,NaN,QKY76214,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3876,NaN,NaN,NaN,QKY76213,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgggtkvqik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3877,NaN,NaN,NaN,QKY76212,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknslawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysiswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3878,NaN,NaN,NaN,QKY76211,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3879,NaN,NaN,NaN,QKY76210,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliygasslqtgvpsrfsgsgsgtdftltirslqpedfasyycqqsystptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3880,NaN,NaN,NaN,QKY76209,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasldiskylnwyqhkpgkapnlliydafnlergvpsrfsgsgsgtdftftisslqpediatyycqqydnlppgvsttfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3881,NaN,NaN,NaN,QKY76208,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqtitnylnwyqlksgrapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3882,NaN,NaN,NaN,QKY76207,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdflavslgeratinckssqsvlhtpknknylawykqkpgqppkvliywastresgvperfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3883,NaN,NaN,NaN,QKY76206,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsyasslsahvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3884,NaN,NaN,NaN,QKY76205,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrashsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3885,NaN,NaN,NaN,QKY76204,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvvgynyvswyqqhpgkapklmiydvrnrpsgvsnrfsgsksgntasltisglqaedeadyfcisytssrtlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3886,NaN,NaN,NaN,QKY76203,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgntasltisglqaedeadyycssytssstpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3887,NaN,NaN,NaN,QKY76202,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvtkrpsgvperfsgsksgntasltisglqaedeadysccsyagsytyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3888,NaN,NaN,NaN,QKY76201,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaisglqaedeadyscqsydsslsgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3889,NaN,NaN,NaN,QKY76200,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnwlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsystwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3890,NaN,NaN,NaN,QKY76199,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkrgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3891,NaN,NaN,NaN,QKY76198,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3892,NaN,NaN,NaN,QKY76197,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnenylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyssytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3893,NaN,NaN,NaN,QKY76196,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppgvtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3894,NaN,NaN,NaN,QKY76195,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3895,NaN,NaN,NaN,QKY76194,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3896,NaN,NaN,NaN,QKY76193,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3897,NaN,NaN,NaN,QKY76192,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysspytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3898,NaN,NaN,NaN,QKY76191,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsfdigrggwifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3899,NaN,NaN,NaN,QKY76190,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvsageratlscrasqsissnlawyhqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynsysltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3900,NaN,NaN,NaN,QKY76189,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqpssvsvspgqtaritcsgdalpkryaywyrqksgqapvlvihedskrpsgiperfsgstsgtmatltitgaqledeadyycfsmdssgdlrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3901,NaN,NaN,NaN,QKY76188,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3902,NaN,NaN,NaN,QKY76187,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssnflawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrspitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3903,NaN,NaN,NaN,QKY76186,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3904,NaN,NaN,NaN,QKY76185,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsinswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqysiyswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3905,NaN,NaN,NaN,QKY76184,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvvtqppsasgtpgqrvtiscsgsssnigynivnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslsisglqsedeadyycaawddslngyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3906,NaN,NaN,NaN,QKY76183,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifinsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslgalfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3907,NaN,NaN,NaN,QKY76182,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,fyeltqppsvsvspgqtagitcsgdklghkyaywyqqkpgqspilliyqddkrpsgiperfsgsnsgtiatltisgtqpvdeadyycqawdndagvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3908,NaN,NaN,NaN,QKY76181,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalptkyaywyqqksgqapvlviyddskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3909,NaN,NaN,NaN,QKY76180,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatfycqqsystpmhtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3910,NaN,NaN,NaN,QKY76179,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalskqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssshwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3911,NaN,NaN,NaN,QKY76178,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygrssgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3912,NaN,NaN,NaN,QKY76177,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmaqtplslpvtpgepasiscrssqslldsddgntyfdwylqkpgqspqlliytlsyrasgvpdrfsgsgsgtdftlkinrveaedvgvyycmqriefpwtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3913,NaN,NaN,NaN,QKY76176,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3914,NaN,NaN,NaN,QKY76175,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalpkhyaywyqqrpgqapvlviykdierpsgiperfsgsssgttvtltitgaqaedeadyycqsvdgsgssvvfgggtklavl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3915,NaN,NaN,NaN,QKY76174,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgetyvswyqqkpgqspvlviyedskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstggvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3916,NaN,NaN,NaN,QKY76173,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyfwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3917,NaN,NaN,NaN,QKY76172,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvassylawyqqkpgqaprlliygasgratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3918,NaN,NaN,NaN,QKY76171,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspgtlsvspgeratlscrasqslsshlawyqqkpgqaprlliygvstratgiparfsgsgsgteftlaisslqsedsavyycqqyhvwppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3919,NaN,NaN,NaN,QKY76170,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrarqsisnylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystfwtfgqgtnveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3920,NaN,NaN,NaN,QKY76169,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggytyvswyqqhpgkapklmiydvnkrpsgvpdrfsgsksgitasltisglqaedeadyyccsyagrytwvfgggttltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3921,NaN,NaN,NaN,QKY76168,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlvisedskrpsgiperfsgsssgtvatltisgaqvedeadyycystdssgnhrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3922,NaN,NaN,NaN,QKY76167,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3923,NaN,NaN,NaN,QKY76166,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyasssivvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3924,NaN,NaN,NaN,QKY76165,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratviparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3925,NaN,NaN,NaN,QKY76164,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsadalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqstdssgsyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3926,NaN,NaN,NaN,QKY76163,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyssnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3927,NaN,NaN,NaN,QKY76162,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqipgtapkllfygnnnrpsgvpdrfsdsksgtsaslaitglqaedeadyycqsydsslsawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3928,NaN,NaN,NaN,QKY76161,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvihqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3929,NaN,NaN,NaN,QKY76160,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfeyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3930,NaN,NaN,NaN,QKY76159,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynfldwylqkpgqspqlliylgsnrasgvpdrfsgsgsgtdftlkisrvqaedvgvyycmqalqtpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3931,NaN,NaN,NaN,QKY76158,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyahwyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyyccstdssgnqrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3932,NaN,NaN,NaN,QKY76157,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspgtlsvspgeratlscrasqtlssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyhcqqynnwplafgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3933,NaN,NaN,NaN,QKY76156,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgygtdftltisslqpedfatyycqqsyntprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3934,NaN,NaN,NaN,QKY76155,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkytywyqqksgqapvvviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgkgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3935,NaN,NaN,NaN,QKY76154,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3936,NaN,NaN,NaN,QKY76153,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspgtlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgvparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3937,NaN,NaN,NaN,QKY76152,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqrgvpsrfsgsgsgtdftltisslqpedfatyycqqanslpltfgggtkvevk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3938,NaN,NaN,NaN,QKY76151,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dfvmtqspgslavslgeratincrssqsvldnssnknhlawhqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyysshwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3939,NaN,NaN,NaN,QKY76150,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3940,NaN,NaN,NaN,QKY76149,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspdfqsvtpkekvtitcrasqnigsslhwyqqkpdqspkviikyasqsfsgvpsrfsgsgsgtdftltinsleaedaatyychqssslpptfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3941,NaN,NaN,NaN,QKY76148,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvvvvyddsdrpsglperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3942,NaN,NaN,NaN,QKY76147,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgnrvein,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3943,NaN,NaN,NaN,QKY76146,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgvpgqrvtvsctgsssnigagfdvywyqqflgtapklliygnnnrpsgvpdrfsasksgtsaslaitglqaedeadyycqsydsslsgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3944,NaN,NaN,NaN,QKY76145,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwyqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3945,NaN,NaN,NaN,QKY76144,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinhylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftitslqpedvatyycqqsdnlpmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3946,NaN,NaN,NaN,QKY76143,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3947,NaN,NaN,NaN,QKY76142,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsvsgspgqsvtisctgtssdvgsynrvswyqqppgtapklmiyevsnrpsgvpdrfsgsksgntasltisglqaedeadyycssytssslrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3948,NaN,NaN,NaN,QKY76141,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3949,NaN,NaN,NaN,QKY76140,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltitslqpedfatyycqqgnsfpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3950,NaN,NaN,NaN,QKY76139,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysptfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3951,NaN,NaN,NaN,QKY76138,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3952,NaN,NaN,NaN,QKY76137,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyhqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrstfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3953,NaN,NaN,NaN,QKY76136,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvsprqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdtsgnhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3954,NaN,NaN,NaN,QKY76135,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdflavslgeratisckssqsvlytpknknylawykqkpgqppkvliywastresgvpdrfsgsgsgtdftliisslqaedaavyycqqyytapltfgggtrveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3955,NaN,NaN,NaN,QKY76134,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqlitifcngsisdvggwnyvswyqqhpdkapkmmiydvrhrpsgvssrfsgsksgntasltisglqaedegdyycssftsrgalvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3956,NaN,NaN,NaN,QKY76133,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgdynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeaeyycssytssstllyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3957,NaN,NaN,NaN,QKY76132,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsvstwlawyqqkpgkapnlliyeasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3958,NaN,NaN,NaN,QKY76131,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvrdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3959,NaN,NaN,NaN,QKY76130,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnhwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3960,NaN,NaN,NaN,QKY76129,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sneltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqstassgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3961,NaN,NaN,NaN,QKY76128,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3962,NaN,NaN,NaN,QKY76127,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydaykrdtgiparfsgsgsgtdftltisslepedfavyycqqrsnwpliftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3963,NaN,NaN,NaN,QKY76126,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvvtqspsasaslgasvkltctldsghrsyaiawhqqrpekgprflmrittdgrhtkgdgipdrfsgsgsgteryltisslqsedeadyycqtwgtfgggtrltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3964,NaN,NaN,NaN,QKY76125,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvltqppsasaslgasvtltctlssgysnykvdwfqqrpgkgprfvmrvgtggivgskgdgipdrfsvlgsglnryltikniqeedesdyhcgadhgsgsnfvyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3965,NaN,NaN,NaN,QKY76124,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswhqqhpgkapknmiydvskrpsgvsnrfsgsksgntasltisglhtedeadyycssytststpwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3966,NaN,NaN,NaN,QKY76123,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqttritcsgdalpkqygywyqqkagqapilviykdserpsgiperfsgsssgttvtltisgvqaedeahyycqsgdssgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3967,NaN,NaN,NaN,QKY76122,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalskqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdrsgtyfnwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3968,NaN,NaN,NaN,QKY76121,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasisckssqsllhsdgktylywylqkpgqspqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3969,NaN,NaN,NaN,QKY76120,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgrtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgskfgntatliisrveagdeadyscqvwdsgsdhvvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3970,NaN,NaN,NaN,QKY76119,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3971,NaN,NaN,NaN,QKY76118,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3972,NaN,NaN,NaN,QKY76117,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtparfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3973,NaN,NaN,NaN,QKY76116,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyycysyagsstwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3974,NaN,NaN,NaN,QKY76115,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3975,NaN,NaN,NaN,QKY76114,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwgfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3976,NaN,NaN,NaN,QKY76113,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3977,NaN,NaN,NaN,QKY76112,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystrtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3978,NaN,NaN,NaN,QKY76111,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3979,NaN,NaN,NaN,QKY76110,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghttyaiawhqqqpekgprylmklnsdgshtrgdgipdrfsgsssgaeryltisslqsedeadyycqswdtgigvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3980,NaN,NaN,NaN,QKY76109,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgtdftltisslqsedfalyycqqynnwwrtfgqgtkvein,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3981,NaN,NaN,NaN,QKY76108,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkprkapklliykastlesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3982,NaN,NaN,NaN,QKY76107,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3983,NaN,NaN,NaN,QKY76106,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatvsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsasgsgteftltisslqsedfavyycqqynnwppmytfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3984,NaN,NaN,NaN,QKY76105,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3985,NaN,NaN,NaN,QKY76104,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpnqyaywyqqkpgqapvlvmckdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3986,NaN,NaN,NaN,QKY76103,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaatslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtystplytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3987,NaN,NaN,NaN,QKY76102,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtftcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgigsgtdftltisslqpedvatyycqkynsapwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3988,NaN,NaN,NaN,QKY76101,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3989,NaN,NaN,NaN,QKY76100,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdigsynlvswyqqypgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyaggntfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3990,NaN,NaN,NaN,QKY76099,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3991,NaN,NaN,NaN,QKY76098,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiyyvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsstlnvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3992,NaN,NaN,NaN,QKY76097,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqspsvsvspgqtasitcsgdklgdkyacwyqqrpgqspvlviyqdsqrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3993,NaN,NaN,NaN,QKY76096,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgstsnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgpsaslaisglqsvdeadyycaawddslngwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3994,NaN,NaN,NaN,QKY76095,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyiswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3995,NaN,NaN,NaN,QKY76094,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3996,NaN,NaN,NaN,QKY76093,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdkmgdkyacwyqqkpgqspvvviyednkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsslvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3997,NaN,NaN,NaN,QKY76092,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nivmtqsplslpvtpgepasiscrssqsllnsngltyldwylqkpgqspqlliyfvsnrasgvsdrfsgsgsgadftltisrveaedvgvyycmqalqtpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3998,NaN,NaN,NaN,QKY76091,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcassagavtsgyypnwfqqkpgqapraliystankhswtlarfsgsllggkaaltlsgvqpedeaeyycllyyggawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
3999,NaN,NaN,NaN,QKY76090,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywppltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4000,NaN,NaN,NaN,QKY76089,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhagkapklmiyevikrpsgvsnrfsgsksgntasltisglqaedeadyyccsyavsttyvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4001,NaN,NaN,NaN,QKY76088,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyfcqqcynwppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4002,NaN,NaN,NaN,QKY76087,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspailslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfafyycqqrgnwwtfaqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4003,NaN,NaN,NaN,QKY76086,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqansfpptfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4004,NaN,NaN,NaN,QKY76085,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcfgdklgdkyacwfqqkpgqspvliiyqgakrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4005,NaN,NaN,NaN,QKY76084,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdiggynyvswyqqhpgkapklliydvsnrpsgvstrfsgsksgntasltisglqaedeadyycssytsssthvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4006,NaN,NaN,NaN,QKY76083,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnignkgvhwyqqkpgqapvlvvdddsdrpsgiperfsgsnsgntatliissvevgdeadfycqvwdsssdhpgvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4007,NaN,NaN,NaN,QKY76082,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypvtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4008,NaN,NaN,NaN,QKY76081,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgitnylawfqqkpgkapksliyavsslqsgvpskfsgsgsgtdftltisslqpedfatyycqqynsypwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4009,NaN,NaN,NaN,QKY76080,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapklliyrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawdaslsghvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4010,NaN,NaN,NaN,QKY76079,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggyhyvswyqhhpgkapkliiydvikrpsgvsnrfsgsksgntasltisglqaedeayyycssytssttwvfgggtrltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4011,NaN,NaN,NaN,QKY76078,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4012,NaN,NaN,NaN,QKY76077,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4013,NaN,NaN,NaN,QKY76076,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4014,NaN,NaN,NaN,QKY76075,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsggssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaswddsligpvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4015,NaN,NaN,NaN,QKY76074,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvvvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4016,NaN,NaN,NaN,QKY76073,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisiylnwyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4017,NaN,NaN,NaN,QKY76072,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylhwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyhnlppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4018,NaN,NaN,NaN,QKY76071,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdistylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllftfgpgtkvdvk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4019,NaN,NaN,NaN,QKY76070,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrpsqsittylnwyqqkpgkaprlliyavsslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpptfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4020,NaN,NaN,NaN,QKY76069,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qpvltqsssasaslgssvkltctlssghssyiiawhqqqpgkaprylmklegsgsynkgsgvpdrfsgsssgadcyltisnlqsedeadyycetwdsntrvfaggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4021,NaN,NaN,NaN,QKY76068,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsylgtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4022,NaN,NaN,NaN,QKY76067,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviyrdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadstgwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4023,NaN,NaN,NaN,QKY76066,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdpfyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4024,NaN,NaN,NaN,QKY76065,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqqydnlysvhfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4025,NaN,NaN,NaN,QKY76064,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsitsylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4026,NaN,NaN,NaN,QKY76063,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsiisylnwyhqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4027,NaN,NaN,NaN,QKY76062,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4028,NaN,NaN,NaN,QKY76061,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcggnnigsknvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdssyyhpvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4029,NaN,NaN,NaN,QKY76060,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasigdrvtitcrasqnirsylnwyqhkpgkapklliyaastlqsgvpsrfsgsesgtdftltisslqpedfatyycqqsssspitfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4030,NaN,NaN,NaN,QKY76059,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsyswtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4031,NaN,NaN,NaN,QKY76058,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdafpkqygywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadsrgavfgsgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4032,NaN,NaN,NaN,QKY76057,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dfqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapnllifaasslhsgvpsrfsgsgsgtdftlsisslqpedfatyycqqsyssewtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4033,NaN,NaN,NaN,QKY76056,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynfvswyqqhpgkapkliiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyyctsytssstlnvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4034,NaN,NaN,NaN,QKY76055,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4035,NaN,NaN,NaN,QKY76054,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcfgdalpkqyaywyqqkpgqgpvlviykdserpsgiperfsgstsgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4036,NaN,NaN,NaN,QKY76053,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4037,NaN,NaN,NaN,QKY76052,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslstsvgdrvtitcrasqsirsylnwyqqkpgkapklliyvasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4038,NaN,NaN,NaN,QKY76051,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytsssipyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4039,NaN,NaN,NaN,QKY76050,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qtvvtqepsltvspggtvtltcasstgavtsgyfpnwfqqkpgqapralifstnnrhswtparfsgsllgdkaaltlsgvqpedeaeyycllyyggpwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4040,NaN,NaN,NaN,QKY76049,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4041,NaN,NaN,NaN,QKY76048,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4042,NaN,NaN,NaN,QKY76047,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4043,NaN,NaN,NaN,QKY76046,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyhqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtsvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4044,NaN,NaN,NaN,QKY76045,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvsnnlawyqqkpgqaprlliygastratgipvrfsgsgsgteftltisslqsedfavyycqqyddwppevtfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4045,NaN,NaN,NaN,QKY76044,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgsrfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4046,NaN,NaN,NaN,QKY76043,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnyvywyqqlpgtapkllisrnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4047,NaN,NaN,NaN,QKY76042,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdawpnqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyfcqssdssgvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4048,NaN,NaN,NaN,QKY76041,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkagkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdvk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4049,NaN,NaN,NaN,QKY76040,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsvsiylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltvsslqpedfatyycqqsysmppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4050,NaN,NaN,NaN,QKY76039,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4051,NaN,NaN,NaN,QKY76038,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsgnpifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4052,NaN,NaN,NaN,QKY76037,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4053,NaN,NaN,NaN,QKY76036,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprtwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4054,NaN,NaN,NaN,QKY76035,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktaritcegnnigsksvhwyqqkpgqapvlvvyddsgrpsgiperfsgsnsgntatltisrveagdeadyfcqvwdsssdhhvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4055,NaN,NaN,NaN,QKY76034,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqhrsnwpprltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4056,NaN,NaN,NaN,QKY76033,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4057,NaN,NaN,NaN,QKY76032,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslksgvpsrfggsgsgtdftltisslqpedfatyycqqsyemppwtfgqgtkveie,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4058,NaN,NaN,NaN,QKY76031,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcstdalpneyiywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsvdssgtyphvifgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4059,NaN,NaN,NaN,QKY76030,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssaayvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4060,NaN,NaN,NaN,QKY76029,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpddiatyycqqydnlplafgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4061,NaN,NaN,NaN,QKY76028,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpnqyaywyhqkpgqapvvviykdserpsgipqrfsgsssgttvtltisgvqaedeadyycqsadssgyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4062,NaN,NaN,NaN,QKY76027,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4063,NaN,NaN,NaN,QKY76026,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhsngynyldwylqkpgqspqlliylgstrasgvpdrfsgsgsgtdftlkisrveaedvgvyycmqalqtplytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4064,NaN,NaN,NaN,QKY76025,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4065,NaN,NaN,NaN,QKY76024,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syvltqppsvsvapgktasitcegnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdrlyvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4066,NaN,NaN,NaN,QKY76023,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4067,NaN,NaN,NaN,QKY76022,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrssgsiassyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssdvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4068,NaN,NaN,NaN,QKY76021,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4069,NaN,NaN,NaN,QKY76020,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvssrdsgvpdrfsgsgsgtaftlkisrveaedvgvyycmqgthwpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4070,NaN,NaN,NaN,QKY76019,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4071,NaN,NaN,NaN,QKY76018,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasigdrvtitcrasqsisswlawyqqipgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4072,NaN,NaN,NaN,QKY76017,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglmtedeadyycqsydgsnhavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4073,NaN,NaN,NaN,QKY76016,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqsvtiscsgsssnignnkvnwyqqlpgtapkvliynsnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslhsyvfgtetkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4074,NaN,NaN,NaN,QKY76015,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dmevtqfpsslsasigdrvtitcratqsistylnwyqqkpgkapnlliysashlqrgvparfsgsgsgteftltittlqpedvgtyychqsygvpitfgggtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4075,NaN,NaN,NaN,QKY76014,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4076,NaN,NaN,NaN,QKY76013,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4077,NaN,NaN,NaN,QKY76012,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycatwddslngpvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4078,NaN,NaN,NaN,QKY76011,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysnpsytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4079,NaN,NaN,NaN,QKY76010,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4080,NaN,NaN,NaN,QKY76009,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysslsitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4081,NaN,NaN,NaN,QKY76008,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagiwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4082,NaN,NaN,NaN,QKY76007,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4083,NaN,NaN,NaN,QKY76006,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrryyaswyqqkpgqapvlviygknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnprwfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4084,NaN,NaN,NaN,QKY76005,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltva,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4085,NaN,NaN,NaN,QKY76004,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssflawyqqkpgqaprlliygasnratgipdrfsgsgsgtdftltisrlepedfavyycqqygnspqfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4086,NaN,NaN,NaN,QKY76003,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklllyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4087,NaN,NaN,NaN,QKY76002,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqekpgqaprllmysassratgipdrfsgsgsatdftltinrlepedfavyycqqyveppftfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4088,NaN,NaN,NaN,QKY76001,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsrynigsnyvywyqqlpgtaprlliysnnqrpsgvpdrfsgsksgtsaslaisglrsedeadyycaawddslsglifgggtkltvq,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4089,NaN,NaN,NaN,QKY76000,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syelaqppsvsvapgetatifcratyigrknvqwyqqkpgqapvlvvyddsdrpsgipgrfsgsnsgdtatltisrieagdeaayycqvwdgindrvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4090,NaN,NaN,NaN,QKY75999,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdirnylnwyqqkpgkapelliydasnletgvpsrfsgsgsgtdfiftisslqpediatyychqydylpytfgqgtkldik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4091,NaN,NaN,NaN,QKY75998,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnerpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsayvfgtgtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4092,NaN,NaN,NaN,QKY75997,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlalsvgeratlscvasqrvssdyiawyqkkpglaprllvyhgsawatgssarfsgsgsgtaftltisslepedfavyycqqygnspftfgpgtkvefk,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4093,NaN,NaN,NaN,QKY75996,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4094,NaN,NaN,NaN,QKY75995,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4095,NaN,NaN,NaN,QKY75994,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtfsctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrwlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4096,NaN,NaN,NaN,QKY75993,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4097,NaN,NaN,NaN,QKY75992,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4098,NaN,NaN,NaN,QKY75991,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4099,NaN,NaN,NaN,QKY75990,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspprytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4100,NaN,NaN,NaN,QKY75989,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyarsstrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4101,NaN,NaN,NaN,QKY75988,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgitasltisglqaedeadyyccsyagsstwlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4102,NaN,NaN,NaN,QKY75987,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkllifgntnrpsgvpdrfsgsksgtstslaitglqaedeadyycqsydsslngdvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4103,NaN,NaN,NaN,QKY75986,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgshgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgstsgntasltisglqaedeadyyccsyagivlfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4104,NaN,NaN,NaN,QKY75985,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4105,NaN,NaN,NaN,QKY75984,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapkllifgnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4106,NaN,NaN,NaN,QKY75983,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspssvsasvgdrvtitcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtnsfptfgqgtrleir,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4107,NaN,NaN,NaN,QKY75982,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgnsgsiasnyvqwyqqrpgsapttviyedsqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsfdsgnvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4108,NaN,NaN,NaN,QKY75981,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedennyycavwddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4109,NaN,NaN,NaN,QKY75980,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyvgsstyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4110,NaN,NaN,NaN,QKY75979,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4111,NaN,NaN,NaN,QKY75978,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4112,NaN,NaN,NaN,QKY75977,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqlpgtapklliydnnqrtsgvpdrlsgsksgtsaslaisglqsedeanyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4113,NaN,NaN,NaN,QKY75976,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4114,NaN,NaN,NaN,QKY75975,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslhsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4115,NaN,NaN,NaN,QKY75974,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4116,NaN,NaN,NaN,QKY75973,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyychqsyftpqtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4117,NaN,NaN,NaN,QKY75972,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qslltqppsvsgapgqrvtlscagatsnigagsdvhwyqqlpgtapklliyyntnrpsgvpdrfsgsksatsaslvitglqtedeadyycqsydislggwvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4118,NaN,NaN,NaN,QKY75971,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdiskylnwyqqkpgkapklliydasnlergvpsrfsgsgsgtdftftisslqaediatyycqqyhnlprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4119,NaN,NaN,NaN,QKY75970,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvseaprqrvtiscsgsssnignnavnwyqqlpgkapklliyyddllpsgvsdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4120,NaN,NaN,NaN,QKY75969,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtfscsgsnsnigsytvnwyqqlpgtapklliydnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4121,NaN,NaN,NaN,QKY75968,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvgtynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeaeyycsayagsnnlvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4122,NaN,NaN,NaN,QKY75967,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsnslnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngswvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4123,NaN,NaN,NaN,QKY75966,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4124,NaN,NaN,NaN,QKY75965,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliynnnqrpsgvpdrlsgsksgtsaslaisglqsedeadyycvawddsrnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4125,NaN,NaN,NaN,QKY75964,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqniasylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpeefatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4126,NaN,NaN,NaN,QKY75963,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlesedfalyycqqynnwwrtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4127,NaN,NaN,NaN,QKY75962,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4128,NaN,NaN,NaN,QKY75961,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4129,NaN,NaN,NaN,QKY75960,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawcqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqyynwpltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4130,NaN,NaN,NaN,QKY75959,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaisglqseaeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4131,NaN,NaN,NaN,QKY75958,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4132,NaN,NaN,NaN,QKY75957,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,syeltqpssvsvspgqtaritcsgdvlaknyarwfqqkpgqapvlviykdserpsgipkrfsgsssgttvtltisgaqvedeadyycysaadnnrvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4133,NaN,NaN,NaN,QKY75956,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4134,NaN,NaN,NaN,QKY75955,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsistylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedyatyycqqsystpgltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4135,NaN,NaN,NaN,QKY75954,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliydasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppitfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4136,NaN,NaN,NaN,QKY75953,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsiagylnwyqqkpgkapklliygttslqsgvpvrfsgsgsgtdftltisslqpedfatyycqqsystpgtfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4137,NaN,NaN,NaN,QKY75952,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvtitcqgdslrshyaswykvkpgqapllviygrnnrpsgipdrfsgsrsgntasltitgaqvddeadyycssgdsstdhhvvfaggtklavv,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4138,NaN,NaN,NaN,QKY75951,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsacvgdrvtitcrasqsissylnwyqqkpgkgpklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4139,NaN,NaN,NaN,QKY75950,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtlsctgsnsnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsdsvfgggtkvtvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4140,NaN,NaN,NaN,QKY75949,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssniesnsvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4141,NaN,NaN,NaN,QKY75948,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpetapklliyansnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4142,NaN,NaN,NaN,QKY75947,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqsplslpvtpgepasiscrssqsllhslgynslswylqkpgqsphlliylgsnrasgvpdrfsgsgsatdftlkisrleaedvgvyycmqalqtpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4143,NaN,NaN,NaN,QKY75946,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklkiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvlfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4144,NaN,NaN,NaN,QKY75945,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4145,NaN,NaN,NaN,QKY75944,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdfsltisslqpedfatyscqqsyttlltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4146,NaN,NaN,NaN,QKY75943,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycvawddsrnglvfgggakltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4147,NaN,NaN,NaN,QKY75942,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaafnlqsgvpsrfsgsgsgtdftltisslqsedfatyycqqsyntpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4148,NaN,NaN,NaN,QKY75941,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,etvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4149,NaN,NaN,NaN,QKY75940,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslesgvpsrfsgsgsgtdftltisslqpedfatyycqqsyeippwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4150,NaN,NaN,NaN,QKY75939,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeraslscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4151,NaN,NaN,NaN,QKY75938,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsissflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqrrsnwppftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4152,NaN,NaN,NaN,QKY75937,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppmytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4153,NaN,NaN,NaN,QKY75936,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydstsrvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4154,NaN,NaN,NaN,QKY75935,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttvisednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydginrawvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4155,NaN,NaN,NaN,QKY75934,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnywvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4156,NaN,NaN,NaN,QKY75933,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsskyvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4157,NaN,NaN,NaN,QKY75932,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasagdrvtitcrasqsiryylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfaayycqqsfstprtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4158,NaN,NaN,NaN,QKY75931,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,nlmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydsnnqvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4159,NaN,NaN,NaN,QKY75930,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdfiftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4160,NaN,NaN,NaN,QKY75929,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4161,NaN,NaN,NaN,QKY75928,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqyanlpftfgpgtkvdik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4162,NaN,NaN,NaN,QKY75927,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscgasqsisssylawyqqkpgqaprlliygassraagipdrfsgsgsgtdftltisrlepedfavyfcqqyggsltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4163,NaN,NaN,NaN,QKY75926,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliytasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4164,NaN,NaN,NaN,QKY75925,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydtsnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4165,NaN,NaN,NaN,QKY75924,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,viqmtqspsslsasvgdrvtitcqasqdinkylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprtfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4166,NaN,NaN,NaN,QKY75923,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigsgsdvhwyqqlpgtapklliygntnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsrlsgfvvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4167,NaN,NaN,NaN,QKY75922,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqksgkapklliydasnletgvpsrfsgsgsgtdftftinslqpediatyycqqydnlpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4168,NaN,NaN,NaN,QKY75921,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspatlsvspgerailscrasqsvrsnlawyqqkpgqaprllisgastrataiparfsgsgsgteftltitslqsedcavyychqynnwpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4169,NaN,NaN,NaN,QKY75920,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtgsdvggsnyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvlfgggtklsvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4170,NaN,NaN,NaN,QKY75919,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsysfetfgpgtkvaik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4171,NaN,NaN,NaN,QKY75918,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdinnylnwyqqkpgkapklliydasnletgvplrfsgsgsgtdftftisslqpediatyycqqydnlppvfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4172,NaN,NaN,NaN,QKY75917,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeanyyclvwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4173,NaN,NaN,NaN,QKY75916,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgisnylawyqqkpgtapnlliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqllnshpltfgqgtrleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4174,NaN,NaN,NaN,QKY75915,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsnsnigsytvnwyqqfpgtapklliydnnqrtsgvpdrfsgsksgtsaslaisglqsedeasyyclawddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4175,NaN,NaN,NaN,QKY75914,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4176,NaN,NaN,NaN,QKY75913,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgistylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypgytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4177,NaN,NaN,NaN,QKY75912,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqvpilviydknnrpsgipdrfsgsssgntasltitgaqaedeadyycnsrdssgnavvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4178,NaN,NaN,NaN,QKY75911,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqtplslsvtpgqpasfsckssqsllhsdgktylywylqkpgqspqlliyavsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4179,NaN,NaN,NaN,QKY75910,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqrpgkapklliyaasslqsgvpsrfsgsgsgtdftltistlqpedfatyycqqsystllytfgqgtkleik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4180,NaN,NaN,NaN,QKY75909,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppkllmywastresgvpdrfsgsgsgaeftltisslqaedvaiyycqqyystltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4181,NaN,NaN,NaN,QKY75908,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqppsasgtpgqrviiscsgsssnigsntvkwyhqlpgtapkllicsnnqrpsgvpdrfsgsksdtsaslaisglqsedeadyycaawddslnalvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4182,NaN,NaN,NaN,QKY75907,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkvliyaastmqsgvpsrfrgsgsgtdftltisslqledfatyycqqsystpqtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4183,NaN,NaN,NaN,QKY75906,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,qsvltqapsasgtpgqrvtiscsgsnsnigsytinwyqqlpgtapklliygndqrtsgvpdrfsgskfgtsaslaisglqsedennyycavwddslnglvfgggtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4184,NaN,NaN,NaN,QKY75905,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgervtlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgggsgteftltisslqsedfavyycqqynnfltfgggtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4185,NaN,NaN,NaN,QKY75904,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,evvltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyhcqhfgsssqwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4186,NaN,NaN,NaN,QKY75903,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygssrgwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4187,NaN,NaN,NaN,QKY75902,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,sseltqdpavsvalgqtvritcqgdslrsyyaswyqqkpgqapllviygknnrpsgipdrfsgsssgntpsltitgaqaedeadyycnfrdssghhpvfgegtkltvl,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4188,NaN,NaN,NaN,QKY75901,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylgwyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspwtfgqgtkveik,"Zost,S.J. et al.; Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein; bioRxiv (2020); 2020.",10.1101/2020.05.12.091462,NaN,"anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4189,NaN,NaN,QKQ15231,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesraemkkpgeslkisckgsgytftnhwiawvrqmpgkglewmgiiypgdsdtryspsfegqvtisadksistaylqwsslkasdtamyycarrgytygadfygldvwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4190,NaN,NaN,QKQ15230,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakmgpdpahdygrkndafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4191,NaN,NaN,QKQ15229,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgfiftnywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycarerylttdgwfdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4192,NaN,NaN,QKQ15228,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdnaknslylqmnslraedtalyycakaepevggydyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4193,NaN,NaN,QKQ15227,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesraevkkpgssvkvsckasggtfssyaiswvrqapgqglewmgriipilgitnyaqkfqgrvtitadkststaymelsslrsedtavyycardapdyydssgptyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4194,NaN,NaN,QKQ15226,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycataysvdtamvrgvgywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4195,NaN,NaN,QKQ15225,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvgsvkstagydfwsgdpfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4196,NaN,NaN,QKQ15224,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvstisgsggntyyadsvkgrftisrdnskntlylqmnslraedtavyycakeiavagcfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4197,NaN,NaN,QKQ15223,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardweeqwlvafdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4198,NaN,NaN,QKQ15222,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargpaatyyyymdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4199,NaN,NaN,QKQ15221,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlscaasgftfddyamhwvrqapgkglewvsgiswnsgsigyadsvkgrftisrdsaknslylqmnslraedtalyycakvatyyydrsgyyyggaldywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4200,NaN,NaN,QKQ15220,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctasggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarhpsglyqllnwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4201,NaN,NaN,QKQ15219,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgaevkkpgasvkisckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargdgdyydssgyyrptlynwldpwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4202,NaN,NaN,QKQ15218,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsykyyadsvkgrftisrdnskntlylqmnsltaedtavyycaregsrqwlviyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4203,NaN,NaN,QKQ15217,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqpgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngdtnyaqklqgrvtmttdtststaymelrslksddtavyycarfdygypysswsvlsidywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4204,NaN,NaN,QKQ15216,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsqtlsltctvsgasitsggyywtwirqhpgkglewigyiyysgssfynpslmsrvsisvdtskkqfslklrsvtaadtavyycakegsgggsqnwfdlwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4205,NaN,NaN,QKQ15215,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscsasgftfsnynmdwvrqapgkglewvssisssssyiyladsvkgrftisrdnaknslylqmnslraedtavyycarvqkdivvvpvaladyyyygmdvwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4206,NaN,NaN,QKQ15214,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgssnynpslksrvtisvdksknqfslklnsvtaadtavyycagrycsggrcgwfdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4207,NaN,NaN,QKQ15213,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviytggttyyadsvkgrftisrdnskntlylqmnslraedtavyycarahvdtamvesgafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4208,NaN,NaN,QKQ15212,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqsgpglvkpsetlpltctvsggsissssyywgwirqppgkglewigsvfysgstyynpslksrvtisvdtsknqlslklssvtaadtavyycarqvrqwleddafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4209,NaN,NaN,QKQ15211,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqapgkgldwmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatspavmsvgwvdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4210,NaN,NaN,QKQ15210,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywidwvrqmpgkglewmgifypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhnpdyydssgpldywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4211,NaN,NaN,QKQ15209,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgggvvqpgrslrlscaasgftfsiygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnsknmvylqmnslraddtavyycardgsnescsggfcsdswgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4212,NaN,NaN,QKQ15208,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4213,NaN,NaN,QKQ15207,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslrisckgsgysftshwiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarlkvitifgvvrddygmdvwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4214,NaN,NaN,QKQ15206,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgratittdeststaymelsslgsedtavyycarthsydnsgqyfdywgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4215,NaN,NaN,QKQ15205,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgvevkkpgasvkvsckafgytftgqdmhwvrqapgqglewmgwinpssagtnyaqkfqgrvtmtrdtsistaymelsrlrsddtsvyycrkmltifgkvnqtmlliswgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4216,NaN,NaN,QKQ15204,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycargvedpvvpaaipwcwfdpwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4217,NaN,NaN,QKQ15203,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssytmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaslpvvpaaigplpafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4218,NaN,NaN,QKQ15202,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmdslraedtamyycakdkappcssgwyyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4219,NaN,NaN,QKQ15201,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsydinwvrqatgqglewmgwmnpnsgntgyaqkfqgrvtmtrntsistaymelsslrsedtavyycarvvgsswypvdafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4220,NaN,NaN,QKQ15200,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrgdsygyyycmdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4221,NaN,NaN,QKQ15199,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckvsgytlpelsmhwvrqtpgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgptiaaaatnwfdpggqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4222,NaN,NaN,QKQ15198,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslrisckgsgysftsywiswvrqmpgkglewmgridpsdsytnyspsfqghvtisadksistaylqwsslkasdtamyycarpnpaggydssgwvdafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4223,NaN,NaN,QKQ15197,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprycsstscyagvyfdywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4224,NaN,NaN,QKQ15196,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsissyywswirqpagkglewigriytsgstnynpslksrvtmsvdtsknqfslklssvtaadtavyycarwkyndrfdywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4225,NaN,NaN,QKQ15195,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslipssvtaadtavyycarggelphynwfdpwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4226,NaN,NaN,QKQ15194,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycaspllltppdyyyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4227,NaN,NaN,QKQ15193,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsysiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycasvvggriaaagclgywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4228,NaN,NaN,QKQ15192,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgttnyaqkfqgrvtittdeststaymelsslrsedtavyycarvysydssgyyleywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4229,NaN,NaN,QKQ15191,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyginwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycasfgddsgdegvrwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4230,NaN,NaN,QKQ15190,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgatvkisckvsgytftdyymhwvqqapgkglewmglvdpedgetiyaekfqgrvtitadtstdtaymelsslrsedtavyycassdssgfvgsrgfdywgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4231,NaN,NaN,QKQ15189,NaN,SARS-CoV-2,Homo sapiens (human),qvqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewasaisgsggstyyadsvegrftisrdnskntlylqmnslraedtavyycakdtgycgddcyiklirggpdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4232,NaN,NaN,QKQ15188,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiiwvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycarvryydssgyyedywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4233,NaN,NaN,QKQ15187,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldtmggmdvwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4234,NaN,NaN,QKQ15186,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfgsysmswvrqapgkglewvssisrsssyiynadsvrgrltisrdnaknslylqmnslrvedtavyycardqplpdiltgyytgpldywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4235,NaN,NaN,QKQ15185,NaN,SARS-CoV-2,Homo sapiens (human),vqtggilgaevkkpgpsvkvscqagrapsssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtittdeststaymelsslrsedtavyycargprgcsstscygsyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4236,NaN,NaN,QKQ15184,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslklscaasgftfssyamswvrqapgkglewvsaisgsgsntyyadsvkgrftisrdnskntlylqmnslraedtavyycakglrgqqlvipteyfqhwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4237,NaN,NaN,QKQ15183,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavsggsfsnyywtwirqppgkglewigeidhsgstnynpslksrvtisvdtsknqfslwlssvtaadtavyycargrnyvlqfsewphprahfdnwgqgtlvtiss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4238,NaN,NaN,QKQ15182,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfsryamywvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarviggnyfgafdiwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4239,NaN,NaN,QKQ15181,NaN,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslrlscaasgltvssnymnwvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycareaygmdvwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4240,NaN,NaN,QKQ15180,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlpltctvsggsissfywswirqppgkglewigyihnngntnynpslksrvtmsidtsknqfslklssvtaadaavyycarggwsldswgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4241,NaN,NaN,QKQ15179,NaN,SARS-CoV-2,Homo sapiens (human),evqllesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarhmrpsiaarpgyqyymdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4242,NaN,NaN,QKQ15178,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvetgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardleraggmdvwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4243,NaN,NaN,QKQ15177,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssysmnwvrqapgkglewvsyissssstiyyadsvkgrftisrdnaknslylqmnslraedtavyycareansdfwsgylgyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4244,NaN,NaN,QKQ15176,NaN,SARS-CoV-2,Homo sapiens (human),vqlqqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarrstsrwgyyymdvwgkgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4245,NaN,NaN,QKQ15175,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssydmhwvrqttgkglqwvsaigtagdtyypgsvkgrftisrenaknslylqmnslragdtavyycarggdrypvgyfdlwgrgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4246,NaN,NaN,QKQ15174,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtpvyycarhnraeewepgfdiwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4247,NaN,NaN,QKQ15173,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsqtlsltctvsggsissggyywswirqlpgkglewigyiyysgstyynpslksrvtisvdtsknqfslnlssvtaadtavyycarqqldyydssgcfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4248,NaN,NaN,QKQ15172,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgpglvkpsetlsltctvsggsisstsyywgwirqppgkglecigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarlnydfwsgyysyalyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4249,NaN,NaN,QKQ15171,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgsgyrfttywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwssltasdtaiyycaryyydsrgytsidfwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4250,NaN,NaN,QKQ15170,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardpppddssgwtmgyfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4251,NaN,NaN,QKQ15169,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngytnsaqklqgrvtmttdtststaymelrslrsddtavyycardlvdtamvqtlddygmdvwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4252,NaN,NaN,QKQ15168,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdntkntlylqmnslraedtavyycardseyydiltgylapthyyyyymdvwgkgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4253,NaN,NaN,QKQ15167,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrddaknslflqmnslraedtavyycagdqnlycsgdscyyhyygmdvwgqgtvvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4254,NaN,NaN,QKQ15166,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssfiyyadsvkgrftisrdnaknslylqmnslraedtavyycarwksdyydssgyypaafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4255,NaN,NaN,QKQ15165,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycarvewaaagtfywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4256,NaN,NaN,QKQ15164,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyyihwvrqapgqglewmgwinpnsgttnyaqrfqgrvtmtrdtsistaymelsrlrsddtavyycareavaarpgnfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4257,NaN,NaN,QKQ15163,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinssggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycarpprnyydrsgyyqraeyfqhwgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4258,NaN,NaN,QKQ15162,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssnamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntmylqmnslraedtavyycarprggnylagfdpwgqgtrvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4259,NaN,NaN,QKQ15161,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsggsmnlyywiwirqppgkglewigyvyytgstnynpslksrvtmsvdtsksqfslkmsavtaadtavyycarrgevngyrgafdiwgqgarvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4260,NaN,NaN,QKQ15160,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnrlraedtavyycaretptstyssgwynyyyymdvwgkgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4261,NaN,NaN,QKQ15159,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgtevkkpgasvkvsckasgytfpgyyihwvrqapgqglewmgwinpnsgvaksaqkfqgrvtmtrdssistvyldvtsddtavyycardlvwatvsgtmdvwgqgttvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4262,NaN,NaN,QKQ15158,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsasgsyygafgywgqrtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4263,NaN,NaN,QKQ15157,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvtstymtwvrrapgkglewvsiiynddttyyadsvkdrvtvsrddskntlylqmnslraedtaiyycarggyyydpsgyysrsfsfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4264,NaN,NaN,QKQ15156,NaN,SARS-CoV-2,Homo sapiens (human),qlqlvesgpglvkpsetlsltctvsggsissyfwswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarhsqgwlqqavafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4265,NaN,NaN,QKQ15155,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpggslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaredyydssgsfdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4266,NaN,NaN,QKQ15154,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtlssyaitwvrqapgqglewvggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvgaydssgysndywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4267,NaN,NaN,QKQ15153,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsggglvqpgrslrlscaasgftfgeyamhwvrqapgkglewvsgiswnsgsidyadsvkgrftisrdnaknslylqmnslraedtalyycakdmgeavagthygmdvwgqgtmvtass,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4268,NaN,NaN,QKQ15152,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatsrvrgvsnwfdpwgqgtpitiss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4269,NaN,NaN,QKQ15151,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycaripgydssgyyrgdywgqgtlvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4270,NaN,NaN,QKQ15150,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycakdgqyydfwsgylgartnphyyyymdvwgkgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4271,NaN,NaN,QKQ15149,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsiyamhwvrqapgkglewvavisydgsnqyyadsvrgrftisrgnskntlylqmnslrpedtavyycararggsyndafdiwgqgtmvtvss,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4272,NaN,NaN,QKQ15148,NaN,SARS-CoV-2,Homo sapiens (human),hqhqveqgpggveqsetlfltccvsggftisscykrggirqpprkgeewavssyyssstyytpslksrvtisvdksknqfslkmssvtaadtavyycarvssgyyftpfdywgqgtrghrlf,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 monoclonal antibody heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4273,NaN,NaN,NaN,QKQ15315,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4274,NaN,NaN,NaN,QKQ15314,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspftfgpgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4275,NaN,NaN,NaN,QKQ15313,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4276,NaN,NaN,NaN,QKQ15312,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpltfgpgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4277,NaN,NaN,NaN,QKQ15311,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4278,NaN,NaN,NaN,QKQ15310,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngphwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4279,NaN,NaN,NaN,QKQ15309,SARS-CoV-2,Homo sapiens (human),NaN,qpvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4280,NaN,NaN,NaN,QKQ15308,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4281,NaN,NaN,NaN,QKQ15307,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4282,NaN,NaN,NaN,QKQ15306,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspsslsasvgdrvtitcrasqsmssylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4283,NaN,NaN,NaN,QKQ15305,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgthftltisslqaedvavyycqqyystppltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4284,NaN,NaN,NaN,QKQ15304,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnllsltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4285,NaN,NaN,NaN,QKQ15303,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4286,NaN,NaN,NaN,QKQ15302,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyttfiytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4287,NaN,NaN,NaN,QKQ15301,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4288,NaN,NaN,NaN,QKQ15300,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvtsnlawyqqkrgqaprlliydasnratgiparfsgsgsgtdftltisglepedfavyycqqrsnwptfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4289,NaN,NaN,NaN,QKQ15299,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqpedfavyycqqcynwppwtfgqgtrvefk,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4290,NaN,NaN,NaN,QKQ15298,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyeaskrpsgisnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkptvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4291,NaN,NaN,NaN,QKQ15297,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevtkrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4292,NaN,NaN,NaN,QKQ15296,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4293,NaN,NaN,NaN,QKQ15295,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapkvliydnnnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgsvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4294,NaN,NaN,NaN,QKQ15294,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsylwtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4295,NaN,NaN,NaN,QKQ15293,SARS-CoV-2,Homo sapiens (human),NaN,qpvltqppsvsvapgqtaritcggdnigskdvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsstdhvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4296,NaN,NaN,NaN,QKQ15292,SARS-CoV-2,Homo sapiens (human),NaN,qtvvtqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlglyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4297,NaN,NaN,NaN,QKQ15291,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiydsskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4298,NaN,NaN,NaN,QKQ15290,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspatlslspgeratlscrasqsvssflawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4299,NaN,NaN,NaN,QKQ15289,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtplslsvtpgqpasiscksgqsllhsdgktylywylqkpgqppqlliyevsnrfsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqsiqlpptfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4300,NaN,NaN,NaN,QKQ15288,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwasssvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4301,NaN,NaN,NaN,QKQ15287,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4302,NaN,NaN,NaN,QKQ15286,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqhkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynywplitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4303,NaN,NaN,NaN,QKQ15285,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstlvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4304,NaN,NaN,NaN,QKQ15284,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4305,NaN,NaN,NaN,QKQ15283,SARS-CoV-2,Homo sapiens (human),NaN,qpvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsrsgdtasltisglqaedeadyycssytssstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4306,NaN,NaN,NaN,QKQ15282,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpqtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4307,NaN,NaN,NaN,QKQ15281,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgvtfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4308,NaN,NaN,NaN,QKQ15280,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4309,NaN,NaN,NaN,QKQ15279,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapkvliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqyntysrtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4310,NaN,NaN,NaN,QKQ15278,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqspsslsvsvgnivtitcrasqgirndlggisrnqgkplsaiygasslqsgvpsrfrgrgwgteftlpisslqledfaiyyciqhnsylwtfgqgpkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4311,NaN,NaN,NaN,QKQ15277,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtclclqgkshplcrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspntfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4312,NaN,NaN,NaN,QKQ15276,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppsitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4313,NaN,NaN,NaN,QKQ15275,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4314,NaN,NaN,NaN,QKQ15274,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypplfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4315,NaN,NaN,NaN,QKQ15273,SARS-CoV-2,Homo sapiens (human),NaN,divmtqsplslpvtlgqpasiscrssqslvysdgntflnwfqqrpgqsprrliyqvsnrdsgvpdrfsgsgsgtdftlkisrveaedvgvyycmqgthwprtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4316,NaN,NaN,NaN,QKQ15272,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqepgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppmytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4317,NaN,NaN,NaN,QKQ15271,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4318,NaN,NaN,NaN,QKQ15270,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlsvspgeratlscrasqsvssslawyqqkpgqaprlliyaastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4319,NaN,NaN,NaN,QKQ15269,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssprltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4320,NaN,NaN,NaN,QKQ15268,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsslltfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4321,NaN,NaN,NaN,QKQ15267,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlfstnsknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4322,NaN,NaN,NaN,QKQ15266,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfalyycqqydnwplftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4323,NaN,NaN,NaN,QKQ15265,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgswsgtdftltisrlepedfavyycqqygsspgtfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4324,NaN,NaN,NaN,QKQ15264,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlplspgeratlscrasqsvtnnylawyqqkpgqaprllihatstratgipdrfsgsgsgtdftltisrlepedfavyycqqyggplpytfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4325,NaN,NaN,NaN,QKQ15263,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4326,NaN,NaN,NaN,QKQ15262,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygslytfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4327,NaN,NaN,NaN,QKQ15261,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpqvtfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4328,NaN,NaN,NaN,QKQ15260,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsisnylnwyqqkpgkapklllyaasdlqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsysthmstfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4329,NaN,NaN,NaN,QKQ15259,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppvtfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4330,NaN,NaN,NaN,QKQ15258,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrasqnvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssplftfgpgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4331,NaN,NaN,NaN,QKQ15257,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlhsypltfgggtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4332,NaN,NaN,NaN,QKQ15256,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsysitfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4333,NaN,NaN,NaN,QKQ15255,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsaapgqkvtiscsgsssnignnfvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdgslsvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4334,NaN,NaN,NaN,QKQ15254,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtysvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4335,NaN,NaN,NaN,QKQ15253,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlvtyqdnkrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstavfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4336,NaN,NaN,NaN,QKQ15252,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlsyrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppgtfgqgtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4337,NaN,NaN,NaN,QKQ15251,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqppsvsvapgktaritcggnnigsksvhwyqqkpgqapvlviyydsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssdhwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4338,NaN,NaN,NaN,QKQ15250,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4339,NaN,NaN,NaN,QKQ15249,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4340,NaN,NaN,NaN,QKQ15248,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqepsltvspggtvtltcgsstgavtsghypywfqqkpgqaprtliydtsnkrswtparfsgsllggkaaltlsgaqpedeaeyycllsysgvwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4341,NaN,NaN,NaN,QKQ15247,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcqasqdisnylnwyqqrpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnppltfgggtkleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4342,NaN,NaN,NaN,QKQ15246,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllidgassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4343,NaN,NaN,NaN,QKQ15245,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4344,NaN,NaN,NaN,QKQ15244,SARS-CoV-2,Homo sapiens (human),NaN,airmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsypwtfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4345,NaN,NaN,NaN,QKQ15243,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdigtynyvswyqqhpgkapklmiyevtkrpsgvpdrfsgsksgntasltvsglqaddegdyycssyvgnnnwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4346,NaN,NaN,NaN,QKQ15242,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvspgqtasitcsgdklgdkyacwyqqkpgqspvlviyqdskrpsgiperfsgsnsgntatltisgtqamdeadyycqawdsstvvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4347,NaN,NaN,NaN,QKQ15241,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgsssdiapytfvswyqqhsgtapkliiydvrnrpsgisdrfsgsrsgntaslsisglqaedeadyycsaytttstswvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4348,NaN,NaN,NaN,QKQ15240,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvrdrvtitcrasqsitsslnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystpytfgqgtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4349,NaN,NaN,NaN,QKQ15239,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstrhwvfgggtkltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4350,NaN,NaN,NaN,QKQ15238,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprvtfgggtkveik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4351,NaN,NaN,NaN,QKQ15237,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsvsvspgqtasipcsgdklgdiyacwyqqkpgqspvlviyqdtkrpsgiperfsgsnsgntatltisgtqamdeadyycqawgsttakvfgggtkltvp,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4352,NaN,NaN,NaN,QKQ15236,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccscagsstyvfgtgtkvtvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4353,NaN,NaN,NaN,QKQ15235,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlslspgeratlscrasqsvssylawyqqkpgqaprlpiydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpprftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4354,NaN,NaN,NaN,QKQ15234,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqgisnylawyqqkpgkvpklliyaastlqsgvpsrfsgsgsgtdftltisslqpedvatyycqkynsappafgqgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4355,NaN,NaN,NaN,QKQ15233,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqpasvsgspgqsitisctgassdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpvvfgggteltvl,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4356,NaN,NaN,NaN,QKQ15232,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspppftfgpgtkvdik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 monoclonal antibody light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4357,NaN,NaN,QJU69682,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnsmntlflqmnslraedtavyycarvlpmygdyldywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4358,NaN,NaN,QJU69680,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycaregycsggscysgyyyyygmdvwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4359,NaN,NaN,NaN,QJU69681,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasvgdrvtitcrasqsisrylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystppeytfgqgtkleikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4360,NaN,NaN,NaN,QJU69679,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtpatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrrnwgtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 immunoglobulin light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4361,NaN,NaN,QJU69735,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvaviwydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardimfgddwlqkqpdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4362,NaN,NaN,QJU69734,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssytinwvrqapgqglewmgriipilgiadyaqkfqgrvtitadkststaymelsslrsedtavyycardlvedtamvtgaaagtwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4363,NaN,NaN,QJU69733,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisaysgntnyaqklqgrvtmttdtststaymevrslrsddtavyycarvglwwlghpdvfdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4364,NaN,NaN,QJU69732,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsikyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4365,NaN,NaN,QJU69731,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvtveaifgvvilplknwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4366,NaN,NaN,QJU69730,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyymhwvrqapgqglewmgiinpsggstsyaqkfqgrvtmtrdtststvymelsslrsedtavyycardltstssspysyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4367,NaN,NaN,QJU69729,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvtvvhfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4368,NaN,NaN,QJU69728,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqkvqgrvtmttdtststaymelrslrsddtavyycardrgyaatfgvfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4369,NaN,NaN,QJU69727,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycartkggsyfapfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4370,NaN,NaN,QJU69726,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfssygiswvrqdpgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarvglwwlghpdafdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4371,NaN,NaN,QJU69725,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrsmrlscaasgfnlssyamhwvrqasgkglewvslisydgsikyyadsvkgrftvsgdnskntlflqmsslraddsalyycvrggvsgpnafdiwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4372,NaN,NaN,QJU69724,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycaraqtahysssfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4373,NaN,NaN,QJU69723,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycararvaydyiwgsyrykafdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4374,NaN,NaN,QJU69722,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyvqkfqgrvtmtrdtsistaymelnrlrsddtavyfcardltttagtdyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4375,NaN,NaN,QJU69721,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4376,NaN,NaN,QJU69720,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsyggsyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4377,NaN,NaN,QJU69719,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsydiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycardsvagiyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4378,NaN,NaN,QJU69718,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsdvtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareardyygsgsldywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4379,NaN,NaN,QJU69717,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4380,NaN,NaN,QJU69716,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgvivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardldvsggmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4381,NaN,NaN,QJU69713,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvalisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsfggsyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4382,NaN,NaN,QJU69712,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycardeayydiltgyinapknyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4383,NaN,NaN,QJU69711,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissgdyywswirqppgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycardhhydfwsgyssyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4384,NaN,NaN,QJU69710,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatappysppsswfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4385,NaN,NaN,QJU69709,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsyamhwvrqapgqrlewmgwinagngntkysqkfqgrvtitrdtsastaymelsslrsedtavyycarvwgycsggscyvdafdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4386,NaN,NaN,QJU69708,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssysmnwvrqapgkglewvssisssssyiyyadsvkgrftisrdnaknslylqmnslraedtavyycardresydiltgysmegcfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4387,NaN,NaN,QJU69707,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsnawmswvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlylqmnslktedtavyycttdrvydyiwgsyryldywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4388,NaN,NaN,QJU69706,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycareyyydssvypyyyyamdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4389,NaN,NaN,QJU69705,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycattspivgaitwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4390,NaN,NaN,QJU69704,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycarvdygsgsygwgwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4391,NaN,NaN,QJU69703,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarqssfyssgwysygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4392,NaN,NaN,QJU69702,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikqdgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycardfnsyqllwyyyygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4393,NaN,NaN,QJU69701,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4394,NaN,NaN,QJU69700,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgfnlsnyamhwvrqasgkglewvslisydgsvkyytdsvkgrftvsgdnskntlflqmnslrpddsalyycvrggvsgpnsfdmwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4395,NaN,NaN,QJU69699,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarettghfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4396,NaN,NaN,QJU69698,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltcnvsggsissyywswirqppgkglewigyiyysgstnynpslksrvtisvdtsknqfslklssvtaadtavyycargfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4397,NaN,NaN,QJU69697,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctvsggsissssyywgwirqppgkglewigsiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycathivvvtatpnwyfdlwgrgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4398,NaN,NaN,QJU69696,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftsygiswvrqapgqglewmgwisayngntnyaqklqgrvtmttdtststaymelrslrsddtavyycarlvptwasyydfwsgypggygmdvwgqgttvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4399,NaN,NaN,QJU69695,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4400,NaN,NaN,QJU69694,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetiyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatgppycsstscehwfdpwgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4401,NaN,NaN,QJU69693,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvtckasgytftsyylhwvrqapgqglewmgiinpsggttsyaqkfqgrvtmtrdtststvymelsslrsedtavyycaragrrysssddgafdiwgqgtmvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4402,NaN,NaN,QJU69692,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsisgsylgafdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4403,NaN,NaN,QJU69691,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgselkkpgasvklscqasgysftnhamnwvrqapgqglewmgwintntgnptyaqgftgrfvfsldtsvsttylhisslkaedtavyycarasarpgvatnldfwgqgtlvvvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4404,NaN,NaN,QJU69690,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvrgsyylfdywgqgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4405,NaN,NaN,QJU69689,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslksrvtisvdtsknqfslklssvtaadtavyycartplslrlrynwyfdlwgrgtlvtvss,NaN,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,"anti-SARS-CoV-2 immunoglobulin gamma heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4406,NaN,NaN,NaN,QJU69782,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntylnwfqqrpgqsprrliykvsnrdsgvpdkfsgsgsgtdftlkisrveaedvgvyycmqgthwpptfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4407,NaN,NaN,NaN,QJU69781,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4408,NaN,NaN,NaN,QJU69780,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4409,NaN,NaN,NaN,QJU69779,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapkfliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqtyitaftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4410,NaN,NaN,NaN,QJU69778,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4411,NaN,NaN,NaN,QJU69777,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4412,NaN,NaN,NaN,QJU69776,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpasiscrssqslvysdgntyvnwfqqrpgqsprrliykvsnrdsgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4413,NaN,NaN,NaN,QJU69775,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppitfgqgtrleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4414,NaN,NaN,NaN,QJU69774,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlprfgpgtkvdikr,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4415,NaN,NaN,NaN,QJU69773,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspqtfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4416,NaN,NaN,NaN,QJU69771,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqgirndlgwyqqkpgkapkrliyaasslqsgvpsrfsgsgsgteftltisslqpedfatyyclqhnsypftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4417,NaN,NaN,NaN,QJU69770,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwpytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4418,NaN,NaN,NaN,QJU69769,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwpltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4419,NaN,NaN,NaN,QJU69768,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssppkytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4420,NaN,NaN,NaN,QJU69767,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssrgtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4421,NaN,NaN,NaN,QJU69766,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4422,NaN,NaN,NaN,QJU69765,SARS-CoV-2,Homo sapiens (human),NaN,dvvmtqsplslpvtlgqpatiscrssqslvysdgntyvnwfqqrpgqsprrliyqvsirasgvpdrfsgsgsgtdfalkisrveaedvgvyycmqgthwpvtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4423,NaN,NaN,NaN,QJU69764,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrsnwppiftfgpgtkvdik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4424,NaN,NaN,NaN,QJU69763,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvssiylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqyagspwtfgqgtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4425,NaN,NaN,NaN,QJU69762,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsspgtfgqgtrleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4426,NaN,NaN,NaN,QJU69761,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4427,NaN,NaN,NaN,QJU69760,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygsssytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4428,NaN,NaN,NaN,QJU69759,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqnvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyyitpytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4429,NaN,NaN,NaN,QJU69758,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspstlsasvgdrvtitcrasqsisswlawyqqkpgkapklliykasslesgvpsrfsgsgsgteftltisslqpddfatyycqqynsytfgqgtkleik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4430,NaN,NaN,NaN,QJU69757,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqnidnylnwyqqkpgkapklliyaasrlhsgvpsrfsgsgsgtdftliisslqpedlatyycqqsysnpltfgpgtkvdir,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4431,NaN,NaN,NaN,QJU69756,SARS-CoV-2,Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppsltfgggtkveik,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin kappa light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4432,NaN,NaN,NaN,QJU69755,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdssgnlyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4433,NaN,NaN,NaN,QJU69754,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydssltlyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4434,NaN,NaN,NaN,QJU69753,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvvviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4435,NaN,NaN,NaN,QJU69752,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydssnwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4436,NaN,NaN,NaN,QJU69751,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdterpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtymifgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4437,NaN,NaN,NaN,QJU69750,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4438,NaN,NaN,NaN,QJU69749,SARS-CoV-2,Homo sapiens (human),NaN,syeltqphsvsvataqmaritcggnnigskavhwyqqkpgqdpvlviysdsnrpsgiperfsgsnpgntatltisrieagdeadyycqvwdsssdhvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4439,NaN,NaN,NaN,QJU69748,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsgpvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4440,NaN,NaN,NaN,QJU69747,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsavvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4441,NaN,NaN,NaN,QJU69746,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4442,NaN,NaN,NaN,QJU69744,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytssstpyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4443,NaN,NaN,NaN,QJU69743,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsasyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4444,NaN,NaN,NaN,QJU69742,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyvvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4445,NaN,NaN,NaN,QJU69741,SARS-CoV-2,Homo sapiens (human),NaN,qlvltqspsasaslgasvkltctlssghssyaiawhqqqpekgprylmklnsdgshskgdgipdrfsgsssgaeryltisslqsedeadyycqtwgtgirvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4446,NaN,NaN,NaN,QJU69740,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsaapgqkvtiscsgsssnignnyvswyqqlpgtapklliydnnkrpsgipdrfsgsksgtsatlgitglqtgdeadyycgtwdsslsagpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4447,NaN,NaN,NaN,QJU69739,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstyvfgtgtkvtvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4448,NaN,NaN,NaN,QJU69738,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqprsvsgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvpdrfsgsksgntasltisglqaedeadyyccsyagsytwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4449,NaN,NaN,NaN,QJU69737,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvsnrpsgvsnrfsgsksgntasltisglqaedeadyycssytsistwvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4450,NaN,NaN,NaN,QJU69736,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapklliysnnqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Seydoux,E. et al.; Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual; bioRxivorg (2020) In press; 2020.",https://doi.org/10.1101/2020.05.12.091298,NaN,"anti-SARS-CoV-2 immunoglobulin lambda light chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4451,NaN,NaN,QIQ28229,NaN,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qqlkesggrlvtpgtpltltctasgfslssyyvswvrqapgkglewigiipgtgptycaswakgrftisktsttvdlkitspttedtatyfcarvyagfstwlyfdlwgpgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-03-15,NaN,NaN,NaN
4452,NaN,NaN,QIQ28228,NaN,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssyamswvrqapgkglewigiisksgstyyaswakgrftisktsttvdlkitspttedtatyfcarddilytsssgyyygmdlwgpgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-03-15,NaN,NaN,NaN
4453,NaN,NaN,QIQ28227,NaN,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssydmiwvrqapgeglewigiidtaggayyaswakgrftisrtsttvdlkitspttedtatyfcarafygsgwgftrldlwgqgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-03-15,NaN,NaN,NaN
4454,NaN,NaN,QIQ28226,NaN,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),eqlkesggrlvtpgtpltltctvsgfdlsscsmgwvrqapgkgleyigiisssgstyyaswpkgrftisktsttvdlkitspttedtatyfcargfwyfnlwgqgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-03-15,NaN,NaN,NaN
4455,NaN,NaN,QIQ28225,NaN,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctasgfslssyymswvrqapgkglewigiiyassstnyaswatgrftisktsttvdlkitspttedtatyfcarvyssgwgdafdlwgpgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-03-15,NaN,NaN,NaN
4456,NaN,NaN,QIQ28224,NaN,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),qsvkesggrlvtpgtpltltctvsgfslssywmswvrqapgkglewigiiftggstyyaswakgrftisktsttvdlkitspttedtatyfcartsyydvsgwgvgrldlwgqgtlvtvss,NaN,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin heavy chain variable region, partial [Oryctolagus cuniculus]",NaN,2022-03-15,NaN,NaN,NaN
4457,NaN,NaN,NaN,QIQ28235,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),NaN,dpmltqtaspvsaavggtvtincqasqsisssnwlswyqqkpgqppklliykastlasgvpsrfkgsgsgtqftltisgvqcddaatyyclgyysftsadnafgggtevvvk,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-15,NaN,NaN,NaN
4458,NaN,NaN,NaN,QIQ28234,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),NaN,alvmtqtpasvsaavggtvtincqasediysnlawyqqkpgqppklliygastlasgvpsrfkgsgsgteytltisgvqcddaatyycqctydsssytfgggteleik,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-15,NaN,NaN,NaN
4459,NaN,NaN,NaN,QIQ28233,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),NaN,dpvltqtpssasepvggtvnikcqasqsigtrlawyqqkpgqppklliyyastlasgvpsrfkgsgsgteytltisgvqcddaatyyclgehsyssgdgrtafgggtevvvk,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-15,NaN,NaN,NaN
4460,NaN,NaN,NaN,QIQ28232,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),NaN,alvmtqtpssvsepvggtvtincqasediysnlawyqqkpgqppklliydasnlasgvpsrfsgsgsgteytltisgvqcadaatyycqtyystvtrafgagtkveik,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-15,NaN,NaN,NaN
4461,NaN,NaN,NaN,QIQ28231,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),NaN,apvltqtpspvsaavggtvtincqaseniysflawyqqkpgqppklliytasklasgvpsrfkgsgsgtqftltisdvqcddaatyycqqtdtysnvdnafgggtevvve,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-15,NaN,NaN,NaN
4462,NaN,NaN,NaN,QIQ28230,"SARS-CoV-2, Spike protein RBD",Oryctolagus cuniculus (rabbit),NaN,dpmltqtassvsaavggtvtiscqssqsvydnnwlgwyqqkpgqppklliysastlasgvpsrfkgsgsgtqftltisdlecddaatyycaggysgnifafgggteleil,"Hong,J. et al.; Generation and characterization of rabbit neutralizing monoclonal antibodies against SARS-CoV-2; Unpublished; 2020.",NaN,NaN,"anti-SARS-CoV-2 RBD antibody immunoglobulin light chain variable region, partial [Oryctolagus cuniculus]",2022-03-15,NaN,NaN,NaN
4463,NaN,NaN,NaN,ABG79005,SARS-CoV,Homo sapiens (human),NaN,eltqspatlslspgeratlscrtsqnigtwlawfqqkpgqtprlliydaskraagiparfsgsgsgtdftltinsleaedfavyycqqrlqwatentfgrgtrldikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec,"Kang,X. et al.; Human neutralizing SARS-CoV specific Fab molecules generated by phage display; Unpublished; 2006.",NaN,NaN,"anti-SARS-CoV S protein immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4464,NaN,NaN,QBK47409,NaN,not determined,Homo sapiens (human),mgwsciilflvatatgvhsqvqlvqsgaevkkpgasvkvsckasgytftayymhwvrqapgqglewmgwinpntgvtnfaqkfqgrvtmtrdtsigtayielswlrsddtavyycardrdasmasyyyygmdvwgqgttvtvssastkgpsvfplapcsrstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkrvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Lindner,J.M. et al.; Human Memory B Cells Harbor Diverse Cross-Neutralizing Antibodies against BK and JC Polyomaviruses; Immunity (2019) In press; 2019.",10.1016/j.immuni.2019.02.003,immunoglobulin heavy chain [Homo sapiens],NaN,2022-03-15,NaN,NaN,NaN
4465,NaN,NaN,AAA02914,NaN,not determined,Homo sapiens (human),mdwtwrflfvvaaatgvqsqmqvvqsgaevkkpgssvtvsckasggtfsnyaiswvrqapgqglewmggiiplfgtptysqnfqgrvtitadkststahmelislrsedtavyycatdryrqanfdrarvgwfdpwgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Lewis,A.P. et al.; Rescue, expression, and analysis of a neutralizing human anti-hepatitis A virus monoclonal antibody; J. Immunol. 151 (5), 2829-2838 (1993); 1993.",NaN,IgG [Homo sapiens],NaN,2022-03-15,NaN,NaN,NaN
4466,ANTI-PLASMODIUM,NaN,AAX82494,NaN,not determined,Homo sapiens (human),qvqlqesggglvkpggslklscaasgftfssygmswvrqtpdkrlewvatissggsytyypdsvkgrftisrdnakntlylqmsslksedtamyycarlyygyryyfdywgqgtmvtvss,NaN,"Lundquist,R. et al.; Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties; Infect. Immun. 74 (6), 3222-3231 (2006); 2006.",10.1128/IAI.00928-05,"anti-Plasmodium falciparum merozoite surface protein 3 immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4467,NaN,NaN,AFR78282,NaN,not determined,Homo sapiens (human),vqlvqsggglvkpggslrlscaasgftfssysvtwvrqapgkglewvssisssssyisyadsvkgrftisrdnaknslylqmnslraedtavyfcardplrvavagevmdywgqgtlvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Jin,H. et al.; Direct Submission; Submitted (09-JUL-2012) Department of Immunochemistry, Research Institute for Microbial Diseases, Osaka University, Yamadaoka 3-1, Suita, Osaka 565-0871, Japan; 2012.",NaN,"immunoglobulin heavy chain, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4468,NaN,NaN,ACT68971,NaN,not determined,Homo sapiens (human),vsgysisggyywgwirqppgkglewigslfysgsphynpslksrvtisldtsknqfslnlssvtaadtavyfcasgrlgycctnscnyngldvwg,NaN,"Morbach,H. et al.; Clonally Expanded CD27+ and CD27- Memory B Cells Might Function as Antigen Presenting Cells in the Joints of Children with Juvenile Idiopathic Arthritis; Unpublished; 2009.",NaN,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4469,NaN,NaN,CEF94348,NaN,not determined,Homo sapiens (human),gaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarvfigycsstscytggfcnwfdpwgqgtl,NaN,"Hansen,T.O. et al.; Sterile DJH rearrangements reveal that distance between gene segments on the human Ig H chain locus influences their ability to rearrange; J. Immunol. 194 (3), 973-982 (2015); 2015.",10.4049/jimmunol.1401443,"immunoglobulin heavy chain variable region, partial [Homo sapiens]",NaN,2022-03-15,NaN,NaN,NaN
4470,NaN,NaN,NaN,AKL91145,not determined,Homo sapiens (human),NaN,aeivltqspgtlslspgeratlscrasqsvsssylawyqqkagqaprlliygassratgiperfsgsgsgtdftltisrlepedfaiyycqqygssrfifgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs,"Beernink,P.T. et al.; Functional Analysis of the Human Antibody Response to Meningococcal Factor H Binding Protein; MBio 6 (3), e00842-15 (2015); 2015.",10.1128/mBio.00842-15,NaN,"immunoglobulin kappa light chain, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4471,NaN,NaN,AAG39162,NaN,not determined,Mus musculus (house mouse),evqlqqsgtvlagpgasvkmsckasgytftsywmhwvkqrpgqglewigaiypgnsdtsynqkfkgkakltavtststaymelssltnedsavyyctr,NaN,"Haines,B.B. et al.; Germline diversity of the expressed BALB/c VhJ558 gene family; Mol. Immunol. 38 (1), 9-18 (2001); 2000.",NaN,"immunoglobulin heavy chain variable region, partial [Mus musculus]",NaN,2022-03-15,NaN,NaN,NaN
4472,ANTI-HUMAN,NaN,AJD85777,NaN,not determined,synthetic construct,mnlglsliflvlvlkgvqcevklvesggglvqpggslklscatsgftfsdyymywvrqtpekrlewvayinsgggstyypdtvkgrftisrdnakntlylqmsrlksedtamyycarrglpfhamdywgqgtsvtvssaktkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtktytcnvdhkpsntkvdkrveskygppcppcpapefeggpsvflfppkpkdtlmisrtpevtcvvvdvsqedpevqfnwyvdgvevhnaktkpreeqfnstyrvvsvltvlhqdwlngkeykckvsnkglpssiektiskakgqprepqvytlppsqeemtknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflysrltvdksrwqegnvfscsvmhealhnhytqkslslslgkasqtptntisvtptnnstptnnsnpkpnpasekirlrpggkkkyklkhivasssvspttsvhptptsvpptptksspasnppipvgeiykrwiilglnkivrmysptsildasptstpadsstitptatptatptikgashtqgyfpdwqnytpgpgvrypltfgwlyklastvtptatatpsaivttitptattkpasvgfpvtpqvplrpmtykaavdlshflkekgglastngsitvaataptvtptvnatpsaaasaifqssmtkilepfrkqnpdiviyqymddlyas,NaN,"Flamar,A.L. et al.; Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells; AIDS 27 (13), 2041-2051 (2013); 2015.",10.1097/QAD.0b013e3283624305,anti-human CD40 12E12 antibody HIV antigen fusion protein [synthetic construct],NaN,2022-03-15,NaN,NaN,NaN
4473,NaN,NaN,NaN,CAC94292,not determined,Homo sapiens (human),NaN,qsitisctgtsghvgnynlvswyqqhpgkapklmiyegskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsgtxvfgg,"Goossens,T. et al.; Receptor revision plays no major role in shaping the receptor repertoire of human memory B cells after the onset of somatic hypermutation; Eur. J. Immunol. In press; 2001.",NaN,NaN,"immunoglobulin lambda chain variable region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4474,NaN,NaN,CAD19025,NaN,not determined,Homo sapiens (human),mdwtwrilflvaaatgahsqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinphsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycartyyydssgyyhdafdiwgqgtmvtvssastkgpsvfplapcsrstsestaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssnfgtqtytcnvdhkpsntkvdktverkccvecppcpappvagpsvflfppkpkdtlmisrtpevtcvvvdvshedpevqfnwyvdgvevhnaktkpreeqfnstfrvvsvltvvhqdwlngkeykckvsnkglpapiektisktkgqprepqvytlppsreemtknqvsltclvkgfypsdiavewesngqpennykttppmldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk,NaN,"Takashi,T. et al.; Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof; EP1158004-A2 28-NOV-2001 Japan Tobacco Inc. (JP); 2001.",NaN,unnamed protein product [Homo sapiens],NaN,2022-03-15,NaN,NaN,NaN
4475,NaN,NaN,NaN,BAC01727,not determined,Homo sapiens (human),NaN,mkyllptaaagllllaaqpamadiqmtqspsslsasvgdrvtitcrasqsissylnwyqqkpgkapklliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsystprtfgqgtkveikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhklyacevthqglsspvtksfnrgecsarqstpfvceyqgqssdlpqppvnagggsgggsgggseggg,"Akahori,Y. et al.; Construction and characterization of antibody libraries: isolation of therapeutic human antibodies and application to functional genomics; Unpublished; 2002.",NaN,NaN,"immunoglobulin kappa light chain VLJ region, partial [Homo sapiens]",2022-03-15,NaN,NaN,NaN
4476,NaN,NaN,S42399,NaN,not determined,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytfamyaihwvrqapgqslewmgwisvadgktkysqkfqdrvtitrdtsattaymevrglrsedtavyycar,NaN,"Chouchane,L. et al.; Molecular characterization of a human anti-Rh(D) antibody with a DH segment encoded by a germ-line sequence; Eur. J. Biochem. 207 (3), 1115-1121 (1992); 1993.",NaN,"IgVH Rh D [human, mRNA Partial, 296 nt]",NaN,2022-03-15,NaN,NaN,NaN
4477,ANTI-HUMAN,NaN,E14571,NaN,not determined,Mus musculus (house mouse),mgwswiflfllsgtagvhsevqlqqsgpelvkpgasvkisckasgytftdynmhwvkqshgkslewigyiypynggtgynqkfkskatltvdnssstaymelrsltsedsavyycarsyyamdywgqgtsvtvssesqsfpnvfplvscesplsdknlvamgclardflpstisftwnyqnnteviqgirtfptlrtggkylatsqvllspksilegsdeylvckihyggknrdlhvpipavaemnpnvnvfvpprdgfsgpaprkskliceatnftpkpitvswlkdgklvesgfttdpvtienkgstpqtykvistltiseidwlnlnvytcrvdhrgltflknvsstcaaspstdiltftippsfadiflsksanltclvsnlatyetlniswasqsgepletkikimeshpngtfsakgvasvcvedwnnrkefvctvthrdlpspqkkfiskpnevhkhppavyllppareqlnlresatvtclvkgfspadisvqwlqrgqllpqekyvtsapmpepgapgfyfthsiltvteeewnsgetytcvvghealphlvtertvdkstgkptlynvslimsdtggtcy*,NaN,"Serizawa,N. et al.; DNA CODING VARIABLE REGION OF MONOCLONAL ANTIBODY, AND RECOMBINED ANTIBODY; JP1997322796-A 1 16-DEC-1997 SANKYO CO LTD; 1999.",NaN,Mouse mRNA for immunoglobulin heavy chain of anti-human Fas mouse monoclonal antibody CH11,NaN,2022-03-15,NaN,NaN,NaN
4478,NaN,NaN,MZ927184,NaN,SARS-CoV-2,synthetic construct,qvqlvqsgaevkkpgasvkvsckvsgytspatihwvrqapgkglewmggispykgdtiyaqkfqgrvtmtedtstdtaymelsslksedtavyycakdsyyydssgsglgggfdywgqgtlvtvss,NaN,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,"Synthetic construct clone 41 immunoglobulin heavy chain variable region gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4479,NaN,NaN,NaN,MZ927183,SARS-CoV-2,synthetic construct,NaN,diqmtqspssvsasvgdrvtitcrasrdissylawyqqkpgkapklliygastrasgvpsrfsgsgsgtdftltisslqpedfanyyclqysiypwtfgggtkveik,"Ferrara,F. et al.; The unique antibody discovery competition triggered by COVID-19: a naive library directly delivering antibodies as potent as immune sources; Unpublished; 2021.",NaN,NaN,"Synthetic construct clone 41 immunoglobulin light chain variable region gene, partial cds",2022-03-15,NaN,NaN,NaN
4480,H.SAPIENS,NaN,Z14302,NaN,not determined,Homo sapiens (human),*gas*s*g*grdpglvkedfihpcvlstgvqsqvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadkststaymelsslrsedtavyycar,NaN,"Sasso,E.H. et al.; A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles; J. Clin. Invest. 91 (6), 2358-2367 (1993); 1992.",10.1172/JCI116468,H.sapiens gene for immunoglobulin heavy chain variable region (VH1),NaN,2022-03-15,NaN,NaN,NaN
4481,FLJ41806,NaN,AK123800,NaN,not determined,Homo sapiens (human),n*ippl*qplgaqlftmdwtwrflfvvaaaagvqsllqlvqsgaevkkpgssvtvsceasgdssptytiswvrqapgqglewmgditpvfgtkemsqkfqdrvsitadsvsvtadtrrtvylevrrltsddsavyycaksetdhsfyyyielwgqgttvtvssastkgpsvfplapsskstsggtaalgclvkdyfpepvtvswnsgaltsgvhtfpavlqssglyslssvvtvpssslgtqtyicnvnhkpsntkvdkkvepkscdkthtcppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepqvytlppsrdeltknqvsltclvkgfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk*vrrpasprspgsrgrarmlgtypvyilpgrpawk*stqrcpgpl,NaN,"Suzuki,O. et al.; NEDO human cDNA sequencing project; Unpublished; 2003.",NaN,"Homo sapiens cDNA FLJ41806 fis, clone NOVAR2001108, highly similar to Human (hybridoma H210) anti-hepatitis A IgG variable region, constant region, complementarity-determining regions mRNA, complete cds",NaN,2022-03-15,NaN,NaN,NaN
4482,ANTI-HUMAN,NaN,E13088,NaN,not determined,Mus sp.,vqlqesgaepakpgasvkmsckasgytfttywmhwvkqrpgqglewigyinpssgyteynqkfkdkatltadkssstaymqlisltsedsavyycarrgnyyyfdywgqgttvtvss,NaN,"Kiyono,K. et al.; THERAPEUTIC AGENT FOR HEPATITIS; JP1997124509-A 8 13-MAY-1997 SUMITOMO ELECTRIC IND LTD; 1998.",NaN,cDNA encoding variable region of H chain of anti-human Fas ligand antibody which hybridoma NOK5 produces,NaN,2022-03-15,NaN,NaN,NaN
4483,ANTI-HUMAN,NaN,E12189,NaN,not determined,Homo sapiens (human),qvqlqesgpglvkpsgtlsltcavsggsisssnwwswvrqppgkglewigeiyhsgstnynpslksrvtisadtsknqfslkvnsvtaadtavyycarrnydfwsggdgpfdywgqgtlvtvss,NaN,"Murakami,H. et al.; ANTIBODY AND ANTIBODY CDNA; JP1996280386-A 1 29-OCT-1996 MORINAGA & CO LTD; 1998.",NaN,DNA encoding variable region of heavy chain of human anti-human pulmonary carcinoma antibody,NaN,2022-03-15,NaN,NaN,NaN
4484,NaN,NaN,E13412,NaN,not determined,unidentified,makvklqesgaelvrpgssvkisckasgyvfssywmnwvkqrpgqglewigqinpgdgdtnyngkfkgkvtltadkssstahmqlssltsedsavyfctrmgvrrdywgqgttvtvssggggsggggsggggsdieltqspaimsaslgervtmtctasssvsssnlhwyqqksetspkpwiygtsnlasgipvrfsgsgsgtsysltissmegedaatyycqqwssnpftfgsgtkleikgglendenivygpepfypieegsagaqlrkymdryaklgaiaftnaltgvdytyaeylekscclgealknyglvvdgrialcsenceeffipvlaglfigvgvaptneiytlrelvhslgiskptivfsskkgldkvitvqktvtaiktivildskvdyrgyqsmdnfikkntpqgfkgssfktvevnrkeqvalimnssgstglpkgvqlthenlvtrfshardpiygnqvspgtailtvvpfhhgfgmfttlgyltcgfrivmltkfdeetflktlqdykcssvilvptlfailnrselldkydlsnlveiasggaplskeigeavarrfnlpgvrqgygltettsaiiitpegddkpgasgkvvplfkakvidldtkktlgpnrrgevcvkgpmlmkgyvdnpeatreiideegwlhtgdigyydeekhffivdrlkslikykgyqvppaelesvllqhpnifdagvagvpdpiagelpgavvvlekgksmtekevmdyvasqvsnakrlrggvrfvdevpkgltgkidgkaireilkkpvakm,NaN,"Masuda,S. et al.; ANTIBODY-FIREFLY LUCIFERASE FUSION PROTEIN, GENE OBTAINED THEREFROM, NOVEL RECOMBINANT DNA AND PRODUCTION OF ANTIBODY-FIREFLY LUCIFERASE FUSION PROTEIN; JP1997187281-A 3 22-JUL-1997 KIKKOMAN CORP; 1998.",NaN,cDNA encoding fused protein consisted of antibody and firefly luciferase,NaN,2022-03-15,NaN,NaN,NaN
4485,15G9,NaN,MZ751046,NaN,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),vqlqqsgpevvrpgvsvkisckgsgytftdyaihwvkqshakslewigvisshngnrgynqkfkgmatvtvdrssstaymelarltsedsaiyycaifdydfdywgqgttvmvss,NaN,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARS-CoV-2 RBD-based antigen; Unpublished; 2021.",NaN,"Mus musculus clone 15G9 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4486,10D2,NaN,MZ751049,NaN,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),vqlqqsgpelkkpgetvkisckasgytftkyrmhwvkqapgkglkwmgwintntgestyaddfkgrfafsletsastaylqinnlknedtatyfcassmdywgqgttvtvss,NaN,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",NaN,"Mus musculus clone 10D2 anti-SARS-CoV-2 spike protein immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4487,NaN,15G9/10D2,NaN,MZ751050,"SARS-CoV-2, Spike protein RBD",Mus musculus (house mouse),NaN,divltqspaslavslgqratisyrasksvstsgysymhwnqqkpgqpprlliylvsnlesgvparfsgsgsgtdftlnihpveeedaatyycqhireltrseggpsw,"Zhang,G. et al.; Epitope profiling reveals the critical antigenic determinants in SARSCoV-2 RBD-based antigen; Unpublished; 2021.",NaN,NaN,"Mus musculus clone 15G9/10D2 anti-SARS-CoV-2 spike protein immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4488,NaN,CA1,NaN,MT470194,SARS-CoV-2,Homo sapiens (human),NaN,divmtqtpatlslspgeratlscrasqsvssylawyqqkpgqaprlliydasnratgiparfsgsgsgtdftltisslepedfavyycqqrrnwgtfgpgtkvdikrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgecs*,"Shi,R. et al.; A potent human neutralizing monoclonal antibody targeting the receptor binding site of SARS-CoV-2 virus; Unpublished; 2020.",NaN,NaN,"Homo sapiens clone CA1 anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4489,NaN,L-CHAIN,NaN,E01737,not determined,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkprqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystprtfgqgtkveik,"Nakatani,T. et al.; HUMAN ANTIBODY, ANTIBODY GENE AND CORRESPONDING RECOMBINANT; JP1988267295-A 6 04-NOV-1988 SUMITOMO CHEM CO LTD, SUMITOMO PHARMACEUT CO LTD; 1997.",NaN,NaN,Genomic DNA encoding V region of L-chain of monoclonal antibody against pseudomonas aeruginosa exotoxin,2022-03-15,NaN,NaN,NaN
4490,P5A-1D2HC,NaN,MZ151910,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgfivssnymswvrqapgkglewvsiiysggstyyadsvkgrftisrdnsnntlylqmnslraedtavyycaralqvgatsdyfdywgqgtlvtvss,NaN,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",NaN,"Homo sapiens isolate P5A-1D2HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4491,P5A-3C8HC,NaN,MZ151912,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsfiysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqehgmdvwgqgttvtvss,NaN,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",NaN,"Homo sapiens isolate P5A-3C8HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4492,P22A-1D1HC,NaN,MZ151914,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardrdyygmdvwgqgttvtvss,NaN,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",NaN,"Homo sapiens isolate P22A-1D1HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4493,P2B-2F6HC,NaN,MW259136,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglvkpsetlsltctvsgysissgyywgwirqppgkglewigsiyhsgstyynpslktrvtisvdtsknqfslklssvtaadtavyycaravvgivvvpaagrrafdiwgqgtmvtvss,NaN,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",NaN,"Homo sapiens isolate P2B-2F6HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4494,P2C-1F11HC,NaN,MW259138,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgitvssnymnwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyhcardlvvygmdvwgqgttvtvss,NaN,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",NaN,"Homo sapiens isolate P2C-1F11HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4495,P2C-1A3HC,NaN,MW259140,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssgstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardfshqqlvpswgqgtlvtvss,NaN,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",NaN,"Homo sapiens isolate P2C-1A3HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4496,NaN,P5A-1D2LC,NaN,MZ151911,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsvsgapgqrvtisctgsssnigagydvhwyqqlpgtapklliygnsnrpsgvpdrfsgsksgtsaslaitglqaedetdyycqscdsslsvvvfgggtkltvl,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",NaN,NaN,"Homo sapiens isolate P5A-1D2LC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4497,NaN,P5A-3C8KC,NaN,MZ151913,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsslsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgtdftltisslqpedfatyycqhlnsyppgytfgqgtkleik,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",NaN,NaN,"Homo sapiens isolate P5A-3C8KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4498,NaN,P22A-1D1KC,NaN,MZ151915,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyyclhlnsyrtfglgtkveik,"Ju,B. et al.; Direct Submission; Submitted (06-MAY-2021) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2021.",NaN,NaN,"Homo sapiens isolate P22A-1D1KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4499,NaN,P2B-2F6LC,NaN,MW259137,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgspgqsvtisctgtssdvggynyvswyqqhpgkapklmiyevskrpsgvpdrfsgsksgntasltvsglqaedeadyycssyagsnnlvfgggtkltvl,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",NaN,NaN,"Homo sapiens isolate P2B-2F6LC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4500,NaN,P2C-1F11KC,NaN,MW259139,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqqygssptfgqgtkleik,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",NaN,NaN,"Homo sapiens isolate P2C-1F11KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4501,NaN,P2C-1A3KC,NaN,MW259141,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypltfgggtkveik,"Ju,B. et al.; Direct Submission; Submitted (13-NOV-2020) Institute for Hepatology, Shenzhen Third People Hospital, Bulan, Shenzhen 518112, China; 2020.",NaN,NaN,"Homo sapiens isolate P2C-1A3KC anti-SARS-CoV-2 immunoglobulin light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4502,F4,NaN,E01610,NaN,not determined,Homo sapiens (human),evqllesggglvqpggslrlsctasgftfstyamswvrqtpgkglhwvsaisgsdtgtyhaesvrgrltisrdnskntlylqmnnlrvedtalyfcak,NaN,"Hozumi,T. et al.; DNA CODING H-CHAIN OF ANTIPYOCYANIC HUMAN-TYPE ANTIBODY; JP1988152983-A 1 25-JUN-1988 WAKUNAGA PHARMACEUT CO LTD; 1997.",NaN,DNA encoding variable region H chain of anti pseudomonas aeruginosa (F4 type) antibody,NaN,2022-03-15,NaN,NaN,NaN
4503,368.07.28.GC.1A11.HC,NaN,MW926396,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsyawmtwvrqapgkglewvgriksktdggttdyaapvkgrftisrddskntlflqmnslktedtavyfcttgwftgtygdyfdywgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.28.GC.1A11.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4504,368.20.28.GC.3C08.HC,NaN,MW926407,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssywmswvrqapgkglewvanikedgsekyyvdsvkgrftisrdnaknslylqmnslraedtavyycaregtyyydssayynggldywgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.20.28.GC.3C08.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4505,368.22.28.GC.1B08.HC,NaN,MW926409,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaeakkpgasvniscrtsgytfsnyyihwvrqapgqglewmgifnpsgggtsyaqnfqgrltmtsdtststvfmelsslgsedtavyycardprvpavtnvndafdlwgqgtmvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.22.28.GC.1B08.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4506,368.07.GC.28.1A12.HC,NaN,MZ292481,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpgrslrlsctasgftfgdyamnwvrqapgkglewvgfirskpyggttqyaasvkgrftisrddsksiaylqmnslktedtavyyctrvkycsggscygyhfdhwgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.GC.28.1A12.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4507,368.07.28.GC.1H09.HC,NaN,MW926397,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgiivssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmsslraedtavyycardfregafdiwgqgtmvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.28.GC.1H09.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4508,368.22.28.GC.3A11.HC,NaN,MW926418,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqqwgagllkpsetlsltcavyggsfsgyywswirqppgkglewlgeinhsgstnynpslksrvtisvdtsknqfslklssvtaadtavyycarvwvrwwyfdlwgrgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.22.28.GC.3A11.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4509,368.07.28.GC.3D07.HC,NaN,MW926401,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsrytmhwvrqapgkglewvafisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarvlwlrgmfdywgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.28.GC.3D07.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4510,368.07.28.GC.4B05.HC,NaN,MW926403,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgssvkvsckasggtfssyainwvrqapgqglewmgriipilgianyaqkfqgrvtitadkststaymelsslrsedtavyycargrldsysgsyyswfdpwgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.28.GC.4B05.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4511,368.07.28.GC.2A10.HC,NaN,MW926399,NaN,SARS-CoV-2,Homo sapiens (human),qvqlqesgpglakpsqtlsltctvsggsissggyywswirqhpgkglewigyiyysgstyynpslksrvtisvdtsknqfslklssvtaadtavyycarypvwgafdiwgqgtmvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.28.GC.2A10.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4512,368.22.28.GC.1E11.HC,NaN,MW926412,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlflqmsslraedtavyycakmggvycsagncysgrleywglgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.22.28.GC.1E11.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4513,368.07.28.GC.2C08.HC,NaN,MW926400,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmstntaymelsslrsedtavyycaaaycsggscsdgfdiwgqgtmvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.28.GC.2C08.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4514,368.22.28.GC.1B12.HC,NaN,MW926410,NaN,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslrlscavseftvssnymswvrqapgeglewvsviylggstdyadsvkgrftisrdnskntlylqmnslraedtavyycarshlevrgvfdnwgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.22.28.GC.1B12.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4515,368.22.28.GC.2B06.HC,NaN,MW926415,NaN,SARS-CoV-2,Homo sapiens (human),evqlvetgggliqpggslrlscaasgftvssnymtwvrqapgkglewvsliysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycardlqlygmdvwgqgttvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.22.28.GC.2B06.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4516,368.22.GC.28.1B04.HC,NaN,MZ292499,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggvvvqpgrslrlscaasgftfssygmhwvrqapgkglewvavisydgsdkyyadsvkgrftisrdnskntlylqmnslraedtavyycakqgggtycgggscyrgyfdywgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.22.GC.28.1B04.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4517,368.07.28.GC.4A07.HC,NaN,MW926402,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfssyamfwvrqapgkglewvavisydgsneyyadsvkgrftisrdnskntlylqmnslraedtavyycargdyygsgsypgktfdywgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.07.28.GC.4A07.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4518,368.22.28.GC.2A06.HC,NaN,MW926414,NaN,SARS-CoV-2,Homo sapiens (human),evqlvqsgaevkkpgeslkisckgsgysftsywigwvrqmpgrglewmgiiypgdsdtryspsfqgqvtisadksistaylqwsslkasdtamyycarrewggslghidywgqgtlvtvss,NaN,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,"Homo sapiens isolate 368.22.28.GC.2A06.HC immunoglobulin variable region heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4519,NaN,368.20.28.GC.3C08.LC,NaN,MW926430,SARS-CoV-2,Homo sapiens (human),NaN,svtsyeltqppsvsmspgqtaritcsgdalpkkyaywyqqksgqapvlviyedskrpsgiperfsgsssgtmatltisgaqvedeadyycystdsggnpqgvfgggtkltvl,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.20.28.GC.3C08.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4520,NaN,368.22.28.GC.1B08.LC,NaN,MW926432,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasqsvssylawyqhkpgqaprliiynasnratgiparfsgsrsgtdftltisslepedfavyycqqrsnrpprwtfgqgtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.28.GC.1B08.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4521,NaN,368.22.28.GC.3A11.LC,NaN,MW926441,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigrksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltlsrveagdeadyycqvwdnssdqpnyvfgtgtkvtvl,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.28.GC.3A11.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4522,NaN,368.22.GC.28.3F08.LC,NaN,MZ292510,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwdsssyhavfgggtqltvl,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.GC.28.3F08.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4523,NaN,368.22.28.GC.2A06.LC,NaN,MW926437,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctrsrgsiagnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeaeyycqsfdssnvvfgggtkvtvl,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.28.GC.2A06.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4524,NaN,368.07.28.GC.2C08.LC,NaN,MW926423,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprllicatssratgipdrfsgsgsgtdftltirrlepedfalyycqqygsspwtfgqgtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.07.28.GC.2C08.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4525,NaN,368.07.28.GC.3D07.LC,NaN,MW926424,SARS-CoV-2,Homo sapiens (human),NaN,nfmltqphsvsespgktvtisctgssgsiasnyvqwyqqrpgsapttviyednqrpsgvpdrfsgsidsssnsasltisglktedeadyycqsydisnhwvfgggtkltvl,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.07.28.GC.3D07.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4526,NaN,368.07.28.GC.4A07.LC,NaN,MW926425,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqditnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.07.28.GC.4A07.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4527,NaN,368.22.28.GC.2B06.LC,NaN,MW926438,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvapgqtaritcggnnigsnsvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyhcqvwdsssdpvvfgggtkltvl,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.28.GC.2B06.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4528,NaN,368.22.28.GC.1E11.LC,NaN,MW926435,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlltfgpgtkvdik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.28.GC.1E11.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4529,NaN,368.07.28.GC.4B05.LC,NaN,MW926426,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnkdylawyqqkpgqppnlliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpytfgqgtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.07.28.GC.4B05.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4530,NaN,368.22.28.GC.1B12.LC,NaN,MW926433,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratvnckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpcsfgqgtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.28.GC.1B12.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4531,NaN,368.07.28.GC.1A11.LC,NaN,MW926419,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapklliydasnlqtgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpptfgggtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.07.28.GC.1A11.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4532,NaN,368.07.28.GC.1H09.LC,NaN,MW926420,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliyaastlqsgvpsrfsgsgsgteftltisslqpedfatyycqqlnsypptfgggtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.07.28.GC.1H09.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4533,NaN,368.07.28.GC.2A10.LC,NaN,MW926422,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpedfatyycqhydnlpptfgpgtkvdik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.07.28.GC.2A10.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4534,NaN,368.22.GC.28.1B04.LC,NaN,MZ292500,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcqasqdisnylnwyqqkpgkapnlliydasnletgvpsrfsgsgsgtdftftisslqpediatyycqqydnlpltfgggtkveik,"Turner,J.S. et al.; SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses; Nature 596 (7870), 109-113 (2021); 2021.",10.1038/s41586-021-03738-2,NaN,"Homo sapiens isolate 368.22.GC.28.1B04.LC immunoglobulin variable region light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4535,NaN,ANTI-RABIES,NaN,AY172962,not determined,Homo sapiens (human),NaN,mawtvlllgllshctgsvtsyvltqppsvsvapgktarincggnnieyrsvhwyqqksgqapvaviydnsdrpsgiperfsgsksgntatltisrveagdeadyycqvwdissdvvfgggtkltvlgqpkaapsvtlfppsseelqankatlvclisdfypgavtvawkadsspvkagvetttpskqsnnkyaassylsltpeqwkshrsyscqvthegstvektvaptecs*,"Prosniak,M. et al.; Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies; J. Infect. Dis. 188 (1), 53-56 (2003); 2003.",10.1086/375247,NaN,"Homo sapiens anti-rabies SOJB immunoglobulin lambda light chain mRNA, complete cds",2022-03-15,NaN,NaN,NaN
4536,NaN,NaN,NaN,JQ837832,not determined,Homo sapiens (human),NaN,mdmrvpaqllgllllwlrrvrcdiqmtqspsslsacvgdrvtitcraghnitnflswyqqkpgkaptlliyavsnlqrgvpsrfsgsgsgaeftltisslqpedfatyycqqnynfsftfgggtkvdnkrtvaapsvfifppsdeqlksgtasvvcllnnfypreakvqwkvdnalqsgnsqesvteqdskdstyslsstltlskadyekhkvyacevthqglsspvtksfnrgec*,"Hirayasu,K. et al.; Direct Submission; Submitted (27-MAR-2012) Department of Immunochemistry, Immunology Frontier Research Center, Osaka University, Yamadaoka 3-1, Suita, Osaka 565-0871, Japan; 2012.",NaN,NaN,"Homo sapiens immunoglobulin kappa light chain mRNA, complete cds",2022-03-15,NaN,NaN,NaN
4537,CV2-1,NaN,MW681614,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesgggvvqpgrslrlscaasgftfssyamhwvrqapgkglewvavisydgsnkyyadsvkgrftisrdnskntlylqmnslraedtaiyycarpysgsyyayfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"Homo sapiens isolate CV2-1 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4538,CN2-39,NaN,MZ151260,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgssvkvsckasggtfssyaiswvrqapgqglewmggiipifgtanyaqkfqgrvtitadeststaymelsslrsedtavyycarvassgnrreidywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"Homo sapiens isolate CN2-39 anti-SARS-CoV-2 immunoglobulin gamma heavy chain gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4539,PCV1-1,NaN,MW806097,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgaevkkpgeslkisckgsgysftsywigwvrqmpgkglewmgiiypgdsdtryspsfqgqvtisadrsintaflqwsslkasdtamyycarqrfsgslyfyygmdvwgqgttvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"Homo sapiens isolate PCV1-1 anti-SARS-CoV-2 immunoglobulin gamma gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4540,CN1-1,NaN,MZ151189,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdrssswhyyfdywgqgtlvtvss,NaN,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,"Homo sapiens isolate CN1-1 anti-SARS-CoV-2 immunoglobulin gamma heavy chain gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4541,NaN,CV3-48,NaN,MW681613,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspsslsasigdrvtitcrasqsinnylnwyqqkpgkapelliyaasslqsgvpsrfsgsgsgtdftltisslqpedfatyycqqsyspytfgqgtkleik,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"Homo sapiens isolate CV3-48 anti-SARS-CoV-2 immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4542,NaN,PCV1-66L,NaN,MW806188,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvggynyvswyqqhpgkapklmiydvskrpsgvsnrfsgsksgntasltisglqaedeadyycssytssspyvfgtgtkvtvl,"Jennewein,M.F. et al.; Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects; Unpublished; 2021.",NaN,NaN,"Homo sapiens isolate PCV1-66L anti-SARS-CoV-2 immunoglobulin lambda gene, partial cds",2022-03-15,NaN,NaN,NaN
4543,NaN,DK580821,NaN,DK580821,not determined,Macaca fascicularis (crab-eating macaque),NaN,klstnlaltdqdssghlltmklpaqllgllvlwlpgssgdivmtqtplslpvtpgepasiscrssqslldsedgstfldwylqkpgqspqlliyevsnrasgvpdrfsgsgsdtdftlkisrveaedvgvyycmqalefpltfgggtkveikravaapsvfifppsedqvksgtvsvvcllnnfypreasvkwkvdgalktgnsqesvteqdskdntyslsstltlsstdyqshnvyacevthqglsspvtksfnrgec*rgevpqaphlllspsltpshplasgpfptgelplfrsssssftsssssssalimlilggelinkvnlckkkkkk,"Osada,N. et al.; Collection of Macaca fascicularis cDNAs derived from bone marrow, kidney, liver, pancreas, spleen, and thymus; BMC Res Notes 2, 199 (2009); 2008.",NaN,NaN,"DK580821 macaque thymus cDNA library QthA Macaca fascicularis cDNA clone QthA-17029 5', mRNA sequence",2022-03-15,NaN,NaN,NaN
4544,ADI-56674_HC,NaN,MW457639,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgptlvkptqtltltctfsgfslstsgvgvgwirqppgkalewlaliywdddkryrsslksrltitkdtsknqvvltmtnmdpvdtatyycahynplyvfdywgqgtlvtvss,NaN,"Sakharkar,M. et al.; Prolonged evolution of the human B cell response to SARS-CoV-2 infection; Sci Immunol 6 (56) (2021); 2021.",10.1126/sciimmunol.abg6916,"Homo sapiens clone ADI-56674_HC immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4545,ADI-63420_HC,NaN,MW458926,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgeslkisckgfgysftnywiawvrqmpgkglewmgiiypgdsdtryspsfqgqvtmsadkssttaylqwsslkasdtamyycarqrrgvsapgthyyygtevwgqgttvtvss,NaN,"Sakharkar,M. et al.; Prolonged evolution of the human B cell response to SARS-CoV-2 infection; Sci Immunol 6 (56) (2021); 2021.",10.1126/sciimmunol.abg6916,"Homo sapiens clone ADI-63420_HC immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4546,TAU-1109_HC_VDJ,NaN,MW367317,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgpevkkpgasvkvsckasgytftsysinwvrqapgqglewmgwistyngntnyaqrlqgrvtmttdtstgtahmelrslrsddtaiyycareeplycsggscyefqhwgqgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-1109_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4547,TAU-2189_HC_VDJ,NaN,MW367319,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlfcaasgftfssfamswvrqapgkglewvstisgsggrtyyadsvkgrftifrdnskntlylqmnslraedtalyycakdmdivvvitgdafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-2189_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4548,TAU-1145_HC_VDJ,NaN,MW367321,NaN,SARS-CoV-2,Homo sapiens (human),qlqlqesgpglvkpsetlsltctlsggairsgsyywgwirqtpgkglewigsifhignafynpslksrvtisadkaknqislnvrsvtaadtavyycvrpnnehggfffdywgqgilvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-1145_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4549,TAU-2220_HC_VDJ,NaN,MW367323,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftnyfihwvrqapgqglewmgminpsvgsttyaqnfqgrvtmtrdtststvymelsslrsedtaiyycarthvaqlweiwyfdiwgrgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-2220_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4550,TAU-2230_HC_VDJ,NaN,MW367325,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfssyamnwvrqapgkglewvsvisgsggrtyyadsvkgrftisrdnskntlylqmnslraedtavyycakdldivvvitgdafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-2230_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4551,TAU-2212_HC_VDJ,NaN,MW367327,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgwvtmtrdtsistaymelsrlrsddtavyycargwatyydiltgyslfdywgqgtlvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-2212_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4552,TAU-2303_HC_VDJ,NaN,MW367329,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftvrsnymswvrqapgkglewvsliysggstyyadsvkgrfiisrdnskntlylqmnslraedtavyycardlavygmdvwgqgttvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-2303_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4553,TAU-2310_HC_VDJ,NaN,MW367331,NaN,SARS-CoV-2,Homo sapiens (human),evqllesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgiggsgdstyyadsvkgrftisrdnskntlylqinslraedtavyycakgaapyyyyyygmdvwgqgttvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-2310_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4554,TAU-1115_HC_VDJ,NaN,MW367333,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsnyvmswvrqapgkglewvsgisgsggstyyadsmkgrftisrdnskntlylqmnslraedtavyycakdltrdyydssgyqtgafdiwgqgtmvtvss,NaN,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,"Homo sapiens clone TAU-1115_HC_VDJ anti-SARS-CoV-2 neutralizing immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4555,NaN,TAU-1109_LC_VJ,NaN,MW367318,SARS-CoV-2,Homo sapiens (human),NaN,eivltqsparlslspgeratlscrasqsvssdlawyqqkpgqaprlliydashratgiparfsgsgsgtdftltisslepedfavyycqqrinwppiftfgpgtkvdik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-1109_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4556,NaN,TAU-2189_LC_VJ,NaN,MW367320,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalpkqyaywyqqkpgqapvlviykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-2189_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4557,NaN,TAU-1145_LC_VJ,NaN,MW367322,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppslsvapgktariscggnnigsrsvhwyqqkpgqapvvvisydtdrpseiperfsgsksgntatltisrveagdeadyycqvwvstfdhvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-1145_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4558,NaN,TAU-2220_LC_VJ,NaN,MW367324,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsgstsnigsnavnwyqqlpgtapklliysdnhrpsgvpdrfsgsrsgtsaslaisrlqsedeadyycaawddslkgvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-2220_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4559,NaN,TAU-2230_LC_VJ,NaN,MW367326,SARS-CoV-2,Homo sapiens (human),NaN,syeltqppsvsvspgqtaritcsgdalprhysywyqqkpgqapvlliykdserpsgiperfsgsssgttvtltisgvqaedeadyycqsadssgtyrvfgigtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-2230_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4560,NaN,TAU-2212_LC_VJ,NaN,MW367328,SARS-CoV-2,Homo sapiens (human),NaN,qsvltqpasvsgspgqsitisctgtssdvgsynlvswyqqhpgkapklmiyevskrpsgvsnrfsgsksgntasltisglqaedeadyyccsyagsstphvvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-2212_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4561,NaN,TAU-2303_LC_VJ,NaN,MW367330,SARS-CoV-2,Homo sapiens (human),NaN,diqltqspsflsasvgdrvtitcrasqgissylawyqqkpgkapklliygastlqsgvpsrfsgsgsgtefkltisslqpedfatyycqqlnnyppvtfgqgtrleik,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-2303_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin kappa light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4562,NaN,TAU-2310_LC_VJ,NaN,MW367332,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggydyvswyqqhpgkapklmiyevsdrpsgvsnrfsgsksgstasltisglqaedeadyycssytsssalyvfgtgtkvtvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-2310_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4563,NaN,TAU-1115_LC_VJ,NaN,MW367334,SARS-CoV-2,Homo sapiens (human),NaN,syelnqppsvsvapgqtaritcggnnigsksvhwyqqkpgqapvlvvyddsdrpsgiperfsgsnsgntatltisrveagdeadyycqvwggvfgggtkltvl,"Mor,M. et al.; Multi-Clonal SARS-CoV-2 Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors; Unpublished; 2021.",NaN,NaN,"Homo sapiens clone TAU-1115_LC_VJ anti-SARS-CoV-2 neutralizing immunoglobulin lambda light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4564,COVA1-01,NaN,MT599820,NaN,SARS-CoV-2,Homo sapiens (human),hqhqveqgpggveqsetlfltccvsggftisscykrggirqpprkgeewavssyyssstyytpslksrvtisvdksknqfslkmssvtaadtavyycarvssgyyftpfdywgqgtrghrlf,NaN,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,"Homo sapiens isolate COVA1-01 anti-SARS-CoV-2 monoclonal antibody heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4565,NaN,COVA3-10,NaN,MT599987,SARS-CoV-2,Homo sapiens (human),NaN,divmtqspdslavslgeratinckssqsvlyssnnknylawyqqkpgqppklliywastresgvpdrfsgsgsgtdftltisslqaedvavyycqqyystpitfgqgtrleik,"Brouwer,P.J.M. et al.; Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability; Unpublished; 2020.",NaN,NaN,"Homo sapiens isolate COVA3-10 anti-SARS-CoV-2 monoclonal antibody light chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4566,ADI-55688,NaN,MW417369,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfssyymnwvrqapgkglewvssissdgyntyypdslkgrftisrdsaknslylqmnslraddtavyycardfsghtavagtgfeywgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"Homo sapiens isolate ADI-55688 immunoglobulin heavy chain variable region gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4567,ADI-57993,NaN,MW417400,NaN,SARS-CoV,Homo sapiens (human),qvqlvesggglvqpggslrlscsasgfdfsrfamhwvrqapgkgleyvsainlhgdsryytdsvrgrftisrdnskntlylqmssvrpddtafyycvkdggyydssgpghwgqgtlvtvss,NaN,"Rappazzo,C.G. et al.; Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody; Science 371 (6531), 823-829 (2021); 2021.",10.1126/science.abf4830,"Homo sapiens isolate ADI-57993 immunoglobulin heavy chain variable region gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4568,NaN,ADG-1,NaN,MZ439265,SARS-CoV,Homo sapiens (human),NaN,eivltqspatlslspgeratlscrasenilhylawyqqkpgqaprlviydasrratgipgrfsgsgagtdftltinslepedfavyycqqranwpqnfgggtkveik,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"Homo sapiens isolate ADG-1 immunoglobulin light chain variable region gene, partial cds",2022-03-15,NaN,NaN,NaN
4569,NaN,ADG-2,NaN,MZ439267,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsvsgapgqritisctgsssnigagydvhwyqqlpgtapklliygsssrnsgvpdrfsgsksgtsaslaitglqaedeadyycqsydsslsvlytfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"Homo sapiens isolate ADG-2 immunoglobulin light chain variable region gene, partial cds",2022-03-15,NaN,NaN,NaN
4570,NaN,ADG-3,NaN,MZ439269,SARS-CoV,Homo sapiens (human),NaN,qsvltqppsasgtpgqrvtiscsggssnigsnsvnwyqqlpgtapklliysnsqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslntfryvfgtgtkvtvl,"Wec AZ et al.; Broad neutralization of SARS-related viruses by human monoclonal antibodies; Science 369 (6504), 731-736 (2020); 2021.",10.1126/science.abc7424,NaN,"Homo sapiens isolate ADG-3 immunoglobulin light chain variable region gene, partial cds",2022-03-15,NaN,NaN,NaN
4571,RBD-SPECIFIC,NaN,MT784731,NaN,"SARS-CoV-2, Spike protein RBD",Vicugna pacos (alpaca),qvqlvetggglvqpggslrlscaasgftfssvymnwvrqapgkgpewvsrispnsgnigytdsvkgrftisrdnakntlylqmnnlkpedtalyycaiglnlssssvrgqgtqvtvss,NaN,"Hanke,L. et al.; An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction; Nat Commun 11 (1) (2020) In press; 2020.",10.1038/s41467-020-18174-5,"Vicugna pacos SARS-CoV-2 RBD-specific neutralizing immunoglobulin heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4572,CC12.1-HC,NaN,MT594038,NaN,SARS-CoV-2,Homo sapiens (human),evqlvesgggliqpggslrlscaasgltvssnymswvrqapgkglewvsviysggstfyadsvkgrftisrdnskntlylqmnslraedtavyycardldvygldvwgqgttvtvss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"Homo sapiens isolate CC12.1-HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4573,CC12.25-HC,NaN,MT594062,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsgdstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdryyefwsgysnwfdpwgqgtlvtiss,NaN,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,"Homo sapiens isolate CC12.25-HC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4574,NaN,CC6.33-KC,NaN,MT594103,SARS-CoV-2,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsssylawyqqkpgqaprlliygassratgipdrfsgsgsgtdftltisrlepedfavyycqhygsslwtfgqgtkleik,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"Homo sapiens isolate CC6.33-KC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4575,NaN,CC12.25-LC,NaN,MT594095,SARS-CoV-2,Homo sapiens (human),NaN,qsaltqppsasgtpgqrvtiscsgsssnigsntvnwyqqlpgtapkvlvysndqrpsgvpdrfsgsksgtsaslaisglqsedeadyycaawddslngpvfgggtkltvl,"Rogers,T.F. et al.; Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model; Science (2020) In press; 2020.",10.1126/science.abc7520,NaN,"Homo sapiens isolate CC12.25-LC anti-SARS-CoV-2 immunoglobulin heavy chain variable region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4576,NaN,ANTI-LIPOPOLYSACCHARIDE,NaN,E10414,not determined,Homo sapiens (human),NaN,qsaltqpasvsgspgqsitisctgtssdvggynyvswyqqhpdtapklliydvsnrpsgvstrfsgsksgntasltisglqaedeaeyycsshaitstlifgggtkltvlg,"Bizen,F. et al.; GENE CODING HUMAN ANTIBODY CONTAINING B TYPE PSEUDOMONAS AERUGINOS AS ANTIGEN; JP1995327677-A 2 19-DEC-1995 MITSUI TOATSU CHEM INC; 1997.",NaN,NaN,cDNA encoding the variable region of lambda chain of human anti-Lipopolysaccharide of Pseudomonas sp,2022-03-15,NaN,NaN,NaN
4577,NaN,1-1,NaN,AF334738,not determined,Sus scrofa (pig),NaN,aivltqsplslsvspgepasiscrsshsleiygsnllswyqqkpgqsprlliyfatnkasgvpdrfsgsgsgtdftlkisrveaedagvyycqqhkeslvfgsgtkleik,"Perez,C.J. et al.; Direct Submission; Submitted (10-JAN-2001) Immunology Unit, School of Veterinary Sciences, University of Buenos Aires, Chorroarin 280, Capital Federal, Buenos Aires 1427, Argentina; 2002.",NaN,NaN,"Sus scrofa clone 1-1 immunoglobulin kappa light chain VJ region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4578,NaN,G502,NaN,AF334742,not determined,Sus scrofa (pig),NaN,aivltqtplslsvspgepasiscrssqsllhttgknylnwylqkpgqspqrliyqatnrdtgvpdrftgsgsgtdftlkisrveaedagvyyclqfkesppgfgagtklelk,"Perez,C.J. et al.; Direct Submission; Submitted (10-JAN-2001) Immunology Unit, School of Veterinary Sciences, University of Buenos Aires, Chorroarin 280, Capital Federal, Buenos Aires 1427, Argentina; 2002.",NaN,NaN,"Sus scrofa clone G502 immunoglobulin kappa light chain VJ region mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4579,NB21,NaN,KX278382,NaN,MERS-CoV,Camelus dromedarius (Arabian camel),qvqlqesgggsvqtggslrlscaasgsvycmgwirqapgkeregvarinsdgsvtyygssakgrfsisrdsakntvtllmnslkpedtaiytctagtrkcmdlgswidfdyrgqgtqvtvss,NaN,"Stalin Raj,V. et al.; Rapid identification of nanobodies by direct cloning from a bone marrow cDNA library; Unpublished; 2020.",NaN,"Camelus dromedarius clone nb21 anti-MERS-CoV immunoglobulin heavy chain VHDJ region (IgVH) mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4580,NBP2E6,NaN,KX278416,NaN,MERS-CoV,Camelus dromedarius (Arabian camel),qvqlqesgggsvqaggslrlscaaswhtyssnclgwfrqapgkerdlvaalyinggstyyadsvkgrfaisqdsarnsvylqmnslkpedtamyycaaddpalddlssggycsraygyhywgqgtqvtvss,NaN,"Stalin Raj,V. et al.; Rapid identification of nanobodies by direct cloning from a bone marrow cDNA library; Unpublished; 2020.",NaN,"Camelus dromedarius clone nbp2E6 anti-MERS-CoV immunoglobulin heavy chain VHDJ region (IgVH) mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4581,NaN,NaN,NaN,JN093123,not determined,Homo sapiens (human),NaN,eivltqspgtlslspgeratlscrasqsvsmnylawfqqkpgqaprlliygasrratgipdrisgsgsgtdftltisrlepadfavyycqqygtsprt,"Ekiert,D.C. et al.; A highly conserved neutralizing epitope on group 2 influenza A viruses; Science 333 (6044), 843-850 (2011); 2011.",10.1126/science.1204839,NaN,"Homo sapiens immunoglobulin light chain variable region mRNA, complete cds",2022-03-15,NaN,NaN,NaN
4582,4A8,NaN,MT622682,NaN,not determined,Homo sapiens (human),mnfglsliflvlilkgvqcevqlvesgaevkkpgasvkvsckvsgytltelsmhwvrqapgkglewmggfdpedgetmyaqkfqgrvtmtedtstdtaymelsslrsedtavyycatstavagtpdlfdyyygmdvwgqgttvtvss,NaN,"Chen,W. et al.; Direct Submission; Submitted (12-JUN-2020) Vaccine and Antibody, Beijing Insititute of Biotechonology, Dongdajie Street, Beijing, MB 100071, China; 2020.",NaN,"Homo sapiens clone 4A8 immunoglobulin heavy chain variable region gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4583,NaN,IG=IDIOTOPES,NaN,S80615,not determined,Cricetulus migratorius (Armenian hamster),NaN,diqmtqcpsslpaslgdrvtincqasqdignylswyqqkpgkapqlliyyinkladgvpsrfsgsgsgrdysftisslesedigsyycqqysnfpltfgdgtkleikradakptvsifppsseqlgtgsatlvcfvnnfypkdinvkwkvdgsgkrdgvlqsvtdqdskdstysmsstltltkdeyerhnsytceathktstspivksfnrnec,"Mallender,W.D. et al.; Primary structures of three Armenian hamster monoclonal antibodies specific for idiotopes and metatopes of the monoclonal anti-fluorescein antibody 4-4-20; Mol. Immunol. 32 (14-15), 1093-1103 (1995); 1997.",NaN,NaN,"Ig=idiotopes and metatopes of anti-fluorescein antibody 4-4-20-specific antibody {clone 1F4} [Cricetulus migratorius=Armenian hamster, mRNA Partial, 642 nt]",2022-03-15,NaN,NaN,NaN
4584,6A,NaN,AY530312,NaN,SARS-CoV,Homo sapiens (human),qvqlvqsgggvvqpgrslrlscaasgftvssnymswvrqapgkglewvsviysggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakdygegfdywgqgtlvtvss,NaN,"Sui,J. et al.; Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association; Proc. Natl. Acad. Sci. U.S.A. 101 (8), 2536-2541 (2004); 2004.",NaN,"Homo sapiens clone 6A anti-SARS S protein immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4585,03-013,NaN,AY554177,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycakgltplyfdywgqgtlvtvss,NaN,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-013 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4586,03-002,NaN,AY554174,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvkpggslrlscaasgftfsgysmswvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycaryysrslkafdywgqgtlvtvle,NaN,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-002 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4587,03-009,NaN,AY554176,NaN,SARS-CoV,Homo sapiens (human),evqlvesgggvvqpgrslrlscaasgftfsdypmnwvrqapgkglewvssisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakglfmvttyafdywgqgtlvtvle,NaN,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-009 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4588,03-018,NaN,AY554180,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfssyamswvrqapgkglewvsaisgsggstyyadsvkgrftisrdnskntlylqmnslraedtavyycakfnpftsfdywgqgtlvtvss,NaN,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-018 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4589,03-014,NaN,AY554178,NaN,SARS-CoV,Homo sapiens (human),evqlvesggglvqpggslrlscaasgftfsdhymdwvrqapgkglewvgrtrnkansytteyaasvkgrftisrddsknslylqmnslktedtavyycargispfyfdywgqgtlvtvss,NaN,"van den Brink,E.N. et al.; Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus; J. Virol. 79 (3), 1635-1644 (2005); 2005.",10.1128/JVI.79.3.1635-1644.2005,"Homo sapiens clone 03-014 anti-SARS-CoV immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4590,NaN,NaN,MT350284,NaN,SARS-CoV,Lama glama (llama),qvqlqesggglvqaggslrlscaasgrtfseyamgwfrqapgkerefvatiswsggstyytdsvkgrftisrdnakntvylqmnslkpddtavyycaaaglgtvvsewdydydywgqgtqvtvss,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies; Cell (2020) In press; 2020.",NaN,"Lama glama immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4591,NaN,NaN,MT350283,NaN,SARS-CoV,Lama glama (llama),qvqlqesgggsvqaggslrlscvasgsifsinamdwyrqapgkqrelvagitsggstnygdfvkgrftisrdnakntvylqmdslkpedtavyycaaevggwgpprpdywghgtqvtvss,NaN,"Wrapp,D. et al.; Structural Basis for Potent Neutralization of Betacoronaviruses by Single-domain Camelid Antibodies; Cell (2020) In press; 2020.",NaN,"Lama glama immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4592,F26G8,NaN,AY605273,NaN,SARS-CoV,Mus musculus (house mouse),vqllesgaelvkpgasvkvsckasgytftsywihwvkqrpgqglewigeinpsngrtnyngnfeskatltvdkssntaymhlssltyedsavyhctrldywgqgttltvssakttapsvypla,NaN,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G8 immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4593,F26G3,NaN,AY605265,NaN,SARS-CoV,Mus musculus (house mouse),mewswvflfllsgtagvlsevrlqqsgpelvkpgasvkiscktsgytfteytmhwvkqshgknlewigginpnnggttynqkfkgkatltvdkssntaymelrsltsedsavyycsrgdygtsygyfdvwgagttvtvssakttapsvypla,NaN,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G3 immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4594,F26G6,NaN,AY605272,NaN,SARS-CoV,Mus musculus (house mouse),qvqlqqpgaelvkpgasvkvsckasgytftnywihwvkqrpgqglewigeinpgngrtnyngnfmnkatltvdkssntaymqlssltsedsavyhcarldywgqgttltvssakttppsv,NaN,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G6 immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4595,F26G10,NaN,AY605268,NaN,SARS-CoV,Mus musculus (house mouse),evqleesgtvlarpgasvkmsckasgysftsywmhwvkqrpgqgldwigaiypensdtsynqkfkgkakltavtsastaymehssltnedsavyyctrsvyygygyfdvwgagttvtvssakttapsvyplapvcgdttgssvtlgclvkgyfpepvtltwnsgslssgvhtfpavlqsdlytlsssvtvtsstwpsqsitcnvahpasstkvdkkieprvptsqn,NaN,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G10 immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4596,F26G7,NaN,AY605266,NaN,SARS-CoV,Mus musculus (house mouse),vellesgtvlarpgasvkmsceasgytfttywmhwikqrpgqglewigaiypgnsdttynqkfkgkakltavtststaymelssltnedsavyyctregipqllrtmdywgqgtsvtvssakttppsv,NaN,"Gubbins,M.J. et al.; Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus; Mol. Immunol. 42 (1), 125-136 (2005); 2004.",10.1016/j.molimm.2004.06.032,"Mus musculus clone F26G7 immunoglobulin gamma heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4597,NaN,COV2-VAX-69,NaN,MZ555491,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,dvvmtqsplslpvtlgqaasiscrssqslvysdentylnwfqqrpgqsprrliykvsnrdagvpdrfsgsgsgtdftlkisrveaedvgvyycmqgtqwpytfgqgtkleik,"Chen,E.C. et al.; Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals; Cell Rep (2021) In press; 2021.",NaN,NaN,"Homo sapiens isolate COV2-vax-69 immunoglobulin light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4598,NaN,COV2-VAX-13,NaN,MZ555628,"SARS-CoV-2, Spike protein",Homo sapiens (human),NaN,eivmtqspatlsvspgeratlscrasqsvssnlawyqqkpgqaprlliygastratgiparfsgsgsgteftltisslqsedfavyycqqynnwppwtfgqgtkveik,"Chen,E.C. et al.; Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals; Cell Rep (2021) In press; 2021.",NaN,NaN,"Homo sapiens isolate COV2-vax-13 immunoglobulin light chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4599,ANTI-HIV,NaN,E02168,NaN,not determined,Mus musculus (house mouse),qvqlqqsgaelvkpgasvkmsckafgytfttypiewmkqnhgkslewignfhpysddtnynekfkgkakltvekssstvylefsrltsddsavyycaihygsayamdywgqgtsvtvss,NaN,"Maeda,H. et al.; GENE FRAGMENT TO CODE ANTI-HIV ANTIBODY VARIABLE RANGE, ANTI-HIV CHIMERA ANTIBODY MANIFESTED BY USING THE SAME FRAGMENT AND; JP1990002352-A 1 08-JAN-1990 CHEMO SERO THERAPEUT RES INST; 1997.",NaN,DNA encoding variable region of H chain of anti-HIV antibody,NaN,2022-03-15,NaN,NaN,NaN
4600,CV07-209,NaN,MW002770,NaN,SARS-CoV-2,Homo sapiens (human),qvqlvesggglvkpggslrlscaasgftfsdyymswirqapgkglewvsyisssvstiyyadsvkgrftisrdnaknslylqmnslraedtavyycardgvipprfdywgqgtlvtvss,NaN,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.049,"Homo sapiens clone CV07-209 anti SARS-CoV-2 immunoglobulin heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4601,NaN,CV-X2-106,NaN,MW002805,SARS-CoV-2,Homo sapiens (human),NaN,diqmtqspsslsasvgdrvtitcrasqsissflnwyqqkpgkapklliyaasslqsgvpsrfsgsgsvtdftltisslqpedfatyycqqsystpytfgqgtkleik,"Kreye,J. et al.; A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.049,NaN,"Homo sapiens clone CV-X2-106 anti SARS-CoV-2 immunoglobulin kappa chain mRNA, partial cds",2022-03-15,NaN,NaN,NaN
4602,368-28_B30,NaN,MZ615309,NaN,SARS-CoV-2,Homo sapiens (human),qmqlvqsgpevkkpgtsvkvsckasgftftssamqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymelsslrsedtavyycaapncsstscydafdiwgqgtmvtvss,NaN,"Schmitz,A.J. et al.; A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.013,"Homo sapiens clone 368-28_b30 immunoglobulin heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4603,368-07_B7,NaN,MZ615310,NaN,SARS-CoV-2,Homo sapiens (human),qmqllqsgpevkkpgtsvkvsckasgftfsssavqwvrqargqrlewigwivvgsgntnyaqkfqervtitrdmststaymnlsslrsedtavcycaapycsggtcsdgfdiwgqgtmvtvss,NaN,"Schmitz,A.J. et al.; A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants; Immunity (2021) In press; 2021.",10.1016/j.immuni.2021.08.013,"Homo sapiens clone 368-07_b7 immunoglobulin heavy chain mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4604,NaN,IL-6,NaN,E05421,not determined,Mus musculus (house mouse),NaN,mesdtlllwvlllwvpgstgdivliqspaslavslgqratiscrasesvdsygnsfmhwyqqkpgqppklliyrasnlesgiparfsgsgsrtdftltinpveaddvatyycqqsnedpptfgagtklelkra,"Tsuchiya,M. et al.; DNA CAPABLE OF CODING VARIABLE REGION OF MURINE MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN-6 RECEPTOR; JP1993236966-A 28 17-SEP-1993 CHUGAI PHARMACEUT CO LTD; 1997.",NaN,NaN,cDNA sequence encoding mouse monoclonal antibody kappa type L chain variable region against human IL-6 receptor,2022-03-15,NaN,NaN,NaN
4605,ANTI-CARCINOMA,NaN,E12917,NaN,not determined,Homo sapiens (human),mdwtwrilfmvaaatgahsqvqlvqsgaevkkpgasvkvsckasgytftgyymhwvrqapgqglewmgwinpnsggtnyaqkfqgrvtmtrdtsistaymelsrlrsddtavyycargpkgycsstscyfdyyyygmdvwgqgttv,NaN,"Hagiwara,H. et al.; AMINO ACID SEQUENCE OF ANTICANCER HUMAN MONOCLONAL ANTIBODY AND DNA BASE SEQUENCE CODING FOR THE SAME; JP1997100300-A 1 15-APR-1997 HAGIWARA YOSHIHIDE; 1998.",NaN,"Human mRNA for variable region of heavy chain of anti-carcinoma monoclonal antibody CLN''1-IgM,complete cds",NaN,2022-03-15,NaN,NaN,NaN
4606,ANTIBODYKOS-A,NaN,E13306,NaN,not determined,Mus sp.,qesgqesgpdlvkpsqslsltctvtgysitsgyswhwirqlrnnslewvasrhiqenqkfkgkakltavtftyyrdredyygglqmfdswaedtpqlncvttedtsqslsdtwgqgttvts,NaN,"Ishizuka,M. et al.; DNA BASE SEQUENCE AND AMINO ACID SEQUENCE IN VARIABLE REGION OF ANTIHUMAN LIPOPROTEIN (A) MONOCLONAL ANTIBODY; JP1997173063-A 1 08-JUL-1997 COSMO SOGO KENKYUSHO:KK, COSMO OIL CO LTD; 1998.",NaN,"DNA encoding V region of anti human lipoprotein antibody,KOS-A heavy chain",NaN,2022-03-15,NaN,NaN,NaN
4607,NaN,IDIO3,NaN,E09034,not determined,Mus musculus (house mouse),NaN,divltqspaslavsplgqratisyrasksvqlhlaivymhwnqqkpgqpprlliylvsnlesgvparfsgsgsgtdftlnihpveeedaatyycqhirvaytfgggtkleikradaap,"Hagiwara,H. et al.; AMINO ACID SEQUENCE OF ANTI-IDIOTYPE ANTIBODY TO ANTI-CANCER HUMAN MONOCLONAL ANTIBODY AND DNA BASE SEQUENCE CODING FOR THE SAME; JP1995101999-A 6 18-APR-1995 HAGIWARA YOSHIHIDE; 1997.",NaN,NaN,cDNA encoding light chain variable region of mouse antiidiotype antibody named Idio3 against CLN-IgG idiotype,2022-03-15,NaN,NaN,NaN
4608,NaN,NaN,NaN,NaN,not determined,Lactiplantibacillus plantarum subsp. plantarum,NaN,NaN,"Jin,N. et al.; Complete Genome Sequence of Lactobacillus plantarum subsp. plantarum CGMCC 1.557; Unpublished; 2017.",NaN,NaN,NaN,2022-03-15,NaN,NaN,"Lactiplantibacillus plantarum subsp. plantarum strain CGMCC 1.557 chromosome, complete genome"
4609,J558.50,NaN,AF303881,NaN,not determined,Mus musculus (house mouse),evqlqqsgtvlagpgasvkmsckasgytftsywmhwvkqrpgqglewigaiypgnsdtsynqkfkgkakltavtststaymelssltnedsavyyctr,NaN,"Haines,B.B. et al.; Germline diversity of the expressed BALB/c VhJ558 gene family; Mol. Immunol. 38 (1), 9-18 (2001); 2000.",NaN,"Mus musculus clone J558.50 immunoglobulin heavy chain variable region mRNA, partial cds",NaN,2022-03-15,NaN,NaN,NaN
4610,VHAB8,NaN,MT943599,NaN,SARS-CoV-2,synthetic construct,evqlvesggglvqpggslrlscaasgftfddyamswvrqapgkglewigrmynngrtsynpslkslvtisrdnskntlylqmnslraedtatyycardnlgyrpsenlygmdvwgqgttvtvss,NaN,"Li,W. et al.; High potency of a bivalent human VH domain in SARS-CoV-2 animal models; Cell (2020) In press; 2020.",10.1016/j.cell.2020.09.007,"Synthetic construct anti-SARS-CoV-2 immunoglobulin heavy chain variable region VHab8 gene, partial cds",NaN,2022-03-15,NaN,NaN,NaN
